
<html lang="en"     class="pb-page"  data-request-id="3cdac554-1414-49d4-af37-819f695cfa2d"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2020.63.issue-14;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;article:article:10.1021/acs.jmedchem.9b01985;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?" /></meta><meta name="dc.Creator" content="Sarah  Diab" /></meta><meta name="dc.Creator" content="Mingfeng  Yu" /></meta><meta name="dc.Creator" content="Shudong  Wang" /></meta><meta name="dc.Description" content="Cyclin-dependent kinase (CDK) 7 has a unique functional repertoire by virtue of its dual role in transcription and cell cycle progression. Whereas CDK7 is ubiquitously expressed in various types of..." /></meta><meta name="Description" content="Cyclin-dependent kinase (CDK) 7 has a unique functional repertoire by virtue of its dual role in transcription and cell cycle progression. Whereas CDK7 is ubiquitously expressed in various types of..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="March 9, 2020" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b01985" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2020 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01985" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b01985" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b01985" /></link>
        
    
    

<title>CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success? | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b01985" /></meta><meta property="og:title" content="CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0009.jpeg" /></meta><meta property="og:description" content="Cyclin-dependent kinase (CDK) 7 has a unique functional repertoire by virtue of its dual role in transcription and cell cycle progression. Whereas CDK7 is ubiquitously expressed in various types of cancer, its downregulation leads to reduced cell proliferation. Importantly, it is now agreed that targeting transcription selectively limits the synthesis of mRNAs involved in tumor growth without causing an outage of transcription of housekeeping genes. Thus, CDK7 has been considered as a viable therapeutic target in cancer. Indeed, the development of CDK7 inhibitors has gained huge momentum with two molecules, CT7001 and SY-1365, currently under clinical development. Herein, we discuss the latest understanding of the role of CDK7 in cancer cells and provide an overview of the pharmacophores of CDK7 inhibitors, their efficacy in various cancer models, and their clinical development." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b01985"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01985">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b01985&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b01985&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b01985&amp;href=/doi/10.1021/acs.jmedchem.9b01985" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2020</span><span class="cit-fg-volume">, 63</span><span class="cit-fg-issue">, 14</span><span class="cit-fg-pageRange">, 7458-7474</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/63/14" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b01932" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.0c00191" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Sarah Diab</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sarah Diab</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, Lebanese American University, P.O. Box 36, Byblos, Lebanon</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sarah++Diab">Sarah Diab</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath1">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6705-317X" title="Orcid link">http://orcid.org/0000-0002-6705-317X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Mingfeng Yu</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Mingfeng Yu</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development, University of South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Mingfeng++Yu">Mingfeng Yu</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath2">View Biography</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Shudong Wang</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Shudong Wang</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Drug Discovery and Development, University of South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</div></div><span class="conrtib-corresp"><strong>*</strong>Phone: +61-8-8302-2372. Email: <a href="/cdn-cgi/l/email-protection#e3b08b96878c8d84cdb4828d84a3968d8a9082cd868796cd8296"><span class="__cf_email__" data-cfemail="55063d20313a3b327b02343b3215203b3c26347b3031207b3420">[email protected]</span></a></span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Shudong++Wang">Shudong Wang</a></span></div><div class="loa-info-bio"><span><a class="internalNav" href="#ath3">View Biography</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6225-5525" title="Orcid link">http://orcid.org/0000-0001-6225-5525</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01985&amp;href=/doi/10.1021%2Facs.jmedchem.9b01985" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2020</span></span><span class="cit-volume">, 63</span><span class="cit-issue">, 14</span><span class="cit-pageRange">, 7458–7474</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">March 9, 2020</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>29 November 2019</li><li><span class="item_label"><b>Published</b> online</span>9 March 2020</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 23 July 2020</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01985</a></div><div class="article_header-article-copyright"><strong>Copyright © 2020 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7458%26pageCount%3D17%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DSarah%2BDiab%252C%2BMingfeng%2BYu%252C%2BShudong%2BWang%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D63%26issueNum%3D14%26contentID%3Dacs.jmedchem.9b01985%26title%3DCDK7%2BInhibitors%2Bin%2BCancer%2BTherapy%253A%2BThe%2BSweet%2BSmell%2Bof%2BSuccess%253F%26numPages%3D17%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7474%26publicationDate%3DJuly%2B2020">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b01985"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">3641</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">10</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b01985" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;CDK7 Inhibitors in Cancer Therapy: The Sweet Smell of Success?&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Sarah&quot;,&quot;last_name&quot;:&quot;Diab&quot;},{&quot;first_name&quot;:&quot;Mingfeng&quot;,&quot;last_name&quot;:&quot;Yu&quot;},{&quot;first_name&quot;:&quot;Shudong&quot;,&quot;last_name&quot;:&quot;Wang&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2020&quot;,&quot;month&quot;:&quot;03&quot;,&quot;day&quot;:&quot;09&quot;,&quot;issue&quot;:&quot;14&quot;,&quot;volume&quot;:&quot;63&quot;,&quot;pages&quot;:&quot;7458-7474&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b01985&quot;},&quot;abstract&quot;:&quot;Cyclin-dependent kinase (CDK) 7 has a unique functional repertoire by virtue of its dual role in transcription and cell cycle progression. Whereas CDK7 is ubiquitously expressed in various types of cancer, its downregulation leads to reduced cell proliferation. Importantly, it is now agreed that targeting transcription selectively limits the synthesis of mRNAs involved in tumor growth without causing an outage of transcription of housekeeping genes. Thus, CDK7 has been considered as a viable therapeutic target in cancer. Indeed, the development of CDK7 inhibitors has gained huge momentum with two molecules, CT7001 and SY-1365, currently under clinical development. Herein, we discuss the latest understanding of the role of CDK7 in cancer cells and provide an overview of the pharmacophores of CDK7 inhibitors, their efficacy in various cancer models, and their clinical development.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01985&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01985" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01985&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01985" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b01985&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01985" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b01985&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b01985&amp;href=/doi/10.1021/acs.jmedchem.9b01985" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b01985" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b01985" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b01985%26sid%3Dliteratum%253Aachs%26pmid%3D32150405%26genre%3Darticle%26aulast%3DDiab%26date%3D2020%26atitle%3DCDK7%2BInhibitors%2Bin%2BCancer%2BTherapy%253A%2BThe%2BSweet%2BSmell%2Bof%2BSuccess%253F%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D63%26issue%3D14%26spage%3D7458%26epage%3D7474%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=291305" title="Cell physiology">Cell physiology</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/63/14" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/jmcmar.2020.63.issue-14/20200723/jmcmar.2020.63.issue-14.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Cyclin-dependent kinase (CDK) 7 has a unique functional repertoire by virtue of its dual role in transcription and cell cycle progression. Whereas CDK7 is ubiquitously expressed in various types of cancer, its downregulation leads to reduced cell proliferation. Importantly, it is now agreed that targeting transcription selectively limits the synthesis of mRNAs involved in tumor growth without causing an outage of transcription of housekeeping genes. Thus, CDK7 has been considered as a viable therapeutic target in cancer. Indeed, the development of CDK7 inhibitors has gained huge momentum with two molecules, CT7001 and SY-1365, currently under clinical development. Herein, we discuss the latest understanding of the role of CDK7 in cancer cells and provide an overview of the pharmacophores of CDK7 inhibitors, their efficacy in various cancer models, and their clinical development.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Background</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15201" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15201" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Prodigious anticancer research worldwide has been steered in the last decades toward dissecting the cancer circuitry and revealing pivotal targets that are amenable to patient-tailored therapies. Well-established evidence has espoused the genetic alterations that disrupt the transcriptional programs of many cancer types as potential vulnerabilities and stimulated enthusiasm for the development of therapies that stall the overly activated transcription. On the other hand, cell cycle dysregulation is a hallmark of cancer; agents that target cell cycle regulators are already in the market. Owing to its role in dysregulating transcription and cell cycle progression in many cancers, cyclin-dependent kinase (CDK) 7 has become an intensively pursued anticancer therapeutic avenue.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><div class="NLM_p">CDKs are serine/threonine protein kinases that regulate transcription (CDKs 7–13 and 19–20) or the progression of cells through their cycle (CDKs 1–6 and 14–18).<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> Almost all of the known CDKs are activated via (i) their binding to a cyclin and (ii) phosphorylation of their T-loops by a CDK-activating kinase (CAK). CAK, a trimeric complex comprising CDK7, cyclin H, and the RING-finger protein MAT1, renders CDK7 uniquely involved in the regulation of both transcription and the cell cycle. CDK7 becomes activated following autophosphorylation at Thr170 of its T-loop and binding to cyclin H. However, this autophosphorylation is not required for its CAK activity as the interaction of CDK7 with MAT1 is a suitable substitute. MAT1 is essential for forming the ternary complex because the assembly of CDK7 with cyclin H is not stable. Unlike other CDKs that have only one phosphorylation site in the T-loop, CDK7 has a second one, Ser164, phosphorylation of which increases its affinity for cyclin H.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> Both residues in CDK7 are phosphorylated by CDK1 and CDK2, rewiring positive feedback where the latter two cell cycle regulators influence gene expression.<a onclick="showRef(event, 'ref4 ref5'); return false;" href="javascript:void(0);" class="ref ref4 ref5">(4,5)</a></div><div class="NLM_p">CDK7 orchestrates different phases of the transcription cycle of RNA polymerase II (RNAP II). At the initiation phase, CDK7, as part of the general transcription factor II human (TFIIH), phosphorylates Ser5 residues of the carboxy-terminal domain (CTD) heptapeptide repeats of the RNAP II to facilitate promoter escape (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>A). Nilson et al. have recently proposed that inhibition of CDK7 impairs RNAP II pausing and mRNA capping.<a onclick="showRef(event, 'ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref6 ref7">(6,7)</a> They posited that the binding of THZ1, a small-molecule covalent inhibitor of CDK7/12/13 (<i>vide infra</i>), to CDK7 averted the binding of DRB-sensitivity inducing factor (DSIF) and negative elongation factor (NELF) to RNAP II, thus preventing productive elongation of transcription. Conversely, CDK7 releases the pause by phosphorylating CDK9, a component of the positive transcription elongation factor b (P-TEFb), which in turn phosphorylates Ser2 residues of the CTD, thereby promoting productive transcription.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> On the other hand, ample evidence is supporting the role of phase separation in transcription regulation.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12 ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12 ref13 ref14 ref15">(9−15)</a> Various transcriptional regulators contain low-complexity disordered regions that form liquid-like hubs via transient interactions.<a onclick="showRef(event, 'ref9 ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref9 ref10 ref11 ref12">(9−12)</a> Hubs might then undergo liquid–liquid phase separation, thus compartmentalizing the transcription apparatus in an orderly fashion. It is being suggested that CDK7 plays a role in phase separation regulating gene transcription.<a onclick="showRef(event, 'ref13 ref14 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref14 ref15">(13−15)</a> CTD of RNAP II is a low-complexity disordered region that clusters in hubs. Together with studies by Boehning et al., Lu et al. propose that unphosphorylated CTD of RNAP II undergoes phase separation via hydrophobic interactions, whereas its phosphorylation by CDK7 promotes its incorporation into phase-separated droplets formed by cyclin T1 and the histidine-rich domain via electrostatic interactions.<a onclick="showRef(event, 'ref13 ref15'); return false;" href="javascript:void(0);" class="ref ref13 ref15">(13,15)</a> Boehning et al. have also proposed that such phosphorylation liberates RNAP II from the hub, thereby activating transcription elongation.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Finally, CDK7 phosphorylates numerous transcription factors including p53 and nuclear hormone receptors such as androgen receptors (ARs) and estrogen receptors (ERs), thus modulating their activation and target gene expression.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a> A comprehensive review on the roles of CDK7 in transcription was provided by Fisher.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Roles of CDK7 in mRNA transcription (A) and cell cycle progression (B). (A) CDK7, as part of TFIIH, phosphorylates Ser5 at the CTD of RNAP II for the initiation of transcription and subsequently affects the phosphorylation of CDK9 to release the pause and further prompt the productive elongation. (B) CDK7, as the key component of CAK, phosphorylates CDK1/2/4/6 to regulate cell cycle progression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Besides its role in transcription, CDK7 regulates cell cycle progression by virtue of its CAK function (<a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>B). Previous studies have confirmed the role of CDK7 in phosphorylating CDK4/6 to phosphorylate the retinoblastoma (Rb) protein for G1 progression, CDK2 to promote the progression from the G1 to S phase, and CDK1 to regulate G2/M transition.<a onclick="showRef(event, 'ref17 ref18'); return false;" href="javascript:void(0);" class="ref ref17 ref18">(17,18)</a> Phosphorylation by CDK7 seems to regulate the cyclin-pairing order and progression through the cell cycle. For instance, CDK7 in its monomeric form phosphorylates CDK2, but in complex with cyclin H affects the phosphorylation of CDK1. This would give CDK2 the priority, vs CDK1, to bind to cyclin A during the cell cycle. Whereas CDK7-mediated phosphorylation of CDK1/2 is essential only for their activation, it is required to activate as well as maintain CDK4/6 activity. Phosphorylation of CDK7 is stimulated during G0–G1 progression, which leads to the activation of CDK4 and surmises the presence of a yet unknown CDK7-activating kinase in the early phases of the cell cycle.<a onclick="showRef(event, 'ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref18 ref19">(18,19)</a> A controversy has also arisen of the potential existence of a CAK other than CDK7. A previous study showed that CDK1/2 remained phosphorylated in T121-expressing <i>CDK7</i><sup><i>mut/mut</i></sup> mouse embryonic fibroblasts (MEFs), implying non-CDK7-mediated phosphorylation of CDK1/2 upon inactivation of the Rb family of proteins (T121 is a polypeptide that inactivates the Rb family).<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> In contrast, losing <i>CDK7</i> in MEFs impaired the phosphorylation of cell cycle CDKs, and CDK7 inhibitors have generally abolished the CAK activity <i>in vitro</i>. Thus, although CDK7 was avowed as the major CAK, the jury remains out on the presence of a CDK7-independent kinase that phosphorylates other CDKs.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i3">CDK7 in Cancer: The Ups and Downs</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_60408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_60408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Aberrant overabundance of CDK7 has been detected in a myriad of cancer types and correlated with aggressive clinicopathological features and poor prognosis. <i>CDK7</i> is amplified in hepatocellular carcinoma, gastric cancer, and colorectal cancer (CRC).<a onclick="showRef(event, 'ref21 ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23">(21−23)</a> Immunohistochemistry analyses of 173 gastric cancer specimens revealed elevated levels of CDK7, which were correlated with tumor grade.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> Similarly, CDK7 was overexpressed in a large fraction of oral squamous cell carcinoma samples, which was associated with a higher T-stage and reduced overall and disease-free survival, suggesting its utility as a prognostic biomarker.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> Protein and mRNA levels of CDK7 are also upregulated in cancerous compared to adjacent normal tissues of the breast.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> Interestingly, an elevated expression of CDK7 was associated with poor clinical outcomes of the patients with triple-negative breast cancer (TNBC), but linked to a better prognosis for those with ER<sup>+</sup> breast cancer; this phenomenon was attributed to the heterogeneous genetic backgrounds of the two breast cancer types.<a onclick="showRef(event, 'ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref26 ref27">(26,27)</a></div><div class="NLM_p last">On the other hand, knockdown of <i>CDK7</i> using siRNA reduced gastric cancer cell proliferation and increased the G2/M cell population.<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> CRISPR/Cas9-mediated knockdown of <i>CDK7</i> in BT549 and MDA-MB-231 TNBC cells decreased their proliferation.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> Likewise, genetic silencing of <i>CDK7</i> with adeno/lentiviral vectors in MEFs impaired T-loop phosphorylation of other CDKs and reduced the transcription of E2F-driven genes, thereby arresting the cell cycle and impeding cell proliferation.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> However, little effect on global transcription was observed. Mouse embryos lacking <i>CDK7</i> faced early lethality, but there was no obvious phenotype in young adult mice. Organs with a low rate of proliferation, e.g., the brain, retained their physiological parameters; however, highly proliferating tissues like the intestine maintained high levels of CDK7 expression, indicating that the pools of CDK7-expressing stem cells would be depleted with aging without the capability for renewal. It was presumably considered for a long time that targeting gene transcription is risky, fearing this tactic would lack selectivity toward malignant cells over normal cells. However, this paradigm was gradually revised. An early study revealed that inhibition of Kin28<sup>as</sup>, an engineered Kin28 (a yeast CDK7 homologue) form that was selectively inhibited by bulky adenine analogues (e.g., 1-NA-PP1), did not impair global transcription.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Antitranscriptional agents may selectively shut off the genes addicted to aberrant transcription to fuel the growth of the cancer cells without adversely affecting the transcription of housekeeping genes. Collectively, these studies suggest CDK7 as a promising therapeutic target against cancer with a sufficient therapeutic window.</div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Structure-Based Design of CDK7 Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_47685" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_47685" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The discovery of CDK inhibitors has been a long-term pursuit by academia and pharmaceutical companies, with a cornucopia of pan-CDK inhibitors brought to the fore over the years. Lacking selectivity, the first generation of CDK inhibitors showed conspicuous side effects, which has slowed their clinical development. These pan-CDK inhibitors are beyond the scope of this review; they have been reviewed extensively elsewhere.<a onclick="showRef(event, 'ref2 ref30 ref31'); return false;" href="javascript:void(0);" class="ref ref2 ref30 ref31">(2,30,31)</a> In contrast, only a few reviews that describe selective CDK7 inhibitors are available,<a onclick="showRef(event, 'ref32 ref33'); return false;" href="javascript:void(0);" class="ref ref32 ref33">(32,33)</a> which spurred us to write this review that focuses on the state-of-the-art CDK7 inhibitors with refined selectivity profiles.</div><div class="NLM_p">Structure-guided design of selective CDK7 inhibitors was anchored on the foundation of previous pan-CDK inhibitors, but also on the only crystal structure of this kinase (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2">1UA2</a>).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a> The latter shows that CDK7 exits in the common bilobal scaffold with the ATP binding site located in the cleft between the N-terminal lobe (residues 13–90) formed of a β-sheet and an α-helix, and the C-terminal lobe (residues 97–311) comprises α-helices. CDK7 has a 44% sequence identity to CDK2, and their structures are similar to a root-mean-square deviation of 1.49 Å over 262 equivalent Cα atoms (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>A); reviews comparing different CDK structures are referenced herein.<a onclick="showRef(event, 'ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref35 ref36">(35,36)</a> The adenine of ATP forms two hydrogen bonds with the hinge region of CDK7, while the three γ-phosphate oxygens develop hydrogen bonds with Phe23, Ala24, and Lys41 (<a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>B). This crystal structure has paved the way for developing selective CDK7 inhibitors based on docking and molecular dynamic (MD) simulations.</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Superposition of the crystal structures of CDK7 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2">1UA2</a>) in cyan and CDK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HCK">1HCK</a>) in light purple. (B) Crystal structure of ATP-bound CDK7 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2">1UA2</a>). The hinge region of CDK7 is colored in yellow and the ATP in pink. The hinge region of CDK2 is colored in green and ATP in gold. Hydrogen bonds are shown as black dashed lines. The figure was generated using Pymol v.1.7.0.1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Purine-isostere-based Analogues</h3><div class="NLM_p">In a bid to identify a potent and selective CDK7 inhibitor, Ali et al. utilized roscovitine as a starting point for their modeling-based structural design.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Roscovitine is a first-generation pan-CDK inhibitor, and its structure has been extensively deployed to tailor inhibitors of individual CDKs. This has included replacement of the purine core with an array of its isosteres, including pyrazolo[1,5-<i>a</i>]pyrimidine (e.g., BS-181 and CT7001),<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(37−39)</a> and pyrazolo[1,5-<i>a</i>][1,3,5]triazine (e.g., LDC3140 and LDC4297),<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> and diversification of substituents at different cardinal positions of the molecule (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>). Compounds bearing a pyrazolo[1,5-<i>a</i>]pyrimidine or a pyrazolo[1,5-<i>a</i>][1,3,5]triazine scaffold instead of the purine core of roscovitine, were proposed to be more efficient inhibitors of CDK2 based on computational studies.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> A pyrazolo[1,5-<i>a</i>]pyrimidine seemed to strengthen the bond with Leu83 at the hinge region and to compact the geometry of the molecule, thus rendering it more conformationally stable. The difference in binding between the pyrazolo[1,5-<i>a</i>]pyrimidine and the pyrazolo[1,5-<i>a</i>][1,3,5]triazine cores was subtle; from one side, a nitrogen atom at position a (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) prevented the clash between the hydrogen atom otherwise at this position and the adjacent benzylamino group, thus stabilizing the molecular geometry. From the other side, the presence of this nitrogen atom resulted in lower interaction with the protein as the benzyl ring was turned to the protein when coupled with the pyrazolo[1,5-<i>a</i>]pyrimidine instead. Collectively, both cores were well-tolerated in CDK2 and could further form suitable frameworks for the design of other CDK inhibitors.</div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structures of roscovitine, LDC3140, and LDC4297. (B) Optimization of CDK7 inhibition of pyrazolo[1,5-<i>a</i>]pyrimidine analogues; R′ = H unless specified otherwise. IC<sub>50</sub> refers to the inhibitory potency against CDK7 unless specified otherwise.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Ali et al. started with substitution of the purine by the pyrazolo[1,5-<i>a</i>]pyrimidine based on computational calculations of free energies of solvation, affording compound <b>1</b> (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B); the pyrazolo[1,5-<i>a</i>]pyrimidine core gave rise to a lower, favorable aqueous solvation energy, which facilitates its accommodation within the hydrophobic binding pocket. Compound <b>1</b> had a slightly better docking score compared to roscovitine, yet its binding to CDK7 could be improved further (IC<sub>50</sub> = 70 nM).<a onclick="showRef(event, 'ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref42 ref43">(42,43)</a> Thus, a back pocket of CDK7 was exploited by excising the hydroxyethyl moiety of compound <b>1</b> and replacing the remaining propylamino group at pyrazolo[1,5-<i>a</i>]pyrimidinyl-C5 (i.e., R position in <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>B) with a 1,6-diaminohexyl substituent, i.e., BS-181.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Structural optimization has mainly investigated the effects of various functionalities at the R position and substitutions on the phenyl ring (largely an <i>ortho</i>-fluoro group) on CDK7 inhibition.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> According to the data presented in the corresponding patent, an interplay between substituents at these two sites determines CDK7 inhibitory potency. For instance, grafting an <i>ortho</i>-fluoro group on the phenyl ring of BS-181, i.e., compound <b>2</b>, has substantially decreased CDK7 inhibitory activity (IC<sub>50</sub> > 1000 nM). In opposition, the <i>ortho</i>-fluoro group increased CDK7 inhibition by >24 times in the presence of a 1,7-diaminoheptyl group at the R position (<b>3a</b> vs <b>3b</b>). The same holds true in the case of (<i>R</i>)-2,7-diaminoheptan-1-ol instead of the 1,6-diaminohexyl substituent as CDK7 inhibition was improved by 5-fold via the introduction of the <i>ortho</i>-fluoro group to the phenyl ring (<b>4a</b> vs <b>4b</b>). Also, in some cases, compounds bearing a ramified side chain with a heteroaryl ring (e.g., pyridine or pyrimidine) at its end retained CDK7 inhibitory activity (<b>5</b>, IC<sub>50</sub> = 20 nM); CDK7 inhibition and selectivity depended on the length and ramification of the side chain as well as the type of its embedded ring. On the other hand, shorter hydroxylated side chains were deployed to develop CDK2 inhibitors, e.g., BS-194.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a> Out of the entire series, BS-181 was the most studied CDK7 inhibitor.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> It was administered i.p. for <i>in vivo</i> studies with a half-life (<i>t</i><sub>1/2</sub>) in the mouse of 405 min. It is not a substrate for ATP-binding cassette (ABC) drug transporters but has a poor bioavailability attributed to its primary amine (p<i>K</i><sub>a</sub> = 10.2) that gets protonated at physiological pH and therefore reduces the gastric permeability of the molecule.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a></div><div class="NLM_p">Structural refinement of BS-181 was undertaken to improve its oral bioavailability.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a> Main modifications explored the presence of substituted aminopiperidine, aminomethylpiperidine, aminopyrrolidine, and aminomethylpyrrolidine at the R position. Inhibition of CDK7 varied with the nature of substituents, including their stereochemistry. For instance, CDK7 inhibition was significantly reduced when the hydroxyl group of <b>6a</b> was masked with a methyl (<b>6a</b> vs <b>6b</b>). The compound bearing (3<i>R</i>,4<i>S</i>)-4-aminopyrrolidin-3-ol at the R position resulted in not only a potent inhibition of CDK7 (<b>7</b> IC<sub>50</sub> = 27 nM) but also 48- and 146-fold selectivity over CDK2 and CDK1, respectively. (3<i>S</i>,4<i>S</i>)-4-Aminomethylpiperidin-3-ol was also well-tolerated (IC<sub>50</sub> = 40 nM), giving rise to CT7001 (also known as ICEC0942) that showed 37-fold and 14-fold selectivity for CDK7 over CDK1 and CDK2, respectively. The diastereomer of CT7001, i.e., compound <b>8a</b>, was a far less potent inhibitor of CDK7 (IC<sub>50</sub> > 1000 nM). Interestingly, grafting a hydroxyl group at C4 of the piperidine ring of <b>8a</b>, i.e., <b>8b</b>, not only reinstated CDK7 inhibition (IC<sub>50</sub> = 18 nM) but also showed excellent selectivity over CDK1 (77-fold) and CDK2 (113-fold). Omitting the hydroxyl group of CT7001 or replacing its piperidine ring with cyclohexane (i.e., compounds <b>9</b> and <b>10</b>, respectively) has resulted in the corresponding 7-fold or 17-fold reduction in CDK7 inhibition. CT7001 was progressed for further studies and was shown to be 30% orally bioavailable.<a onclick="showRef(event, 'ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref38 ref39">(38,39)</a> Nevertheless, CT7001 has a high efflux ratio of 86.5, a plasma protein binding of 90.8%, an IC<sub>50</sub> for CYP3A4 inhibition of 5.1 μM, and a half-life in a mouse of 1.9 h. Also, CT7001 was demonstrated to be a substrate for ABC subfamily B member 1 (ABCB1), a transport that could mediate resistance to the drug.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> A synthetic route to CT7001 is presented in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01985/suppl_file/jm9b01985_si_001.pdf" class="ext-link">Scheme S1</a>.</div><div class="NLM_p">Various attempts to obtain a cocrystal structure of CT7001 with CDK7 were unsuccessful. Therefore, Hazel et al. solved the crystal structure of CDK2 in complex with CT7001 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JQ5">5JQ5</a>).<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> This cocrystal structure shows that the pyrazolo[1,5-<i>a</i>]pyrimidine core forms two hydrogen-bonding interactions with the backbone of Leu83 at the hinge region. A third hydrogen bond is developed between the nitrogen of the piperidine ring and Asn132; the former moiety additionally makes electrostatic contact with Asp145 (<a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>).</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of CT7001 (yellow) with CDK2 in light purple (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JQ5">5JQ5</a>). The hinge region and selected amino acid residues are illustrated in green. Hydrogen bonds are shown as black dashed lines. The figure was generated using Pymol v.1.7.0.1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">MD simulations and isothermal titration calorimetry (ITC) were deployed to postulate the binding mode of CT7001 to CDK7 and to rationalize its selectivity for CDK7 over CDK2.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> Since a sequence alignment revealed that many residues of the ATP binding site are conserved between CDK2 and CDK7, the authors reasoned that the difference in the potency is likely related to the local structures of their binding sites and is affected by the inherent flexibility of the two proteins. The cocrystal structure of CDK2-CT7001 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JQ5">5JQ5</a>) was used to generate a starting binding mode of CT7001 in the crystal structure of CDK7 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1U2A">1U2A</a>), and MD simulations were carried out. CT7001 adopts the same binding poses in CDK7 as in CDK2 and maintains hydrogen bonding with the hinge region, specifically CDK7-Met94. Moreover, it is able to form an additional interaction with Asp137 of CDK7, which is not within reach in the case of CDK2. Most importantly, CT7001 can bridge Asp155 of the C-terminal lobe and Gly21 of the G-rich loop of CDK7 through polar interactions, thus limiting the loop flexibility. However, such an interaction was detected in only 5% of the simulations with CDK2, suggesting that it could be the reason for the lower potency toward CDK2 as compared to CDK7. Indeed, evaluating the binding affinity of CT7001 for recombinant CDK7<sup>Asp155Ala</sup> and CDK2<sup>Asp145Ala</sup> by ITC indicated that CT7001 maintained the same binding affinity for CDK2<sup>Asp145Ala</sup> as for wild-type CDK2, whereas its binding to CDK7<sup>Asp155Ala</sup> was 3–4 times weaker than to wild-type CDK7. Then again, Val100 in CDK7 results in a larger pocket than the one created by its equivalent CDK2-Lys89. ITC studies showed that the binding of CT7001 to CDK7<sup>Val100Lys</sup> was less favored than to wild-type CDK7, confirming that the size of the binding site in CDK7 also contributes to the selectivity of CT7001 for the kinase.</div><div class="NLM_p last">LDC3140 and LDC4297 were identified following the screening of a BS-181-centered library of compounds and medicinal chemistry optimization of the thus-obtained hits (<a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref40 ref48'); return false;" href="javascript:void(0);" class="ref ref40 ref48">(40,48)</a> Both bear the pyrazolo[1,5-<i>a</i>][1,3,5]triazine as a central core, a piperidinyloxy moiety that has displaced the amino-linker at C5 of the pyrazolo[1,5-<i>a</i>]pyrimidine, and a substituted <i>N</i>-benzyl group. Analogues derived from this scaffold were deemed potent, ATP-competitive inhibitors of CDK7. Both LDCs showed good selectivity for CDK7 over a panel of 150 kinases.</div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i6" class="anchor-spacer"></div><h3 class="article-section__title" id="_i6"> Covalent Inhibitors</h3><div class="NLM_p">THZ1 was the first covalent CDK inhibitor discovered (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). It engages with a cysteine located out of the global constellation of the ATP binding site, thus offering an inimitable opportunity for enhancing selectivity toward CDK7.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> THZ1 contains the <i>N</i>-phenylpyrimidin-2-amine scaffold that has served as a common core for discovering many kinase inhibitors, including imatinib and CDKI-73 (one of the most potent CDK9 inhibitors).<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> Distinctively, THZ1 comprises an acrylamide moiety; a warhead that is responsible for its irreversible bonding to Cys312 in the vicinity. Indeed, THZ1-R, which lacks this warhead, was less inhibitory of CDK7 and cell proliferation. Also, CDK7<sup>Cys312Ser</sup> was not inhibited by THZ1, further attesting to the value of a covalent bond with Cys312 for optimal inhibition. Bearing a cysteine at a similar position to CDK7, CDK12/13 were also inhibited by THZ1. This compound inhibited tumor growth substantially in various mouse models (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>); however, it is a substrate for the ABC drug transporters, raising a concern for potential drug resistance.<a onclick="showRef(event, 'ref46 ref51'); return false;" href="javascript:void(0);" class="ref ref46 ref51">(46,51)</a></div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures and enzymatic potency of covalent CDK7 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of Some of the Current CDK7 Inhibitors<a onclick="showRef(event, 'ref63 ref64 ref74 ref75 ref82 ref87'); return false;" href="javascript:void(0);" class="ref ref63 ref64 ref74 ref75 ref82 ref87">(63,64,74,75,82,87)</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0008.gif" alt="" id="gr8" /></img><div></div></div><div class="NLM_p">Iterative structural optimization of THZ1 was performed to improve its metabolic stability <i>in vivo</i> (<i>t</i><sub>1/2</sub> = 45 min in mouse plasma, CL = 129 mL/min/kg).<a onclick="showRef(event, 'ref28 ref52'); return false;" href="javascript:void(0);" class="ref ref28 ref52">(28,52)</a> Moving the acrylamide from the <i>para</i>- to a <i>meta</i>-position on the benzamide (THZ2, <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>) extended the <i>t</i><sub>1/2</sub> by 5-fold <i>in vivo</i> while retaining selective inhibition of CDK7. Replacing the benzene-1,3-diamine with 1<i>S</i>,3<i>R</i>-cyclohexanediamine, i.e., SY-314, lowered the clearance by 7.6-fold in the mouse (CL = 17 mL/min/kg), but this reduced the efficiency of covalent inhibition. Substituting the benzamide with an electron-withdrawing picolinamide, i.e., SY-351, reinstated cellular target engagement but increased clearance to 29 mL/min/kg. Iterative optimization involved grafting a methyl group on the cyclohexanediamine moiety to give SY-1365, which restricted the accessible conformations of the warhead by increasing hindrance around the amide linker. SY-1365 had a markedly reduced clearance of 5.6 mL/min/kg and a higher value for <i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> of 0.131 μM<sup>–1</sup> s<sup>–1</sup>. Notably, replacing the cyclohexylamine with piperidine gave THZ531, which is 53-fold more selective for CDK12 over CDK7 (IC<sub>50</sub> 158 nM vs 8,500 nM).<a onclick="showRef(event, 'ref51 ref53'); return false;" href="javascript:void(0);" class="ref ref51 ref53">(51,53)</a> A synthetic route to SY-1365 is delineated in <a href="/doi/suppl/10.1021/acs.jmedchem.9b01985/suppl_file/jm9b01985_si_001.pdf" class="ext-link">Scheme S2</a>.</div><div class="NLM_p">Inhibition of CDK12/13 by THZ1, in addition to CDK7, has obfuscated the cellular phenotype of CDK7 inhibition;<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> this has prompted a quest to identify a more selective CDK7 inhibitor. The design was based on PF-3758309 (<a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>), a PAK4 inhibitor, which retains an inhibition of CDK7.<a onclick="showRef(event, 'ref55 ref56 ref57'); return false;" href="javascript:void(0);" class="ref ref55 ref56 ref57">(55−57)</a> Hybridization of the covalent warhead of THZ1 with the pyrrolidinopyrazole framework from PF-3758309 gave rise to YKL-1-116; the latter retained inhibitory activity and selectivity for CDK7 (IC<sub>50</sub> = 7.6 nM), but somehow displayed a low antiproliferative activity <i>in vitro</i>.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In an attempt to increase potency, structural modifications considered optimizing the length and trajectory of the covalent warhead. Shortening the covalent warhead by omitting the aniline moiety afforded YKL-5-124 that maintained its ability to bind covalently through its acrylamide moiety and thus retained CDK7 potency (IC<sub>50</sub> = 9.7 nM).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> In fact, YKL-5-124 was a more potent inhibitor with faster kinetics toward CDK7 than THZ1 (<i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> = 103 nM<sup>–1</sup> μs<sup>–1</sup> vs 9 nM<sup>–1</sup> μs<sup>–1</sup>); it also exhibited no inhibition of CDK12/13 at the concentrations tested (10<sup>–4</sup> to 10 mM) and was >130-fold more selective for CDK7 over CDK2/9 (IC<sub>50</sub>s of 1300 and 3020 nM, respectively). YKL-5-167, in which the acrylamide was replaced by a propionamide, lost its ability to inhibit CDK7 in the <i>in vitro</i> kinase assay.</div><div class="NLM_p">Docking studies were performed to gauge the binding of some of the aforementioned covalent inhibitors to CDK7<a onclick="showRef(event, 'ref49 ref52 ref54'); return false;" href="javascript:void(0);" class="ref ref49 ref52 ref54">(49,52,54)</a> but also to guide further structural design. THZ1 and SY-1365 adopt similar binding poses in a model of the CDK7 structure. Besides forming a covalent bond with Cys312, the N1 and C2-NH of the pyrimidin-2-amine engage via two hydrogen bonds with the backbone of Met94, and the chlorine forms a hydrophobic interaction with the gatekeeper Phe91 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>A). In the case of SY-1365, the cyclohexane-1,3-diamine core results in improved shape complementarity and hydrophobic interactions, accounting for increased potency and selectivity compared to THZ1. On the other hand, YKL-5-124 interacts with the hinge region through its 3-aminopyrazolopyrrolidine core that forms three hydrogen bonds with Asp92 and Met94 (<a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>B). Additionally, another two hydrogen bonds are made with Lys41 and Asn141, which would increase its binding affinity for CDK7.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic representations of the predicted modes of binding of SY-1365 (A) or YKL-5-124 (B) to CDK7. Hydrogen bonds are shown as red dashed lines and covalent bonds as red solid lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i8">CDK7 Inhibitors in Action</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14847" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14847" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> BS-181</h3><div class="NLM_p last">Available CDK7 inhibitors have been exploited as chemical probes to unravel the role(s) of CDK7 in cancer cell biology and to investigate, <i>in vitro</i> and <i>in vivo</i>, whether CDK7 inhibition would be translated into an effective anticancer strategy. BS-181 was the first selective CDK7 inhibitor (IC<sub>50</sub> = 21 nM); being >41-fold more potent against CDK7 over CDK2 and some of the other CDK family members, i.e., CDK1/4–6/9 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). It also exhibited selectivity over 69 non-CDK kinases that all showed >15% remaining kinase activity when treated with 10 μM BS-181.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Studies have verified the capability of BS-181 in inhibiting the growth of MCF-7 breast cancer, BT549 and MDA-MB-231 TNBC, and various gastric cancer cell lines <i>in vitro</i>, inducing apoptosis and impeding cell cycle progression.<a onclick="showRef(event, 'ref27 ref37 ref58'); return false;" href="javascript:void(0);" class="ref ref27 ref37 ref58">(27,37,58)</a> It reduced the phosphorylation of Ser5/7 of the RNAP II CTD in TNBC cells, suggestive of a stalling of mRNA transcription.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> When administered i.p. at 10 and 20 mg/kg bid for 14 days, BS-181 reduced the growth of the MCF-7 breast tumor xenograft by 25 and 50%, respectively, compared to the control group, with no detected toxicity.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> Using the same regimen, it inhibited tumor growth in a dose-dependent manner compared to the control group in a BGC823 gastric cancer xenograft model.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Taken together, BS-181 has provided the first proof-of-concept of the efficacy of a CDK7 inhibitor against breast and gastric cancers and has suggested that targeting transcription can be an effective therapeutic approach. However, the poor oral bioavailability of BS-181 has precluded its further development.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> CT7001</h3><div class="NLM_p last">CT7001 is an orally bioavailable analogue of BS-181. It retains a similar CDK7 inhibitory activity to BS-181 with good selectivity over CDK1/2/4–6/7/9 (their IC<sub>50</sub>s were 1–3 orders of magnitude higher, <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and many non-CDK kinases.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> It returned a median GI<sub>50</sub> of 0.25 μM when assessed against a panel of 60 cancer cell lines and led to cell demise in a panel of patient-derived small-cell lung cancer (SCLC) cell lines. CT7001 activated caspase 3/7 and prompted PARP cleavage, indicative of apoptosis, and arrested the cell cycle at the G2/M phase of HCT-116 cells after 24 h of exposure. CT7001 inhibited tumor growth by 60% (<i>p</i> = 0.0001) at days 13 and 14 when administered orally to mice at 100 mg/kg/day as a single agent in HCT116 CRC and MCF-7 breast cancer xenografts, respectively. Also, CT7001 was evaluated against a mouse model of TNBC, resulting in strong and sustained tumor regression and with little effect on body weight (<10%).<a onclick="showRef(event, 'ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref59 ref60">(59,60)</a> A once-daily oral administration of CT7001 to mice led to a near-complete regression in an MV-4-11 acute myeloid leukemia (AML) xenograft model.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> CT7001 was also well-tolerated in 28-day toxicity studies using rats and dogs with no sign of neutropenia.<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The compound is now in a phase I clinical trial (NCT03363893) as monotherapy for TNBC and prostate cancer, with an estimated completion date of March 2021.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> THZ1 and THZ2</h3><div class="NLM_p">As a first-in-class covalent inhibitor of CDK7, THZ1 was a major breakthrough in irreversible CDK-targeted therapies.<a onclick="showRef(event, 'ref49 ref62'); return false;" href="javascript:void(0);" class="ref ref49 ref62">(49,62)</a> THZ1 inhibited CDK7 with an IC<sub>50</sub> of 238 nM but remained inhibitory of CDK12/13 (IC<sub>50</sub>s of 893 and 628 nM, respectively).<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Its antiproliferative potency was similar to that of BS-181, with IC<sub>50</sub> values of <200 nM against a panel of 598 cancer cell lines, an effect that was mainly attributed to its modulation of the expression of (proto)oncogenic transcription factors.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Exposure of T-cell acute lymphoblastic leukemia (T-ALL) Jurkat cells to THZ1 dampened cell proliferation along with the expression of antiapoptotic proteins including MCL1 and XIAP, thus leading to apoptosis. It also reduced the phosphorylation of CDK1/2, thereby causing cell cycle arrest at G2. Treatment of Jurkat cells with high doses of THZ1 reduced global mRNA levels, whereas exposure to low doses downregulated a subset of genes, including <i>RUNX1</i>, a superenhancer (SE)-associated gene. THZ1 was efficacious against patient-derived T-ALL and chronic lymphocytic leukemia cells, and in a T-ALL xenograft mouse model with no systemic toxicity observed.</div><div class="NLM_p">The discovery of THZ1 has invigorated efforts to assess the potential value of CDK7 inhibitors against aggressive tumors, for which currently there is an unmet clinical need. Early studies observed that THZ1 is particularly efficacious against cancers addicted to the preponderant expression of SE-driven genes.<a onclick="showRef(event, 'ref49 ref65 ref67 ref68'); return false;" href="javascript:void(0);" class="ref ref49 ref65 ref67 ref68">(49,65,67,68)</a> While transcription relies on numerous regulators, SEs usurp the transcriptional machinery to favor a high level of expression of their target genes; therefore, targeting transcription regulators, including CDK7, has the potential to impair the transcription boosted by SEs. Treatment with THZ1 of the mice xenografted with small-cell lung cancer produced a significant tumor response due to the vulnerability of amplified <i>C-MYC</i> and <i>MYCN</i> proto-oncogenes to THZ1.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The concept was mirrored when melanoma cell lines were treated with THZ1, identifying SE-associated <i>MITF</i> and <i>SOX10</i> as being prone to the effect of THZ1 in a subset of human melanomas.<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> THZ1 repressed the growth of melanoma cells <i>in vitro</i> and of the xenografted tumor <i>in vivo</i> by dismantling the SE apparatus at <i>MITF</i> and <i>SOX10</i> and preventing their oncogenic transcription. In neuroblastoma, <i>MYCN</i>-amplified cells were 10-fold more sensitive to THZ1 compared to those without this gene amplification, which seemed the result of a downregulation by the drug of the transcription of <i>MYCN</i> and SE-associated genes that were transcribed actively in <i>MYCN</i>-amplified cells.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> THZ1 induced apoptosis in high <i>MYCN</i>-expressing cells and arrested their cell cycle <i>in vitro</i> and showed <i>in vivo</i> efficacy in a mouse xenograft model with no overt toxicity, further highlighting the selectivity of antitranscriptional agents in downregulating SE-associated genes in cancer cells with little effect on global transcription in normal cells.</div><div class="NLM_p">Also, incubation with THZ1 of OCI-Ly12 peripheral T-cell lymphoma-not otherwise specified (PTCL-NOS) cells harboring <i>STAT3</i><sup><i>Tyr640Phe</i></sup>, a mutation that confers a high transcriptional activity, downregulated the expression of highly transcribed STAT3 target genes including <i>MYC</i>, <i>PIM1</i>, and <i>MCL1</i>.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> THZ1 triggered cell death that was associated with caspases 3/7 activation and PARP cleavage and inhibited the phosphorylation of Ser2 of RNAP II CTD, but induced minimal perturbation of the cell cycle after 9 h exposure; this suggests that CDK7 transcriptional activity was required for the survival of PTCL-NOS cells.</div><div class="NLM_p">TNBC, widely renowned for its aggressive nature,<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> was challenged by THZ2, a <i>meta</i>-isomer of THZ1 yet with one order of magnitude higher CDK7 inhibitory activity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Wang et al. suggested that TNBC growth relies on a compilation of genes encoding transcriptional regulators and signaling components.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> THZ2 offered the chance to target this “Achilles cluster” of genes, not just a few oncogenic drivers, as has generally been the case with other “targeted therapies”. Noteworthy, only 40% of genes of the “Achilles cluster” in TNBC were associated with SEs; it was hypothesized that SE-nonassociated genes rely on a continuous expression of SE-driven transcription factors, thus being secondary responders. In line with this, Greenall et al. have shown that the sensitivity of high-grade glioma to THZ1 was related to downregulation of the mitochondrial ribosomal protein (MRP) family that are also not associated with SEs, and suggested that there might be other factors that contribute to the efficacy of the inhibitor.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> THZ1 downregulated the receptor tyrosine kinase (RTK) family of oncogenes, including EGFR, PDGFR, MET, AXL, and their downstream effectors, i.e., AKT, ERK, and STAT3 pathways, and caused DNA damage through arresting cells at G2 phase.</div><div class="NLM_p">On the other hand, THZ1 has also shown efficacy against cancers that have acquired resistance against therapies. For instance, it has resulted in significant growth inhibition <i>in vitro</i> in breast cancer T47D palbociclib-resistant (PDR) cells.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Also, treatment with THZ1 has restored growth inhibition of enzalutamide-resistance castration-resistant prostate cancer (CRPC) cells <i>in vitro</i> and resulted in a significant tumor growth inhibition in mice bearing AR-positive prostate cancer.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> Patients afflicted with CRPC face resistance to androgen deprivation therapies (including enzalutamide) due to restoration of the AR signaling. It has been suggested that CDK7 inhibition prevents phosphorylation of the mediator of RNA polymerase II transcription subunit 1 (MED1), thereby blocking AR signaling and recruitment of ligand-activated MED1 to chromatin. Albeit acknowledging the need for further phase-separation studies, Rasool et al. have suggested a role for CDK7-mediated phosphorylation of MED1 in the formation of MED1 condensates that trigger the assembly of the apparatus and activate SE-driven transcription.</div><div class="NLM_p last">The efficacy of THZ1 or THZ2 was further confirmed <i>in vitro</i> and/or <i>in vivo</i> in hepatocellular,<a onclick="showRef(event, 'ref22 ref66'); return false;" href="javascript:void(0);" class="ref ref22 ref66">(22,66)</a> gastric,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> cervical,<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> pancreatic,<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> colorectal,<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> and nonsmall-cell lung (NSCL) cancers<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> and <i>SOX-2</i>-amplified lung squamous cell carcinomas.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> Cells of these cancer types succumbed to the exposure to THZ1 or THZ2, with induction of apoptosis and/or impairment of cell cycle progression.<a onclick="showRef(event, 'ref21 ref22 ref23 ref66 ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref21 ref22 ref23 ref66 ref69 ref70">(21−23,66,69,70)</a> In the case of hepatocellular carcinoma, greater sensitivity to THZ1 was observed in cell types featuring an ectopic expression of <i>MYC</i>.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Additionally, THZ1 was shown to suppress glycolysis in NSCL cancer cells and markedly inhibit their migration.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> In fact, the role of THZ1 on cell migration remains controversial. In one study, THZ1 increased the motility of CRC cells and triggered their metastasis via a protein kinase D1(PKD1)/snail pathway.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> However, other studies showed that interaction of CDK7/cyclin H with C-terminal binding protein 2 (CtBP2) in esophageal squamous cell carcinoma with lymph node metastases and in breast cancer promoted cell invasion and that silencing of CDK7 or cyclin H ubiquitinated CtBP2 and thus impeded epithelial-mesenchymal transition.<a onclick="showRef(event, 'ref94 ref95'); return false;" href="javascript:void(0);" class="ref ref94 ref95">(94,95)</a> It appears that the CDK7 protein, rather than its kinase activity, is needed to activate the CDK7/cyclin H-CtBP2 axis and augment cell migration. In line with this, the knockdown of CDK7 in BT549 and MDA-MB-231 TNBC cells reduced cell migration.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Aside from this, THZ1 was found to inhibit myogenic differentiation, raising concerns about potential side-effects on muscle functions.<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> Overall, THZ1/2 were efficacious against various recalcitrant tumors <i>in vitro</i> and <i>in vivo</i> with no apparent systemic toxicity. Although neither progresses beyond preclinical studies, both formed the foundation for the discovery of SY-1365, the first CDK7 inhibitor that has reached clinical trials.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> SY-1365</h3><div class="NLM_p last">Iterative structural optimization of THZ1 has given rise to SY-1365 which has improved potency (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>), higher efficiency in covalent inhibition of CDK7, and enhanced stability (<i>k</i><sub>inact</sub>/<i>K</i><sub>I</sub> = 0.131 μM<sup>–1</sup> s<sup>–1</sup> vs 0.003 μM<sup>–1</sup> s<sup>–1</sup>; CL = 5.6 mL/min/kg vs 129 mL/min/kg).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> With ATP concentration at apparent <i>K</i><sub>m</sub>, SY-1365 exhibited an IC<sub>50</sub> of 84 nM against CDK7 and remained inhibitory of CDK12 (IC<sub>50</sub> = 204 nM). SY-1365 was 25- and 10-fold more selective over CDK2 and CDK9, respectively (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). SY-1365 mediated its anticancer activity by downregulating oncogenic transcription factors, antiapoptotic proteins (e.g., MCL1 and MYC), and the pathways governing progression through the cell cycle and DNA repair (specifically, homologous recombination repair and mismatch repair), thereby leading to apoptosis in THP1 cells.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Notably, minimal apoptosis was observed in hTERT-immortalized noncancerous cells despite full target occupancy. SY-1365 was evaluated in multiple <i>in vivo</i> mouse models, including AML (Kasumi-1 and ML-2), ovarian (OVCAR3 and a patient-derived xenograft (PDX) OV15398), and TNBC (HCC70, MDA-MB-468, BR1458 PDX, and BR1282 PDX), where it caused tumor regression when dosed intravenously at 30–40 mg/kg once or twice a week.<a onclick="showRef(event, 'ref52 ref76 ref77 ref78 ref79 ref97'); return false;" href="javascript:void(0);" class="ref ref52 ref76 ref77 ref78 ref79 ref97">(52,76−79,97)</a> SY-1365 seemed well-tolerated with no sign of myelosuppression and minimal loss of body weight. In May 2017, a two-part phase I clinical study was initiated; part 1 was to evaluate the safety of escalating doses of SY-1365 administered intravenously to the patients with heavily pretreated advanced solid tumors, followed by part 2 where its efficacy was assessed as a single agent or in combination against ovarian and breast cancers (NCT03134638).<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a> Initial clinical data revealed that 87.5% of patients withdrew from the treatment, mainly due to progressive disease. Dose-limiting toxicities were low-grade events, e.g., headache and fatigue; neutropenia was not detected. Preliminary clinical activities were subsequently reported in a total of 19 response-evaluable patients.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a></div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> YKL-5-124</h3><div class="NLM_p">The success of THZ1 as a selective CDK7 inhibitor was not upheld as sacrosanct because its mechanism of action did not match with that of selective silencing of <i>CDK7</i>, particularly in regard to the effect of CDK7 inhibition on transcription. For instance, inhibition of CDK7<sup>Phe91Gly/Asp92Glu</sup> in HCT116 cells by bulky ATP analogues, e.g., 1-NMPP1, did not dampen the phosphorylation of Ser residues of RNAP II CTD as was the case with THZ1 in other cancer cells.<a onclick="showRef(event, 'ref17 ref49 ref57'); return false;" href="javascript:void(0);" class="ref ref17 ref49 ref57">(17,49,57)</a> Likewise, genetic inactivation of <i>CDK7</i> reduced cell proliferation and impeded cell cycle progression, but had little effect on transcription.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> This has spurred research to identify a more selective CDK7 inhibitor, YKL-5-124, which does not inhibit CDK12/13 and has been used to decipher the role of selective CDK7 inhibition in cancer.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> YKL-5-124 failed to exert its effects in <i>CDK7</i><sup><i>Cys312Ser</i></sup>-mutated cells, which attested that irreversible inhibition of CDK7 kinase activity is responsible for the effect of YKL-5-124.</div><div class="NLM_p last">The biological response of cancer cells to YKL-5-124 did not match with that to THZ1 and SY-1365; however, it copied the phenotype of <i>CDK7</i> silencing. For instance, YKL-5-124 inhibited CDK1 and CDK2 phosphorylation, resulting in an increase in G1 and G2/M cell content and a decrease in S phase content in HAP1 and Jurkat cells.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> However, PARP was not cleaved, and apoptosis was not induced upon exposing these cells to YKL-5-124. This is incongruous with CDK7/12/13 inhibitors, THZ1 and SY-1365, that induced apoptosis in various types of cancer.<a onclick="showRef(event, 'ref49 ref52 ref68'); return false;" href="javascript:void(0);" class="ref ref49 ref52 ref68">(49,52,68)</a> Also, YKL-5-124 failed to inhibit the phosphorylation of Ser5 on RNAP II CTD even at higher concentrations in Jurkat cells, whereas THZ1 was previously shown to do so at low concentrations.<a onclick="showRef(event, 'ref49 ref54 ref98'); return false;" href="javascript:void(0);" class="ref ref49 ref54 ref98">(49,54,98)</a> Similar to THZ1, SY-1365 inhibited the phosphorylation of Ser2, 5, and 7 at CTD of RNAP II in a dose- and time-dependent manner in AML (THP1), TNBC (HCC70), and immortalized normal RPE-hTERT cell lines.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Profiling the effects of YKL-5-124 on E2F-driven genes showed potent inhibition of the cell cycle transcriptional program, which is in agreement with previous results demonstrating that genetic inactivation of <i>CDK7</i> had no effect on global RNAP II-mediated transcription with the exception of E2F-controlled genes.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> It was subsequently suggested that the effect of YKL-5-124 on cell proliferation is mainly due to its impairment of cell cycle progression in a CDK7-dependent manner. In contrast, the potent cytotoxic effects of THZ1 and SY-1365 are due to an inhibition of phosphorylation of Ser residues at the CTD of RNAP II and to a wider loss in gene expression, which was caused by the concomitant inhibition of CDK7/12/13. Indeed, combining YKL-5-124 with THZ531, a selective CDK12/13 inhibitor, recapitulated the broader inhibitory effects of THZ1 and SY-1365 on CDK7/12/13, expression of transcription factor genes, and CTD phosphorylation.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> These findings support the deviation from the paradigm of targeting an individual genetic alteration to attacking multiple oncogenic checkpoints that feed the proliferation of cancer cells.</div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">CDK7 Inhibitors in Combinations</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_65061" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_65061" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Combination therapies have also shown improved anticancer activity compared to the sole inhibition of CDK7. Treatment of CRC cells with YKL-1-116 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and a direct p53 stabilizer (or 5-fluorouracil as an antimetabolite) had a synergistic cytotoxic effect.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> Combining SY-1365 with fulvestrant, a selective ER modulator, in breast cancer T47D PDR cells showed synergistic activity at lower concentrations.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> Furthermore, SY-1365 was synergistic when combined with carboplatin in ovarian cancer xenografts.<a onclick="showRef(event, 'ref99'); return false;" href="javascript:void(0);" class="ref ref99">(99)</a> The combination of CT7001 (50 mg/kg/day) with tamoxifen (100 μg/day) achieved greater inhibition of tumor growth of the MCF-7 xenograft (<i>p</i> = 0.0002) than did either drug alone (<i>p</i> = 0.008 and 0.003 compared to tamoxifen and CT7001, respectively).<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a></div><div class="NLM_p">CDK7 inhibitors have shown enhanced inhibition of cancer cell growth when combined with inhibitors of the BCL-2 family of proteins. In PTCL-NOS cells, the combination of THZ1 with obatoclax, a pan inhibitor of BCL-2 family proteins, displayed antilymphoma activity <i>in vitro</i>, <i>ex vivo</i>, and <i>in vivo</i> with no increased toxicity.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Likewise, THZ1, in combination with ABT-263 (an inhibitor of BCL-2 and BCL-XL), inhibited proliferation synergistically of BT549, HCC1143, HCC1937, and Hs578T TNBC cell lines.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> In a similar fashion, concomitant treatment of the HuCCT1 or HuH28 cholangiocarcinoma cell line with THZ1 and ABT-263 resulted in synergistic cell death <i>in vitro</i> through downregulation of MCL-1.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> When combined with venetoclax (a BCL-2 inhibitor), SY-1365 has also resulted in synergistic growth inhibition <i>in vitro</i> of Kasumi-1, ML-2, THP1, and KG-1 AML cell lines and in a higher tumor growth inhibition (87.5% compared to 62.6% for SY-1365 alone and 48.4% for venetoclax alone) <i>in vivo</i> in a KG-1 mouse model.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div><div class="NLM_p">On the other hand, it has been shown that THZ1 rescues the anticancer activity of various targeted therapies that succumbed to resistance.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100,101)</a> A combination of THZ1 with BGJ398 (an FGFR inhibitor), erlotinib (an EGFR inhibitor), or crizotinib (an ALK inhibitor) prevented the emergence of colonies resistant to tyrosine kinase inhibition in the respective RT112 (FGFR), PC9 (EGFR), and H3122 (ALK) cell populations by preventing active enhancer formation at genes that promote the development of resistance.<a onclick="showRef(event, 'ref100'); return false;" href="javascript:void(0);" class="ref ref100">(100)</a> Furthermore, combining THZ1 with (i) BGJ398 in xenograft models of FGFR mutant bladder carcinoma or (ii) erlotinib in an EGFR mutant NSCLC-bearing mouse model retarded tumor growth compared to each single alone. Likewise, a combination of THZ1 with lapatinib, a dual EGFR and HER2 inhibitor, sensitized HER2<sup>+</sup> breast cancer cells that were resistant to HER2 inhibitors and resulted in optimal and durable tumor regression in HCC1569 and HCC1954 xenograft models.<a onclick="showRef(event, 'ref101'); return false;" href="javascript:void(0);" class="ref ref101">(101)</a> Likewise, dual inhibition of CDK7 and BRD4 has also resulted in synergistic inhibition of the growth of K562 AML cell lines <i>in vitro</i> and in xenograft mice bearing bromo- and extra-terminal domain (BET)-resistant cells.<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a></div><div class="NLM_p last">Combination therapies might also spare the potential resistance to CDK7 inhibitors. Recent studies have shown that depletion of BRD4 sensitizes head and neck squamous cell carcinoma (HNSCC) cells to THZ1.<a onclick="showRef(event, 'ref103'); return false;" href="javascript:void(0);" class="ref ref103">(103)</a> A concomitant use of THZ1 and JQ1, a BRD4 inhibitor, synergizes the inhibition of the proliferation of HNSCC cells through induction of apoptosis and senescence; this induction was caused by BRD4- and CDK7-mediated disruption of SE-driven YAP1. On the other hand, <i>MYC</i>-amplified cancer cell lines, including neuroblastoma, SCLC, and TNBC, have shown great sensitivity to THZ1.<a onclick="showRef(event, 'ref28 ref65 ref68 ref104'); return false;" href="javascript:void(0);" class="ref ref28 ref65 ref68 ref104">(28,65,68,104)</a> However, Lu et al. showed that prolonged treatment of pancreatic cancer cells with a sublethal THZ1 concentration resulted in acquired resistance of the cells to the drug through downregulation of <i>MYC</i>.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> Combination of THZ1 with a lipid nanoparticle (LNP)-formulated Dicer substrate siRNA (DsiRNA) targeting <i>MYC</i> mRNA showed additive antitumor efficacy in mouse models of hepatocarcinoma.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> However, it remains to be answered whether such a double-pronged inhibition of <i>MYC</i> would circumvent <i>MYC</i>-mediated resistance. Whereas treatment combinations seemed to offer additive effects, selective inhibition of CDK7 might remain valuable in some types of cancer, e.g., those that depend on E2F-driven genes for cell cycle progression.</div></div><div id="sec6" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i15">Miscellaneous CDK7 Inhibitors in the Pipeline</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13282" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13282" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Preclinical studies have highlighted the potential application of CDK7 inhibitors as anticancer agents and have predicted a bright future for their therapeutic uses in the clinic; those have set the stage for others to identify novel and selective CDK7 inhibitors. Some of the newer chemical entities are already at their preclinical stages of development. SY-5609 (<i>K</i><sub>d</sub> = 0.059 nM) was developed to overcome the low oral bioavailability of SY-1365.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> It is a potent, orally bioavailable CDK7 inhibitor with 13,000- to 49,000-fold greater selectivity over CDK2/9/12. It was screened at 1 μM against 485 kinases, and only nine kinases were inhibited by ≥70% of their activity, including CDK13/16–18. It inhibited cell growth (EC<sub>50</sub>s of 6–17 nM), instigated cell cycle arrest, and prompted apoptosis in a panel of ovarian and TNBC cell lines, with no effects observed in noncancerous cells. SY-5609, administered orally at 2.5 mg/kg and 5 mg/kg bid for 21 days, showed complete tumor regression in cell-derived xenograft models of TNBC (HCC70) and ovarian cancer (OVCAR3), and this regression was maintained for a further 14 days after the last dose. Further studies demonstrated that it substantially inhibited tumor growth in PDX models of both cancers at doses (3–5 mg/kg, p.o., bid) that are below the maximum tolerated dose (MTD). Downregulated levels of MYC and MCL1 were used as markers for inhibition of CDK7 <i>in vivo</i>. Preclinical studies have supported its current progression through Investigational New Drug (IND)-enabling studies with a view to initiating a phase I trial in 2020.</div><div class="NLM_p">UD-017 is a substituted dihydropyrrolopyrazole derivative that exhibits reversible and selective CDK7 inhibition with 50% oral bioavailability and a <i>t</i><sub>1/2</sub> of 6.8 h in a mouse.<a onclick="showRef(event, 'ref85 ref106 ref107'); return false;" href="javascript:void(0);" class="ref ref85 ref106 ref107">(85,106,107)</a> It showed great selectivity over CDK1–6/9 (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>) and a panel of 313 kinases.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> It reduced cancer volumes at oral doses of 25, 50, and 100 mg/kg administered q.d. for 14 days in a CRC (HCT-116) mouse xenograft model with no sign of body weight loss or myelosuppression.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> It almost completely inhibited cancer growth when dosed orally at 50 mg/kg once daily for 14 days in a multiple myeloma (NCI-H929) xenograft model.<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> It also regressed/inhibited tumor growth when dosed orally to PDX models of a range of solid tumors including NSCL cancer (LXFL1121), gastric cancer (GXA3067), sarcoma (SXFS117), and pleuramesothelioma (PXF541).<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> Downregulation of C-MYC correlated with <i>in vivo</i> CDK7 inhibition and antitumor efficacy.</div><div class="NLM_p">YPN005 is an oral and potent CDK7 inhibitor that has shown promise for the treatment of MYC-dependent cancers, including hepatocellular carcinoma and TNBC.<a onclick="showRef(event, 'ref108'); return false;" href="javascript:void(0);" class="ref ref108">(108)</a> Also, Aurigene has previously disclosed that they have developed two covalent, selective and orally bioavailable CDK7 inhibitors from two different chemical classes, pyrazolo[1,5-<i>a</i>][1,3,5]triazine or pyrazolo[1,5-<i>a</i>]pyrimidine derivatives and pyrazole derivatives, and their CDK7 programs are still undergoing.<a onclick="showRef(event, 'ref109 ref110 ref111'); return false;" href="javascript:void(0);" class="ref ref109 ref110 ref111">(109−111)</a> One of them, Au-12122 (CDK7 IC<sub>50</sub> = 2 nM), inhibited tumor growth by 77% and 87% in an MV4-11 mouse xenograft model when dosed at 30 mg/kg q.d. and bid, respectively.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> No significant body weight loss was observed.</div><div class="NLM_p">TGN-1062 is a reversible CDK7 inhibitor with 62% oral bioavailability in the mouse. A bid to optimize its selectivity over other CDKs afforded TGN-1069, which is currently under investigation for kinome profiling, ADME-TOX, and efficacy studies.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> QS1189 is a pyrazolo-triazine inhibitor of CDK7 that inhibited the growth of tumors derived from various lymphomas <i>in vitro</i>.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Despite being reasonably selective over the kinome panel, QS1189 lacks specificity for CDK7 over other CDKs. The structures of all of the inhibitors in this section remain concealed.</div><div class="NLM_p">On the other hand, a patent review has shed light on other chemical scaffolds that might form the basis for the merging generation of CDK7 inhibitors. However, given that the structures of the aforementioned inhibitors have not been disclosed yet, the possibility that some of these scaffolds resemble the above inhibitors cannot be ruled out. Design approaches of the new scaffolds included the development of irreversible analogues of BS-181, covalent polycyclic analogues of THZ1, and reversible analogues of SY-1365 (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>). Akin to Samajdar et al.,<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> various patents explored grafting electrophilic warheads while keeping the pyrazolo[1,5-<i>a</i>][1,3,5]triazine core of LDC-compounds or the pyrazolo[1,5-<i>a</i>]pyrimidine framework of BS-181 and CT7001.<a onclick="showRef(event, 'ref114 ref115 ref116'); return false;" href="javascript:void(0);" class="ref ref114 ref115 ref116">(114−116)</a> Nam et al. retained the <i>N</i>-benzylpyrazolo[1,5-<i>a</i>][1,3,5]triazin-4-amine core (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>, structure I) of LDC3140 and explored several Michael acceptor-type substituents at the C2 position of the benzylamino moiety (R<sup>1</sup>) and various functionalities at the C2 position of the pyrazolo[1,5-<i>a</i>][1,3,5]triazine (R<sup>2</sup>).<a onclick="showRef(event, 'ref116'); return false;" href="javascript:void(0);" class="ref ref116">(116)</a> The electrophilic warhead was generally bound through an amide linker to an aryl/heteroaryl/heterocycloalkyl that was further connected to the benzylamino moiety. Commonly well-tolerated heteroaryls at R<sup>1</sup> included the isoquinoline (e.g., R<sup>1</sup> = a) and the indole (e.g., R<sup>1</sup> = b); phenyloxy or piperidinyloxy derivatives have also resulted in IC<sub>50</sub>s against CDK7 of <100 nM. However, isoquinoline derivatives seemed to impart a better selectivity for CDK7 over CDK1/2/5, especially when combined with the 4-aminopiperidinyl at R<sup>2</sup>, e.g., I: R<sup>1</sup> = a and R<sup>2</sup> = 1. Alternative R<sup>2</sup> substituents included already optimized moieties such as the 1-methylpiperidin-4-yloxy present in LDC3140, the (<i>S</i>)-piperidin-3-yloxy contained in LDC4297 and the (3<i>S</i>,4<i>S</i>)-4-aminomethylpiperidin-3-ol of CT7001, all of which have generally resulted in good inhibitory potency toward CDK7 and selectivity over CDK1/2/5. Selectivity across the kinome remains to be known.</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of new CDK7 inhibitors under development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Structure II (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) follows the same aforementioned analogue-based design approach, and it bears the pyrazolo[1,5-<i>a</i>]pyrimidine core but has a 4-aminopiperidine moiety that replaces the benzylamino group of the previous series.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Also, the substitution at C5 of the pyrazolo[1,5-<i>a</i>]pyrimidine ring was limited to a methyl group. Structure II returned an IC<sub>50</sub> of 93 nM against CDK7 with ATP concentration at the apparent <i>K</i><sub>m</sub> but was a weaker inhibitor of CDK4 (IC<sub>50</sub> = 2.83 μM) and CDK9 (IC<sub>50</sub> = 6.32 μM).<a onclick="showRef(event, 'ref115'); return false;" href="javascript:void(0);" class="ref ref115">(115)</a> IC<sub>50</sub>s against CDK1/2/6/8/12/13/18/19 were greater than 8 μM, thus reflecting a good selectivity within the CDK family, but its selectivity over the wider kinome panel is yet to be disclosed. Potent CDK7 inhibition was mirrored in cell-based assays; structure II inhibited phosphorylation of Ser5 at the CTD (IC<sub>50</sub> = 0.148 μM), but resulted in an IC<sub>50</sub> of >20 mM when tested for inhibition of phosphorylation of Ser2 (CDK9 substrate) in HCT-116 cells. It inhibited the proliferation of various cancer cell lines <i>in vitro</i>, including the ones originating from the colon, breast, lung, ovary, and stomach, with IC<sub>50</sub>s spanning from 0.14 to 0.48 μM, and showed significant inhibition of these tumors in xenograft models when dosed orally at 20 mg/kg.</div><div class="NLM_p last">The design of newer CDK7 inhibitors was also based on the structure of THZ1 and its analogues. Chen and Lou combined the macrocycle of TG02, a CDK, JAK2, and FLT3 inhibitor,<a onclick="showRef(event, 'ref117'); return false;" href="javascript:void(0);" class="ref ref117">(117)</a> with electrophilic warheads as in the THZ/SY series to obtain covalent CDK7 inhibitors. Among them was CY-16–1 (i.e., structure III in <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>).<a onclick="showRef(event, 'ref118'); return false;" href="javascript:void(0);" class="ref ref118">(118)</a> CY-16–1 inhibited CDK7 with an IC<sub>50</sub> of <15 nM and a <i>K</i><sub>d</sub> value of <1 nM and suppressed a series of SCLC cell lines with IC<sub>50</sub> in a range of 0.018–0.032 μM <i>in vitro</i>. On the other hand, a few patents considered the development of reversible analogues that retain the 4-(1<i>H</i>-indol-3-yl)pyrimidin-2-amine core of THZ1 and SY-1365 or that further replace the indole with indazole or 1<i>H</i>-pyrazolo[3,4-<i>b</i>]pyridine.<a onclick="showRef(event, 'ref119 ref120 ref121 ref122'); return false;" href="javascript:void(0);" class="ref ref119 ref120 ref121 ref122">(119−122)</a> Introducing various five-membered heteroaryl groups at R<sup>3</sup> of structure IV (<a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a>) coupled with a substituted piperidin-3-ylamine at R<sup>4</sup> has resulted in compounds with IC<sub>50</sub>s of <30 nM against CDK7 and good selectivity over CDK2/9/12 (IC<sub>50</sub>s > 500 nM).<a onclick="showRef(event, 'ref121'); return false;" href="javascript:void(0);" class="ref ref121">(121)</a> However, these compounds exerted varying antiproliferative effects on the same cancer cell type, with IC<sub>50</sub>s ranging from low nM to higher than 1 μM. This could potentially be attributed to their divergent inhibitory activities across the kinome. Collectively, there is a continuing interest in developing new CDK7 inhibitors worldwide, which will be fuelling the development of new structures, making their way to clinical trials very soon.</div></div><div id="sec7" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i16">Summary and Perspectives</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46033" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46033" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">CDK7 is uniquely involved in the transcription regulation and cell cycle progression, on the one hand, and is aberrantly overexpressed in many types of cancer, on the other hand. CDK7 inhibitors have thus been developed as therapeutic agents and have shown promising anticancer activity in numerous preclinical models. Their roles in impairing overactive gene expression and in disrupting cell cycle progression seemed to offer considerable opportunities for the treatment of cancers, particularly those that have eluded currently available therapies, thus presenting a potentially transformative therapeutic approach. The mechanism of action of the current CDK7 inhibitors seems contingent on the molecular genetics of cancer cells; for instance, THZ1 impaired cell cycle progression in <i>MYCN</i>-amplified neuroblastoma cells 24 h post treatment, but effected minimally on the cell cycle of <i>MYCN</i>-nonamplified cells even after 48 h of drug exposure. Also, the biological effects of different inhibitors are a little inconsistent; THZ1 generally caused cell cycle arrest and induced apoptosis, whereas no significant apoptosis was detected with the more selective YKL-5-124, which could be due to their distinct biochemical profiles. Thus, despite the significant progress made in achieving the desired selectivity and pharmacology, the development of CDK7-targeted anticancer agents is still in its infancy. CDK7 inhibitors have so far demonstrated a promising profile of safety with low-grade side effects, and regimens against various advanced solid tumors are in place to assess their clinical efficacy as a single agent and in combination. These results are of utmost importance to determine whether preclinical efficacy can be translated into the clinic so that CDK7 inhibitors could breathe in the sweet smell of success.</div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i17"><a href="/doi/suppl/10.1021/acs.jmedchem.9b01985" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31732" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31732" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a href="/doi/10.1021/acs.jmedchem.9b01985?goto=supporting-info" class="ext-link">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01985</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthetic routes to CT7001 and SY-1365 (<a href="/doi/suppl/10.1021/acs.jmedchem.9b01985/suppl_file/jm9b01985_si_001.pdf" class="ext-link">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01985/suppl_file/jm9b01985_si_001.pdf">jm9b01985_si_001.pdf (111.61 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b01985" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_85383" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_85383" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Shudong Wang</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development, University of
South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6225-5525" title="Orcid link">http://orcid.org/0000-0001-6225-5525</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#02516a77666d6c652c55636c6542776c6b71632c6766772c6377"><span class="__cf_email__" data-cfemail="590a312c3d36373e770e38373e192c37302a38773c3d2c77382c">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sarah Diab</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, Lebanese American University, P.O. Box 36, Byblos, Lebanon</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6705-317X" title="Orcid link">http://orcid.org/0000-0002-6705-317X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mingfeng Yu</span> - <span class="hlFld-Affiliation affiliation">Drug
Discovery and Development, University of
South Australia Cancer Research Institute, Adelaide, SA 5000, Australia</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08415" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08415" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Sarah Diab</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=BIO-d7e1929-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Sarah Diab</b> has received her Ph.D. in medicinal chemistry under the supervision of Prof. Shudong Wang at the University of South Australia (UniSA), where she worked on developing kinase inhibitors as anticancer therapeutic agents. She has three years of postdoctoral experience at UniSA and the Monash Institute of Pharmaceutical Science. She is currently a lecturer in medicinal chemistry at the Lebanese American University in Lebanon.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Mingfeng Yu</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=BIO-d7e1934-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Mingfeng Yu</b> completed his Ph.D. in Organic Chemistry under the supervision of Professors Matthew H. Todd and Peter J. Rutledge at the University of Sydney in 2013. Upon the completion of his Ph.D., he was appointed as a Postdoctoral Research Fellow at the University of South Australia. Under the guidance of Professor Shudong Wang, he conducts research to discover and develop novel, potent, and selective protein kinase inhibitors for targeted cancer therapy.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Shudong Wang</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=BIO-d7e1939-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Shudong Wang</b> is Chair of Medicinal Chemistry at the University of South Australia. She began her research and academic career in a British biotech company (CYCC) and then the School of Pharmacy at the University of Nottingham, U.K. She is currently the Head of the Centre for Drug Discovery and Development, where she leads a multidisciplinary team with research spanning computational & medicinal chemistry, biochemistry, cell biology, pharmacology, and preclinical drug evaluation. Her research interests focus on the discovery and development of novel classes of kinase-targeted anticancer therapeutic agents.</p></figure></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations Used</td></tr><tr><td class="NLM_term">ABC</td><td class="NLM_def"><p class="first last">ATP-binding cassette</p></td></tr><tr><td class="NLM_term">ABCB1</td><td class="NLM_def"><p class="first last">ABC subfamily B member 1 (ABCB1)</p></td></tr><tr><td class="NLM_term">ADME-TOX</td><td class="NLM_def"><p class="first last">absorption, distribution, metabolism, excretion, and toxicity</p></td></tr><tr><td class="NLM_term">AKT</td><td class="NLM_def"><p class="first last">Ak thymoma</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">AR</td><td class="NLM_def"><p class="first last">androgen receptor</p></td></tr><tr><td class="NLM_term">BCL-2</td><td class="NLM_def"><p class="first last">B-cell lymphoma 2</p></td></tr><tr><td class="NLM_term">CAK</td><td class="NLM_def"><p class="first last">CDK-activating kinase</p></td></tr><tr><td class="NLM_term">CDK</td><td class="NLM_def"><p class="first last">cyclin-dependent kinase</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">CRC</td><td class="NLM_def"><p class="first last">colorectal cancer</p></td></tr><tr><td class="NLM_term">CtBP2</td><td class="NLM_def"><p class="first last">C-terminal binding protein 2</p></td></tr><tr><td class="NLM_term">CTD</td><td class="NLM_def"><p class="first last">carboxy-terminal domain</p></td></tr><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">ER</td><td class="NLM_def"><p class="first last">estrogen receptor</p></td></tr><tr><td class="NLM_term">ERK</td><td class="NLM_def"><p class="first last">extracellular signal-regulated kinase</p></td></tr><tr><td class="NLM_term">ITC</td><td class="NLM_def"><p class="first last">isothermal titration calorimetry</p></td></tr><tr><td class="NLM_term">MCL1</td><td class="NLM_def"><p class="first last">myeloid cell leukemia sequence 1</p></td></tr><tr><td class="NLM_term">MD</td><td class="NLM_def"><p class="first last">molecular dynamics</p></td></tr><tr><td class="NLM_term">MED1</td><td class="NLM_def"><p class="first last">mediator of RNA polymerase II transcription subunit 1</p></td></tr><tr><td class="NLM_term">MEF</td><td class="NLM_def"><p class="first last">mouse embryonic fibroblast</p></td></tr><tr><td class="NLM_term">MITF</td><td class="NLM_def"><p class="first last">melanocyte inducing transcription factor</p></td></tr><tr><td class="NLM_term">MYC</td><td class="NLM_def"><p class="first last">myelocytomatosis oncogene</p></td></tr><tr><td class="NLM_term">PARP</td><td class="NLM_def"><p class="first last">poly(ADP-ribose) polymerase</p></td></tr><tr><td class="NLM_term">PDGFR</td><td class="NLM_def"><p class="first last">platelet-derived growth factor receptor</p></td></tr><tr><td class="NLM_term">PDX</td><td class="NLM_def"><p class="first last">patient-derived xenograft</p></td></tr><tr><td class="NLM_term">RNAP</td><td class="NLM_def"><p class="first last">RNA polymerase</p></td></tr><tr><td class="NLM_term">PTCL-NOS</td><td class="NLM_def"><p class="first last">peripheral T-cell lymphoma-not otherwise specified</p></td></tr><tr><td class="NLM_term">Rb</td><td class="NLM_def"><p class="first last">retinoblastoma</p></td></tr><tr><td class="NLM_term">SE</td><td class="NLM_def"><p class="first last">superenhancer</p></td></tr><tr><td class="NLM_term">SOX10</td><td class="NLM_def"><p class="first last">SRY-box 10</p></td></tr><tr><td class="NLM_term">STAT</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term"><i>t</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">T-ALL</td><td class="NLM_def"><p class="first last">T-cell acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">TF</td><td class="NLM_def"><p class="first last">transcription factor</p></td></tr><tr><td class="NLM_term">TFIIH</td><td class="NLM_def"><p class="first last">general transcription factor II human</p></td></tr><tr><td class="NLM_term">TNBC</td><td class="NLM_def"><p class="first last">triple negative breast cancer</p></td></tr><tr><td class="NLM_term">XIAP</td><td class="NLM_def"><p class="first last">X-linked inhibitor of apoptosis</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61640" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61640" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 122 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">CDK7: a Kinase at the Core of Transcription and in the Crosshairs of Cancer Drug Discovery</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1553483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1080%2F21541264.2018.1553483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30488763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKit7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=47-56&issue=2&author=R.+P.+Fisher&title=CDK7%3A+a+Kinase+at+the+Core+of+Transcription+and+in+the+Crosshairs+of+Cancer+Drug+Discovery&doi=10.1080%2F21541264.2018.1553483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery</span></div><div class="casAuthors">Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The transcription cycle of RNA polymerase II (Pol II) is regulated by a set of cyclin-dependent kinases (CDKs).  Cdk7, assocd. with the transcription initiation factor TFIIH, is both an effector CDK that phosphorylates Pol II and other targets within the transcriptional machinery, and a CDK-activating kinase (CAK) for at least one other essential CDK involved in transcription.  Recent studies have illuminated Cdk7 functions that are executed throughout the Pol II transcription cycle, from promoter clearance and promoter-proximal pausing, to co-transcriptional chromatin modification in gene bodies, to mRNA 3'-end formation and termination.  Cdk7 has also emerged as a target of small-mol. inhibitors that show promise in the treatment of cancer and inflammation.  The challenges now are to identify the relevant targets of Cdk7 at each step of the transcription cycle, and to understand how heightened dependence on an essential CDK emerges in cancer, and might be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofoFEzSkAQxLVg90H21EOLACvtfcHk0lhbLaZKgO70nA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKit7jJ&md5=b6344f44b27d777d4fb7aad3a609d087</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1553483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1553483%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DCDK7%253A%2520a%2520Kinase%2520at%2520the%2520Core%2520of%2520Transcription%2520and%2520in%2520the%2520Crosshairs%2520of%2520Cancer%2520Drug%2520Discovery%26jtitle%3DTranscription%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D47%26epage%3D56%26doi%3D10.1080%2F21541264.2018.1553483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinases as Cancer Therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+Cyclin-Dependent+Kinases+as+Cancer+Therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0ljd1eUc8IGYcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinases%2520as%2520Cancer%2520Therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devault, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesquet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavadore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doree, M.</span></span> <span> </span><span class="NLM_article-title">MAT1 (‘Menage à Trois’) a New RING Finger Protein Subunit Stabilizing Cyclin H-CDK7 Complexes in Starfish and Xenopus CAK</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5027</span>– <span class="NLM_lpage">5036</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1995.tb00185.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fj.1460-2075.1995.tb00185.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=7588631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADyaK2MXptFyju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=5027-5036&issue=20&author=A.+Devaultauthor=A.+Martinezauthor=D.+Fesquetauthor=J.+Labbeauthor=N.+Morinauthor=J.+Tassanauthor=E.+Niggauthor=J.+Cavadoreauthor=M.+Doree&title=MAT1+%28%E2%80%98Menage+%C3%A0+Trois%E2%80%99%29+a+New+RING+Finger+Protein+Subunit+Stabilizing+Cyclin+H-CDK7+Complexes+in+Starfish+and+Xenopus+CAK&doi=10.1002%2Fj.1460-2075.1995.tb00185.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">MAT1 ('menage a trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK</span></div><div class="casAuthors">Devault, Alain; Martinez, Anne-Marie; Fesquet, Didier; Labbe, Jean-Claude; Morin, Nathalie; Tassan, Jean-Pierre; Nigg, Erich A.; Cavadore, Jean-Claude; Doree, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5027-36</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The kinase responsible for Thr161-Thr160 phosphorylation and activation of cdc2/cdk2 (CAK:cdk-activating kinase) has been shown previously to comprise at least two subunits, cdk7 and cyclin H.  An addnl. protein co-purified with CAK in starfish oocytes, but its sequencing did not reveal any similarity with any known protein.  In the present work, a cDNA encoding this protein is cloned and sequenced in both starfish and Xenopus oocytes.  It is shown to encode a new member of the RING finger family of proteins with a characteristic C3HC4 motif located in the N-terminal domain.  The authors demonstrate that the RING finger protein (MAT1: 'menage a trois') is a new subunit of CAK in both vertebrate and invertebrates.  However, CAK may also exist in oocytes as heterodimeric complexes between cyclin H and cdk7 only.  Stable heterotrimeric CAK complexes were generated in reticulocyte lysates programmed with mRNAs encoding Xenopus cdk7, cyclin H and MAT1.  In contrast, no heterodimeric cyclin H-cdk7 complex be immunopptd. from reticulocyte lysates programmed with cdk7 and cyclin H mRNAs only.  Stabilization of CAK complexes by MAT1 does not involve phosphorylation of Thr176, as the Thr176 → Ala mutant of Xenopus cdk7 could engage as efficiently as wild-type cdk7 in ternary complexes.  Even though starfish MAT1 is almost identical to Xenopus MAT1 in the RING finger domain, the starfish subunit could not replace the Xenopus subunit and stabilize cyclin H-cdk7 in reticulocyte lysate, suggesting that the MAT1 subunit does not (or not only) interact with cyclin H-cdk7 through the RING finger domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgk12ErxosA7Vg90H21EOLACvtfcHk0ljd1eUc8IGYcA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptFyju7k%253D&md5=8abb5e85707d591651677780b5ceff0b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1995.tb00185.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1995.tb00185.x%26sid%3Dliteratum%253Aachs%26aulast%3DDevault%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DFesquet%26aufirst%3DD.%26aulast%3DLabbe%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DN.%26aulast%3DTassan%26aufirst%3DJ.%26aulast%3DNigg%26aufirst%3DE.%26aulast%3DCavadore%26aufirst%3DJ.%26aulast%3DDoree%26aufirst%3DM.%26atitle%3DMAT1%2520%2528%25E2%2580%2598Menage%2520%25C3%25A0%2520Trois%25E2%2580%2599%2529%2520a%2520New%2520RING%2520Finger%2520Protein%2520Subunit%2520Stabilizing%2520Cyclin%2520H-CDK7%2520Complexes%2520in%2520Starfish%2520and%2520Xenopus%2520CAK%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26issue%3D20%26spage%3D5027%26epage%3D5036%26doi%3D10.1002%2Fj.1460-2075.1995.tb00185.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knights, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Reciprocal Activation by Cyclin-Dependent Kinases 2 and 7 Is Directed by Substrate Specificity Determinants Outside the T Loop</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1128/MCB.21.1.88-99.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FMCB.21.1.88-99.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=11113184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFyh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=88-99&issue=1&author=S.+Garrettauthor=W.+A.+Bartonauthor=R.+Knightsauthor=P.+Jinauthor=D.+O.+Morganauthor=R.+P.+Fisher&title=Reciprocal+Activation+by+Cyclin-Dependent+Kinases+2+and+7+Is+Directed+by+Substrate+Specificity+Determinants+Outside+the+T+Loop&doi=10.1128%2FMCB.21.1.88-99.2001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop</span></div><div class="casAuthors">Garrett, Sarah; Barton, William A.; Knights, Ronald; Jin, Pei; Morgan, David O.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) is the catalytic subunit of the metazoan CDK-activating kinase (CAK), which activates CDKs, such as CDC2 and CDK2, through phosphorylation of a conserved threonine residue in the T loop.  Full activation of CDK7 requires assocn. with a pos. regulatory subunit, cyclin H, and phosphorylation of a conserved threonine residue at position 170 in its own T loop.  We show that threonine-170 of CDK7 is phosphorylated in vitro by its targets, CDC2 and CDK2, which also phosphorylate serine-164 in the CDK7 T loop, a site that perfectly matches their consensus phosphorylation site.  In contrast, neither CDK4 nor CDK7 itself can phosphorylate the CDK7 T loop in vitro.  The ability of CDC2 or CDK2 and CDK7 to phosphorylate each other but not themselves implies that each kinase can discriminate among closely related sequences and can recognize a substrate site that diverges from its usual preferred site.  To understand the basis for this paradoxical substrate specificity, we constructed a chimeric CDK with the T loop of CDK7 grafted onto the body of CDK2.  Surprisingly, the hybrid enzyme, CDK2-7, was efficiently activated in cyclin A-dependent fashion by CDK7 but not at all by CDK2.  CDK2-7, moreover, phosphorylated wild-type CDK7 but not CDK2.  Our results suggest that the primary amino acid sequence of the T loop plays only a minor role, if any, in detg. the specificity of cyclin-dependent CAKs for their CDK substrates and that protein-protein interactions involving sequences outside the T loop can influence substrate specificity both pos. and neg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZCqCtS5KpbVg90H21EOLACvtfcHk0liIUaT6T6tSew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFyh&md5=a55831bd5cb8f80b2658edf177c4cb2d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1128%2FMCB.21.1.88-99.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.21.1.88-99.2001%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DS.%26aulast%3DBarton%26aufirst%3DW.%2BA.%26aulast%3DKnights%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DReciprocal%2520Activation%2520by%2520Cyclin-Dependent%2520Kinases%25202%2520and%25207%2520Is%2520Directed%2520by%2520Substrate%2520Specificity%2520Determinants%2520Outside%2520the%2520T%2520Loop%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D21%26issue%3D1%26spage%3D88%26epage%3D99%26doi%3D10.1128%2FMCB.21.1.88-99.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leresche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesfeld, J. M.</span></span> <span> </span><span class="NLM_article-title">Repression of TFIIH Transcriptional Activity and TFIIH-Associated CDK7 Kinase Activity at Mitosis</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1476</span>, <span class="refDoi"> DOI: 10.1128/MCB.18.3.1467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FMCB.18.3.1467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=9488463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADyaK1cXhtleiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=1467-1476&issue=3&author=J.+J.+Longauthor=A.+Lerescheauthor=R.+W.+Kriwackiauthor=J.+M.+Gottesfeld&title=Repression+of+TFIIH+Transcriptional+Activity+and+TFIIH-Associated+CDK7+Kinase+Activity+at+Mitosis&doi=10.1128%2FMCB.18.3.1467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Repression of TFIIH transcriptional activity and TFIIH-associated cdk7 kinase activity at mitosis</span></div><div class="casAuthors">Long, John J.; Leresche, Anne; Kriwacki, Richard W.; Gottesfeld, Joel M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1467-1476</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Nuclear transcription is repressed when eukaryotic cells enter mitosis.  Mitotic repression of transcription of various cellular and viral gene promoters by RNA polymerase II can be reproduced in vitro either with exts. prepd. from cells arrested at mitosis with the microtubule polymn. inhibitor nocodazole or with nuclear exts. prepd. from asynchronous cells and the mitotic protein kinase cdc2/cyclin B.  Purified cdc2/cyclin B kinase is also sufficient to inhibit transcription in reconstituted transcription reactions with biochem. purified and recombinant basal transcription factors and RNA polymerase II.  The cyclin-dependent kinase inhibitor p21Waf1/Cip1/Sdi1 can reverse the effect of cdc2/cyclin B kinase, indicating that repression of transcription is due to protein phosphorylation.  Transcription rescue and inhibition expts. with each of the basal factors and the polymerase suggest that multiple components of the transcription machinery are inactivated by cdc2/cyclin B kinase.  For an activated promoter, targets of repression are TFIID and TFIIH, while for a basal promoter, TFIIH is the major target for mitotic inactivation of transcription.  Protein labeling expts. indicate that the p62 and p36 subunits of TFIIH are in vitro substrates for mitotic phosphorylation.  Using the carboxy-terminal domain of the large subunit of RNA polymerase II as a test substrate for phosphorylation, the TFIIH-assocd. kinase, cdk7/cyclin H, is inhibited concomitant with inhibition of transcription activity.  Our results suggest that there exist multiple phosphorylation targets for the global shutdown of transcription at mitosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJcoMMr5slibVg90H21EOLACvtfcHk0liIUaT6T6tSew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtleiu7c%253D&md5=b487a7a93040f77478eed2a403387f3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2FMCB.18.3.1467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.18.3.1467%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BJ.%26aulast%3DLeresche%26aufirst%3DA.%26aulast%3DKriwacki%26aufirst%3DR.%2BW.%26aulast%3DGottesfeld%26aufirst%3DJ.%2BM.%26atitle%3DRepression%2520of%2520TFIIH%2520Transcriptional%2520Activity%2520and%2520TFIIH-Associated%2520CDK7%2520Kinase%2520Activity%2520at%2520Mitosis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1998%26volume%3D18%26issue%3D3%26spage%3D1467%26epage%3D1476%26doi%3D10.1128%2FMCB.18.3.1467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nilson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogie, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luse, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">THZ1 Reveals Roles for CDK7 in Co-transcriptional Capping and Pausing</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2015.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=26257281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSju7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=576-587&issue=4&author=K.+A.+Nilsonauthor=J.+Guoauthor=M.+E.+Turekauthor=J.+E.+Brogieauthor=E.+Delaneyauthor=D.+S.+Luseauthor=D.+H.+Price&title=THZ1+Reveals+Roles+for+CDK7+in+Co-transcriptional+Capping+and+Pausing&doi=10.1016%2Fj.molcel.2015.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing</span></div><div class="casAuthors">Nilson, Kyle A.; Guo, Jiannan; Turek, Michael E.; Brogie, John E.; Delaney, Elizabeth; Luse, Donal S.; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">576-587</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The Cdk7 subunit of TFIIH phosphorylates RNA polymerase II (Pol II) during initiation, and, while recent studies show that inhibition of human Cdk7 neg. influences transcription, the mechanisms involved are unclear.  Using in vitro transcription with nuclear ext., we demonstrate that THZ1, a covalent Cdk7 inhibitor, causes defects in Pol II phosphorylation, co-transcriptional capping, promoter proximal pausing, and productive elongation.  THZ1 does not affect initiation but blocks essentially all Pol II large subunit C-terminal domain (CTD) phosphorylation.  We found that guanylylation of nascent RNAs is length dependent and modulated by a THZ1-sensitive factor present in nuclear ext.  THZ1 impacts pausing through a capping-independent block of DSIF and NELF loading.  The P-TEFb-dependent transition into productive elongation was also inhibited by THZ1, likely due to loss of DSIF.  Capping and pausing were also reduced in THZ1-treated cells.  Our results provide mechanistic insights into THZ1 action and how Cdk7 broadly influences transcription and capping.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6vyXXJUmAULVg90H21EOLACvtfcHk0liIUaT6T6tSew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSju7bP&md5=6a38991e587b7e0c199627b0f5ea6696</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DNilson%26aufirst%3DK.%2BA.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DTurek%26aufirst%3DM.%2BE.%26aulast%3DBrogie%26aufirst%3DJ.%2BE.%26aulast%3DDelaney%26aufirst%3DE.%26aulast%3DLuse%26aufirst%3DD.%2BS.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DTHZ1%2520Reveals%2520Roles%2520for%2520CDK7%2520in%2520Co-transcriptional%2520Capping%2520and%2520Pausing%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D59%26issue%3D4%26spage%3D576%26epage%3D587%26doi%3D10.1016%2Fj.molcel.2015.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egly, J.-M.</span></span> <span> </span><span class="NLM_article-title">Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2015.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=26295956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlymtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=513-514&issue=4&author=F.+Coinauthor=J.-M.+Egly&title=Revisiting+the+Function+of+CDK7+in+Transcription+by+Virtue+of+a+Recently+Described+TFIIH+Kinase+Inhibitor&doi=10.1016%2Fj.molcel.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the function of CDK7 in transcription by virtue of a recently described TFIIH kinase inhibitor</span></div><div class="casAuthors">Coin, Frederic; Egly, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-514</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  In this issue of Mol. Cell, Nilson et al. (2015) took advantage of THZ1, a recently described covalent inhibitor of the TFIIH kinase CDK7, to further characterize the role of this enzyme in the early stages of transcription and postprocessing events.  They unveiled an unexpected function of CDK7 in RNA polymerase II pausing and mRNA capping.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh76M4cZqjzLVg90H21EOLACvtfcHk0lj0P-5ENyCOCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlymtLvK&md5=360b4bf4d63a7c2a8e9f0e77f083ca9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DCoin%26aufirst%3DF.%26aulast%3DEgly%26aufirst%3DJ.-M.%26atitle%3DRevisiting%2520the%2520Function%2520of%2520CDK7%2520in%2520Transcription%2520by%2520Virtue%2520of%2520a%2520Recently%2520Described%2520TFIIH%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D59%26issue%3D4%26spage%3D513%26epage%3D514%26doi%3D10.1016%2Fj.molcel.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover-Cutter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansó, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Control of the Initiation-to-Elongation Switch of RNA Polymerase II</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1108</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnsmb.2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=23064645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1108-1115&issue=11&author=S.+Larochelleauthor=R.+Amatauthor=K.+Glover-Cutterauthor=M.+Sans%C3%B3author=C.+Zhangauthor=J.+J.+Allenauthor=K.+M.+Shokatauthor=D.+L.+Bentleyauthor=R.+P.+Fisher&title=Cyclin-Dependent+Kinase+Control+of+the+Initiation-to-Elongation+Switch+of+RNA+Polymerase+II&doi=10.1038%2Fnsmb.2399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II</span></div><div class="casAuthors">Larochelle, Stephane; Amat, Ramon; Glover-Cutter, Kira; Sanso, Miriam; Zhang, Chao; Allen, Jasmina J.; Shokat, Kevan M.; Bentley, David L.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Promoter-proximal pausing by RNA polymerase II (Pol II) ensures gene-specific regulation and RNA quality control.  Structural considerations suggested a requirement for initiation-factor eviction in elongation-factor engagement and pausing of transcription complexes.  Here we show that selective inhibition of Cdk7-part of TFIIH-increases TFIIE retention, prevents DRB sensitivity-inducing factor (DSIF) recruitment and attenuates pausing in human cells.  Pause release depends on Cdk9-cyclin T1 (P-TEFb); Cdk7 is also required for Cdk9-activating phosphorylation and Cdk9-dependent downstream events-Pol II C-terminal domain Ser2 phosphorylation and histone H2B ubiquitylation-in vivo.  Cdk7 inhibition, moreover, impairs Pol II transcript 3'-end formation.  Cdk7 thus acts through TFIIE and DSIF to establish, and through P-TEFb to relieve, barriers to elongation: incoherent feedforward that might create a window to recruit RNA-processing machinery.  Therefore, cyclin-dependent kinases govern Pol II handoff from initiation to elongation factors and cotranscriptional RNA maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUhQtYIcdjLbVg90H21EOLACvtfcHk0lj0P-5ENyCOCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI&md5=e483e572df1f8645db9da40800dffe4d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2399%26sid%3Dliteratum%253Aachs%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DAmat%26aufirst%3DR.%26aulast%3DGlover-Cutter%26aufirst%3DK.%26aulast%3DSans%25C3%25B3%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DJ.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DBentley%26aufirst%3DD.%2BL.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DCyclin-Dependent%2520Kinase%2520Control%2520of%2520the%2520Initiation-to-Elongation%2520Switch%2520of%2520RNA%2520Polymerase%2520II%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D11%26spage%3D1108%26epage%3D1115%26doi%3D10.1038%2Fnsmb.2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spille, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grube, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisse, I. I.</span></span> <span> </span><span class="NLM_article-title">Mediator and RNA Polymerase II Clusters Associate in Transcription-Dependent Condensates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>),  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1126/science.aar4199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aar4199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29930094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyitrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&pages=412-415&issue=6400&author=W.-K.+Choauthor=J.-H.+Spilleauthor=M.+Hechtauthor=C.+Leeauthor=C.+Liauthor=V.+Grubeauthor=I.+I.+Cisse&title=Mediator+and+RNA+Polymerase+II+Clusters+Associate+in+Transcription-Dependent+Condensates&doi=10.1126%2Fscience.aar4199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mediator and RNA polymerase II clusters associate in transcription-dependent condensates</span></div><div class="casAuthors">Cho, Won-Ki; Spille, Jan-Hendrik; Hecht, Micca; Lee, Choongman; Li, Charles; Grube, Valentin; Cisse, Ibrahim I.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6400</span>),
    <span class="NLM_cas:pages">412-415</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Models of gene control have emerged from genetic and biochem. studies, with limited consideration of the spatial organization and dynamics of key components in living cells.  Here, we used live-cell super-resoln. and light-sheet imaging to study the organization and dynamics of the Mediator coactivator and RNA polymerase II (Pol II) directly.  Mediator and Pol II each formed small transient and large stable clusters in living embryonic stem cells.  Mediator and Pol II were colocalized in the stable clusters, which assocd. with chromatin, have properties of phase-sepd. condensates, and are sensitive to transcriptional inhibitors.  We suggest that large clusters of Mediator, recruited by transcription factors at large or clustered enhancer elements, interact with large Pol II clusters in transcriptional condensates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrryxgv6U-HA7Vg90H21EOLACvtfcHk0lj0P-5ENyCOCw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyitrrJ&md5=02ade395f3f4df7f9d85662c8a6e5677</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4199%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DW.-K.%26aulast%3DSpille%26aufirst%3DJ.-H.%26aulast%3DHecht%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DGrube%26aufirst%3DV.%26aulast%3DCisse%26aufirst%3DI.%2BI.%26atitle%3DMediator%2520and%2520RNA%2520Polymerase%2520II%2520Clusters%2520Associate%2520in%2520Transcription-Dependent%2520Condensates%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26spage%3D412%26epage%3D415%26doi%3D10.1126%2Fscience.aar4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugast-Darzacq, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dailey, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattoglio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjian, R.</span></span> <span> </span><span class="NLM_article-title">Imaging Dynamic and Selective Low-Complexity Domain Interactions that Control Gene Transcription</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>), <span class="NLM_elocation-id">eaar2555</span> <span class="refDoi"> DOI: 10.1126/science.aar2555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aar2555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29930090" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&issue=6400&author=S.+Chongauthor=C.+Dugast-Darzacqauthor=Z.+Liuauthor=P.+Dongauthor=G.+M.+Daileyauthor=C.+Cattoglioauthor=A.+Heckertauthor=S.+Banalaauthor=L.+Lavisauthor=X.+Darzacqauthor=R.+Tjian&title=Imaging+Dynamic+and+Selective+Low-Complexity+Domain+Interactions+that+Control+Gene+Transcription&doi=10.1126%2Fscience.aar2555"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar2555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar2555%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DS.%26aulast%3DDugast-Darzacq%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DP.%26aulast%3DDailey%26aufirst%3DG.%2BM.%26aulast%3DCattoglio%26aufirst%3DC.%26aulast%3DHeckert%26aufirst%3DA.%26aulast%3DBanala%26aufirst%3DS.%26aulast%3DLavis%26aufirst%3DL.%26aulast%3DDarzacq%26aufirst%3DX.%26aulast%3DTjian%26aufirst%3DR.%26atitle%3DImaging%2520Dynamic%2520and%2520Selective%2520Low-Complexity%2520Domain%2520Interactions%2520that%2520Control%2520Gene%2520Transcription%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26doi%3D10.1126%2Fscience.aar2555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plys, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingston, R. E.</span></span> <span> </span><span class="NLM_article-title">Dynamic Condensates Activate Transcription</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1126/science.aau4795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aau4795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30049863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKlsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&pages=329-330&issue=6400&author=A.+J.+Plysauthor=R.+E.+Kingston&title=Dynamic+Condensates+Activate+Transcription&doi=10.1126%2Fscience.aau4795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic condensates activate transcription</span></div><div class="casAuthors">Plys, Aaron J.; Kingston, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6400</span>),
    <span class="NLM_cas:pages">329-330</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-W9HQuyn2u7Vg90H21EOLACvtfcHk0lgc2SRnhA8Mow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKlsbfF&md5=6c61a3593836e3918894c976b17cbd83</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.aau4795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aau4795%26sid%3Dliteratum%253Aachs%26aulast%3DPlys%26aufirst%3DA.%2BJ.%26aulast%3DKingston%26aufirst%3DR.%2BE.%26atitle%3DDynamic%2520Condensates%2520Activate%2520Transcription%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26spage%3D329%26epage%3D330%26doi%3D10.1126%2Fscience.aau4795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabari, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Agnese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boija, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrinivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamudio, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manteiga, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuijers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnisz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisse, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeder, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span> <span> </span><span class="NLM_article-title">Coactivator Condensation at Super-Enhancers Links Phase Separation and Gene Control</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>), <span class="NLM_elocation-id">eaar3958</span> <span class="refDoi"> DOI: 10.1126/science.aar3958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aar3958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29930091" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&issue=6400&author=B.+R.+Sabariauthor=A.+Dall%E2%80%99Agneseauthor=A.+Boijaauthor=I.+A.+Kleinauthor=E.+L.+Coffeyauthor=K.+Shrinivasauthor=B.+J.+Abrahamauthor=N.+M.+Hannettauthor=A.+V.+Zamudioauthor=J.+C.+Manteigaauthor=C.+H.+Liauthor=Y.+E.+Guoauthor=D.+S.+Dayauthor=J.+Schuijersauthor=E.+Vasileauthor=S.+Malikauthor=D.+Hniszauthor=T.+I.+Leeauthor=I.+I.+Cisseauthor=R.+G.+Roederauthor=R.+A.+Sharpauthor=A.+K.+Chakrabortyauthor=R.+A.+Young&title=Coactivator+Condensation+at+Super-Enhancers+Links+Phase+Separation+and+Gene+Control&doi=10.1126%2Fscience.aar3958"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar3958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar3958%26sid%3Dliteratum%253Aachs%26aulast%3DSabari%26aufirst%3DB.%2BR.%26aulast%3DDall%25E2%2580%2599Agnese%26aufirst%3DA.%26aulast%3DBoija%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DI.%2BA.%26aulast%3DCoffey%26aufirst%3DE.%2BL.%26aulast%3DShrinivas%26aufirst%3DK.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DZamudio%26aufirst%3DA.%2BV.%26aulast%3DManteiga%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DC.%2BH.%26aulast%3DGuo%26aufirst%3DY.%2BE.%26aulast%3DDay%26aufirst%3DD.%2BS.%26aulast%3DSchuijers%26aufirst%3DJ.%26aulast%3DVasile%26aufirst%3DE.%26aulast%3DMalik%26aufirst%3DS.%26aulast%3DHnisz%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DT.%2BI.%26aulast%3DCisse%26aufirst%3DI.%2BI.%26aulast%3DRoeder%26aufirst%3DR.%2BG.%26aulast%3DSharp%26aufirst%3DR.%2BA.%26aulast%3DChakraborty%26aufirst%3DA.%2BK.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26atitle%3DCoactivator%2520Condensation%2520at%2520Super-Enhancers%2520Links%2520Phase%2520Separation%2520and%2520Gene%2520Control%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26doi%3D10.1126%2Fscience.aar3958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boehning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugast-Darzacq, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marie-Nelly, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSwiggen, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dailey, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweckstetter, M.</span></span> <span> </span><span class="NLM_article-title">RNA Polymerase II Clustering Through Carboxy-Terminal Domain Phase Separation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0112-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41594-018-0112-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30127355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGjtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=833-840&issue=9&author=M.+Boehningauthor=C.+Dugast-Darzacqauthor=M.+Rankovicauthor=A.+S.+Hansenauthor=T.+Yuauthor=H.+Marie-Nellyauthor=D.+T.+McSwiggenauthor=G.+Kokicauthor=G.+M.+Daileyauthor=P.+Cramerauthor=X.+Darzacqauthor=M.+Zweckstetter&title=RNA+Polymerase+II+Clustering+Through+Carboxy-Terminal+Domain+Phase+Separation&doi=10.1038%2Fs41594-018-0112-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">RNA polymerase II clustering through carboxy-terminal domain phase separation</span></div><div class="casAuthors">Boehning, Marc; Dugast-Darzacq, Claire; Rankovic, Marija; Hansen, Anders S.; Yu, Taekyung; Marie-Nelly, Herve; McSwiggen, David T.; Kokic, Goran; Dailey, Gina M.; Cramer, Patrick; Darzacq, Xavier; Zweckstetter, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">833-840</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The carboxy-terminal domain (CTD) of RNA polymerase (Pol) II is an intrinsically disordered low-complexity region that is crit. for pre-mRNA transcription and processing.  The CTD consists of hepta-amino acid repeats varying in no. from 52 in humans to 26 in yeast.  Here we report that human and yeast CTDs undergo cooperative liq. phase sepn., with the shorter yeast CTD forming less-stable droplets.  In human cells, truncation of the CTD to the length of the yeast CTD decreases Pol II clustering and chromatin assocn., whereas CTD extension has the opposite effect.  CTD droplets can incorporate intact Pol II and are dissolved by CTD phosphorylation with the transcription initiation factor IIH kinase CDK7.  Together with published data, our results suggest that Pol II forms clusters or hubs at active genes through interactions between CTDs and with activators and that CTD phosphorylation liberates Pol II enzymes from hubs for promoter escape and transcription elongation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJaIan4V-y0LVg90H21EOLACvtfcHk0lgc2SRnhA8Mow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGjtLvF&md5=eea3ebfe4634197a90a513a72b71621e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0112-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0112-y%26sid%3Dliteratum%253Aachs%26aulast%3DBoehning%26aufirst%3DM.%26aulast%3DDugast-Darzacq%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DA.%2BS.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DMarie-Nelly%26aufirst%3DH.%26aulast%3DMcSwiggen%26aufirst%3DD.%2BT.%26aulast%3DKokic%26aufirst%3DG.%26aulast%3DDailey%26aufirst%3DG.%2BM.%26aulast%3DCramer%26aufirst%3DP.%26aulast%3DDarzacq%26aufirst%3DX.%26aulast%3DZweckstetter%26aufirst%3DM.%26atitle%3DRNA%2520Polymerase%2520II%2520Clustering%2520Through%2520Carboxy-Terminal%2520Domain%2520Phase%2520Separation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D9%26spage%3D833%26epage%3D840%26doi%3D10.1038%2Fs41594-018-0112-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Balanced Between Order and Disorder: a New Phase in Transcription Elongation Control and Beyond</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1080/21541264.2019.1570812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1080%2F21541264.2019.1570812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30663929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=157-163&issue=3&author=H.+Luauthor=R.+Liuauthor=Q.+Zhou&title=Balanced+Between+Order+and+Disorder%3A+a+New+Phase+in+Transcription+Elongation+Control+and+Beyond&doi=10.1080%2F21541264.2019.1570812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Balanced between order and disorder: a new phase in transcription elongation control and beyond</span></div><div class="casAuthors">Lu, Huasong; Liu, Rongdiao; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-163</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  We recently reported that the cyclin T1 histidine-rich domain creates a phase-sepd. environment to promote hyperphosphorylation of RNA polymerase II C-terminal domain and robust transcriptional elongation by P-TEFb.  Here, we discuss this and several other recent discoveries to demonstrate that phase sepn. is important for controlling various aspects of transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDO99TGC9RyLVg90H21EOLACvtfcHk0lhV2hxoXMcDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCquro%253D&md5=06e87862905ef912c3fb2f1aa19a8a74</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F21541264.2019.1570812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2019.1570812%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DBalanced%2520Between%2520Order%2520and%2520Disorder%253A%2520a%2520New%2520Phase%2520in%2520Transcription%2520Elongation%2520Control%2520and%2520Beyond%26jtitle%3DTranscription%26date%3D2019%26volume%3D10%26issue%3D3%26spage%3D157%26epage%3D163%26doi%3D10.1080%2F21541264.2019.1570812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Phase-Separation Mechanism for C-Terminal Hyperphosphorylation of RNA Polymerase II</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>558</i></span> (<span class="NLM_issue">7709</span>),  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0174-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41586-018-0174-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29849146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGitLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=558&publication_year=2018&pages=318-323&issue=7709&author=H.+Luauthor=D.+Yuauthor=A.+S.+Hansenauthor=S.+Gangulyauthor=R.+Liuauthor=A.+Heckertauthor=X.+Darzacqauthor=Q.+Zhou&title=Phase-Separation+Mechanism+for+C-Terminal+Hyperphosphorylation+of+RNA+Polymerase+II&doi=10.1038%2Fs41586-018-0174-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II</span></div><div class="casAuthors">Lu, Huasong; Yu, Dan; Hansen, Anders S.; Ganguly, Sourav; Liu, Rongdiao; Heckert, Alec; Darzacq, Xavier; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">558</span>
        (<span class="NLM_cas:issue">7709</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Hyperphosphorylation of the C-terminal domain (CTD) of the RPB1 subunit of human RNA polymerase (Pol) II is essential for transcriptional elongation and mRNA processing.  The CTD contains 52 heptapeptide repeats of the consensus sequence YSPTSPS.  The highly repetitive nature and abundant possible phosphorylation sites of the CTD exert special constraints on the kinases that catalyze its hyperphosphorylation.  Pos. transcription elongation factor b (P-TEFb) - which consists of CDK9 and cyclin T1 - is known to hyperphosphorylate the CTD and neg. elongation factors to stimulate Pol II elongation.  The sequence determinant on P-TEFb that facilitates this action is currently unknown.  Here we identify a histidine-rich domain in cyclin T1 that promotes the hyperphosphorylation of the CTD and stimulation of transcription by CDK9.  The histidine-rich domain markedly enhances the binding of P-TEFb to the CTD and functional engagement with target genes in cells.  In addn. to cyclin T1, at least one other kinase - DYRK1A - also uses a histidine-rich domain to target and hyperphosphorylate the CTD.  As a low-complexity domain, the histidine-rich domain also promotes the formation of phase-sepd. liq. droplets in vitro, and the localization of P-TEFb to nuclear speckles that display dynamic liq. properties and are sensitive to the disruption of weak hydrophobic interactions.  The CTD - which in isolation does not phase sep., despite being a low-complexity domain - is trapped within the cyclin T1 droplets, and this process is enhanced upon pre-phosphorylation by CDK7 of transcription initiation factor TFIIH.  By using multivalent interactions to create a phase-sepd. functional compartment, the histidine-rich domain in kinases targets the CTD into this environment to ensure hyperphosphorylation and efficient elongation of Pol II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpWrNiDYPH0bVg90H21EOLACvtfcHk0lhV2hxoXMcDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGitLrN&md5=d05bcba86158d961de0834c86adab64c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0174-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0174-3%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DHansen%26aufirst%3DA.%2BS.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHeckert%26aufirst%3DA.%26aulast%3DDarzacq%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DPhase-Separation%2520Mechanism%2520for%2520C-Terminal%2520Hyperphosphorylation%2520of%2520RNA%2520Polymerase%2520II%26jtitle%3DNature%26date%3D2018%26volume%3D558%26issue%3D7709%26spage%3D318%26epage%3D323%26doi%3D10.1038%2Fs41586-018-0174-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, J. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Transcriptional Cyclin-Dependent Kinases</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1539615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1080%2F21541264.2018.1539615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30409083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=118-136&issue=2&author=M.+D.+Galbraithauthor=H.+Benderauthor=J.+M.+Espinosa&title=Therapeutic+Targeting+of+Transcriptional+Cyclin-Dependent+Kinases&doi=10.1080%2F21541264.2018.1539615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of transcriptional cyclin-dependent kinases</span></div><div class="casAuthors">Galbraith, Matthew D.; Bender, Heather; Espinosa, Joaquin M.</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-136</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The fact that many cancer types display transcriptional addiction driven by dysregulation of oncogenic enhancers and transcription factors has led to increased interest in a group of protein kinases, known as transcriptional cyclin dependent kinases (tCDKs), as potential therapeutic targets.  Despite early reservations about targeting a process that is essential to healthy cell types, there is now evidence that targeting tCDKs could provide enough therapeutic window to be effective in the clinic.  Here, we discuss recent developments in this field, with an emphasis on highly-selective inhibitors and the challenges to be addressed before these inhibitors could be used for therapeutic purposes.: CAK: CDK-activating kinase;CDK: cyclin-dependent kinase;CMGC group: CDK-, MAPK-, GSK3-, and CLK-like;CTD: C-terminal repeat domain of the RPB1 subunit of RNA polymerase II;DRB: 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole;mCRPC: metastatic castration-resistant prostate cancer;NSCLC: non-small cell lung cancer;P-TEFb: pos. elongation factor b;RNAPII: RNA polymerase II;S2: serine-2 of CTD repeats;S5: serine-5 of CTD repeats;S7: serine-7 of CTD repeats;SEC: super elongation complex;tCDK: transcriptional cyclin-dependent kinase;TNBC: triple-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptgAOjkQMqqbVg90H21EOLACvtfcHk0lhV2hxoXMcDgQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP&md5=1700138890acfc08ad2ab2a81f62c476</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1539615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1539615%26sid%3Dliteratum%253Aachs%26aulast%3DGalbraith%26aufirst%3DM.%2BD.%26aulast%3DBender%26aufirst%3DH.%26aulast%3DEspinosa%26aufirst%3DJ.%2BM.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Transcriptional%2520Cyclin-Dependent%2520Kinases%26jtitle%3DTranscription%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D118%26epage%3D136%26doi%3D10.1080%2F21541264.2018.1539615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terret, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlbold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboza, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallepalli, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Requirements for CDK7 in the Assembly of CDK1/Cyclin B and Activation of CDK2 Revealed by Chemical Genetics in Human Cells</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">850</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2007.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=17386261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFCgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=839-850&issue=6&author=S.+Larochelleauthor=K.+A.+Merrickauthor=M.-E.+Terretauthor=L.+Wohlboldauthor=N.+M.+Barbozaauthor=C.+Zhangauthor=K.+M.+Shokatauthor=P.+V.+Jallepalliauthor=R.+P.+Fisher&title=Requirements+for+CDK7+in+the+Assembly+of+CDK1%2FCyclin+B+and+Activation+of+CDK2+Revealed+by+Chemical+Genetics+in+Human+Cells&doi=10.1016%2Fj.molcel.2007.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells</span></div><div class="casAuthors">Larochelle, Stephane; Merrick, Karl A.; Terret, Marie-Emilie; Wohlbold, Lara; Barboza, Nora M.; Zhang, Chao; Shokat, Kevan M.; Jallepalli, Prasad V.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">839-850</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cell division is controlled by cyclin-dependent kinases (CDKs).  In metazoans, S phase onset coincides with activation of Cdk2, whereas Cdk1 triggers mitosis.  Both Cdk1 and -2 require cyclin binding and T loop phosphorylation for full activity.  The only known CDK-activating kinase (CAK) in metazoans is Cdk7, which is also part of the transcription machinery.  To test the requirements for Cdk7 in vivo, we replaced wild-type Cdk7 with a version sensitive to bulky ATP analogs in human cancer cells.  Selective inhibition of Cdk7 in G1 prevents activation (but not formation) of Cdk2/cyclin complexes and delays S phase.  Inhibiting Cdk7 in G2 blocks entry to mitosis and disrupts Cdk1/cyclin B complex assembly, indicating that the two steps of Cdk1 activation-cyclin binding and T loop phosphorylation-are mutually dependent.  Therefore, by combining chem. genetics and homologous gene replacement in somatic cells, we reveal different modes of CDK activation by Cdk7 at two distinct execution points in the cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptnQJb6qpSabVg90H21EOLACvtfcHk0lizjfQsZ4AgHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFCgsbo%253D&md5=fe003624658619167adf3429e04cf58f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DTerret%26aufirst%3DM.-E.%26aulast%3DWohlbold%26aufirst%3DL.%26aulast%3DBarboza%26aufirst%3DN.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DJallepalli%26aufirst%3DP.%2BV.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DRequirements%2520for%2520CDK7%2520in%2520the%2520Assembly%2520of%2520CDK1%252FCyclin%2520B%2520and%2520Activation%2520of%2520CDK2%2520Revealed%2520by%2520Chemical%2520Genetics%2520in%2520Human%2520Cells%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D25%26issue%3D6%26spage%3D839%26epage%3D850%26doi%3D10.1016%2Fj.molcel.2007.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">A CDK7-CDK4 T-Loop Phosphorylation Cascade Promotes G1 Progression</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2013.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2013.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=23622515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2013&pages=250-260&issue=2&author=M.+M.+Schachterauthor=K.+A.+Merrickauthor=S.+Larochelleauthor=A.+Hirschiauthor=C.+Zhangauthor=K.+M.+Shokatauthor=S.+M.+Rubinauthor=R.+P.+Fisher&title=A+CDK7-CDK4+T-Loop+Phosphorylation+Cascade+Promotes+G1+Progression&doi=10.1016%2Fj.molcel.2013.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression</span></div><div class="casAuthors">Schachter, Miriam Merzel; Merrick, Karl A.; Larochelle, Stephane; Hirschi, Alexander; Zhang, Chao; Shokat, Kevan M.; Rubin, Seth M.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-260</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Eukaryotic cell division is controlled by cyclin-dependent kinases (CDKs), which require phosphorylation by a CDK-activating kinase (CAK) for full activity.  Chem. genetics uncovered requirements for the metazoan CAK Cdk7 in detg. cyclin specificity and activation order of Cdk2 and Cdk1 during S and G2 phases.  It was unknown if Cdk7 also activates Cdk4 and Cdk6 to promote passage of the restriction (R) point, when continued cell-cycle progression becomes mitogen independent, or if CDK-activating phosphorylation regulates G1 progression.  Here we show that Cdk7 is a Cdk4- and Cdk6-activating kinase in human cells, required to maintain activity, not just to establish the active state, as is the case for Cdk1 and Cdk2.  Activating phosphorylation of Cdk7 rises concurrently with that of Cdk4 as cells exit quiescence and accelerates Cdk4 activation in vitro.  Therefore, mitogen signaling drives a CDK-activation cascade during G1 progression, and CAK might be rate-limiting for R point passage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5WwOfxdUtXbVg90H21EOLACvtfcHk0lizjfQsZ4AgHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVWitb8%253D&md5=5a5f10c30bd6c9ff5d8e6bfb5c3c8b6e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DSchachter%26aufirst%3DM.%2BM.%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DHirschi%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRubin%26aufirst%3DS.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DA%2520CDK7-CDK4%2520T-Loop%2520Phosphorylation%2520Cascade%2520Promotes%2520G1%2520Progression%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D50%26issue%3D2%26spage%3D250%26epage%3D260%26doi%3D10.1016%2Fj.molcel.2013.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">The CDK-Activating Kinase CDK7: Taking Yes for an Answer</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3239</span>– <span class="NLM_lpage">3240</span>, <span class="refDoi"> DOI: 10.4161/cc.26355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.4161%2Fcc.26355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=24036541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=3239-3240&issue=20&author=M.+M.+Schachterauthor=R.+P.+Fisher&title=The+CDK-Activating+Kinase+CDK7%3A+Taking+Yes+for+an+Answer&doi=10.4161%2Fcc.26355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK-activating kinase Cdk7: taking yes for an answer</span></div><div class="casAuthors">Schachter, Miriam Merzel; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3239-3240</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  This article discusses about role of human cyclin-dependent kinase 7 in cell division, proliferation and activation of Cdk1, Cdk2, Cdk4, Cdk6 and effect of Cdk7 inhibition on phosphorylation of G1, S phase and mitotic cyclin-dependent kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZHU-gaVkMLVg90H21EOLACvtfcHk0lizjfQsZ4AgHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWhuro%253D&md5=dad0ee8b9477ff235ab6feaeea1da85e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.4161%2Fcc.26355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.26355%26sid%3Dliteratum%253Aachs%26aulast%3DSchachter%26aufirst%3DM.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DThe%2520CDK-Activating%2520Kinase%2520CDK7%253A%2520Taking%2520Yes%2520for%2520an%2520Answer%26jtitle%3DCell%2520Cycle%26date%3D2013%26volume%3D12%26issue%3D20%26spage%3D3239%26epage%3D3240%26doi%3D10.4161%2Fcc.26355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganuza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sáiz-Ladera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cañamero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Genetic Inactivation of CDK7 Leads to Cell Cycle Arrest and Induces Premature Aging Due to Adult Stem Cell Exhaustion</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">2510</span>, <span class="refDoi"> DOI: 10.1038/emboj.2012.94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Femboj.2012.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=22505032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=2498-2510&issue=11&author=M.+Ganuzaauthor=C.+S%C3%A1iz-Laderaauthor=M.+Ca%C3%B1ameroauthor=G.+G%C3%B3mezauthor=R.+Schneiderauthor=M.+A.+Blascoauthor=D.+Pisanoauthor=J.+M.+Paramioauthor=D.+Santamar%C3%ADaauthor=M.+Barbacid&title=Genetic+Inactivation+of+CDK7+Leads+to+Cell+Cycle+Arrest+and+Induces+Premature+Aging+Due+to+Adult+Stem+Cell+Exhaustion&doi=10.1038%2Femboj.2012.94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion</span></div><div class="casAuthors">Ganuza, Miguel; Saiz-Ladera, Cristina; Canamero, Marta; Gomez, Gonzalo; Schneider, Ralph; Blasco, Maria A.; Pisano, David; Paramio, Jesus M.; Santamaria, David; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2498-2510</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase (Cdk)7, the catalytic subunit of the Cdk-activating kinase (CAK) complex has been implicated in the control of cell cycle progression and of RNA polymerase II (RNA pol II)-mediated transcription.  Genetic inactivation of the Cdk7 locus revealed that whereas Cdk7 is completely dispensable for global transcription, is essential for the cell cycle via phosphorylation of Cdk1 and Cdk2.  In vivo, Cdk7 is also indispensable for cell proliferation except during the initial stages of embryonic development.  Interestingly, widespread elimination of Cdk7 in adult tissues with low proliferative indexes had no phenotypic consequences.  However, ablation of conditional Cdk7 alleles in tissues with elevated cellular turnover led to the efficient repopulation of these tissues with Cdk7-expressing cells most likely derived from adult stem cells that may have escaped the inactivation of their targeted Cdk7 alleles.  This process, a physiol. attempt to maintain tissue homeostasis, led to the attrition of adult stem cell pools and to the appearance of age-related phenotypes, including telomere shortening and early death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsIzd_tP1b7Vg90H21EOLACvtfcHk0lh7FJPWnd2fqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbk%253D&md5=c12ca2a3563a387e1edd95d443cd405b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.94%26sid%3Dliteratum%253Aachs%26aulast%3DGanuza%26aufirst%3DM.%26aulast%3DS%25C3%25A1iz-Ladera%26aufirst%3DC.%26aulast%3DCa%25C3%25B1amero%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBlasco%26aufirst%3DM.%2BA.%26aulast%3DPisano%26aufirst%3DD.%26aulast%3DParamio%26aufirst%3DJ.%2BM.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DGenetic%2520Inactivation%2520of%2520CDK7%2520Leads%2520to%2520Cell%2520Cycle%2520Arrest%2520and%2520Induces%2520Premature%2520Aging%2520Due%2520to%2520Adult%2520Stem%2520Cell%2520Exhaustion%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D31%26issue%3D11%26spage%3D2498%26epage%3D2510%26doi%3D10.1038%2Femboj.2012.94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Inhibitor THZ2 Inhibits the Growth of Human Gastric Cancer in Vitro and in Vivo</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3664</span>– <span class="NLM_lpage">3676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30662617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCmu7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=3664-3676&issue=11&author=J.-R.+Huangauthor=W.-M.+Qinauthor=K.+Wangauthor=D.-R.+Fuauthor=W.-J.+Zhangauthor=Q.-W.+Jiangauthor=Y.+Yangauthor=M.-L.+Yuanauthor=Z.-H.+Xingauthor=M.-N.+Weiauthor=Y.+Liauthor=Z.+Shi&title=Cyclin-Dependent+Kinase+7+Inhibitor+THZ2+Inhibits+the+Growth+of+Human+Gastric+Cancer+in+Vitro+and+in+Vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo</span></div><div class="casAuthors">Huang, Jia-Rong; Qin, Wu-Ming; Wang, Kun; Fu, Deng-Rui; Zhang, Wen-Ji; Jiang, Qi-Wei; Yang, Yang; Yuan, Meng-Ling; Xing, Zi-Hao; Wei, Meng-Ning; Li, Yao; Shi, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3664-3676</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) is a member of the CDK family, which forms the CDK activating kinase complex with Cyclin H and RING finger protein Mat1 to control cell cycle progression and transcription by phosphorylating other CDKs and RNA polymerase II.  In this study, we analyzed TCGA data and found that upregulation of CDK7 frequently occurred in human gastric cancer.  A potent and selective irreversible CDK7 inhibitor THZ2 was able to induce cell growth inhibition, cell cycle arrest at G2/M phase and apoptosis with the increasing intracellular reactive oxidative species (ROS) levels in gastric cancer cells.  Pretreatment with ROS scavenger N-acety-L-cysteine partially reversed cell apoptosis induced by THZ2.  In the nude mice, THZ2 also suppressed the growth of xenograft tumors of gastric cancer.  Overall, our data showed that inhibition of CDK7 with THZ2 in gastric cancer presented outstanding anticancer effect in vitro and in vivo, suggesting that CDK7 is a potential therapeutic target for gastric cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIxSbm1DrtsrVg90H21EOLACvtfcHk0lh7FJPWnd2fqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCmu7zK&md5=b59e672e5665e3fc20fd0ad0577b634a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.-R.%26aulast%3DQin%26aufirst%3DW.-M.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DFu%26aufirst%3DD.-R.%26aulast%3DZhang%26aufirst%3DW.-J.%26aulast%3DJiang%26aufirst%3DQ.-W.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DM.-L.%26aulast%3DXing%26aufirst%3DZ.-H.%26aulast%3DWei%26aufirst%3DM.-N.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DZ.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Inhibitor%2520THZ2%2520Inhibits%2520the%2520Growth%2520of%2520Human%2520Gastric%2520Cancer%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2018%26volume%3D10%26issue%3D11%26spage%3D3664%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">A CRISPR Screen Identifies CDK7 as a Therapeutic Target in Hepatocellular Carcinoma</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/s41422-018-0020-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41422-018-0020-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29507396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ektb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=690-692&issue=6&author=C.+Wangauthor=H.+Jinauthor=D.+Gaoauthor=L.+Wangauthor=B.+Eversauthor=Z.+Xueauthor=G.+Jinauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=W.+Qinauthor=R.+Bernards&title=A+CRISPR+Screen+Identifies+CDK7+as+a+Therapeutic+Target+in+Hepatocellular+Carcinoma&doi=10.1038%2Fs41422-018-0020-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma</span></div><div class="casAuthors">Wang, Cun; Jin, Haojie; Gao, Dongmei; Wang, Liqin; Evers, Bastiaan; Xue, Zheng; Jin, Guangzhi; Lieftink, Cor; Beijersbergen, Roderick L.; Qin, Wenxin; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">690-692</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Liver cancer is one of the most frequent malignancies and the second leading cause of cancer-related mortality worldwide.  We analyzed CDK7 expression using a tissue microarray (TMA) contg. 80 HCC specimens by immunochem. anal.  Kaplan- Meier anal. indicated that HCC patients with high expression of CDK7 exhibited worse overall survival as compared to patients with low expression of CDK7 (n = 80, P = 0.048, log-rank test, Fig. 1d).  We also analyzed the growth inhibitory effects of shCDK7 in five addnl. cell lines (SNU398, JHH1, SNU449, PLC/PRF/5 and MHCC97H).  We found that SNU398 and JHH1 are also very sensitive to CDK7 knockdown, whereas SNU449, PLC/PRF/5 and MHCC97H cells are resistant to CDK7 knockdown (Supplementary information, Figure S2a, b).  To test the sensitivity of HCC cells to THZ1, we treated the panel of 10 HCC cell lines with increasing concns. of THZ1 for about 2 wk in colony formation assays.  Together, our data indicate that there may be a subgroup of liver cancer cells with a profound dependence on CDK7 for survival and CDK7 may represent a novel therapeutic target in this subgroup.  MYC deregulation is a common event in liver cancer.  We analyzed the correlation between CDK7 and MYC mRNA levels in two clin. HCC cohorts (GSE14520 n = 225 and TCGA database n= 371).  As shown in Supplementary information, Figure S5, we obsd. a significant correlation between CDK7 and MYC mRNA expression in both GSE14520 (R = 0.274, P < 0.001) and TCGA database (R = 0.348, P < 0.001).  Our work now identifies CDK7 inhibition as vulnerability of HCC tumors having high MYC expression.  The recent start of a clin. study with a CDK7 inhibitor (NCT03134638) may enable clin. validation of this notion in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrvRikdDFXhbVg90H21EOLACvtfcHk0lh7FJPWnd2fqQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ektb7J&md5=4b113b9a72ad206d52e91b176ffe4fc7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41422-018-0020-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-018-0020-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DG.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DA%2520CRISPR%2520Screen%2520Identifies%2520CDK7%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Hepatocellular%2520Carcinoma%26jtitle%3DCell%2520Res.%26date%3D2018%26volume%3D28%26issue%3D6%26spage%3D690%26epage%3D692%26doi%3D10.1038%2Fs41422-018-0020-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK7 Increases the Stability of Snail to Promote the Dissemination of Colorectal Cancer</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1038/s41418-018-0222-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41418-018-0222-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30451989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1442-1452&issue=8&author=Y.+Zhouauthor=L.+Luauthor=G.+Jiangauthor=Z.+Chenauthor=J.+Liauthor=P.+Anauthor=L.+Chenauthor=J.+Duauthor=H.+Wang&title=Targeting+CDK7+Increases+the+Stability+of+Snail+to+Promote+the+Dissemination+of+Colorectal+Cancer&doi=10.1038%2Fs41418-018-0222-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer</span></div><div class="casAuthors">Zhou, Yan; Lu, Linlin; Jiang, Guanmin; Chen, Zhuojia; Li, Jiexin; An, Panpan; Chen, Likun; Du, Jun; Wang, Hongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1442-1452</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted inhibition of cyclin-dependent kinase 7 (CDK7) via its covalent inhibitor THZ1 can suppress the growth of various cancers, while its roles on colorectal cancer (CRC) remain obscure.  Here we report that the expression of CDK7 is upregulated in CRC cells and tissues.  THZ1 exhibits high potency and selectivity against CRC cells both in vitro and in vivo via induction of cell apoptosis rather than cell cycle disruption.  Intriguingly, THZ1 treatment increases the ability of epithelial mesenchymal transition (EMT) and in vivo metastasis to liver of CRC cells.  Mechanistical studies reveal that THZ1 increases the expression of Snail, while not other EMT-transcription factors, via enhancing its protein stability rather than mRNA expression or translation.  By screening Snail stability related factors via qRT-PCR, results indicate THZ1 and si-CDK7 decrease the expression of protein kinase D1 (PKD1) in CRC cells.  Down regulation of PKD1 mediates THZ1 up regulated Snail via dephosphorylation of Snail Ser 11 and prevention of proteasome mediated degrdn.  Clin. anal. confirms that CDK7 is significantly (p < 0.05) neg. correlated with the expression of mesenchymal markers including FN1, VIM, and MMP2.  CRC patients whose tumors expressing less CDK7/SNAI1 or PKD1/SNAI1 showed significant (p < 0.05) poorer overall survival (OS) rate as compared with those with greater levels.  Collectively, our data suggest that targeted inhibition of CDK7 can trigger the metastasis of CRC during cancer development via PKD1/Snail axis, which imposes great challenge that inhibition of CDK7 is a potential approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy89Fkw4m-F7Vg90H21EOLACvtfcHk0liDrvnf5-GFdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ&md5=6674d36ade83d70a05060d69632d3737</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41418-018-0222-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-018-0222-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DTargeting%2520CDK7%2520Increases%2520the%2520Stability%2520of%2520Snail%2520to%2520Promote%2520the%2520Dissemination%2520of%2520Colorectal%2520Cancer%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2019%26volume%3D26%26issue%3D8%26spage%3D1442%26epage%3D1452%26doi%3D10.1038%2Fs41418-018-0222-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span> <span> </span><span class="NLM_article-title">Upregulation of CDK7 in Gastric Cancer Cell Promotes Tumor Cell Proliferation and Predicts Poor Prognosis</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1016/j.yexmp.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.yexmp.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27155449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVWisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2016&pages=514-521&issue=3&author=Q.+Wangauthor=M.+Liauthor=X.+Zhangauthor=H.+Huangauthor=J.+Huangauthor=J.+Keauthor=H.+Dingauthor=J.+Xiaoauthor=X.+Shanauthor=Q.+Liuauthor=B.+Baoauthor=L.+Yang&title=Upregulation+of+CDK7+in+Gastric+Cancer+Cell+Promotes+Tumor+Cell+Proliferation+and+Predicts+Poor+Prognosis&doi=10.1016%2Fj.yexmp.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis</span></div><div class="casAuthors">Wang, Qiuhong; Li, Manhua; Zhang, Xunlei; Huang, Hua; Huang, Jianfei; Ke, Jing; Ding, Haifang; Xiao, Jinzhang; Shan, Xiaohang; Liu, Qingqing; Bao, Bojun; Yang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">CDK7 has been known as a component of CDK activating kinase (CAK) complex, the complex was composed of CDK7, Cyclin H and RING finger protein Mat1 that contribute to cell cycle progression by phosphorylating other CDKs.  In addn., the complex is also an essential component of general transcription factor TFIIH which controls transcription via activating RNA polymerase II by serines 5 and 7 phosphorylation of the carboxyl-terminal domain (CTD) of its largest subunit.  However, the role of CDK7 in the pathogenesis of gastric cancer has not been identified.  Our study showed that CDK7 was significantly upregulated and pos. correlated with tumor grade, infiltration depth, lymph node, Ki-67, and predicted poor prognosis in 173 gastric cancer specimens by immunohistochemistrical analyses.  Furthermore, in vitro results indicated that CDK7 promoted proliferation of gastric cancer cells by CCK8, clone formation analyses and flow cytometric analyses, while CDK7 knockdown led to decreased cell proliferation.  Our study will provide a theor. basis for the study of CDK7 in gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kTib1JYcwrVg90H21EOLACvtfcHk0liDrvnf5-GFdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVWisLw%253D&md5=fca329fa2cd174bc1837bc32168e2e19</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DUpregulation%2520of%2520CDK7%2520in%2520Gastric%2520Cancer%2520Cell%2520Promotes%2520Tumor%2520Cell%2520Proliferation%2520and%2520Predicts%2520Poor%2520Prognosis%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2016%26volume%3D100%26issue%3D3%26spage%3D514%26epage%3D521%26doi%3D10.1016%2Fj.yexmp.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Overexpression of CDK7 Is Associated with Unfavourable Prognosis in Oral Squamous Cell Carcinoma</span>. <i>Pathology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.pathol.2018.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.pathol.2018.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30473182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1yls7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=74-80&issue=1&author=L.+Jiangauthor=R.+Huangauthor=Y.+Wuauthor=P.+Diaoauthor=W.+Zhangauthor=J.+Liauthor=Z.+Liauthor=Y.+Wangauthor=J.+Chengauthor=J.+Yang&title=Overexpression+of+CDK7+Is+Associated+with+Unfavourable+Prognosis+in+Oral+Squamous+Cell+Carcinoma&doi=10.1016%2Fj.pathol.2018.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of CDK7 is associated with unfavourable prognosis in oral squamous cell carcinoma</span></div><div class="casAuthors">Jiang, Lei; Huang, Rong; Wu, Yaping; Diao, Pengfei; Zhang, Wei; Li, Jin; Li, Zhongwu; Wang, Yanling; Cheng, Jie; Yang, Jianrong</div><div class="citationInfo"><span class="NLM_cas:title">Pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-80</span>CODEN:
                <span class="NLM_cas:coden">PTLGAX</span>;
        ISSN:<span class="NLM_cas:issn">0031-3025</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Increased expression of cyclin-dependent kinase 7 (CDK7), an ubiquitous kinase assocd. with cell cycle and transcription, contributes to human tumorigenesis and assocs. with patient's prognosis.  In the present study, we sought to investigate the expression pattern of CDK7 and its clinicopathol. significance in primary oral squamous cell carcinoma (OSCC).  The expression of CDK7 mRNA in OSCC was detd. by data mining and interrogation using the Oncomine database.  Its protein expression was measured by immunohistochem. in clin. samples from a retrospective cohort of 113 patients with primary OSCC which were treated at our institution from Jan. 2006 to Dec. 2016.  The potential assocns. between CDK7 abundance and multiple clinicopathol. parameters as well as patient's survival were assessed.  The 4-nitroquinoline 1-oxide (4NQO)-induced OSCC mouse model was developed to monitor CDK7 expression during cancer initiation and progression.  The bioinformatics analyses revealed higher CDK7 mRNA in OSCC samples compared to normal counterparts.  Our immunohistochem. staining data revealed significant aberrant overexpression of CDK7 in a large subset of OSCC.  Elevated CDK7 expression was found to be significantly assocd. with higher T-stage (p = 0.009) and reduced overall and disease-free survival (Log-rank test, p = 0.022, 0.010, resp.).  Both univariate and multivariate Cox regression anal. identified the expression status of CDK7 as an important independent prognostic factor for patient's survival.  Increased CDK7 expression was parallel with OSCC development in the 4NQO-induced animal model.  Our findings indicate that aberrant CDK7 overexpression assocs. with T-stage and reduced survival in OSCC, thus suggesting that it might play crit. roles underlying oral tumorigenesis and also serve as a novel biomarker with diagnostic and prognostic significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGDjIhULb497Vg90H21EOLACvtfcHk0liDrvnf5-GFdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1yls7rP&md5=2ce562a61569b6ff111c070d805d9b54</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.pathol.2018.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pathol.2018.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DDiao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DOverexpression%2520of%2520CDK7%2520Is%2520Associated%2520with%2520Unfavourable%2520Prognosis%2520in%2520Oral%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DPathology%26date%3D2019%26volume%3D51%26issue%3D1%26spage%3D74%26epage%3D80%26doi%3D10.1016%2Fj.pathol.2018.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abduljabbar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerjees, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remenyi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomm, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Győrffy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller-Pace, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shousha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buluwela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakha, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5929</span>– <span class="NLM_lpage">5938</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1078-0432.CCR-15-1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27301701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5929-5938&issue=23&author=H.+Patelauthor=R.+Abduljabbarauthor=C.-F.+Laiauthor=M.+Periyasamyauthor=A.+Harrodauthor=C.+Gemmaauthor=J.+H.+Steelauthor=N.+Patelauthor=C.+Busoneroauthor=D.+Jerjeesauthor=J.+Remenyiauthor=S.+Smithauthor=J.+J.+Gommauthor=L.+Magnaniauthor=B.+Gy%C5%91rffyauthor=L.+J.+Jonesauthor=F.+Fuller-Paceauthor=S.+Shoushaauthor=L.+Buluwelaauthor=E.+A.+Rakhaauthor=I.+O.+Ellisauthor=R.+C.+Coombesauthor=S.+Ali&title=Expression+of+CDK7%2C+Cyclin+H%2C+and+MAT1+Is+Elevated+in+Breast+Cancer+and+Is+Prognostic+in+Estrogen+Receptor%E2%80%93Positive+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-15-1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Patel, Hetal; Abduljabbar, Rezvan; Lai, Chun-Fui; Periyasamy, Manikandan; Harrod, Alison; Gemma, Carolina; Steel, Jennifer H.; Patel, Naina; Busonero, Claudia; Jerjees, Dena; Remenyi, Judit; Smith, Sally; Gomm, Jennifer J.; Magnani, Luca; Gyaorffy, Balazs; Jones, Louise J.; Fuller-Pace, Frances; Shousha, Sami; Buluwela, Laki; Rakha, Emad A.; Ellis, Ian O.; Coombes, R. Charles; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5929-5938</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: CDK-activating kinase (CAK) is required for the regulation of the cell cycle and is a trimeric complex consisting of cyclin-dependent kinase 7 (CDK7), Cyclin H, and the accessory protein, MAT1.  CDK7 also plays a crit. role in regulating transcription, primarily by phosphorylating RNA polymerase II, as well as transcription factors such as estrogen receptor-α (ER).  Deregulation of cell cycle and transcriptional control are general features of tumor cells, highlighting the potential for the use of CDK7 inhibitors as novel cancer therapeutics.  Exptl. Design: mRNA and protein expression of CDK7 and its essential cofactors cyclin H and MAT1 were evaluated in breast cancer samples to det. if their levels are altered in cancer.  Immunohistochem. staining of >900 breast cancers was used to det. the assocn. with clinicopathol. features and patient outcome.  Results: We show that expressions of CDK7, cyclin H, and MAT1 are all closely linked at the mRNA and protein level, and their expression is elevated in breast cancer compared with the normal breast tissue.  Intriguingly, CDK7 expression was inversely proportional to tumor grade and size, and outcome anal. showed an assocn. between CAK levels and better outcome.  Moreover, CDK7 expression was pos. assocd. with ER expression and in particular with phosphorylation of ER at serine 118, a site important for ER transcriptional activity.  Conclusions: Expressions of components of the CAK complex, CDK7, MAT1, and Cyclin H are elevated in breast cancer and correlate with ER.  Like ER, CDK7 expression is inversely proportional to poor prognostic factors and survival.  Clin Cancer Res; 22(23); 5929-38. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0KlK2HCGsrVg90H21EOLACvtfcHk0lhos9KtIxCBNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegt7zP&md5=14eebdf0a0f46cc759def88fdcc3d74b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1104%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DAbduljabbar%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DC.-F.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DHarrod%26aufirst%3DA.%26aulast%3DGemma%26aufirst%3DC.%26aulast%3DSteel%26aufirst%3DJ.%2BH.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DBusonero%26aufirst%3DC.%26aulast%3DJerjees%26aufirst%3DD.%26aulast%3DRemenyi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DGomm%26aufirst%3DJ.%2BJ.%26aulast%3DMagnani%26aufirst%3DL.%26aulast%3DGy%25C5%2591rffy%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DL.%2BJ.%26aulast%3DFuller-Pace%26aufirst%3DF.%26aulast%3DShousha%26aufirst%3DS.%26aulast%3DBuluwela%26aufirst%3DL.%26aulast%3DRakha%26aufirst%3DE.%2BA.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DExpression%2520of%2520CDK7%252C%2520Cyclin%2520H%252C%2520and%2520MAT1%2520Is%2520Elevated%2520in%2520Breast%2520Cancer%2520and%2520Is%2520Prognostic%2520in%2520Estrogen%2520Receptor%25E2%2580%2593Positive%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D23%26spage%3D5929%26epage%3D5938%26doi%3D10.1158%2F1078-0432.CCR-15-1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chonghaile, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hurley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udupi, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardwell, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirstrom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, W. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3834</span>– <span class="NLM_lpage">3845</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F0008-5472.CAN-16-2546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28455421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=3834-3845&issue=14&author=B.+Liauthor=T.+N.+Chonghaileauthor=Y.+Fanauthor=S.+F.+Maddenauthor=R.+Klingerauthor=A.+E.+O%E2%80%99Connorauthor=L.+Walshauthor=G.+O%E2%80%99Hurleyauthor=G.+M.+Udupiauthor=J.+Josephauthor=F.+Tarrantauthor=E.+Conroyauthor=A.+Gaberauthor=S.+F.+Chinauthor=H.+A.+Bardwellauthor=E.+Provenzanoauthor=J.+Crownauthor=T.+Duboisauthor=S.+Linnauthor=K.+Jirstromauthor=C.+Caldasauthor=D.+P.+O%E2%80%99Connorauthor=W.+M.+Gallagher&title=Therapeutic+Rationale+to+Target+Highly+Expressed+CDK7+Conferring+Poor+Outcomes+in+Triple-Negative+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-16-2546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Li, Bo; Ni Chonghaile, Triona; Fan, Yue; Madden, Stephen F.; Klinger, Rut; O'Connor, Aisling E.; Walsh, Louise; O'Hurley, Gillian; Mallya Udupi, Girish; Joseph, Jesuchristopher; Tarrant, Finbarr; Conroy, Emer; Gaber, Alexander; Chin, Suet-Feung; Bardwell, Helen A.; Provenzano, Elena; Crown, John; Dubois, Thierry; Linn, Sabine; Jirstrom, Karin; Caldas, Carlos; O'Connor, Darran P.; Gallagher, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3834-3845</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of biomarkers and effective targeted therapies for this disease.  Here, we report evidence highlighting the cell-cycle-related kinase CDK7 as a driver and candidate therapeutic target in TNBC.  Using publicly available transcriptomic data from a collated set of TNBC patients (n = 383) and the METABRIC TNBC dataset (n = 217), we found CDK7 mRNA levels to be correlated with patient prognosis.  High CDK7 protein expression was assocd. with poor prognosis within the RATHER TNBC cohort (n = 109) and the METABRIC TNBC cohort (n = 203).  The highly specific CDK7 kinase inhibitors, BS-181 and THZ1, each downregulated CDK7-mediated phosphorylation of RNA polymerase II, indicative of transcriptional inhibition, with THZ1 exhibiting 500-fold greater potency than BS-181.  Mechanistic investigations revealed that the survival of MDA-MB-231 TNBC cells relied heavily on the BCL-2/BCL-XL signaling axes in cells.  Accordingly, we found that combining the BCL-2/BCL-XL inhibitors ABT-263/ABT199 with the CDK7 inhibitor THZ1 synergized in producing growth inhibition and apoptosis of human TNBC cells.  Collectively, our results highlight elevated CDK7 expression as a candidate biomarker of poor prognosis in TNBC, and they offer a preclin. proof of concept for combining CDK7 and BCL-2/BCL-XL inhibitors as a mechanism-based therapeutic strategy to improve TNBC treatment.  Cancer Res; 77(14); 3834-45. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxGf2Y8smdbVg90H21EOLACvtfcHk0ljTrqWQOZE5xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurvE&md5=af2710f8621b18c53f616f27967b061a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2546%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DChonghaile%26aufirst%3DT.%2BN.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DMadden%26aufirst%3DS.%2BF.%26aulast%3DKlinger%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%2BE.%26aulast%3DWalsh%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Hurley%26aufirst%3DG.%26aulast%3DUdupi%26aufirst%3DG.%2BM.%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DTarrant%26aufirst%3DF.%26aulast%3DConroy%26aufirst%3DE.%26aulast%3DGaber%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DBardwell%26aufirst%3DH.%2BA.%26aulast%3DProvenzano%26aufirst%3DE.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DDubois%26aufirst%3DT.%26aulast%3DLinn%26aufirst%3DS.%26aulast%3DJirstrom%26aufirst%3DK.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%2BP.%26aulast%3DGallagher%26aufirst%3DW.%2BM.%26atitle%3DTherapeutic%2520Rationale%2520to%2520Target%2520Highly%2520Expressed%2520CDK7%2520Conferring%2520Poor%2520Outcomes%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D14%26spage%3D3834%26epage%3D3845%26doi%3D10.1158%2F0008-5472.CAN-16-2546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzugullu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglehart, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.08.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.cell.2015.08.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=26406377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=174-186&issue=1&author=Y.+Wangauthor=T.+Zhangauthor=N.+Kwiatkowskiauthor=B.+J.+Abrahamauthor=T.+I.+Leeauthor=S.+Xieauthor=H.+Yuzugulluauthor=T.+Vonauthor=H.+Liauthor=Z.+Linauthor=D.+G.+Stoverauthor=E.+Limauthor=Z.+C.+Wangauthor=J.+D.+Iglehartauthor=R.+A.+Youngauthor=N.+S.+Grayauthor=J.+J.+Zhao&title=CDK7-Dependent+Transcriptional+Addiction+in+Triple-Negative+Breast+Cancer&doi=10.1016%2Fj.cell.2015.08.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7-dependent transcriptional addiction in triple-negative breast cancer</span></div><div class="casAuthors">Wang, Yubao; Zhang, Tinghu; Kwiatkowski, Nicholas; Abraham, Brian J.; Lee, Tong Ihn; Xie, Shaozhen; Yuzugullu, Haluk; Von, Thanh; Li, Heyuan; Lin, Ziao; Stover, Daniel G.; Lim, Elgene; Wang, Zhigang C.; Iglehart, J. Dirk; Young, Richard A.; Gray, Nathanael S.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-186</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly aggressive form of breast cancer that exhibits extremely high levels of genetic complexity and yet a relatively uniform transcriptional program.  We postulate that TNBC might be highly dependent on uninterrupted transcription of a key set of genes within this gene expression program and might therefore be exceptionally sensitive to inhibitors of transcription.  Utilizing kinase inhibitors and CRISPR/Cas9-mediated gene editing, we show here that triple-neg. but not hormone receptor-pos. breast cancer cells are exceptionally dependent on CDK7, a transcriptional cyclin-dependent kinase.  TNBC cells are unique in their dependence on this transcriptional CDK and suffer apoptotic cell death upon CDK7 inhibition.  An "Achilles cluster" of TNBC-specific genes is esp. sensitive to CDK7 inhibition and frequently assocd. with super-enhancers.  We conclude that CDK7 mediates transcriptional addiction to a vital cluster of genes in TNBC and CDK7 inhibition may be a useful therapy for this challenging cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEe3LZxVCwWLVg90H21EOLACvtfcHk0ljTrqWQOZE5xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrjP&md5=34441125e931816d29e419f3f7dc0346</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.08.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.08.063%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DLee%26aufirst%3DT.%2BI.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DVon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DIglehart%26aufirst%3DJ.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DCDK7-Dependent%2520Transcriptional%2520Addiction%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DCell%26date%3D2015%26volume%3D163%26issue%3D1%26spage%3D174%26epage%3D186%26doi%3D10.1016%2Fj.cell.2015.08.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanin, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slattery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A. Z.</span></span> <span> </span><span class="NLM_article-title">Chemical Inhibition of the TFIIH-Associated Kinase CDK7/Kin28 Does Not Impair Global mRNA Synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5812</span>– <span class="NLM_lpage">5817</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611505104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1073%2Fpnas.0611505104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=17392431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Kgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=5812-5817&issue=14&author=E.+I.+Kaninauthor=R.+T.+Kippauthor=C.+Kungauthor=M.+Slatteryauthor=A.+Vialeauthor=S.+Hahnauthor=K.+M.+Shokatauthor=A.+Z.+Ansari&title=Chemical+Inhibition+of+the+TFIIH-Associated+Kinase+CDK7%2FKin28+Does+Not+Impair+Global+mRNA+Synthesis&doi=10.1073%2Fpnas.0611505104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical inhibition of TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis</span></div><div class="casAuthors">Kanin, Elenita I.; Kipp, Ryan T.; Kung, Charles; Slattery, Matthew; Viale, Agnes; Hahn, Steven; Shokat, Kevan M.; Ansari, Aseem Z.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5812-5817</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The process of gene transcription requires the recruitment of a hypophosphorylated form of RNA polymerase II (Pol II) to a gene promoter.  The TFIIH-assocd. kinase Cdk7/Kin28 hyperphosphorylates the promoter-bound polymerase; this event is thought to play a crucial role in transcription initiation and promoter clearance.  Studies using temp.-sensitive mutants of Kin28 have provided the most compelling evidence for an essential role of its kinase activity in global mRNA synthesis.  In contrast, using a small mol. inhibitor that specifically inhibits Kin28 in vivo, we find that the kinase activity is not essential for global transcription.  Unlike the temp.-sensitive alleles, the small-mol. inhibitor does not perturb protein-protein interactions nor does it provoke the disassocn. of TFIIH from gene promoters.  These results lead us to conclude that other functions of TFIIH, rather than the kinase activity, are crit. for global gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-64JGuvGdl7Vg90H21EOLACvtfcHk0ljTrqWQOZE5xA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Kgtro%253D&md5=f6c870b29f092771809b9b5759d01072</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611505104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611505104%26sid%3Dliteratum%253Aachs%26aulast%3DKanin%26aufirst%3DE.%2BI.%26aulast%3DKipp%26aufirst%3DR.%2BT.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DSlattery%26aufirst%3DM.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DHahn%26aufirst%3DS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DAnsari%26aufirst%3DA.%2BZ.%26atitle%3DChemical%2520Inhibition%2520of%2520the%2520TFIIH-Associated%2520Kinase%2520CDK7%252FKin28%2520Does%2520Not%2520Impair%2520Global%2520mRNA%2520Synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26issue%3D14%26spage%3D5812%26epage%3D5817%26doi%3D10.1073%2Fpnas.0611505104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Recent Progress of Cyclin-Dependent Kinase Inhibitors as Potential Anticancer Agents</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2047</span>– <span class="NLM_lpage">2076</span>, <span class="refDoi"> DOI: 10.4155/fmc-2016-0129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.4155%2Ffmc-2016-0129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27774795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=2047-2076&issue=17&author=T.+Liauthor=T.+Wengauthor=M.+Zuoauthor=Z.+Weiauthor=M.+Chenauthor=Z.+Li&title=Recent+Progress+of+Cyclin-Dependent+Kinase+Inhibitors+as+Potential+Anticancer+Agents&doi=10.4155%2Ffmc-2016-0129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents</span></div><div class="casAuthors">Li, Tinghan; Weng, Tianwei; Zuo, Minzan; Wei, Zhihui; Chen, Ming; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2047-2076</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Deregulation of the cell cycle is a common feature in human cancer.  The inhibition of cyclin-dependent kinases (CDKs), which play a crucial role in control of the cell cycle, has always been one of the most promising areas in cancer chemotherapy.  This review first summarizes the biol. of CDKs and then focuses on the recent advances in both broad-range and selective CDK inhibitors during the last 5 years.  The design rationale, structural optimization and structure-activity relationships anal. of these small mols. have been discussed in detail and the key interactions with the amino-acid residues of the most important compds. are highlighted.  Future perspectives for CDKs inhibitors will be defined in the development of highly selective CDK inhibitors, an accurate knowledge of gene control mechanism and further predictive biomarker research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKW1A5UEVYeLVg90H21EOLACvtfcHk0ljutZWWygksjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbnJ&md5=90331b2b80a383eaee6483a6e6e6e1e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0129%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWeng%26aufirst%3DT.%26aulast%3DZuo%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DRecent%2520Progress%2520of%2520Cyclin-Dependent%2520Kinase%2520Inhibitors%2520as%2520Potential%2520Anticancer%2520Agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26issue%3D17%26spage%3D2047%26epage%3D2076%26doi%3D10.4155%2Ffmc-2016-0129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The History and Future of Targeting Cyclin-Dependent Kinases in Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&issue=2&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+History+and+Future+of+Targeting+Cyclin-Dependent+Kinases+in+Cancer+Therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0ljutZWWygksjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520History%2520and%2520Future%2520of%2520Targeting%2520Cyclin-Dependent%2520Kinases%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Martínez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfeliciano, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin Dependent Kinase (CDK) Inhibitors as Anticancer Drugs: Recent Advances (2015–2019)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126637</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.bmcl.2019.126637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31477350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126637&author=C.+S%C3%A1nchez-Mart%C3%ADnezauthor=M.+J.+Lallenaauthor=S.+G.+Sanfelicianoauthor=A.+de+Dios&title=Cyclin+Dependent+Kinase+%28CDK%29+Inhibitors+as+Anticancer+Drugs%3A+Recent+Advances+%282015%E2%80%932019%29&doi=10.1016%2Fj.bmcl.2019.126637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019)</span></div><div class="casAuthors">Sanchez-Martinez, Concepcion; Lallena, Maria Jose; Sanfeliciano, Sonia Gutierrez; de Dios, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">126637</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sustained proliferative capacity and gene dysregulation are hallmarks of cancer.  In mammalian cells, cyclin-dependent kinases (CDKs) control crit. cell cycle checkpoints and key transcriptional events in response to extracellular and intracellular signals leading to proliferation.  Significant clin. activity for the treatment of hormone receptor pos. metastatic breast cancer has been demonstrated by palbociclib, ribociclib and abemaciclib, dual CDK4/6 inhibitors recently FDA-approved.  SY-1365, a CDK7 inhibitor has shown initial encouraging data in phase I for solid tumors treatment.  These results have rejuvenated the CDKs research field.  This review provides an overview of relevant advances on CDK inhibitor research since 2015 to 2019, with special emphasis on transcriptional CDK inhibitors, new emerging strategies such as target protein degrdn. and compds. under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcZ4sKIv0DfrVg90H21EOLACvtfcHk0ljutZWWygksjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N&md5=2808e04d5c09daad462133bcf9b9cb3d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126637%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3DSanfeliciano%26aufirst%3DS.%2BG.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%2520as%2520Anticancer%2520Drugs%253A%2520Recent%2520Advances%2520%25282015%25E2%2580%25932019%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126637%26doi%3D10.1016%2Fj.bmcl.2019.126637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingarra, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oumata, N.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Development of Cyclin-Dependent Kinase 7 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">111641</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.ejmech.2019.111641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31514062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGmsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2019&pages=111641&author=Y.+Tengauthor=K.+Luauthor=Q.+Zhangauthor=L.+Zhaoauthor=Y.+Huangauthor=A.+M.+Ingarraauthor=H.+Galonsauthor=T.+Liauthor=S.+Cuiauthor=P.+Yuauthor=N.+Oumata&title=Recent+Advances+in+the+Development+of+Cyclin-Dependent+Kinase+7+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of cyclin-dependent kinase 7 inhibitors</span></div><div class="casAuthors">Teng, Yuou; Lu, Kui; Zhang, Qian; Zhao, Lianbo; Huang, Yuna; Ingarra, Angela Maria; Galons, Herve; Li, Tingshen; Cui, Shanshan; Yu, Peng; Oumata, Nassima</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111641</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Cyclin dependent kinase 7 (CDK7) plays a double role as it activates several other cyclin dependent kinases and participates to the initiation of transcription.  This kinase is overexpressed in various types of tumors.  Relatively few selective CDK7 inhibitors have been up to now disclosed.  Most of these inhibitors belong to two chem. families: pyrazolopyrimidines and pyrazolotriazines on one side and pyrimidines on another side.  They also differ by their mol. mechanism of action.  Some are acting as competitive inhibitors and some others are covalent inhibitors.  With these tools, the understanding of the potential therapeutic interest of CDK7 inhibitors in cancer is rapidly growing.  They display antiproliferative activity against various types of tumors and leukemia and synergies have been identified.  Two inhibitors are undergoing clin. testing.  The most potent compds. inhibit a large no. of cell-lines with IC50 < 200 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvrYOLV98iBLVg90H21EOLACvtfcHk0ljutZWWygksjA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGmsrrP&md5=b9610495cc6fb3e1aafc621cb18fe292</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111641%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DIngarra%26aufirst%3DA.%2BM.%26aulast%3DGalons%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DOumata%26aufirst%3DN.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Development%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D183%26spage%3D111641%26doi%3D10.1016%2Fj.ejmech.2019.111641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The Crystal Structure of Human CDK7 and its Protein Recognition Properties</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2079</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.str.2004.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=15530371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVOrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2067-2079&issue=11&author=G.+Lolliauthor=E.+D.+Loweauthor=N.+R.+Brownauthor=L.+N.+Johnson&title=The+Crystal+Structure+of+Human+CDK7+and+its+Protein+Recognition+Properties&doi=10.1016%2Fj.str.2004.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of Human CDK7 and Its Protein Recognition Properties</span></div><div class="casAuthors">Lolli, Graziano; Lowe, Edward D.; Brown, Nick R.; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2067-2079</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle.  CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex.  For max. activity and stability, CDK7 requires phosphorylation, assocn. with cyclin H, and assocn. with a third protein, MAT1.  We have detd. the crystal structure of human CDK7 in complex with ATP at 3Å resoln.  The kinase is in the inactive conformation, similar to that obsd. for inactive CDK2.  The activation segment is phosphorylated at Thr170 and is in a defined conformation that differs from that in phospho-CDK2 and phospho-CDK2/cyclin A.  The functional properties of the enzyme against CDK2 and CTD as substrates are characterized through kinase assays.  Expts. confirm that CDK7 is not a substrate for kinase-assocd. phosphatase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpKkVuAvQ7LVg90H21EOLACvtfcHk0liA73i3Edu1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVOrs7Y%253D&md5=b090d554993e8968c64d28fabaf6a507</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520Crystal%2520Structure%2520of%2520Human%2520CDK7%2520and%2520its%2520Protein%2520Recognition%2520Properties%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26issue%3D11%26spage%3D2067%26epage%3D2079%26doi%3D10.1016%2Fj.str.2004.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span> <span> </span><span class="NLM_article-title">Structural Dissection of Cyclin Dependent Kinases Regulation and Protein Recognition Properties</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1561</span>, <span class="refDoi"> DOI: 10.4161/cc.9.8.11195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.4161%2Fcc.9.8.11195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=20372077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1551-1561&issue=8&author=G.+Lolli&title=Structural+Dissection+of+Cyclin+Dependent+Kinases+Regulation+and+Protein+Recognition+Properties&doi=10.4161%2Fcc.9.8.11195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural dissection of cyclin dependent kinases regulation and protein recognition properties</span></div><div class="casAuthors">Lolli, Graziano</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1551-1561</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addn. to functions in the nervous system.  They are regulated by their cyclin partners and by a variety of addnl. protein effectors (inhibitors, kinases, phosphatases).  Each CDK serves its function by means of specific protein recognition properties.  These are also responsible for the differential regulation of CDKs/Cyclin couples involved in processes as different as cell cycle and transcription.  The structural features detg. general and specific properties for CDKs/Cyclin complexes are analyzed.  They reside in an overall conserved architecture with divergent spots used by the complexes to present themselves to specific substrates or other protein effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq28MAQ6SOxDLVg90H21EOLACvtfcHk0liA73i3Edu1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP&md5=34d193f3e930ba5043f152a252063f36</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.8.11195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.8.11195%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DG.%26atitle%3DStructural%2520Dissection%2520of%2520Cyclin%2520Dependent%2520Kinases%2520Regulation%2520and%2520Protein%2520Recognition%2520Properties%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26issue%3D8%26spage%3D1551%26epage%3D1561%26doi%3D10.4161%2Fcc.9.8.11195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into the Functional Diversity of the CDK–Cyclin Family</span>. <i>Open Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">180112</span>, <span class="refDoi"> DOI: 10.1098/rsob.180112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1098%2Frsob.180112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30185601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVajsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=180112&issue=9&author=D.+J.+Woodauthor=J.+A.+Endicott&title=Structural+Insights+into+the+Functional+Diversity+of+the+CDK%E2%80%93Cyclin+Family&doi=10.1098%2Frsob.180112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the functional diversity of the CDK - cyclin family</span></div><div class="casAuthors">Wood, Daniel J.; Endicott, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">Open Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">180112/1-180112/26</span>CODEN:
                <span class="NLM_cas:coden">OBPICQ</span>;
        ISSN:<span class="NLM_cas:issn">2046-2441</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Since their characterization as conserved modules that regulate progression through the eukaryotic cell cycle, cyclin-dependent protein kinases (CDKs) in higher eukaryotic cells are now also emerging as significant regulators of transcription, metab. and cell differentiation.  The cyclins, though originally characterized as CDK partners, also have CDK-independent roles that include the regulation of DNA damage repair and transcriptional programs that direct cell differentiation, apoptosis and metabolic flux.  This review compares the structures of the members of the CDK and cyclin families detd. by X-ray crystallog., and considers what mechanistic insights they provide to guide functional studies and distinguish CDK- and cyclin-specific activities.  Aberrant CDK activity is a hallmark of a no. of diseases, and structural studies can provide important insights to identify novel routes to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOkS3eVCOYErVg90H21EOLACvtfcHk0liA73i3Edu1tA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVajsrc%253D&md5=f3ae7b31eb93ebe607a68f46b1a7bf58</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1098%2Frsob.180112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsob.180112%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DD.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Functional%2520Diversity%2520of%2520the%2520CDK%25E2%2580%2593Cyclin%2520Family%26jtitle%3DOpen%2520Biol.%26date%3D2018%26volume%3D8%26issue%3D9%26spage%3D180112%26doi%3D10.1098%2Frsob.180112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolhurst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span> <span> </span><span class="NLM_article-title">The Development of a Selective Cyclin-Dependent Kinase Inhibitor that Shows Antitumor Activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6208</span>– <span class="NLM_lpage">6215</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-0301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F0008-5472.CAN-09-0301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=19638587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Cgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6208-6215&issue=15&author=S.+Aliauthor=D.+A.+Heathcoteauthor=S.+H.+Krollauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=H.+Patelauthor=J.+Brackowauthor=A.+Siwickaauthor=M.+J.+Fuchterauthor=M.+Periyasamyauthor=R.+S.+Tolhurstauthor=S.+K.+Kannegantiauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=E.+O.+Aboagyeauthor=A.+G.+Barrettauthor=R.+C.+Coombes&title=The+Development+of+a+Selective+Cyclin-Dependent+Kinase+Inhibitor+that+Shows+Antitumor+Activity&doi=10.1158%2F0008-5472.CAN-09-0301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity</span></div><div class="casAuthors">Ali, Simak; Heathcote, Dean A.; Kroll, Sebastian H. B.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Patel, Hetal; Brackow, Jan; Siwicka, Alekasandra; Fuchter, Matthew J.; Periyasamy, Manikandan; Tolhurst, Robert S.; Kanneganti, Seshu K.; Snyder, James P.; Liotta, Dennis C.; Aboagye, Eric O.; Barrett, Anthony G. M.; Coombes, R. Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6208-6215</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Normal progression through the cell cycle requires the sequential action of cyclin-dependent kinases CDK1, CDK2, CDK4, and CDK6.  Direct or indirect deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents.  The CDK-activating kinase (CAK) plays a crit. role in regulating cell cycle by mediating the activating phosphorylation of CDK1, CDK2, CDK4, and CDK6.  As such, CDK7, which also regulates transcription as part of the TFIIH basal transcription factor, is an attractive target for the development of anticancer drugs.  Computer modeling of the CDK7 structure was used to design potential potent CDK7 inhibitors.  Here, we show that a pyrazolo[1,5-a]pyrimidine-derived compd., BS-181, inhibited CAK activity with an IC50 of 21 nmol/L.  Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concns. lower than 1 μmol/L, with CDK2 being inhibited 35-fold less potently (IC50 880 nmol/L) than CDK7.  In MCF-7 cells, BS-181 inhibited the phosphorylation of CDK7 substrates, promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines, and showed antitumor effects in vivo.  The drug was stable in vivo with a plasma elimination half-life in mice of 405 min after i.p. administration of 10 mg/kg.  The same dose of drug inhibited the growth of MCF-7 human xenografts in nude mice.  BS-181 therefore provides the first example of a potent and selective CDK7 inhibitor with potential as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqID6wwGAnx6LVg90H21EOLACvtfcHk0ljLgiKlh2vuug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Cgtbs%253D&md5=9a6fa4d9871a203ee3ba27fd971ceb98</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-0301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-0301%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DS.%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DTolhurst%26aufirst%3DR.%2BS.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26atitle%3DThe%2520Development%2520of%2520a%2520Selective%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%2520that%2520Shows%2520Antitumor%2520Activity%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D15%26spage%3D6208%26epage%3D6215%26doi%3D10.1158%2F0008-5472.CAN-09-0301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span>; <span class="NLM_string-name">Kroll, S.</span>; <span class="NLM_string-name">Barrett, A.</span>; <span class="NLM_string-name">Fuchter, M.</span>; <span class="NLM_string-name">Slafer, B.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, C.</span>; <span class="NLM_string-name">Snyder, J. P.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]pyrimidine-5,7-diamine Compounds as CDK Inhibitors and their Therapeutic Use</span>. <span class="NLM_patent">US20160362410A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Bondke&author=S.+Kroll&author=A.+Barrett&author=M.+Fuchter&author=B.+Slafer&author=S.+Ali&author=C.+Coombes&author=J.+P.+Snyder&title=Pyrazolo%5B1%2C5-a%5Dpyrimidine-5%2C7-diamine+Compounds+as+CDK+Inhibitors+and+their+Therapeutic+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBondke%26aufirst%3DA.%26atitle%3DPyrazolo%255B1%252C5-a%255Dpyrimidine-5%252C7-diamine%2520Compounds%2520as%2520CDK%2520Inhibitors%2520and%2520their%2520Therapeutic%2520Use%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slafer, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buluwela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1535-7163.MCT-16-0847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29545334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1156-1166&issue=6&author=H.+Patelauthor=M.+Periyasamyauthor=G.+P.+Savaauthor=A.+Bondkeauthor=B.+W.+Slaferauthor=S.+H.+Krollauthor=M.+Barbazangesauthor=R.+Starkeyauthor=S.+Ottavianiauthor=A.+Harrodauthor=E.+O.+Aboagyeauthor=L.+Buluwelaauthor=M.+J.+Fuchterauthor=A.+G.+M.+Barrettauthor=R.+C.+Coombesauthor=S.+Ali&title=ICEC0942%2C+an+Orally+Bioavailable+Selective+Inhibitor+of+CDK7+for+Cancer+Treatment&doi=10.1158%2F1535-7163.MCT-16-0847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment</span></div><div class="casAuthors">Patel, Hetal; Periyasamy, Manikandan; Sava, Georgina P.; Bondke, Alexander; Slafer, Brian W.; Kroll, Sebastian H. B.; Barbazanges, Marion; Starkey, Richard; Ottaviani, Silvia; Harrod, Alison; Aboagye, Eric O.; Buluwela, Laki; Fuchter, Matthew J.; Barrett, Anthony G. M.; Coombes, R. Charles; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1156-1166</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent reports indicate that some cancer types are esp. sensitive to transcription inhibition, suggesting that targeting the transcriptional machinery provides new approaches to cancer treatment.  Cyclin-dependent kinase (CDK)7 is necessary for transcription, and acts by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (PolII) to enable transcription initiation.  CDK7 addnl. regulates the activities of a no. of transcription factors, including estrogen receptor (ER)-α.  Here we describe a new, orally bioavailable CDK7 inhibitor, ICEC0942.  It selectively inhibits CDK7, with an IC50 of 40 nmol/L; IC50 values for CDK1, CDK2, CDK5, and CDK9 were 45-, 15-, 230-, and 30-fold higher.  In vitro studies show that a wide range of cancer types are sensitive to CDK7 inhibition with GI50 values ranging between 0.2 and 0.3 μmol/L.  In xenografts of both breast and colorectal cancers, the drug has substantial antitumor effects.  In addn., combination therapy with tamoxifen showed complete growth arrest of ER-pos. tumor xenografts.  Our findings reveal that CDK7 inhibition provides a new approach, esp. for ER-pos. breast cancer and identify ICEC0942 as a prototype drug with potential utility as a single agent or in combination with hormone therapies for breast cancer.  ICEC0942 may also be effective in other cancers that display characteristics of transcription factor addiction, such as acute leukemia and small-cell lung cancer.  Mol Cancer Ther; 17(6); 1156-66. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5aOnz0_JSSbVg90H21EOLACvtfcHk0ljLgiKlh2vuug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3M&md5=097bb6632e5c57b5e0a128385b319d7d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0847%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DSava%26aufirst%3DG.%2BP.%26aulast%3DBondke%26aufirst%3DA.%26aulast%3DSlafer%26aufirst%3DB.%2BW.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DStarkey%26aufirst%3DR.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DHarrod%26aufirst%3DA.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DBuluwela%26aufirst%3DL.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%2BM.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DICEC0942%252C%2520an%2520Orally%2520Bioavailable%2520Selective%2520Inhibitor%2520of%2520CDK7%2520for%2520Cancer%2520Treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D6%26spage%3D1156%26epage%3D1166%26doi%3D10.1158%2F1535-7163.MCT-16-0847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemcke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisterernst, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3688</span>, <span class="refDoi"> DOI: 10.1128/MCB.00595-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FMCB.00595-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25047832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12jsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3675-3688&issue=19&author=T.+W.+Kelsoauthor=K.+Baumgartauthor=J.+Eickhoffauthor=T.+Albertauthor=C.+Antrechtauthor=S.+Lemckeauthor=B.+Kleblauthor=M.+Meisterernst&title=Cyclin-Dependent+Kinase+7+Controls+mRNA+Synthesis+by+Affecting+Stability+of+Preinitiation+Complexes%2C+Leading+to+Altered+Gene+Expression%2C+Cell+Cycle+Progression%2C+and+Survival+of+Tumor+Cells&doi=10.1128%2FMCB.00595-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression and survival of tumor cells</span></div><div class="casAuthors">Kelso, Timothy W. R.; Baumgart, Karen; Eickhoff, Jan; Albert, Thomas; Antrecht, Claudia; Lemcke, Sarah; Klebl, Bert; Meisterernst, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3675-3688, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) activates cell cycle CDKs and is a member of the general transcription factor TFIIH.  Although there is substantial evidence for an active role of CDK7 in mRNA synthesis and assocd. processes, the degree of its influence on global and gene-specific transcription in mammalian species is unclear.  In the current study, we utilize two novel inhibitors with high specificity for CDK7 to demonstrate a restricted but robust impact of CDK7 on gene transcription in vivo and in in vitro-reconstituted reactions.  We distinguish between relative low- and high-dose responses and relate them to distinct mol. mechanisms and altered physiol. responses.  Low inhibitor doses cause rapid clearance of paused RNA polymerase II (RNAPII) mols. and sufficed to cause genome-wide alterations in gene expression, delays in cell cycle progression at both the G1/S and G2/M checkpoints and diminished survival of human tumor cells.  Higher doses and prolonged inhibition led to strong redns. in RNAPII carboxyl-terminal domain (CTD) phosphorylation, eventual activation of the p53 program and increased cell death.  Together, our data reason for a quant. contribution of CDK7 to mRNA synthesis, which is crit. for cellular homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcBXPoLwf8YLVg90H21EOLACvtfcHk0ljLgiKlh2vuug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12jsL%252FL&md5=69cdab044f79f1e71b9fe30dedda717c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FMCB.00595-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00595-14%26sid%3Dliteratum%253Aachs%26aulast%3DKelso%26aufirst%3DT.%2BW.%26aulast%3DBaumgart%26aufirst%3DK.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DAlbert%26aufirst%3DT.%26aulast%3DAntrecht%26aufirst%3DC.%26aulast%3DLemcke%26aufirst%3DS.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMeisterernst%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Controls%2520mRNA%2520Synthesis%2520by%2520Affecting%2520Stability%2520of%2520Preinitiation%2520Complexes%252C%2520Leading%2520to%2520Altered%2520Gene%2520Expression%252C%2520Cell%2520Cycle%2520Progression%252C%2520and%2520Survival%2520of%2520Tumor%2520Cells%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26issue%3D19%26spage%3D3675%26epage%3D3688%26doi%3D10.1128%2FMCB.00595-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekardová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vymĕtalová, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khirsariya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kováčová, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylsová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanfrlík, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and its Analogues Having Bioisosteric Central Heterocycles</span>. <i>ChemPhysChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1002/cphc.201601319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fcphc.201601319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28128514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislOgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=785-795&issue=7&author=M.+Nekardov%C3%A1author=L.+Vym%C4%95talov%C3%A1author=P.+Khirsariyaauthor=S.+Kov%C3%A1%C4%8Dov%C3%A1author=M.+Hylsov%C3%A1author=R.+Jordaauthor=V.+Kry%C5%A1tofauthor=J.+Fanfrl%C3%ADkauthor=P.+Hobzaauthor=K.+Paruch&title=Structural+Basis+of+the+Interaction+of+Cyclin-Dependent+Kinase+2+with+Roscovitine+and+its+Analogues+Having+Bioisosteric+Central+Heterocycles&doi=10.1002%2Fcphc.201601319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles</span></div><div class="casAuthors">Nekardova, Michaela; Vymetalova, Ladislava; Khirsariya, Prashant; Kovacova, Silvia; Hylsova, Michaela; Jorda, Radek; Krystof, Vladimir; Fanfrlik, Jindrich; Hobza, Pavel; Paruch, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">ChemPhysChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">785-795</span>CODEN:
                <span class="NLM_cas:coden">CPCHFT</span>;
        ISSN:<span class="NLM_cas:issn">1439-4235</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The structural basis for the interaction of roscovitine and analogs contg. 13 different bioisosteric central heterocycles with the enzyme cyclin-dependent kinase 2 (CDK2) is elucidated.  Although all the central scaffolds are very similar to the purine core of roscovitine, the exptl. detd. IC50 values of the inhibitors span three orders of magnitude.  By using an extensive computational chem. approach, the affinities of the inhibitors to CDK2 are detd. as calcd. binding scores of complexes of the inhibitors with the protein.  The interactions of the inhibitors with CDK2 are computationally described by using a hybrid quantum mechanics/semi-empirical quantum mechanics method (QM/SQM), which combines the DFT-D method for the QM part and the PM6-D3H4X method for the SQM part.  The solvent effect is described by the COSMO implicit solvation model at the SQM level for the whole system.  The contributions of the scaffolds and the individual substituents, quantified and evaluated in relation to conformations of optimized protein-inhibitor complexes, are found not to be simply additive.  The inhibitory activity of the selected candidates, including two newly prepd. compds., is tested against CDK2.  The results of the calcns. are in close agreement with the exptl. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHTqWv47eXK7Vg90H21EOLACvtfcHk0lgzsRkRXx8kUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislOgt78%253D&md5=222a27e05756ada8610ba14c87fa4627</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcphc.201601319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphc.201601319%26sid%3Dliteratum%253Aachs%26aulast%3DNekardov%25C3%25A1%26aufirst%3DM.%26aulast%3DVym%25C4%2595talov%25C3%25A1%26aufirst%3DL.%26aulast%3DKhirsariya%26aufirst%3DP.%26aulast%3DKov%25C3%25A1%25C4%258Dov%25C3%25A1%26aufirst%3DS.%26aulast%3DHylsov%25C3%25A1%26aufirst%3DM.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26aulast%3DFanfrl%25C3%25ADk%26aufirst%3DJ.%26aulast%3DHobza%26aufirst%3DP.%26aulast%3DParuch%26aufirst%3DK.%26atitle%3DStructural%2520Basis%2520of%2520the%2520Interaction%2520of%2520Cyclin-Dependent%2520Kinase%25202%2520with%2520Roscovitine%2520and%2520its%2520Analogues%2520Having%2520Bioisosteric%2520Central%2520Heterocycles%26jtitle%3DChemPhysChem%26date%3D2017%26volume%3D18%26issue%3D7%26spage%3D785%26epage%3D795%26doi%3D10.1002%2Fcphc.201601319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span>; <span class="NLM_string-name">Snyder, J. P.</span>; <span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Barrett, A. G.</span>; <span class="NLM_string-name">Coombes, R. C. D. S.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Siwicka, A.</span>; <span class="NLM_string-name">Brackow, J.</span>; <span class="NLM_string-name">Scheiper, B.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors for Cyclin-Dependent Kinases</span>. CA<span class="NLM_patent">CA2688616A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+S.+Jogalekar&author=J.+P.+Snyder&author=D.+C.+Liotta&author=A.+G.+Barrett&author=R.+C.+D.+S.+Coombes&author=S.+Ali&author=A.+Siwicka&author=J.+Brackow&author=B.+Scheiper&title=Selective+Inhibitors+for+Cyclin-Dependent+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26atitle%3DSelective%2520Inhibitors%2520for%2520Cyclin-Dependent%2520Kinases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2974</span>– <span class="NLM_lpage">2980</span>, <span class="refDoi"> DOI: 10.2174/138161212800672804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.2174%2F138161212800672804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=22571665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2974-2980&issue=20&author=R.+Jordaauthor=K.+Paruchauthor=V.+Krystof&title=Cyclin-Dependent+Kinase+Inhibitors+Inspired+by+Roscovitine%3A+Purine+Bioisosteres&doi=10.2174%2F138161212800672804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres</span></div><div class="casAuthors">Jorda, Radek; Paruch, Kamil; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2974-2980</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clin. trials as a candidate drug for some oncol. indications.  Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies.  This article reviews known roscovitine bioisosteres that have been prepd. as CDK inhibitors using different core heterocycles.  The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochem. activity - only six direct analogs contg. different purine bioisosteres have been prepd. and evaluated side by side with roscovitine.  Only four types of bioisosteres have demonstrated improved biol. properties, namely pyrazolo[1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotYtawOBwFJLVg90H21EOLACvtfcHk0lgzsRkRXx8kUw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFalt74%253D&md5=f5a2841359f53407dbbb667cb7b5772d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F138161212800672804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672804%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DCyclin-Dependent%2520Kinase%2520Inhibitors%2520Inspired%2520by%2520Roscovitine%253A%2520Purine%2520Bioisosteres%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26issue%3D20%26spage%3D2974%26epage%3D2980%26doi%3D10.2174%2F138161212800672804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alikian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemont, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">A Novel Pyrazolo[1,5-<i>a</i>]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8508</span>– <span class="NLM_lpage">8522</span>, <span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&issue=24&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazangesauthor=A.+Blumauthor=J.+Brackowauthor=A.+Siwickaauthor=R.+D.+Paceauthor=M.+J.+Fuchterauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=P.+S.+Freemontauthor=E.+O.+Aboagyeauthor=R.+C.+Coombesauthor=A.+G.+Barrettauthor=S.+Ali&title=A+Novel+Pyrazolo%5B1%2C5-a%5Dpyrimidine+Is+a+Potent+Inhibitor+of+Cyclin-Dependent+Protein+Kinases+1%2C+2%2C+and+9%2C+Which+Demonstrates+Antitumor+Effects+in+Human+Tumor+Xenografts+Following+Oral+Administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0lhD-nPaNY-T6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DR.%2BD.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DA%2520Novel%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin-Dependent%2520Protein%2520Kinases%25201%252C%25202%252C%2520and%25209%252C%2520Which%2520Demonstrates%2520Antitumor%2520Effects%2520in%2520Human%2520Tumor%2520Xenografts%2520Following%2520Oral%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaliszczak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span> <span> </span><span class="NLM_article-title">Development of a Cyclin-Dependent Kinase Inhibitor Devoid of ABC Transporter-Dependent Drug Resistance</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2367</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fbjc.2013.584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=24071597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFeqt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2013&pages=2356-2367&issue=9&author=M.+Kaliszczakauthor=H.+Patelauthor=S.+Krollauthor=L.+Carrollauthor=G.+Smithauthor=S.+Delaneyauthor=D.+Heathcoteauthor=A.+Bondkeauthor=M.+Fuchterauthor=R.+Coombesauthor=A.+G.+Barrettauthor=S.+Aliauthor=E.+O.+Aboagye&title=Development+of+a+Cyclin-Dependent+Kinase+Inhibitor+Devoid+of+ABC+Transporter-Dependent+Drug+Resistance&doi=10.1038%2Fbjc.2013.584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance</span></div><div class="casAuthors">Kaliszczak, M.; Patel, H.; Kroll, S. H. B.; Carroll, L.; Smith, G.; Delaney, S.; Heathcote, D. A.; Bondke, A.; Fuchter, M. J.; Coombes, R. C.; Barrett, A. G. M.; Ali, S.; Aboagye, E. O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2356-2367</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Cyclin-dependent kinases (CDKs) control cell cycle progression, RNA transcription and apoptosis, making them attractive targets for anticancer drug development.  Unfortunately, CDK inhibitors developed to date have demonstrated variable efficacy.  Methods: We generated drug-resistant cells by continuous low-dose exposure to a model pyrazolo[1,5-a]pyrimidine CDK inhibitor and investigated potential structural alterations for optimal efficacy.  Results: We identified induction of the ATP-binding cassette (ABC) transporters, ABCB1 and ABCG2, in resistant cells.  Assessment of features involved in the ABC transporter substrate specificity from a compd. library revealed high polar surface area (>100 Å2) as a key determinant of transporter interaction.  We developed ICEC-0782 that preferentially inhibited CDK2, CDK7 and CDK9 in the nanomolar range.  The compd. inhibited phosphorylation of CDK substrates and downregulated the short-lived proteins, Mcl-1 and cyclin D1.  ICEC-0782 induced G2/M arrest and apoptosis.  The permeability and cytotoxicity of ICEC-0782 were unaffected by ABC transporter expression.  Following daily oral dosing, the compd. inhibited growth of human colon HCT-116 and human breast MCF7 tumor xenografts in vivo by 84% and 94%, resp.  Conclusion: We identified a promising pyrazolo[1,5-a]pyrimidine compd. devoid of ABC transporter interaction, highly suitable for further preclin. and clin. evaluation for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi1gofdYFccrVg90H21EOLACvtfcHk0lhD-nPaNY-T6A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFeqt7bP&md5=ebc44722d641bd567b7899f10de4c137</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.584%26sid%3Dliteratum%253Aachs%26aulast%3DKaliszczak%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%26aulast%3DCarroll%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DDelaney%26aufirst%3DS.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DBondke%26aufirst%3DA.%26aulast%3DFuchter%26aufirst%3DM.%26aulast%3DCoombes%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26atitle%3DDevelopment%2520of%2520a%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%2520Devoid%2520of%2520ABC%2520Transporter-Dependent%2520Drug%2520Resistance%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D109%26issue%3D9%26spage%3D2356%26epage%3D2367%26doi%3D10.1038%2Fbjc.2013.584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lusvarghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buluwela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">ABC-Transporter Upregulation Mediates Resistance to the CDK7 Inhibitors THZ1 and ICEC0942</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-1008-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41388-019-1008-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31462710" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=1-13&author=G.+P.+Savaauthor=H.+Fanauthor=R.+A.+Fisherauthor=S.+Lusvarghiauthor=S.+Pancholiauthor=S.+V.+Ambudkarauthor=L.-A.+Martinauthor=R.+C.+Coombesauthor=L.+Buluwelaauthor=S.+Ali&title=ABC-Transporter+Upregulation+Mediates+Resistance+to+the+CDK7+Inhibitors+THZ1+and+ICEC0942&doi=10.1038%2Fs41388-019-1008-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-1008-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-1008-y%26sid%3Dliteratum%253Aachs%26aulast%3DSava%26aufirst%3DG.%2BP.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DLusvarghi%26aufirst%3DS.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DMartin%26aufirst%3DL.-A.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBuluwela%26aufirst%3DL.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DABC-Transporter%2520Upregulation%2520Mediates%2520Resistance%2520to%2520the%2520CDK7%2520Inhibitors%2520THZ1%2520and%2520ICEC0942%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D1%26epage%3D13%26doi%3D10.1038%2Fs41388-019-1008-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemont, P. S.</span></span> <span> </span><span class="NLM_article-title">Inhibitor Selectivity for Cyclin-Dependent Kinase 7: a Structural, Thermodynamic, and Modelling Study</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fcmdc.201600535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28125165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFegsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=372-380&issue=5&author=P.+Hazelauthor=S.+H.+Krollauthor=A.+Bondkeauthor=M.+Barbazangesauthor=H.+Patelauthor=M.+J.+Fuchterauthor=R.+C.+Coombesauthor=S.+Aliauthor=A.+G.+Barrettauthor=P.+S.+Freemont&title=Inhibitor+Selectivity+for+Cyclin-Dependent+Kinase+7%3A+a+Structural%2C+Thermodynamic%2C+and+Modelling+Study&doi=10.1002%2Fcmdc.201600535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor selectivity for cyclin-dependent kinase 7: A structural, thermodynamic, and modeling study</span></div><div class="casAuthors">Hazel, Pascale; Kroll, Sebastian H. B.; Bondke, Alexander; Barbazanges, Marion; Patel, Hetal; Fuchter, Matthew J.; Coombes, R. Charles; Ali, Simak; Barrett, Anthony G. M.; Freemont, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Deregulation of the cell cycle by mechanisms that lead to elevated activities of cyclin-dependent kinases (CDKs) is a feature of many human diseases, cancer in particular.  Here, we identified small-mol.-wt. inhibitors that selectively inhibit CDK7, the kinase that phosphorylates cell-cycle CDKs to promote their activities.  To investigate the selectivity of these inhibitors, we used a combination of structural, biophys., and modeling approaches.  We detd. the crystal structures of CDK7-selective compds. ICEC 0942 and ICEC 0943 bound to CDK2, and used these to build models of inhibitor binding to CDK7.  Mol. dynamics (MD) simulations of inhibitors bound to CDK2 and CDK7 generated possible models of inhibitor binding.  To exptl. validate these models, we gathered isothermal titrn. calorimetry (ITC) binding data for recombinant wild-type and binding site mutants of CDK7 and CDK2.  We identified specific residues of CDK7, notably Asp-155, that were involved in detg. inhibitor selectivity.  The MD simulations also showed that the flexibility of the G-rich and activation loops of CDK7 is likely an important determinant of inhibitor specificity similar to CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkKGwMKK6Xb7Vg90H21EOLACvtfcHk0lhSDICO4rhqAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFegsb8%253D&md5=7fb792661b58d7e3d0859c2630dccdae</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600535%26sid%3Dliteratum%253Aachs%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DBondke%26aufirst%3DA.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26atitle%3DInhibitor%2520Selectivity%2520for%2520Cyclin-Dependent%2520Kinase%25207%253A%2520a%2520Structural%252C%2520Thermodynamic%252C%2520and%2520Modelling%2520Study%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26issue%3D5%26spage%3D372%26epage%3D380%26doi%3D10.1002%2Fcmdc.201600535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutterer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milbradt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeitträger, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahsi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zischinsky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, M.</span></span> <span> </span><span class="NLM_article-title">A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2062</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1128/AAC.04534-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FAAC.04534-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25624324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=2062-2071&issue=4&author=C.+Huttererauthor=J.+Eickhoffauthor=J.+Milbradtauthor=K.+Kornauthor=I.+Zeittr%C3%A4gerauthor=H.+Bahsiauthor=S.+Wagnerauthor=G.+Zischinskyauthor=A.+Wolfauthor=C.+Degenhartauthor=A.+Ungerauthor=M.+Baumannauthor=B.+Kleblauthor=M.+Marschall&title=A+Novel+CDK7+Inhibitor+of+the+Pyrazolotriazine+Class+Exerts+Broad-Spectrum+Antiviral+Activity+at+Nanomolar+Concentrations&doi=10.1128%2FAAC.04534-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations</span></div><div class="casAuthors">Hutterer Corina; Milbradt Jens; Korn Klaus; Zeittrager Isabel; Bahsi Hanife; Wagner Sabrina; Marschall Manfred; Eickhoff Jan; Zischinsky Gunther; Wolf Alexander; Degenhart Carsten; Unger Anke; Baumann Matthias; Klebl Bert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial agents and chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2062-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein kinases represent central and multifunctional regulators of a balanced virus-host interaction.  Cyclin-dependent protein kinase 7 (CDK7) plays crucial regulatory roles in cell cycle and transcription, both connected with the replication of many viruses.  Previously, we developed a CDK7 inhibitor, LDC4297, that inhibits CDK7 in vitro in the nano-picomolar range.  Novel data from a kinome-wide evaluation (>330 kinases profiled in vitro) demonstrate a kinase selectivity.  Importantly, we provide first evidence for the antiviral potential of the CDK7 inhibitor LDC4297, i.e., in exerting a block of the replication of human cytomegalovirus (HCMV) in primary human fibroblasts at nanomolar concentrations (50% effective concentration, 24.5 ± 1.3 nM).  As a unique feature compared to approved antiherpesviral drugs, inhibition occurred already at the immediate-early level of HCMV gene expression.  The mode of antiviral action was considered multifaceted since CDK7-regulated cellular factors that are supportive of HCMV replication were substantially affected by the inhibitors.  An effect of LDC4297 was identified in the interference with HCMV-driven inactivation of retinoblastoma protein (Rb), a regulatory step generally considered a hallmark of herpesviral replication.  In line with this finding, a broad inhibitory activity of the drug could be demonstrated against a selection of human and animal herpesviruses and adenoviruses, whereas other viruses only showed intermediate drug sensitivity.  Summarized, the CDK7 inhibitor LDC4297 is a promising candidate for further antiviral drug development, possibly offering new options for a comprehensive approach to antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZOhFUzosBFOdfST00W0BcfW6udTcc2eZTVcy4i4PHybntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D&md5=57c36db4aa7415d9023016868151ba3f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1128%2FAAC.04534-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04534-14%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DMilbradt%26aufirst%3DJ.%26aulast%3DKorn%26aufirst%3DK.%26aulast%3DZeittr%25C3%25A4ger%26aufirst%3DI.%26aulast%3DBahsi%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DZischinsky%26aufirst%3DG.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DDegenhart%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMarschall%26aufirst%3DM.%26atitle%3DA%2520Novel%2520CDK7%2520Inhibitor%2520of%2520the%2520Pyrazolotriazine%2520Class%2520Exerts%2520Broad-Spectrum%2520Antiviral%2520Activity%2520at%2520Nanomolar%2520Concentrations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D4%26spage%3D2062%26epage%3D2071%26doi%3D10.1128%2FAAC.04534-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahl, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amzallag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Transcription Regulation in Cancer with a Covalent CDK7 Inhibitor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>511</i></span> (<span class="NLM_issue">7511</span>),  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1038/nature13393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnature13393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25043025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=616-620&issue=7511&author=N.+Kwiatkowskiauthor=T.+Zhangauthor=P.+B.+Rahlauthor=B.+J.+Abrahamauthor=J.+Reddyauthor=S.+B.+Ficarroauthor=A.+Dasturauthor=A.+Amzallagauthor=S.+Ramaswamyauthor=B.+Tesarauthor=C.+E.+Jenkinsauthor=N.+M.+Hannettauthor=D.+McMillinauthor=T.+Sandaauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Lookauthor=C.+S.+Mitsiadesauthor=A.+P.+Wengauthor=J.+R.+Brownauthor=C.+H.+Benesauthor=J.+A.+Martoauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Targeting+Transcription+Regulation+in+Cancer+with+a+Covalent+CDK7+Inhibitor&doi=10.1038%2Fnature13393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting transcription regulation in cancer with a covalent CDK7 inhibitor</span></div><div class="casAuthors">Kwiatkowski, Nicholas; Zhang, Tinghu; Rahl, Peter B.; Abraham, Brian J.; Reddy, Jessica; Ficarro, Scott B.; Dastur, Anahita; Amzallag, Arnaud; Ramaswamy, Sridhar; Tesar, Bethany; Jenkins, Catherine E.; Hannett, Nancy M.; McMillin, Douglas; Sanda, Takaomi; Sim, Taebo; Kim, Nam Doo; Look, Thomas; Mitsiades, Constantine S.; Weng, Andrew P.; Brown, Jennifer R.; Benes, Cyril H.; Marto, Jarrod A.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">616-620</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state, but direct pharmacol. inhibition of transcription factors has so far proven difficult.  However, the transcriptional machinery contains various enzymic cofactors that can be targeted for the development of new therapeutic candidates, including cyclin-dependent kinases (CDKs).  Here the authors present the discovery and characterization of a covalent CDK7 inhibitor, THZ1, which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.  Cancer cell-line profiling indicates that a subset of cancer cell lines, including human T-cell acute lymphoblastic leukemia (T-ALL), have exceptional sensitivity to THZ1.  Genome-wide anal. in Jurkat T-ALL cells shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and the key role of RUNX1 in the core transcriptional regulatory circuitry of these tumor cells.  Pharmacol. modulation of CDK7 kinase activity may thus provide an approach to identify and treat tumor types that are dependent on transcription for maintenance of the oncogenic state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVD-DeTAQCqrVg90H21EOLACvtfcHk0lh1989GYVXQMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF&md5=895a28fb536663a31e7558fe79ce628b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnature13393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13393%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DDastur%26aufirst%3DA.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DTesar%26aufirst%3DB.%26aulast%3DJenkins%26aufirst%3DC.%2BE.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DMcMillin%26aufirst%3DD.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DLook%26aufirst%3DT.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWeng%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Transcription%2520Regulation%2520in%2520Cancer%2520with%2520a%2520Covalent%2520CDK7%2520Inhibitor%26jtitle%3DNature%26date%3D2014%26volume%3D511%26issue%3D7511%26spage%3D616%26epage%3D620%26doi%3D10.1038%2Fnature13393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1021/jm301475f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&issue=3&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28Thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+Are+Highly+Active+CDK9+Inhibitors%3A+Synthesis%2C+X-ray+Crystal+Structures%2C+Structure%E2%80%93Activity+Relationship%2C+and+Anticancer+Activities&doi=10.1021%2Fjm301475f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities</span></div><div class="casAuthors">Shao, Hao; Shi, Shenhua; Huang, Shiliang; Hole, Alison J.; Abbas, Abdullahi Y.; Baumli, Sonja; Liu, Xiangrui; Lam, Frankie; Foley, David W.; Fischer, Peter M.; Noble, Martin; Endicott, Jane A.; Pepper, Chris; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">640-659</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death.  CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells.  We designed a series of 4-thiazol-2-anilinopyrimidine derivs. with functional groups attached to the C5-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity.  One of the most selective compds., 12u (I) inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 vs. CDK2.  X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes.  This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper, provides a rationale for the obsd. SAR.  12U demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B- and T-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOOiqFBF6S7Vg90H21EOLACvtfcHk0lh1989GYVXQMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oqsg%253D%253D&md5=5f490a79f72e445c8d8f9fcb23f5e917</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528Thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520Are%2520Highly%2520Active%2520CDK9%2520Inhibitors%253A%2520Synthesis%252C%2520X-ray%2520Crystal%2520Structures%252C%2520Structure%25E2%2580%2593Activity%2520Relationship%252C%2520and%2520Anticancer%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D3%26spage%3D640%26epage%3D659%26doi%3D10.1021%2Fjm301475f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.chembiol.2017.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29276047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVehtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=135-142&issue=2&author=Y.+Gaoauthor=T.+Zhangauthor=H.+Teraiauthor=S.+B.+Ficarroauthor=N.+Kwiatkowskiauthor=M.-F.+Haoauthor=B.+Sharmaauthor=C.+L.+Christensenauthor=E.+Chipumuroauthor=K.-k.+Wongauthor=J.+A.+Martoauthor=P.+S.+Hammermanauthor=N.+S.+Grayauthor=R.+E.+George&title=Overcoming+Resistance+to+the+THZ+Series+of+Covalent+Transcriptional+CDK+Inhibitors&doi=10.1016%2Fj.chembiol.2017.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors</span></div><div class="casAuthors">Gao, Yang; Zhang, Tinghu; Terai, Hideki; Ficarro, Scott B.; Kwiatkowski, Nicholas; Hao, Ming-Feng; Sharma, Bandana; Christensen, Camilla L.; Chipumuro, Edmond; Wong, Kwok-kin; Marto, Jarrod A.; Hammerman, Peter S.; Gray, Nathanael S.; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-142.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a therapeutic strategy for cancers that rely on aberrant transcription; however, lack of understanding of resistance mechanisms to these agents will likely impede their clin. evolution.  Here, we demonstrate upregulation of multidrug transporters ABCB1 and ABCG2 as a major mode of resistance to THZ1, a covalent inhibitor of CDKs 7, 12, and 13 in neuroblastoma and lung cancer.  To counter this obstacle, we developed a CDK inhibitor, E9, that is not a substrate for ABC transporters, and by selecting for resistance, detd. that it exerts its cytotoxic effects through covalent modification of cysteine 1039 of CDK12.  These results highlight the importance of considering this common mode of resistance in the development of clin. analogs of THZ1, identify a covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux, and demonstrate that target deconvolution can be accomplished through selection for resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrANNBJPMcYQbVg90H21EOLACvtfcHk0liB7y0KxbCh4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVehtLzL&md5=2b579072d0f53f8381886149a31f4e18</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DTerai%26aufirst%3DH.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DHao%26aufirst%3DM.-F.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DChipumuro%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DK.-k.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DOvercoming%2520Resistance%2520to%2520the%2520THZ%2520Series%2520of%2520Covalent%2520Transcriptional%2520CDK%2520Inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3D135%26epage%3D142%26doi%3D10.1016%2Fj.chembiol.2017.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemy, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciblat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprott, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carulli, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Tomaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3491</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-0119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F0008-5472.CAN-19-0119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31064851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3M7jtl2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=3479-3491&issue=13&author=S.+Huauthor=J.+J.+Marineauauthor=N.+Rajagopalauthor=K.+B.+Hammanauthor=Y.+J.+Choiauthor=D.+R.+Schmidtauthor=N.+Keauthor=L.+Johannessenauthor=M.+J.+Bradleyauthor=D.+A.+Orlandoauthor=S.+R.+Alnemyauthor=Y.+Renauthor=S.+Ciblatauthor=D.+K.+Winterauthor=A.+Kabroauthor=K.+T.+Sprottauthor=J.+G.+Hodgsonauthor=C.+C.+Fritzauthor=J.+P.+Carulliauthor=E.+di+Tomasoauthor=E.+R.+Olson&title=Discovery+and+Characterization+of+SY-1365%2C+a+Selective%2C+Covalent+Inhibitor+of+CDK7&doi=10.1158%2F0008-5472.CAN-19-0119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7</span></div><div class="casAuthors">Hu Shanhu; Marineau Jason J; Rajagopal Nisha; Hamman Kristin B; Choi Yoon Jong; Schmidt Darby R; Ke Nan; Johannessen Liv; Bradley Michael J; Orlando David A; Alnemy Sydney R; Ren Yixuan; Sprott Kevin T; Hodgson J Graeme; Fritz Christian C; Carulli John P; di Tomaso Emmanuelle; Olson Eric R; Ciblat Stephane; Winter Dana K; Kabro Anzhelika</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3479-3491</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent studies suggest that targeting transcriptional machinery can lead to potent and selective anticancer effects in cancers dependent on high and constant expression of certain transcription factors for growth and survival.  Cyclin-dependent kinase 7 (CDK7) is the catalytic subunit of the CDK-activating kinase complex.  Its function is required for both cell-cycle regulation and transcriptional control of gene expression.  CDK7 has recently emerged as an attractive cancer target because its inhibition leads to decreased transcript levels of oncogenic transcription factors, especially those associated with super-enhancers.  Here, we describe a selective CDK7 inhibitor SY-1365, which is currently in clinical trials in populations of patients with ovarian and breast cancer (NCT03134638).  In vitro, SY-1365 inhibited cell growth of many different cancer types at nanomolar concentrations.  SY-1365 treatment decreased MCL1 protein levels, and cancer cells with low BCL2L1 (BCL-XL) expression were found to be more sensitive to SY-1365.  Transcriptional changes in acute myeloid leukemia (AML) cell lines were distinct from those following treatment with other transcriptional inhibitors.  SY-1365 demonstrated substantial antitumor effects in multiple AML xenograft models as a single agent; SY-1365-induced growth inhibition was enhanced in combination with the BCL2 inhibitor venetoclax.  Antitumor activity was also observed in xenograft models of ovarian cancer, suggesting the potential for exploring SY-1365 in the clinic in both hematologic and solid tumors.  Our findings support targeting CDK7 as a new approach for treating transcriptionally addicted cancers.  SIGNIFICANCE: These findings demonstrate the molecular mechanism of action and potent antitumor activity of SY-1365, the first selective CDK7 inhibitor to enter clinical investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAyWVFYyjv30kUaC_kzhvyfW6udTcc2ebYuApKWlsDeLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7jtl2iug%253D%253D&md5=4fd24fb5eea04eb6e921f52206f69098</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-0119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-0119%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26aulast%3DRajagopal%26aufirst%3DN.%26aulast%3DHamman%26aufirst%3DK.%2BB.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DKe%26aufirst%3DN.%26aulast%3DJohannessen%26aufirst%3DL.%26aulast%3DBradley%26aufirst%3DM.%2BJ.%26aulast%3DOrlando%26aufirst%3DD.%2BA.%26aulast%3DAlnemy%26aufirst%3DS.%2BR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DCiblat%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DD.%2BK.%26aulast%3DKabro%26aufirst%3DA.%26aulast%3DSprott%26aufirst%3DK.%2BT.%26aulast%3DHodgson%26aufirst%3DJ.%2BG.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26aulast%3DCarulli%26aufirst%3DJ.%2BP.%26aulast%3Ddi%2BTomaso%26aufirst%3DE.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520SY-1365%252C%2520a%2520Selective%252C%2520Covalent%2520Inhibitor%2520of%2520CDK7%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%26spage%3D3479%26epage%3D3491%26doi%3D10.1158%2F0008-5472.CAN-19-0119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon-Clarke, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenleaf, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Covalent Targeting of Remote Cysteine Residues to Develop CDK12 and CDK13 Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnchembio.2166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27571479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=876-884&issue=10&author=T.+Zhangauthor=N.+Kwiatkowskiauthor=C.+M.+Olsonauthor=S.+E.+Dixon-Clarkeauthor=B.+J.+Abrahamauthor=A.+K.+Greifenbergauthor=S.+B.+Ficarroauthor=J.+M.+Elkinsauthor=Y.+Liangauthor=N.+M.+Hannettauthor=T.+Manzauthor=M.+Haoauthor=B.+Bartkowiakauthor=A.+L.+Greenleafauthor=J.+A.+Martoauthor=M.+Geyerauthor=A.+N.+Bullockauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Covalent+Targeting+of+Remote+Cysteine+Residues+to+Develop+CDK12+and+CDK13+Inhibitors&doi=10.1038%2Fnchembio.2166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors</span></div><div class="casAuthors">Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M.; Dixon-Clarke, Sarah E.; Abraham, Brian J.; Greifenberg, Ann K.; Ficarro, Scott B.; Elkins, Jonathan M.; Liang, Yanke; Hannett, Nancy M.; Manz, Theresa; Hao, Mingfeng; Bartkowiak, Bartlomiej; Greenleaf, Arno L.; Marto, Jarrod A.; Geyer, Matthias; Bullock, Alex N.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">876-884</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play crit. roles in the regulation of gene transcription.  However, the absence of CDK12 and CDK13 inhibitors has hindered the ability to investigate the consequences of their inhibition in healthy cells and cancer cells.  Here we describe the rational design of a first-in-class CDK12 and CDK13 covalent inhibitor, THZ531.  Co-crystn. of THZ531 with CDK12-cyclin K indicates that THZ531 irreversibly targets a cysteine located outside the kinase domain.  THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II.  In particular, THZ531 substantially decreases the expression of DNA damage response genes and key super-enhancer-assocd. transcription factor genes.  Coincident with transcriptional perturbation, THZ531 dramatically induced apoptotic cell death.  Small mols. capable of specifically targeting CDK12 and CDK13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIyvy8vbjvrVg90H21EOLACvtfcHk0lh6RGsEUde-Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ&md5=5ac265105d1654e129c3c1325572f389</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2166%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DDixon-Clarke%26aufirst%3DS.%2BE.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DManz%26aufirst%3DT.%26aulast%3DHao%26aufirst%3DM.%26aulast%3DBartkowiak%26aufirst%3DB.%26aulast%3DGreenleaf%26aufirst%3DA.%2BL.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DCovalent%2520Targeting%2520of%2520Remote%2520Cysteine%2520Residues%2520to%2520Develop%2520CDK12%2520and%2520CDK13%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D10%26spage%3D876%26epage%3D884%26doi%3D10.1038%2Fnchembio.2166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsarrag, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Düster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorger, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.chembiol.2019.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30905681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=792-803&issue=6&author=C.+M.+Olsonauthor=Y.+Liangauthor=A.+Leggettauthor=W.+D.+Parkauthor=L.+Liauthor=C.+E.+Millsauthor=S.+Z.+Elsarragauthor=S.+B.+Ficarroauthor=T.+Zhangauthor=R.+D%C3%BCsterauthor=M.+Geyerauthor=T.+Simauthor=J.+A.+Martoauthor=P.+K.+Sorgerauthor=K.+D.+Westoverauthor=C.+Y.+Linauthor=N.+Kwiatkowskiauthor=N.+S.+Gray&title=Development+of+a+Selective+CDK7+Covalent+Inhibitor+Reveals+Predominant+Cell-Cycle+Phenotype&doi=10.1016%2Fj.chembiol.2019.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype</span></div><div class="casAuthors">Olson, Calla M.; Liang, Yanke; Leggett, Alan; Park, Woojun D.; Li, Lianbo; Mills, Caitlin E.; Elsarrag, Selma Z.; Ficarro, Scott B.; Zhang, Tinghu; Duster, Robert; Geyer, Matthias; Sim, Taebo; Marto, Jarrod A.; Sorger, Peter K.; Westover, Ken D.; Lin, Charles Y.; Kwiatkowski, Nicholas; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">792-803.e10</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and transcription, but its precise role remains elusive.  We previously described THZ1, a CDK7 inhibitor, which dramatically inhibits superenhancer-assocd. gene expression.  However, potent CDK12/13 off-target activity obscured CDK7s contribution to this phenotype.  Here, we describe the discovery of a highly selective covalent CDK7 inhibitor.  YKL-5-124 causes arrest at the G1/S transition and inhibition of E2F-driven gene expression; these effects are rescued by a CDK7 mutant unable to covalently engage YKL-5-124, demonstrating on-target specificity.  Unlike THZ1, treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation; however, inhibition could be reconstituted by combining YKL-5-124 and THZ531, a selective CDK12/13 inhibitor, revealing potential redundancies in CDK control of gene transcription.  These findings highlight the importance of CDK7/12/13 polypharmacol. for anti-cancer activity of THZ1 and posit that selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2AujiJVqR7Vg90H21EOLACvtfcHk0lh6RGsEUde-Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWhtrc%253D&md5=750541769d6848ebbc0dff10ddce8a0a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLeggett%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DW.%2BD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DC.%2BE.%26aulast%3DElsarrag%26aufirst%3DS.%2BZ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DD%25C3%25BCster%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520a%2520Selective%2520CDK7%2520Covalent%2520Inhibitor%2520Reveals%2520Predominant%2520Cell-Cycle%2520Phenotype%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D792%26epage%3D803%26doi%3D10.1016%2Fj.chembiol.2019.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piraino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwick, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamerdin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagostino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraynov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoff, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marakovits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule p21-Activated Kinase Inhibitor PF-3758309 Is a Potent Inhibitor of Oncogenic Signaling and Tumor Growth</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9446</span>– <span class="NLM_lpage">9451</span>, <span class="refDoi"> DOI: 10.1073/pnas.0911863107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1073%2Fpnas.0911863107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=20439741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslWqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=9446-9451&issue=20&author=B.+W.+Murrayauthor=C.+Guoauthor=J.+Pirainoauthor=J.+K.+Westwickauthor=C.+Zhangauthor=J.+Lamerdinauthor=E.+Dagostinoauthor=D.+Knightonauthor=C.-M.+Loiauthor=M.+Zagerauthor=E.+Kraynovauthor=I.+Popoffauthor=J.+G.+Christensenauthor=R.+Martinezauthor=S.+E.+Kephartauthor=J.+Marakovitsauthor=S.+Karlicekauthor=S.+Bergqvistauthor=T.+Smeal&title=Small-Molecule+p21-Activated+Kinase+Inhibitor+PF-3758309+Is+a+Potent+Inhibitor+of+Oncogenic+Signaling+and+Tumor+Growth&doi=10.1073%2Fpnas.0911863107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule p21-activated kinase inhibitor PF3758309 is a potent inhibitor of oncogenic signaling and tumor growth</span></div><div class="casAuthors">Murray, Brion W.; Guo, Chuangxing; Piraino, Joseph; Westwick, John K.; Zhang, Cathy; Lamerdin, Jane; Dagostino, Eleanor; Knighton, Daniel; Loi, Cho-Ming; Zager, Michael; Kraynov, Eugenia; Popoff, Ian; Chrietensen, James G.; Martinez, Ricardo; Kephart, Susan E.; Marakovits, Joseph; Karlicek, Shannon; Bergqvist, Simon; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9446-9451, S9446/1-S9446/18</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite abundant evidence that aberrant Rho-family GTPase activation contributes to most steps of cancer initiation and progression, there is a dearth of inhibitors of their effectors (e.g.. p21-activated kinases).  Through high-throughput screening and structure-based design, the authors identify PF-3758309, a potent (Kd = 2.7 nM), ATP-competitive, pyrrolopyrazole inhibitor of PAK4.  In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7±3 nM).  The mol. underpinnings of PF-3758309 biol. effects were characterized using an integration of traditional and emerging technologies.  Crystallog. characterization of the PF-3758309/PAK4 complex defined determinants of potency and kinase selectivity.  Global high-content cellular anal. confirms that PF-3758309 modulates known PAK4-dependent signaling nodes and identifies unexpected links to addnl. pathways (e.g., p53).  In tumor models, PF-3758309 inhibits PAK4-dependent pathways in proteomic studies and regulates functional activities related to cell proliferation and survival.  PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model.  This study defines PAK4-related pathways, provides addnl. support for PAK4 as a therapeutic target with a unique combination of functions (apoptotic, cytoskeletal, cell-cycle), and identifies a potent, orally available small-mol. PAK inhibitor with significant promise for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWI0STMKt9dbVg90H21EOLACvtfcHk0lh6RGsEUde-Iw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslWqtrw%253D&md5=0080659735ef51f84c00112e573b1c31</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0911863107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0911863107%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DPiraino%26aufirst%3DJ.%26aulast%3DWestwick%26aufirst%3DJ.%2BK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLamerdin%26aufirst%3DJ.%26aulast%3DDagostino%26aufirst%3DE.%26aulast%3DKnighton%26aufirst%3DD.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DZager%26aufirst%3DM.%26aulast%3DKraynov%26aufirst%3DE.%26aulast%3DPopoff%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DMarakovits%26aufirst%3DJ.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DSmall-Molecule%2520p21-Activated%2520Kinase%2520Inhibitor%2520PF-3758309%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Oncogenic%2520Signaling%2520and%2520Tumor%2520Growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D20%26spage%3D9446%26epage%3D9451%26doi%3D10.1073%2Fpnas.0911863107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of p21-Activated Kinases (PAKs) Miniperspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1021/jm501613q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501613q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=111-129&issue=1&author=J.+Rudolphauthor=J.+J.+Crawfordauthor=K.+P.+Hoeflichauthor=W.+Wang&title=Inhibitors+of+p21-Activated+Kinases+%28PAKs%29+Miniperspective&doi=10.1021%2Fjm501613q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of p21-Activated Kinases (PAKs)</span></div><div class="casAuthors">Rudolph, Joachim; Crawford, James J.; Hoeflich, Klaus P.; Wang, Weiru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-129</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The p21-activated kinase (PAK) family of serine/threonine protein kinases plays important roles in cytoskeletal organization, cellular morphogenesis, and survival, and members of this family have been implicated in many diseases including cancer, infectious diseases, and neurol. disorders.  Owing to their large and flexible ATP binding cleft, PAKs, particularly group I PAKs (PAK1, -2, and -3), are difficult to drug; hence, few PAK inhibitors with satisfactory kinase selectivity and druglike properties have been reported to date.  Examples are a recently discovered group II PAK (PAK4, -5, -6) selective inhibitor series based on a benzimidazole core, a group I PAK selective series based on a pyrido[2,3-d]pyrimidine-7-one core, and an allosteric dibenzodiazepine PAK1 inhibitor series.  Only one compd., an aminopyrazole based pan-PAK inhibitor, entered clin. trials but did not progress beyond phase I trials.  Clin. proof of concept for pan-group I, pan-group II, or PAK isoform selective inhibition has yet to be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpILWqNpGwtFrVg90H21EOLACvtfcHk0ljfh3EdN__EGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb7F&md5=f6f95e58da2de3262157f1b00e856b9b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm501613q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501613q%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DWang%26aufirst%3DW.%26atitle%3DInhibitors%2520of%2520p21-Activated%2520Kinases%2520%2528PAKs%2529%2520Miniperspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D111%26epage%3D129%26doi%3D10.1021%2Fjm501613q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to CDK7 Inhibitors</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.09.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.celrep.2017.09.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29020632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=467-481&issue=2&author=S.+Kalanauthor=R.+Amatauthor=M.+M.+Schachterauthor=N.+Kwiatkowskiauthor=B.+J.+Abrahamauthor=Y.+Liangauthor=T.+Zhangauthor=C.+M.+Olsonauthor=S.+Larochelleauthor=R.+A.+Youngauthor=N.+S.+Grayauthor=R.+P.+Fisher&title=Activation+of+the+p53+Transcriptional+Program+Sensitizes+Cancer+Cells+to+CDK7+Inhibitors&doi=10.1016%2Fj.celrep.2017.09.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors</span></div><div class="casAuthors">Kalan, Sampada; Amat, Ramon; Schachter, Miriam Merzel; Kwiatkowski, Nicholas; Abraham, Brian J.; Liang, Yanke; Zhang, Tinghu; Olson, Calla M.; Larochelle, Stephane; Young, Richard A.; Gray, Nathanael S.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">467-481</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cdk7, the CDK-activating kinase and transcription factor IIH component, is a target of inhibitors that kill cancer cells by exploiting tumor-specific transcriptional dependencies.  However, whereas selective inhibition of analog-sensitive (AS) Cdk7 in colon cancer-derived cells arrests division and disrupts transcription, it does not by itself trigger apoptosis efficiently.  Here, we show that p53 activation by 5-fluorouracil or nutlin-3 synergizes with a reversible Cdk7as inhibitor to induce cell death.  Synthetic lethality was recapitulated with covalent inhibitors of wild-type Cdk7, THZ1, or the more selective YKL-1-116.  The effects were allele specific; a CDK7as mutation conferred both sensitivity to bulky adenine analogs and resistance to covalent inhibitors.  Non-transformed colon epithelial cells were resistant to these combinations, as were cancer-derived cells with p53-inactivating mutations.  Apoptosis was dependent on death receptor DR5, a p53 transcriptional target whose expression was refractory to Cdk7 inhibition.  Therefore, p53 activation induces transcriptional dependency to sensitize cancer cells to Cdk7 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc7h-ZFvFgBrVg90H21EOLACvtfcHk0ljfh3EdN__EGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs77M&md5=c210b9906acfad945620fcace4040e77</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.09.056%26sid%3Dliteratum%253Aachs%26aulast%3DKalan%26aufirst%3DS.%26aulast%3DAmat%26aufirst%3DR.%26aulast%3DSchachter%26aufirst%3DM.%2BM.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DActivation%2520of%2520the%2520p53%2520Transcriptional%2520Program%2520Sensitizes%2520Cancer%2520Cells%2520to%2520CDK7%2520Inhibitors%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D21%26issue%3D2%26spage%3D467%26epage%3D481%26doi%3D10.1016%2Fj.celrep.2017.09.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Selective CDK7 Inhibition with BS-181 Suppresses Cell Proliferation and Induces Cell Cycle Arrest and Apoptosis in Gastric Cancer</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S86317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.2147%2FDDDT.S86317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27042010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFOltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=1181-1189&author=B.-Y.+Wangauthor=Q.-Y.+Liuauthor=J.+Caoauthor=J.-W.+Chenauthor=Z.-S.+Liu&title=Selective+CDK7+Inhibition+with+BS-181+Suppresses+Cell+Proliferation+and+Induces+Cell+Cycle+Arrest+and+Apoptosis+in+Gastric+Cancer&doi=10.2147%2FDDDT.S86317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CDK7 inhibition with BS-181 suppressescell proliferation and induces cell cycle arrest andapoptosis in gastric cancer</span></div><div class="casAuthors">Wang, Bo-Yong; Liu, Quan-Yan; Cao, Jun; Chen, Ji-Wei; Liu, Zhi-su</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1181-1189</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase (CDK) family members have been considered as attractive therapeutic targets for cancer.  In this study, we aim to investigate the anticancer effects of a selective CDK7 inhibitor, BS-181, in gastric cancer (GC) cell line.  Human GC cells (BGC823) were cultured with or without BS-181 at different concns. for 24 -72 h.  BS-181 significantly reduced the activity of CDK7 with downregulation of cyclin D1 and XIAP in GC cells.  Treatment with BS-181 induced cell cycle arrest and apoptosis.  The expression of Bax and caspase-3 was significantly increased, while Bcl-2 expression was decreased in cells treated with BS-181.  In addn., the inhibition of CDK7 with BS-181 resulted in reduced rates of proliferation, migration, and invasion of gastric cells.  Those results demonstrated the anticancer activities of selective CDK7 inhibitor BS-181 in BGC823 cells, suggesting that CDK7 may serve as a novel therapeutic target or the treatment of GC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPxGNtLVz75LVg90H21EOLACvtfcHk0ljfh3EdN__EGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFOltbk%253D&md5=5e45dc0a10b1eb473e10ad4d13801e62</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S86317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S86317%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.-Y.%26aulast%3DLiu%26aufirst%3DQ.-Y.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.-W.%26aulast%3DLiu%26aufirst%3DZ.-S.%26atitle%3DSelective%2520CDK7%2520Inhibition%2520with%2520BS-181%2520Suppresses%2520Cell%2520Proliferation%2520and%2520Induces%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%2520in%2520Gastric%2520Cancer%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D1181%26epage%3D1189%26doi%3D10.2147%2FDDDT.S86317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ainscow, E. K.</span>; <span class="NLM_string-name">Leishman, A.</span>; <span class="NLM_string-name">Sullivan, E.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Gallagher, W.</span>; <span class="NLM_string-name">Peall, A.</span>; <span class="NLM_string-name">Clark, K.</span>; <span class="NLM_string-name">Thomson, S.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, R. C.</span>; <span class="NLM_string-name">Bahl, A.</span></span> <span> </span><span class="NLM_article-title">CT7001: An Orally Bioavailable CDK7 Inhibitor Is a Potential Therapy for Breast, Small-Cell Lung and Haematological Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+K.+Ainscow&author=A.+Leishman&author=E.+Sullivan&author=B.+Li&author=W.+Gallagher&author=A.+Peall&author=K.+Clark&author=S.+Thomson&author=S.+Ali&author=R.+C.+Coombes&author=A.+Bahl&title=CT7001%3A+An+Orally+Bioavailable+CDK7+Inhibitor+Is+a+Potential+Therapy+for+Breast%2C+Small-Cell+Lung+and+Haematological+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAinscow%26aufirst%3DE.%2BK.%26atitle%3DCT7001%253A%2520An%2520Orally%2520Bioavailable%2520CDK7%2520Inhibitor%2520Is%2520a%2520Potential%2520Therapy%2520for%2520Breast%252C%2520Small-Cell%2520Lung%2520and%2520Haematological%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26pub%3DAACR%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bahl, A.</span>; <span class="NLM_string-name">Einscow, E.</span>; <span class="NLM_string-name">Leishman, A.</span>; <span class="NLM_string-name">Sullivan, E.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, R.</span>; <span class="NLM_string-name">Barrett, A.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Gallagher, W.</span>; <span class="NLM_string-name">Carragher, N.</span>; <span class="NLM_string-name">Patel, T.</span></span> <span> </span><span class="NLM_article-title">Activity of CT7001 an Orally Bioavailable Cyclin-Dependent Kinase 7 Selective Inhibitor in Models of Triple Negative Breast Cancer</span>.  <i>Proceedings of the 2017 SABCS</i>; <span class="NLM_publisher-loc">San Antonio, TX</span>, Dec 5–9, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Bahl&author=E.+Einscow&author=A.+Leishman&author=E.+Sullivan&author=S.+Ali&author=R.+Coombes&author=A.+Barrett&author=B.+Li&author=W.+Gallagher&author=N.+Carragher&author=T.+Patel&title=Proceedings+of+the+2017+SABCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBahl%26aufirst%3DA.%26atitle%3DActivity%2520of%2520CT7001%2520an%2520Orally%2520Bioavailable%2520Cyclin-Dependent%2520Kinase%25207%2520Selective%2520Inhibitor%2520in%2520Models%2520of%2520Triple%2520Negative%2520Breast%2520Cancer%26btitle%3DProceedings%2520of%2520the%25202017%2520SABCS%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K.</span>; <span class="NLM_string-name">Ainscow, E.</span>; <span class="NLM_string-name">Peall, A.</span>; <span class="NLM_string-name">Thomson, S.</span>; <span class="NLM_string-name">Leishman, A.</span>; <span class="NLM_string-name">Elaine, S.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, R.</span>; <span class="NLM_string-name">Barrett, A.</span>; <span class="NLM_string-name">Bahl, A. K.</span></span> <span> </span><span class="NLM_article-title">CT7001, a Novel Orally Bioavailable CDK7 Inhibitor, Is Highly Active in in Vitro and in Vivo Models of AML</span>.  <i>Proceedings of the 59th ASH Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Dec 7, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+Clark&author=E.+Ainscow&author=A.+Peall&author=S.+Thomson&author=A.+Leishman&author=S.+Elaine&author=S.+Ali&author=R.+Coombes&author=A.+Barrett&author=A.+K.+Bahl&title=CT7001%2C+a+Novel+Orally+Bioavailable+CDK7+Inhibitor%2C+Is+Highly+Active+in+in+Vitro+and+in+Vivo+Models+of+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DK.%26atitle%3DCT7001%252C%2520a%2520Novel%2520Orally%2520Bioavailable%2520CDK7%2520Inhibitor%252C%2520Is%2520Highly%2520Active%2520in%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Models%2520of%2520AML%26jtitle%3DProceedings%2520of%2520the%252059th%2520ASH%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.-R.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Inhibitor THZ1 in Cancer Therapy</span>. <i>Chronic Dis. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.cdtm.2019.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.cdtm.2019.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31891127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3MblsVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=155-169&issue=3&author=B.-B.+Liauthor=B.+Wangauthor=C.-M.+Zhuauthor=D.+Tangauthor=J.+Pangauthor=J.+Zhaoauthor=C.-H.+Sunauthor=M.-J.+Qiuauthor=Z.-R.+Qian&title=Cyclin-Dependent+Kinase+7+Inhibitor+THZ1+in+Cancer+Therapy&doi=10.1016%2Fj.cdtm.2019.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy</span></div><div class="casAuthors">Li Bin-Bin; Li Bin-Bin; Wang Bo; Zhu Cheng-Ming; Tang Di; Pang Jun; Zhao Jing; Sun Chun-Hui; Qiu Miao-Juan; Qian Zhi-Rong; Sun Chun-Hui</div><div class="citationInfo"><span class="NLM_cas:title">Chronic diseases and translational medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-169</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs.  Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies.  In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types.  By introducing the anti-tumor behaviors and the potential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEv1qY9aiKatts4TFFB11gfW6udTcc2eZAL2OSUONZK7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MblsVKqsg%253D%253D&md5=9e9b168b23b986c30540cdcd7c4a7d8f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.cdtm.2019.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cdtm.2019.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.-B.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DC.-M.%26aulast%3DTang%26aufirst%3DD.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DC.-H.%26aulast%3DQiu%26aufirst%3DM.-J.%26aulast%3DQian%26aufirst%3DZ.-R.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Inhibitor%2520THZ1%2520in%2520Cancer%2520Therapy%26jtitle%3DChronic%2520Dis.%2520Transl.%2520Med.%26date%3D2019%26volume%3D5%26issue%3D3%26spage%3D155%26epage%3D169%26doi%3D10.1016%2Fj.cdtm.2019.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmieciak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells in Vitro and in Vivo</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6205</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-3788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1078-0432.CCR-18-3788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31358538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVSnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6195-6205&issue=20&author=Y.+Zhangauthor=L.+Zhouauthor=D.+Bandyopadhyayauthor=K.+Sharmaauthor=A.+J.+Allenauthor=M.+Kmieciakauthor=S.+Grant&title=The+Covalent+CDK7+Inhibitor+THZ1+Potently+Induces+Apoptosis+in+Multiple+Myeloma+Cells+in+Vitro+and+in+Vivo&doi=10.1158%2F1078-0432.CCR-18-3788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The covalent CDK7 inhibitor THZI potently induces apoptosis in multiple myeloma cells in vitro and in vivo</span></div><div class="casAuthors">Zhang, Yu; Zhou, Liang; Bandyopadhyay, Dipankar; Sharma, Kanika; Allen, Alexander Joseph; Kmieciak, Maciej; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6195-6205</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The goal of this study was to characterize the activity of the covalent CDK7 inhibitor THZ1 in multiple myeloma models.  Exptl. Design: Multiple myeloma lines were exposed to varying THZ1 concns. alone or with carfilzomib or ABT-199, after which apoptosis was monitored by flow cytometry, protein expression by Western blot anal., mRNA by RT-PCR.  Analogous studies were performed in cells ectopically expressing c-MYC, MCL-1, or BCI-XI., or CRISPER-Cas CDK7 sgRNA knockout.  Primary multiple myeloma cells were exposed to THZ1 ± carfilzomib or ABT-199.  In vivo effects ofTHZ1 were examd. in a systemic U266 xenograft model.  Results: THZ1 markedly diminished multiple myeloma cell proliferation and survival despite bortezomib orstromal cell resistance in assocn. with G2-M arrest, inactivation of CTD RNAPol H, dephosphorylation ofCDKs 7 as well as 1, 2, and 9, and MCL-1, BCL-xL, and c-MYC mRNA or protein downregulation.  Ectopic MCL-1, c-MYC, or BCL-XL expression significantly protected cells from THZ1 lethality.  Both THZ1 and CRlSPR-Cas CDK7 knockout sharply diminished multiple myeloma cell proliferation and significantly increased carfilzomib and ABT-199 lethality.  Parallel effects and interactions were obsd. in primary CD1 38+ (N = 22) or primitive multiple myeloma cells (CD138-/CD19+/ CD20+/CD27+; N = 16).  THZ1 administration [10 mg/kg i.p. twice daily (BID), 5 days/wk] significantly improved survival in a systemic multiple myeloma xenograft model with minimal toxicity and induced similar events obsd. in vitro, for example, MCL-1 and c-MYC downregulation.  Conclusions: THZ1 potently reduces multiple myeloma cell proliferation through transcriptional downregulation of MCL-1, BCL-XL and c-MYC in vitro and in vivo.  It warrants further attention as a therapeutic agent in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGqk86OMsXrVg90H21EOLACvtfcHk0li9VhIst_SoRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVSnurY%253D&md5=33e5094c26df8236e7697350abb08840</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3788%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DA.%2BJ.%26aulast%3DKmieciak%26aufirst%3DM.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DThe%2520Covalent%2520CDK7%2520Inhibitor%2520THZ1%2520Potently%2520Induces%2520Apoptosis%2520in%2520Multiple%2520Myeloma%2520Cells%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26issue%3D20%26spage%3D6195%26epage%3D6205%26doi%3D10.1158%2F1078-0432.CCR-18-3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Sharma, K.</span>; <span class="NLM_string-name">McCarter, J.</span>; <span class="NLM_string-name">Craun, W.</span>; <span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Transcriptional Regulation in Multiple Myeloma with a Covalent CDK7 Inhibitor THZ1</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Zhou&author=Y.+Zhang&author=K.+Sharma&author=J.+McCarter&author=W.+Craun&author=S.+Grant&title=Targeting+Transcriptional+Regulation+in+Multiple+Myeloma+with+a+Covalent+CDK7+Inhibitor+THZ1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26atitle%3DTargeting%2520Transcriptional%2520Regulation%2520in%2520Multiple%2520Myeloma%2520with%2520a%2520Covalent%2520CDK7%2520Inhibitor%2520THZ1%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Shahrour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter-Sprie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbay, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altabef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanaugh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelsen, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.ccell.2014.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25490451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyhu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=909-922&issue=6&author=C.+L.+Christensenauthor=N.+Kwiatkowskiauthor=B.+J.+Abrahamauthor=J.+Carreteroauthor=F.+Al-Shahrourauthor=T.+Zhangauthor=E.+Chipumuroauthor=G.+S.+Herter-Sprieauthor=E.+A.+Akbayauthor=A.+Altabefauthor=J.+Zhangauthor=T.+Shimamuraauthor=M.+Capellettiauthor=J.+B.+Reibelauthor=J.+D.+Cavanaughauthor=P.+Gaoauthor=Y.+Liuauthor=S.+R.+Michaelsenauthor=H.+S.+Poulsenauthor=A.+R.+Arefauthor=D.+A.+Barbieauthor=J.+E.+Bradnerauthor=R.+E.+Georgeauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=K.+K.+Wong&title=Targeting+Transcriptional+Addictions+in+Small+Cell+Lung+Cancer+with+a+Covalent+CDK7+Inhibitor&doi=10.1016%2Fj.ccell.2014.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor</span></div><div class="casAuthors">Christensen, Camilla L.; Kwiatkowski, Nicholas; Abraham, Brian J.; Carretero, Julian; Al-Shahrour, Fatima; Zhang, Tinghu; Chipumuro, Edmond; Herter-Sprie, Grit S.; Akbay, Esra A.; Altabef, Abigail; Zhang, Jianming; Shimamura, Takeshi; Capelletti, Marzia; Reibel, Jakob B.; Cavanaugh, Jillian D.; Gao, Peng; Liu, Yan; Michaelsen, Signe R.; Poulsen, Hans S.; Aref, Amir R.; Barbie, David A.; Bradner, James E.; George, Rani E.; Gray, Nathanael S.; Young, Richard A.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacol. strategies to target SCLC biol. represents an urgent need.  Using a high-throughput cellular screen of a diverse chem. library, we observe that SCLC is sensitive to transcription-targeting drugs, in particular to THZ1, a recently identified covalent inhibitor of cyclin-dependent kinase 7.  We find that expression of super-enhancer-assocd. transcription factor genes, including MYC family proto-oncogenes and neuroendocrine lineage-specific factors, is highly vulnerability to THZ1 treatment.  We propose that downregulation of these transcription factors contributes, in part, to SCLC sensitivity to transcriptional inhibitors and that THZ1 represents a prototype drug for tailored SCLC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxt0FHVPT1YbVg90H21EOLACvtfcHk0liH3c2r6lPz2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFyhu7fL&md5=997a05226adc37af5f4b85416cb6c73f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DAl-Shahrour%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DChipumuro%26aufirst%3DE.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DAkbay%26aufirst%3DE.%2BA.%26aulast%3DAltabef%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DReibel%26aufirst%3DJ.%2BB.%26aulast%3DCavanaugh%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMichaelsen%26aufirst%3DS.%2BR.%26aulast%3DPoulsen%26aufirst%3DH.%2BS.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DTargeting%2520Transcriptional%2520Addictions%2520in%2520Small%2520Cell%2520Lung%2520Cancer%2520with%2520a%2520Covalent%2520CDK7%2520Inhibitor%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D6%26spage%3D909%26epage%3D922%26doi%3D10.1016%2Fj.ccell.2014.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cyclin-Dependent Kinase 7 Suppresses Human Hepatocellular Carcinoma by Inducing Apoptosis</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">9742</span>– <span class="NLM_lpage">9751</span>, <span class="refDoi"> DOI: 10.1002/jcb.27292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fjcb.27292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30145799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFykurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=9742-9751&issue=12&author=L.+Zhongauthor=S.+Yangauthor=Y.+Jiaauthor=K.+Lei&title=Inhibition+of+Cyclin-Dependent+Kinase+7+Suppresses+Human+Hepatocellular+Carcinoma+by+Inducing+Apoptosis&doi=10.1002%2Fjcb.27292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis</span></div><div class="casAuthors">Zhong, Liqiang; Yang, Sihao; Jia, Yuming; Lei, Kaijian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">9742-9751</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Increasing evidence has shown that THZ1, a covalent cyclin-dependent kinase 7 (CDK7) inhibitor, exhibits therapeutic effects in various tumors.  However, the possible effect of THZ1 on hepatocellular carcinoma (HCC) remains unknown.  Our study was to investigate the roles of THZ1 in HCC cells and in s.c. HCC model and illustrate the mol. mechanisms.  The phosphorylation levels of Ser2, Ser5, and Ser7 within RNA polymerase II (RNAPII) C-terminal domain (CTD) and the expression levels of Ki67, Mcl-1, survivin, XIAP, and p53 in HCC cells under different conditions were examd. by Western blot anal.  Cell growth and apoptosis were assessed via 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay and flow cytometry anal., resp.  Tumor vol. was assessed in HCC mice with THZ1 or vehicle treatment and immunohistochem. (IHC) anal. was conducted on excised tumors.  THZ1 significantly inhibited the phosphorylation of Ser2, Ser5, and Ser7 within RNAPII-CTD in the dose-dependent and irreversible manner.  MTT assay and flow cytometry anal. showed that THZ1 inhibited HCC cell proliferation and induced apoptosis, resp.  Western blot anal. indicated THZ1 significantly upregulated p53 expression and downregulated the expressions of Mcl-1, survivin, XIAP, and Ki67.  THZ1 suppressed tumor growth in Hep3B xenografted mice in a time-dependent manner.  IHC anal. indicated that tumors in THZ1 group had less Ki67+ cells and more cleaved caspase-3+ cells than those in vehicle group.  THZ1 exhibited anti-HCC effects through irreversibly inhibiting CDK7 activity, decreasing RNAPII-CTD phosphorylation, inducing p53 expression and inhibiting antiapoptotic gene expressions, which subsequently induced apoptosis and inhibited proliferation of HCC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc2X2FBXOiurVg90H21EOLACvtfcHk0liH3c2r6lPz2g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFykurfN&md5=3bc1fd9a5563a0bf328737a8ff87aff8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fjcb.27292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.27292%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLei%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520Suppresses%2520Human%2520Hepatocellular%2520Carcinoma%2520by%2520Inducing%2520Apoptosis%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2018%26volume%3D119%26issue%3D12%26spage%3D9742%26epage%3D9751%26doi%3D10.1002%2Fjcb.27292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eliades, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njauw, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, H.</span></span> <span> </span><span class="NLM_article-title">High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1590</span>, <span class="refDoi"> DOI: 10.1016/j.jid.2017.09.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.jid.2017.09.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29408204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2018&pages=1582-1590&issue=7&author=P.+Eliadesauthor=B.+J.+Abrahamauthor=Z.+Jiauthor=D.+M.+Millerauthor=C.+L.+Christensenauthor=N.+Kwiatkowskiauthor=R.+Kumarauthor=C.+N.+Njauwauthor=M.+Taylorauthor=B.+Miaoauthor=T.+Zhangauthor=K.+K.+Wongauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=H.+Tsao&title=High+MITF+Expression+Is+Associated+with+Super-Enhancers+and+Suppressed+by+CDK7+Inhibition+in+Melanoma&doi=10.1016%2Fj.jid.2017.09.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma</span></div><div class="casAuthors">Eliades, Philip; Abraham, Brian J.; Ji, Zhenyu; Miller, David M.; Christensen, Camilla L.; Kwiatkowski, Nicholas; Kumar, Raj; Njauw, Ching Ni; Taylor, Michael; Miao, Benchun; Zhang, Tinghu; Wong, Kwok-Kin; Gray, Nathanael S.; Young, Richard A.; Tsao, Hensin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1582-1590</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cutaneous melanoma is an aggressive tumor that accounts for most skin cancer deaths.  Among the physiol. barriers against therapeutic success is a strong survival program driven by genes such as MITF that specify melanocyte identity, a phenomenon known in melanoma biol. as lineage dependency.  MITF overexpression is occasionally explained by gene amplification, but here we show that super-enhancers are also important determinants of MITF overexpression in some melanoma cell lines and tumors.  Although compds. that directly inhibit MITF are unavailable, a covalent CDK7 inhibitor, THZ1, has recently been shown to potently suppress the growth of various cancers through the depletion of master transcription-regulating oncogenes and the disruption of their attendant super-enhancers.  We also show that melanoma cells are highly sensitive to CDK7 inhibition both in vitro and in vivo and that THZ1 can dismantle the super-enhancer app. at MITF and SOX10 in some cell lines, thereby extinguishing their intracellular levels.  Our results show a dimension to MITF regulation in melanoma cells and point to CDK7 inhibition as a potential strategy to deprive oncogenic transcription and suppress tumor growth in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMvazXe7IUebVg90H21EOLACvtfcHk0liTMgZEXDJY3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yqtLw%253D&md5=4b2dcbccf777375608d21585727e772a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.jid.2017.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jid.2017.09.056%26sid%3Dliteratum%253Aachs%26aulast%3DEliades%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DMiller%26aufirst%3DD.%2BM.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DNjauw%26aufirst%3DC.%2BN.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DMiao%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DTsao%26aufirst%3DH.%26atitle%3DHigh%2520MITF%2520Expression%2520Is%2520Associated%2520with%2520Super-Enhancers%2520and%2520Suppressed%2520by%2520CDK7%2520Inhibition%2520in%2520Melanoma%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2018%26volume%3D138%26issue%3D7%26spage%3D1582%26epage%3D1590%26doi%3D10.1016%2Fj.jid.2017.09.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatheway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altabef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>159</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1139</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.cell.2014.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25416950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2014&pages=1126-1139&issue=5&author=E.+Chipumuroauthor=E.+Marcoauthor=C.+L.+Christensenauthor=N.+Kwiatkowskiauthor=T.+Zhangauthor=C.+M.+Hathewayauthor=B.+J.+Abrahamauthor=B.+Sharmaauthor=C.+Yeungauthor=A.+Altabefauthor=A.+Perez-Ataydeauthor=K.+K.+Wongauthor=G.+C.+Yuanauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=R.+E.+George&title=CDK7+Inhibition+Suppresses+Super-Enhancer-Linked+Oncogenic+Transcription+in+MYCN-Driven+Cancer&doi=10.1016%2Fj.cell.2014.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer</span></div><div class="casAuthors">Chipumuro, Edmond; Marco, Eugenio; Christensen, Camilla L.; Kwiatkowski, Nicholas; Zhang, Tinghu; Hatheway, Clark M.; Abraham, Brian J.; Sharma, Bandana; Yeung, Caleb; Altabef, Abigail; Perez-Atayde, Antonio; Wong, Kwok-Kin; Yuan, Guo-Cheng; Gray, Nathanael S.; Young, Richard A.; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1139</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The MYC oncoproteins are thought to stimulate tumor cell growth and proliferation through amplification of gene transcription, a mechanism that has thwarted most efforts to inhibit MYC function as potential cancer therapy.  Using a covalent inhibitor of cyclin-dependent kinase 7 (CDK7) to disrupt the transcription of amplified MYCN in neuroblastoma cells, the authors demonstrate downregulation of the oncoprotein with consequent massive suppression of MYCN-driven global transcriptional amplification.  This response translated to significant tumor regression in a mouse model of high-risk neuroblastoma, without the introduction of systemic toxicity.  The striking treatment selectivity of MYCN-overexpressing cells correlated with preferential downregulation of super-enhancer-assocd. genes, including MYCN and other known oncogenic drivers in neuroblastoma.  These results indicate that CDK7 inhibition, by selectively targeting the mechanisms that promote global transcriptional amplification in tumor cells, may be useful therapy for cancers that are driven by MYC family oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx7Cu3MbB2zbVg90H21EOLACvtfcHk0liTMgZEXDJY3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7zO&md5=670596d985b3d2ef9a557bbbbb93993f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DChipumuro%26aufirst%3DE.%26aulast%3DMarco%26aufirst%3DE.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHatheway%26aufirst%3DC.%2BM.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DYeung%26aufirst%3DC.%26aulast%3DAltabef%26aufirst%3DA.%26aulast%3DPerez-Atayde%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DYuan%26aufirst%3DG.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DCDK7%2520Inhibition%2520Suppresses%2520Super-Enhancer-Linked%2520Oncogenic%2520Transcription%2520in%2520MYCN-Driven%2520Cancer%26jtitle%3DCell%26date%3D2014%26volume%3D159%26issue%3D5%26spage%3D1126%26epage%3D1139%26doi%3D10.1016%2Fj.cell.2014.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span> <span> </span><span class="NLM_article-title">Antitumor Effects of a Covalent Cyclin-Dependent Kinase 7 Inhibitor in Colorectal Cancer</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1097%2FCAD.0000000000000749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30694816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Sgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=466-474&issue=5&author=J.+Wangauthor=Z.+Liauthor=H.+Meiauthor=D.+Zhangauthor=G.+Wuauthor=T.+Zhangauthor=Z.+Lin&title=Antitumor+Effects+of+a+Covalent+Cyclin-Dependent+Kinase+7+Inhibitor+in+Colorectal+Cancer&doi=10.1097%2FCAD.0000000000000749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer</span></div><div class="casAuthors">Wang, Jian; Li, Zhenyu; Mei, Hong; Zhang, Dejun; Wu, Gang; Zhang, Tao; Lin, Zhenyu</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-474</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Although both antiepidermal growth factor receptor and vascular endothelial growth factor therapies have been shown to be effective against colorectal cancer (CRC), their beneficial effects are limited to a small proportion of patients and are not sustainable.  Cyclin-dependent kinase 7 (CDK7) is an important regulator of the transcriptional machinery.  Use of small-mol. inhibitors of the transcriptional machinery has shown promising selectivity for cancer cells and potent antiproliferative effects.  In this study, the effects of a covalent CDK7 inhibitor THZ1 as a potent anti-CRC compd. were evaluated in vitro and in vivo.  THZ1 significantly inhibited cell growth and induced apoptosis of CRC cells in vitro.  In addn., it also decreased xenograft tumor growth in vivo.  RNA-Seq showed that THZ1 induced inhibition of a no. of oncogenic transcripts.  Taken together, our results indicate that pharmacol. modulation of CDK7 kinase activity by THZ1 may represent a potential strategy in the treatment of CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrRw9_3bpukrVg90H21EOLACvtfcHk0liTMgZEXDJY3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Sgu7o%253D&md5=945b1cd2145b82e9dd2102306009a72c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000749%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26atitle%3DAntitumor%2520Effects%2520of%2520a%2520Covalent%2520Cyclin-Dependent%2520Kinase%25207%2520Inhibitor%2520in%2520Colorectal%2520Cancer%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2019%26volume%3D30%26issue%3D5%26spage%3D466%26epage%3D474%26doi%3D10.1097%2FCAD.0000000000000749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, W.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibitor Suppresses Tumor Progression Through Blocking the Cell Cycle at the G2/M Phase and Inhibiting Transcriptional Activity in Cervical Cancer</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.2147/OTT.S195655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.2147%2FOTT.S195655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30962695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGrsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=2137-2147&author=S.+Zhongauthor=Y.+Zhangauthor=X.+Yinauthor=W.+Di&title=CDK7+Inhibitor+Suppresses+Tumor+Progression+Through+Blocking+the+Cell+Cycle+at+the+G2%2FM+Phase+and+Inhibiting+Transcriptional+Activity+in+Cervical+Cancer&doi=10.2147%2FOTT.S195655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer</span></div><div class="casAuthors">Zhong, Shanshan; Zhang, Yi; Yin, Xia; Wen, Di-</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2137-2147</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The disordered cell cycle and dysregulated expression of numerous oncogenes involved in tumor-relevant processes are highly related to the tumorigenesis of cervical cancer.  Cyclin-dependent kinase 7 (CDK7) constitutes the indispensable catalytic subunit of CDKactivating kinase (CAK), which is required for both cell cycle transition and transcriptional regulation.  However, research regarding the antitumor effects of CDK7 inhibition in cervical cancer remains unclear.  Purpose: Our study aims to explore the antineoplastic effects of the CDK7 inhibitor THZ1 in cervical cancer cells and to find a potential agent for cervical cancer treatment.  Methods: The CRISPR-Cas9 system was used to knock down CDK7.  The Cell Counting Kit-8 (CCK-8) assay was used to detect the cell viability after CDK7 depletion and THZ1 treatment.  Western blot was employed to detect protein expression.  The expression levels of mRNA were assayed through qRT-PCR.  Flow cytometry anal. was used to assay the apoptotic cells and cell cycle distribution.  Gene expression microarray anal. was used to identify the differential expression of the genes.  S.c. xenograft mouse model was performed to test the antineoplastic effects of THZ1 in vivo.  Results: We revealed that the genetic depletion of CDK7 using the CRISPR-Cas9 system exhibited great cell growth inhibition in cervical cancer cell lines, consistent with the effects of CDK7 blocking using THZ1.  Cervical cancer cells were highly sensitive to THZ1 treatment, and a low concn. of THZ1 could induce substantial cell apoptosis.  THZ1 specifically perturbed the phosphorylation of cell cycle regulator CDK1 and decreased the expression of cyclin B1, leading to a cell cycle blockage at the G2/M phase and inducing cell growth inhibition.  The gene expression microarray anal. showed that massive oncogene transcripts, esp. those assocd. with tumorigenesis, were preferential suppressed after THZ1 treatment.  The qRT-PCR confirmed that several essential oncogenes in tumorigenesis (c-MYC, hTERT, RAD51, and BCL-2) and HPV viral oncogenes (E6 and E7) were preferentially repressed by THZ1.  Moreover, THZ1 exhibited substantial antineoplastic effects against cervical cancer in vivo without inducing obvious side effects.  Conclusion: These findings indicated that the CDK7 inhibitor THZ1 is a potential option in cervical cancer treatment owing to its ability to inhibit cell cycle progression and transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXsB5OOp0K87Vg90H21EOLACvtfcHk0liQJvWjSu11ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGrsLbJ&md5=37ac3c921d08da0cb85a6bc871ee00ad</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2147%2FOTT.S195655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S195655%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DDi%26aufirst%3DW.%26atitle%3DCDK7%2520Inhibitor%2520Suppresses%2520Tumor%2520Progression%2520Through%2520Blocking%2520the%2520Cell%2520Cycle%2520at%2520the%2520G2%252FM%2520Phase%2520and%2520Inhibiting%2520Transcriptional%2520Activity%2520in%2520Cervical%2520Cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2019%26volume%3D12%26spage%3D2137%26epage%3D2147%26doi%3D10.2147%2FOTT.S195655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibitor THZ1 Inhibits MCL1 Synthesis and Drives Cholangiocarcinoma Apoptosis in Combination with BCL2/BCL-XL Inhibitor ABT-263</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-1831-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41419-019-1831-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-14&issue=8&author=T.+Huangauthor=X.+Dingauthor=G.+Xuauthor=G.+Chenauthor=Y.+Caoauthor=C.+Pengauthor=S.+Shenauthor=Y.+Lvauthor=L.+Wangauthor=X.+Zou&title=CDK7+Inhibitor+THZ1+Inhibits+MCL1+Synthesis+and+Drives+Cholangiocarcinoma+Apoptosis+in+Combination+with+BCL2%2FBCL-XL+Inhibitor+ABT-263&doi=10.1038%2Fs41419-019-1831-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice</span></div><div class="casAuthors">Zheng, Chao; Huang, Lan; Luo, Wu; Yu, Weihui; Hu, Xueting; Guan, Xinfu; Cai, Yan; Zou, Chunpeng; Yin, Haimin; Xu, Zheng; Liang, Guang; Wang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Recent evidences indicate that signal transducer and activator of transcription 3 (STAT3) is one of the crucial signaling pathways in the progression of diabetic nephropathy (DN).  Here, we investigated the hypothesis that pharmacol. blockade of STAT3 limits the progression of DN.  Treatment with selective STAT3 inhibitor, S3I-201 for 16 wk significantly attenuated kidney injuries in streptozotocin (STZ) induced diabetic mice, assocd. with downregulated expression of TGF-β1, ACE/AT1, and VEGF in diabetic mouse kidneys.  Similar results were confirmed using genetic knockdown of STAT3 in mouse kidneys by injections of AAV2 expressing STAT3 shRNA in diabetic mouse.  Further, STAT3 localization in kidney tissue was evaluated using immunofluorescent double-staining anal., which indicated that STAT3 expression was mainly in the tubular epithelial cells.  As expected, in renal tubular epithelial NRK-52E cells, high glucose (HG)-induced overexpression of TGF-β1, ACE/AT1, and VEGF were abrogated by S3I-201 pretreatment, as well as by genetic knockdown of STAT3 using specific siRNA sequence.  This study found that renal tubular epithelial cells contributed to STAT3-mediated progression of DN and provided the first evidence that pharmacol. inhibition of STAT3 attenuates DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNeWGXpYwe97Vg90H21EOLACvtfcHk0liQJvWjSu11ww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrvK&md5=541b619566f2d2bb80169c5ef0c7a2ac</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-1831-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-1831-7%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DX.%26atitle%3DCDK7%2520Inhibitor%2520THZ1%2520Inhibits%2520MCL1%2520Synthesis%2520and%2520Drives%2520Cholangiocarcinoma%2520Apoptosis%2520in%2520Combination%2520with%2520BCL2%252FBCL-XL%2520Inhibitor%2520ABT-263%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1%26epage%3D14%26doi%3D10.1038%2Fs41419-019-1831-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasool, R. u.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natesan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander Effron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell-Velasquez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posimo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carskadon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomerantz, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanisamy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Den, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asangani, I. A.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer Through MED1 Inactivation</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-0189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F2159-8290.CD-19-0189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31466944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3MrjtlOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1538-1555&issue=11&author=R.+u.+Rasoolauthor=R.+Natesanauthor=Q.+Dengauthor=S.+Arasauthor=P.+Lalauthor=S.+Sander+Effronauthor=E.+Mitchell-Velasquezauthor=J.+M.+Posimoauthor=S.+Carskadonauthor=S.+C.+Bacaauthor=M.+M.+Pomerantzauthor=J.+Siddiquiauthor=L.+E.+Schwartzauthor=D.+J.+Leeauthor=N.+Palanisamyauthor=G.+Narlaauthor=R.+B.+Denauthor=M.+L.+Freedmanauthor=D.+C.+Bradyauthor=I.+A.+Asangani&title=CDK7+Inhibition+Suppresses+Castration-Resistant+Prostate+Cancer+Through+MED1+Inactivation&doi=10.1158%2F2159-8290.CD-19-0189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation</span></div><div class="casAuthors">Rasool Reyaz Ur; Natesan Ramakrishnan; Deng Qu; Aras Shweta; Sander Effron Samuel; Mitchell-Velasquez Erick; Posimo Jessica M; Brady Donita C; Asangani Irfan A; Lal Priti; Schwartz Lauren E; Carskadon Shannon; Palanisamy Nallasivam; Baca Sylvan C; Pomerantz Mark M; Freedman Matthew L; Siddiqui Javed; Lee Daniel J; Narla Goutham; Den Robert B; Brady Donita C; Asangani Irfan A; Asangani Irfan A</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1538-1555</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metastatic castration-resistant prostate cancer (CRPC) is a fatal disease, primarily resulting from the transcriptional addiction driven by androgen receptor (AR).  First-line CRPC treatments typically target AR signaling, but are rapidly bypassed, resulting in only a modest survival benefit with antiandrogens.  Therapeutic approaches that more effectively block the AR-transcriptional axis are urgently needed.  Here, we investigated the molecular mechanism underlying the association between the transcriptional coactivator MED1 and AR as a vulnerability in AR-driven CRPC.  MED1 undergoes CDK7-dependent phosphorylation at T1457 and physically engages AR at superenhancer sites, and is essential for AR-mediated transcription.  In addition, a CDK7-specific inhibitor, THZ1, blunts AR-dependent neoplastic growth by blocking AR/MED1 corecruitment genome-wide, as well as reverses the hyperphosphorylated MED1-associated enzalutamide-resistant phenotype.  In vivo, THZ1 induces tumor regression of AR-amplified human CRPC in a xenograft mouse model.  Together, we demonstrate that CDK7 inhibition selectively targets MED1-mediated, AR-dependent oncogenic transcriptional amplification, thus representing a potential new approach for the treatment of CRPC.  SIGNIFICANCE: Potent inhibition of AR signaling is critical to treat CRPC.  This study uncovers a driver role for CDK7 in regulating AR-mediated transcription through phosphorylation of MED1, thus revealing a therapeutically targetable potential vulnerability in AR-addicted CRPC.See related commentary by Russo et al., p. 1490.This article is highlighted in the In This Issue feature, p. 1469.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzekStj1oHtMuCWE5mhx1RfW6udTcc2ea4m67LABkjqbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrjtlOnsQ%253D%253D&md5=46aaa9c4a5aef7793444e97ac6faff4d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-0189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-0189%26sid%3Dliteratum%253Aachs%26aulast%3DRasool%26aufirst%3DR.%2Bu.%26aulast%3DNatesan%26aufirst%3DR.%26aulast%3DDeng%26aufirst%3DQ.%26aulast%3DAras%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DP.%26aulast%3DSander%2BEffron%26aufirst%3DS.%26aulast%3DMitchell-Velasquez%26aufirst%3DE.%26aulast%3DPosimo%26aufirst%3DJ.%2BM.%26aulast%3DCarskadon%26aufirst%3DS.%26aulast%3DBaca%26aufirst%3DS.%2BC.%26aulast%3DPomerantz%26aufirst%3DM.%2BM.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DD.%2BJ.%26aulast%3DPalanisamy%26aufirst%3DN.%26aulast%3DNarla%26aufirst%3DG.%26aulast%3DDen%26aufirst%3DR.%2BB.%26aulast%3DFreedman%26aufirst%3DM.%2BL.%26aulast%3DBrady%26aufirst%3DD.%2BC.%26aulast%3DAsangani%26aufirst%3DI.%2BA.%26atitle%3DCDK7%2520Inhibition%2520Suppresses%2520Castration-Resistant%2520Prostate%2520Cancer%2520Through%2520MED1%2520Inactivation%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D11%26spage%3D1538%26epage%3D1555%26doi%3D10.1158%2F2159-8290.CD-19-0189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span> <span> </span><span class="NLM_article-title">THZ1 Reveals CDK7-Dependent Transcriptional Addictions in Pancreatic Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3932</span>– <span class="NLM_lpage">3945</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-0701-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41388-019-0701-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30692639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVGgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=3932-3945&issue=20&author=P.+Luauthor=J.+Gengauthor=L.+Zhangauthor=Y.+Wangauthor=N.+Niuauthor=Y.+Fangauthor=F.+Liuauthor=J.+Shiauthor=Z.-G.+Zhangauthor=Y.-W.+Sunauthor=L.+W.+Wangauthor=Y.+Tangauthor=J.+Xue&title=THZ1+Reveals+CDK7-Dependent+Transcriptional+Addictions+in+Pancreatic+Cancer&doi=10.1038%2Fs41388-019-0701-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer</span></div><div class="casAuthors">Lu, Ping; Geng, Jing; Zhang, Lei; Wang, Yu; Niu, Ningning; Fang, Yuan; Liu, Fang; Shi, Juanjuan; Zhang, Zhi-Gang; Sun, Yong-Wei; Wang, Li-Wei; Tang, Yujie; Xue, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3932-3945</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with high mortality.  Lack of effective treatment makes novel therapeutic discovery an urgent demand in PDAC research.  By screening an epigenetic-related compd. library, we identified THZ1, a covalent inhibitor of CDK7, as a promising candidate.  Multiple long-established and patient-derived PDAC cell lines (PDC) were used to validate the efficacy of THZ1 in vitro.  In addn., patient-derived xenograft (PDX) models and animal models of PDAC were utilized for examg. THZ1 efficacy in vivo.  Furthermore, RNA-Seq analyze was performed to reveal the mol. mechanism of THZ1 treatment.  Finally, PDAC cell lines with primary or acquired resistance to THZ1 were investigated to explore the potential mechanism of THZ1 susceptibility.  CDK7 inhibition was identified as a selective and potent therapeutic strategy for PDAC progression in multiple preclin. models.  Mechanistic analyses revealed that CDK7 inhibition led to a pronounced downregulation of gene transcription, with a preferential repression of mitotic cell cycle and NF-κB signaling-related transcripts.  MYC transcriptional was found to be involved in susceptibility of PDAC cells to CDK7 inhibition.  In conclusion, Identification of CDK7-dependent transcriptional addiction in PDACs provides a potent therapeutic strategy that targets highly aggressive pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUteB_Lo01sLVg90H21EOLACvtfcHk0lhjbPHNLaBVOQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVGgtrg%253D&md5=86a9469f12f594c9cf42e8826ddd02f1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-0701-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-0701-1%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DP.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.-G.%26aulast%3DSun%26aufirst%3DY.-W.%26aulast%3DWang%26aufirst%3DL.%2BW.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DJ.%26atitle%3DTHZ1%2520Reveals%2520CDK7-Dependent%2520Transcriptional%2520Addictions%2520in%2520Pancreatic%2520Cancer%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26issue%3D20%26spage%3D3932%26epage%3D3945%26doi%3D10.1038%2Fs41388-019-0701-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meghani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting MYC Dependency in Ovarian Cancer Through Inhibition of CDK7 and CDK12/13</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e39030</span> <span class="refDoi"> DOI: 10.7554/eLife.39030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.7554%2FeLife.39030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30422115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyqsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&author=M.+Zengauthor=N.+P.+Kwiatkowskiauthor=T.+Zhangauthor=B.+Nabetauthor=M.+Xuauthor=Y.+Liangauthor=C.+Quanauthor=J.+Wangauthor=M.+Haoauthor=S.+Palakurthiauthor=S.+Zhouauthor=Q.+Zengauthor=P.+T.+Kirschmeierauthor=K.+Meghaniauthor=A.+L.+Leggettauthor=J.+Qiauthor=G.+I.+Shapiroauthor=J.+F.+Liuauthor=U.+A.+Matulonisauthor=C.+Y.+Linauthor=P.+A.+Konstantinopoulosauthor=N.+S.+Gray&title=Targeting+MYC+Dependency+in+Ovarian+Cancer+Through+Inhibition+of+CDK7+and+CDK12%2F13&doi=10.7554%2FeLife.39030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13</span></div><div class="casAuthors">Zeng, Mei; Kwiatkowski, Nicholas P.; Zhang, Tinghu; Nabet, Behnam; Xu, Mousheng; Liang, Yanke; Quan, Chunshan; Wang, Jinhua; Hao, Mingfeng; Palakurthi, Sangeetha; Zhou, Shan; Zeng, Qing; Kirschmeier, Paul T.; Meghani, Khyati; Leggett, Alan L.; Qi, Jun; Shapiro, Geoffrey I.; Liu, Joyce F.; Matulonis, Ursula A.; Lin, Charles Y.; Konstantinopoulos, Panagiotis A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e39030/1-e39030/20</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">High-grade serous ovarian cancer is characterized by extensive copy no. alterations, among which the amplification of MYC oncogene occurs in nearly half of tumors.  We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their oncogenic growth, indicating MYC as a therapeutic target for this difficult-to-treat malignancy.  However, targeting MYC directly has proven difficult.  We screen small mols. targeting transcriptional and epigenetic regulation, and find that THZ1 - a chem. inhibiting CDK7, CDK12, and CDK13 - markedly downregulates MYC.  Notably, abolishing MYC expression cannot be achieved by targeting CDK7 alone, but requires the combined inhibition of CDK7, CDK12, and CDK13.  In 11 patient-derived xenografts models derived from heavily pre-treated ovarian cancer patients, administration of THZ1 induces significant tumor growth inhibition with concurrent abrogation of MYC expression.  Our study indicates that targeting these transcriptional CDKs with agents such as THZ1 may be an effective approach for MYC-dependent ovarian malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2iDbCK3ukbVg90H21EOLACvtfcHk0liqfgxZyHmopQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyqsbvK&md5=40f9184065a1e4551f043ec7eb1cf30d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.7554%2FeLife.39030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.39030%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DN.%2BP.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DNabet%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DM.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DKirschmeier%26aufirst%3DP.%2BT.%26aulast%3DMeghani%26aufirst%3DK.%26aulast%3DLeggett%26aufirst%3DA.%2BL.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520MYC%2520Dependency%2520in%2520Ovarian%2520Cancer%2520Through%2520Inhibition%2520of%2520CDK7%2520and%2520CDK12%252F13%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26doi%3D10.7554%2FeLife.39030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-1418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1078-0432.CCR-19-1418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+Zhangauthor=W.+Liuauthor=C.+Zouauthor=Z.+Zhaoauthor=Y.+Laiauthor=Z.+Shiauthor=X.+Xieauthor=G.+Huangauthor=Y.+Wangauthor=X.+Zhangauthor=Z.+Fanauthor=Q.+Suauthor=J.+Yinauthor=J.+Shen&title=Targeting+Super-Enhancer-Associated+Oncogenes+in+Osteosarcoma+with+THZ2%2C+a+Covalent+CDK7+Inhibitor&doi=10.1158%2F1078-0432.CCR-19-1418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-1418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-1418%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DZ.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DTargeting%2520Super-Enhancer-Associated%2520Oncogenes%2520in%2520Osteosarcoma%2520with%2520THZ2%252C%2520a%2520Covalent%2520CDK7%2520Inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26doi%3D10.1158%2F1078-0432.CCR-19-1418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Johannessen, L.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Eaton, M.</span>; <span class="NLM_string-name">McKeown, M.</span>; <span class="NLM_string-name">Tyner, J. W.</span>; <span class="NLM_string-name">Kurtz, S. E.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">di Tomaso, E.</span></span> <span> </span><span class="NLM_article-title">Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia</span>.  <i>Proceedings of the 59th ASH Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Dec 7, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Hodgson&author=L.+Johannessen&author=N.+Rajagopal&author=S.+Hu&author=D.+Orlando&author=M.+Eaton&author=M.+McKeown&author=J.+W.+Tyner&author=S.+E.+Kurtz&author=K.+Sprott&author=C.+Fritz&author=E.+di+Tomaso&title=Sy-1365%2C+a+Potent+and+Selective+CDK7+Inhibitor%2C+Exhibits+Anti-Tumor+Activity+in+Preclinical+Models+of+Hematologic+Malignancies%2C+and+Demonstrates+Interactions+with+the+BCL-XL%2FBCL2+Mitochondrial+Apoptosis+Signaling+Pathway+in+Leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DG.%26atitle%3DSy-1365%252C%2520a%2520Potent%2520and%2520Selective%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520Anti-Tumor%2520Activity%2520in%2520Preclinical%2520Models%2520of%2520Hematologic%2520Malignancies%252C%2520and%2520Demonstrates%2520Interactions%2520with%2520the%2520BCL-XL%252FBCL2%2520Mitochondrial%2520Apoptosis%2520Signaling%2520Pathway%2520in%2520Leukemia%26jtitle%3DProceedings%2520of%2520the%252059th%2520ASH%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Johannessen, L.</span>; <span class="NLM_string-name">Liu, J. F.</span>; <span class="NLM_string-name">Kirschmeier, P. T.</span>; <span class="NLM_string-name">Zhou, S.</span>; <span class="NLM_string-name">Tran, C. A.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">di Tomaso, E.</span>; <span class="NLM_string-name">Matulonis, U. A.</span></span> <span> </span><span class="NLM_article-title">SY-1365, a Selective CDK7 Inhibitor, Exhibits Potent Antitumor Activity Against Ovarian Cancer Models in Vitro and in Vivo</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+A.+Konstantinopoulos&author=G.+Hodgson&author=N.+Rajagopal&author=L.+Johannessen&author=J.+F.+Liu&author=P.+T.+Kirschmeier&author=S.+Zhou&author=C.+A.+Tran&author=D.+Orlando&author=C.+Fritz&author=E.+di+Tomaso&author=U.+A.+Matulonis&title=SY-1365%2C+a+Selective+CDK7+Inhibitor%2C+Exhibits+Potent+Antitumor+Activity+Against+Ovarian+Cancer+Models+in+Vitro+and+in+Vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26atitle%3DSY-1365%252C%2520a%2520Selective%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520Potent%2520Antitumor%2520Activity%2520Against%2520Ovarian%2520Cancer%2520Models%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Ke, N.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Miljovska, S.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">McKeown, M.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Choi, Y. J.</span>; <span class="NLM_string-name">Olson, E.</span>; <span class="NLM_string-name">Fritz, C. C.</span></span> <span> </span><span class="NLM_article-title">SY-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Promising Anti-Tumor Activity in Multiple Preclinical Models of Aggressive Solid Tumors</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Apr 1–5, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Hu&author=N.+Ke&author=Y.+Ren&author=S.+Miljovska&author=N.+Rajagopal&author=M.+McKeown&author=D.+Orlando&author=K.+Sprott&author=Y.+J.+Choi&author=E.+Olson&author=C.+C.+Fritz&title=SY-1365%2C+a+Potent+and+Selective+CDK7+Inhibitor%2C+Exhibits+Promising+Anti-Tumor+Activity+in+Multiple+Preclinical+Models+of+Aggressive+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26atitle%3DSY-1365%252C%2520a%2520Potent%2520and%2520Selective%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520Promising%2520Anti-Tumor%2520Activity%2520in%2520Multiple%2520Preclinical%2520Models%2520of%2520Aggressive%2520Solid%2520Tumors%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">McKeown, M.</span>; <span class="NLM_string-name">Bush, A.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Olson, E.</span>; <span class="NLM_string-name">di Tomaso, E.</span></span> <span> </span><span class="NLM_article-title">BCL2L1 (BCL-XL) Expression and MYC Super-Enhancer Positivity Predict Sensitivity to the Covalent CDK7 Inhibitor SY-1365 in Triple Negative Breast Cancer (TNBC) Cell Lines</span>.  <i>Proceedings of the 2017 SABCS</i>; <span class="NLM_publisher-loc">San Antonio, TX</span>, Dec 5–9, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Rajagopal&author=G.+Hodgson&author=S.+Hu&author=M.+McKeown&author=A.+Bush&author=C.+Fritz&author=D.+Orlando&author=E.+Olson&author=E.+di+Tomaso&title=Proceedings+of+the+2017+SABCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DN.%26atitle%3DBCL2L1%2520%2528BCL-XL%2529%2520Expression%2520and%2520MYC%2520Super-Enhancer%2520Positivity%2520Predict%2520Sensitivity%2520to%2520the%2520Covalent%2520CDK7%2520Inhibitor%2520SY-1365%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%2520%2528TNBC%2529%2520Cell%2520Lines%26btitle%3DProceedings%2520of%2520the%25202017%2520SABCS%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span>; <span class="NLM_string-name">Papadopoulos, K.</span>; <span class="NLM_string-name">Tolcher, A.</span>; <span class="NLM_string-name">Do, K.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Zamboni, W.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">di Tomaso, E.</span>; <span class="NLM_string-name">Stephens, K.</span>; <span class="NLM_string-name">Roth, D.</span>; <span class="NLM_string-name">Shapiro, G.</span></span> <span> </span><span class="NLM_article-title">Proof-of-Mechanism Based on Target Engagement and Modulation of Gene Expression Following Treatment with SY-1365, a First-in-Class Selective CDK7 Inhibitor in Phase 1 Patients with Advanced Cancer</span>.  <i>Proceedings of the 30th EORTC-NCI-AACR Symposium</i>; <span class="NLM_publisher-loc">Dublin, Ireland</span>, Nov 13–16, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+Juric&author=K.+Papadopoulos&author=A.+Tolcher&author=K.+Do&author=D.+Orlando&author=W.+Zamboni&author=G.+Hodgson&author=E.+di+Tomaso&author=K.+Stephens&author=D.+Roth&author=G.+Shapiro&title=Proceedings+of+the+30th+EORTC-NCI-AACR+Symposium"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26atitle%3DProof-of-Mechanism%2520Based%2520on%2520Target%2520Engagement%2520and%2520Modulation%2520of%2520Gene%2520Expression%2520Following%2520Treatment%2520with%2520SY-1365%252C%2520a%2520First-in-Class%2520Selective%2520CDK7%2520Inhibitor%2520in%2520Phase%25201%2520Patients%2520with%2520Advanced%2520Cancer%26btitle%3DProceedings%2520of%2520the%252030th%2520EORTC-NCI-AACR%2520Symposium%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeseslsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiTomaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span> <span> </span><span class="NLM_article-title">Trial Design of a First-in-Human Phase 1 Evaluation of SY-1365, a First-in-Class Selective CDK7 Inhibitor, with Initial Expansions in Ovarian and Breast Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">TPS2600</span>– <span class="NLM_lpage">TPS2600</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.TPS2600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1200%2FJCO.2018.36.15_suppl.TPS2600" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=TPS2600-TPS2600&issue=15_suppl&author=G.+Shapiroauthor=K.+P.+Papadopoulosauthor=K.+T.+Doauthor=D.+Juricauthor=R.+Jeseslsohnauthor=P.+A.+Konstantinopoulosauthor=U.+A.+Matulonisauthor=G.+Hodgsonauthor=E.+DiTomasoauthor=K.+Stephensauthor=D.+A.+Rothauthor=A.+W.+Tolcher&title=Trial+Design+of+a+First-in-Human+Phase+1+Evaluation+of+SY-1365%2C+a+First-in-Class+Selective+CDK7+Inhibitor%2C+with+Initial+Expansions+in+Ovarian+and+Breast+Cancer&doi=10.1200%2FJCO.2018.36.15_suppl.TPS2600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.TPS2600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.TPS2600%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DDo%26aufirst%3DK.%2BT.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DJeseslsohn%26aufirst%3DR.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26aulast%3DHodgson%26aufirst%3DG.%26aulast%3DDiTomaso%26aufirst%3DE.%26aulast%3DStephens%26aufirst%3DK.%26aulast%3DRoth%26aufirst%3DD.%2BA.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DTrial%2520Design%2520of%2520a%2520First-in-Human%2520Phase%25201%2520Evaluation%2520of%2520SY-1365%252C%2520a%2520First-in-Class%2520Selective%2520CDK7%2520Inhibitor%252C%2520with%2520Initial%2520Expansions%2520in%2520Ovarian%2520and%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15_suppl%26spage%3DTPS2600%26epage%3DTPS2600%26doi%3D10.1200%2FJCO.2018.36.15_suppl.TPS2600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span>; <span class="NLM_string-name">Do, K.</span>; <span class="NLM_string-name">di Tomaso, E.</span>; <span class="NLM_string-name">Waters, N.</span>; <span class="NLM_string-name">Stephens, K.</span>; <span class="NLM_string-name">Roth, D.</span>; <span class="NLM_string-name">Shapiro, G.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors</span>.  <i>Proceedings of the ESMO 2017 Conference</i>; <span class="NLM_publisher-loc">Madrid, Spain</span>, Sep 8–12, <span class="NLM_year">2017</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1093%2Fannonc%2Fmdx367.058" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Tolcher&author=K.+Do&author=E.+di+Tomaso&author=N.+Waters&author=K.+Stephens&author=D.+Roth&author=G.+Shapiro&title=Proceedings+of+the+ESMO+2017+Conference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx367.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx367.058%26sid%3Dliteratum%253Aachs%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DA%2520Phase%25201%2520Study%2520of%2520SY-1365%252C%2520a%2520Selective%2520CDK7%2520Inhibitor%252C%2520in%2520Adult%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26btitle%3DProceedings%2520of%2520the%2520ESMO%25202017%2520Conference%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Marineau, J.</span>; <span class="NLM_string-name">Hamman, K.</span>; <span class="NLM_string-name">Bradley, M.</span>; <span class="NLM_string-name">Savinainen, A.</span>; <span class="NLM_string-name">Alnemy, S.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Chuaqui, C.</span>; <span class="NLM_string-name">Olson, E.</span></span> <span> </span><span class="NLM_article-title">SY-5609, an Orally Available Selective CDK7 Inhibitor Demonstrates Broad Anti-Tumor Activity in Vivo</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 3, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Hu&author=J.+Marineau&author=K.+Hamman&author=M.+Bradley&author=A.+Savinainen&author=S.+Alnemy&author=N.+Rajagopal&author=D.+Orlando&author=C.+Chuaqui&author=E.+Olson&title=SY-5609%2C+an+Orally+Available+Selective+CDK7+Inhibitor+Demonstrates+Broad+Anti-Tumor+Activity+in+Vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26atitle%3DSY-5609%252C%2520an%2520Orally%2520Available%2520Selective%2520CDK7%2520Inhibitor%2520Demonstrates%2520Broad%2520Anti-Tumor%2520Activity%2520in%2520Vivo%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Hasegawa, T.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">In Vitro Anti-Cancer Activity of UD-017, a Novel Potent and Highly Selective CDK7 Reversible Inhibitor</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Apr 1–5, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+Matsushita&author=K.+Onuma&author=H.+Sunamoto&author=A.+Ogawa&author=S.+Ogi&author=T.+Hasegawa&author=S.+Kono&author=N.+Iwase&author=Y.+Aga&author=S.+Ushiyama&title=In+Vitro+Anti-Cancer+Activity+of+UD-017%2C+a+Novel+Potent+and+Highly+Selective+CDK7+Reversible+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushita%26aufirst%3DT.%26atitle%3DIn%2520Vitro%2520Anti-Cancer%2520Activity%2520of%2520UD-017%252C%2520a%2520Novel%2520Potent%2520and%2520Highly%2520Selective%2520CDK7%2520Reversible%2520Inhibitor%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Tokunaga, Y.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Hasegawa, T.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">In Vivo Anti-Tumor Efficacy of UD-017, a Novel Highly Selective and Orally Available CDK7 Inhibitor, in Colorectal Cancer Cells Xenograft Models</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Apr 1–5, <span class="NLM_year">2017</span>; 2017.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Aga&author=S.+Ogi&author=Y.+Tokunaga&author=A.+Ogawa&author=K.+Onuma&author=T.+Matsushita&author=H.+Sunamoto&author=T.+Hasegawa&author=S.+Ushiyama&title=In+Vivo+Anti-Tumor+Efficacy+of+UD-017%2C+a+Novel+Highly+Selective+and+Orally+Available+CDK7+Inhibitor%2C+in+Colorectal+Cancer+Cells+Xenograft+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAga%26aufirst%3DY.%26atitle%3DIn%2520Vivo%2520Anti-Tumor%2520Efficacy%2520of%2520UD-017%252C%2520a%2520Novel%2520Highly%2520Selective%2520and%2520Orally%2520Available%2520CDK7%2520Inhibitor%252C%2520in%2520Colorectal%2520Cancer%2520Cells%2520Xenograft%2520Models%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Hasegawa, T.</span>; <span class="NLM_string-name">Tokunaga, Y.</span>; <span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">UD-017, a Novel Highly Selective and Orally Active CDK7 Inhibitor, Shows a Significant Anticancer Activity in Patient-Derived Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Matsushita&author=S.+Ogi&author=K.+Onuma&author=H.+Sunamoto&author=A.+Ogawa&author=T.+Hasegawa&author=Y.+Tokunaga&author=Y.+Aga&author=S.+Ushiyama&title=UD-017%2C+a+Novel+Highly+Selective+and+Orally+Active+CDK7+Inhibitor%2C+Shows+a+Significant+Anticancer+Activity+in+Patient-Derived+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushita%26aufirst%3DT.%26atitle%3DUD-017%252C%2520a%2520Novel%2520Highly%2520Selective%2520and%2520Orally%2520Active%2520CDK7%2520Inhibitor%252C%2520Shows%2520a%2520Significant%2520Anticancer%2520Activity%2520in%2520Patient-Derived%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical in Vitro and in Vivo Study of UD-017, a Novel Highly Selective and Orally Available CDK7 Inhibitor, in a Variety of Cancers</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">15_suppl</span>), <span class="NLM_elocation-id">e14086-e14086</span> <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.e14086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1200%2FJCO.2017.35.15_suppl.e14086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&issue=15_suppl&author=K.+Onumaauthor=Y.+Agaauthor=S.+Ogiauthor=T.+Matsushitaauthor=H.+Sunamotoauthor=A.+Ogawaauthor=Y.+Tokunagaauthor=S.+Ushiyama&title=Preclinical+in+Vitro+and+in+Vivo+Study+of+UD-017%2C+a+Novel+Highly+Selective+and+Orally+Available+CDK7+Inhibitor%2C+in+a+Variety+of+Cancers&doi=10.1200%2FJCO.2017.35.15_suppl.e14086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.e14086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.e14086%26sid%3Dliteratum%253Aachs%26aulast%3DOnuma%26aufirst%3DK.%26aulast%3DAga%26aufirst%3DY.%26aulast%3DOgi%26aufirst%3DS.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSunamoto%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DA.%26aulast%3DTokunaga%26aufirst%3DY.%26aulast%3DUshiyama%26aufirst%3DS.%26atitle%3DPreclinical%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Study%2520of%2520UD-017%252C%2520a%2520Novel%2520Highly%2520Selective%2520and%2520Orally%2520Available%2520CDK7%2520Inhibitor%252C%2520in%2520a%2520Variety%2520of%2520Cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3D15_suppl%26doi%3D10.1200%2FJCO.2017.35.15_suppl.e14086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Anticancer Activities of UD-017, a Novel Selective and Orally Available CDK7 Inhibitor, in Blood Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Aga&author=S.+Ogi&author=K.+Onuma&author=H.+Sunamoto&author=T.+Matsushita&author=A.+Ogawa&author=S.+Kono&author=N.+Iwase&author=S.+Ushiyama&title=Evaluation+of+Anticancer+Activities+of+UD-017%2C+a+Novel+Selective+and+Orally+Available+CDK7+Inhibitor%2C+in+Blood+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAga%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520Anticancer%2520Activities%2520of%2520UD-017%252C%2520a%2520Novel%2520Selective%2520and%2520Orally%2520Available%2520CDK7%2520Inhibitor%252C%2520in%2520Blood%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cayrol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praditsuktavorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marullo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo-Vidal, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pera, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takpradit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremaschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchietti, L.</span></span> <span> </span><span class="NLM_article-title">THZ1 Targeting CDK7 Suppresses STAT Transcriptional Activity and Sensitizes T-cell Lymphomas to BCL2 Inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14290</span>, <span class="refDoi"> DOI: 10.1038/ncomms14290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fncomms14290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28134252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVGltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14290&author=F.+Cayrolauthor=P.+Praditsuktavornauthor=T.+M.+Fernandoauthor=N.+Kwiatkowskiauthor=R.+Marulloauthor=M.+N.+Calvo-Vidalauthor=J.+Phillipauthor=B.+Peraauthor=S.+N.+Yangauthor=K.+Takpraditauthor=L.+Romanauthor=M.+Gaudianoauthor=R.+Crescenzoauthor=J.+Ruanauthor=G.+Inghiramiauthor=T.+Zhangauthor=G.+Cremaschiauthor=N.+S.+Grayauthor=L.+Cerchietti&title=THZ1+Targeting+CDK7+Suppresses+STAT+Transcriptional+Activity+and+Sensitizes+T-cell+Lymphomas+to+BCL2+Inhibitors&doi=10.1038%2Fncomms14290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors</span></div><div class="casAuthors">Cayrol, Florencia; Praditsuktavorn, Pannee; Fernando, Tharu M.; Kwiatkowski, Nicholas; Marullo, Rosella; Calvo-Vidal, M. Nieves; Phillip, Jude; Pera, Benet; Yang, Shao Ning; Takpradit, Kaipol; Roman, Lidia; Gaudiano, Marcello; Crescenzo, Ramona; Ruan, Jia; Inghirami, Giorgio; Zhang, Tinghu; Cremaschi, Graciela; Gray, Nathanael S.; Cerchietti, Leandro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14290</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival.  Identification of effective strategies to target PTCL biol. represents an urgent need.  Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).  The STAT-signalling pathway is highly vulnerable to THZ1 even in PTCL cells that carry the activating STAT3 mutation Y640F.  In mutant cells, CDK7 inhibition decreases STAT3 chromatin binding and expression of highly transcribed target genes like MYC, PIM1, MCL1, CD30, IL2RA, CDC25A and IL4R.  In surviving cells, THZ1 decreases the expression of STAT-regulated anti-apoptotic BH3 family members MCL1 and BCL-XL sensitizing PTCL cells to BH3 mimetic drugs.  Accordingly, the combination of THZ1 and the BH3 mimetic obatoclax improves lymphoma growth control in a primary PTCL ex vivo culture and in two STAT3-mutant PTCL xenografts, delineating a potential targeted agent-based therapeutic option for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQbPpwOfLObVg90H21EOLACvtfcHk0ljbE5_rvi_aNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVGltr4%253D&md5=55b436fd7c4427da0005b735bea7e622</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fncomms14290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14290%26sid%3Dliteratum%253Aachs%26aulast%3DCayrol%26aufirst%3DF.%26aulast%3DPraditsuktavorn%26aufirst%3DP.%26aulast%3DFernando%26aufirst%3DT.%2BM.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DMarullo%26aufirst%3DR.%26aulast%3DCalvo-Vidal%26aufirst%3DM.%2BN.%26aulast%3DPhillip%26aufirst%3DJ.%26aulast%3DPera%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DS.%2BN.%26aulast%3DTakpradit%26aufirst%3DK.%26aulast%3DRoman%26aufirst%3DL.%26aulast%3DGaudiano%26aufirst%3DM.%26aulast%3DCrescenzo%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DJ.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DCremaschi%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DCerchietti%26aufirst%3DL.%26atitle%3DTHZ1%2520Targeting%2520CDK7%2520Suppresses%2520STAT%2520Transcriptional%2520Activity%2520and%2520Sensitizes%2520T-cell%2520Lymphomas%2520to%2520BCL2%2520Inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14290%26doi%3D10.1038%2Fncomms14290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenall, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensbey, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’neill, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, T. G.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Is a Therapeutic Target in High-Grade Glioma</span>. <i>Oncogenesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e336</span> <span class="refDoi"> DOI: 10.1038/oncsis.2017.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Foncsis.2017.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28504693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&issue=5&author=S.+A.+Greenallauthor=Y.+Limauthor=C.+Mitchellauthor=K.+S.+Ensbeyauthor=B.+W.+Stringerauthor=A.+L.+Wildingauthor=G.+O%E2%80%99neillauthor=K.+McDonaldauthor=D.+Goughauthor=B.+W.+Dayauthor=T.+G.+Johns&title=Cyclin-Dependent+Kinase+7+Is+a+Therapeutic+Target+in+High-Grade+Glioma&doi=10.1038%2Foncsis.2017.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma</span></div><div class="casAuthors">Greenall, S. A.; Lim, Y. C.; Mitchell, C. B.; Ensbey, K. S.; Stringer, B. W.; Wilding, A. L.; O'Neill, G. M.; McDonald, K. L.; Gough, D. J.; Day, B. W.; Johns, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogenesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e336</span>CODEN:
                <span class="NLM_cas:coden">ONCOCT</span>;
        ISSN:<span class="NLM_cas:issn">2157-9024</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">High-grade glioma (HGG) is an incurable brain cancer.  The transcriptomes of cells within HGG tumors are highly heterogeneous.  This renders the tumors unresponsive or able to adapt to therapeutics targeted at single pathways, thereby causing treatment failure.  To overcome this, we focused on cyclin-dependent kinase 7 (CDK7), a ubiquitously expressed mol. involved in two major drivers of HGG pathogenesis: cell cycle progression and RNA polymerase-II-based transcription.  We tested the activity of THZ1, an irreversible CDK7 inhibitor, on patient-derived primary HGG cell lines and ex vivo HGG patient tissue slices, using proliferation assays, microarray anal., high-resoln. respirometry, cell cycle anal. and in vivo tumor orthografts.  The cellular processes affected by CDK7 inhibition were analyzed by reverse transcriptase-quant. PCR, western blot, flow cytometry and immunofluorescence.  THZ1 perturbed the transcriptome and disabled CDK activation, leading to cell cycle arrest at G2 and DNA damage.  THZ1 halted transcription of the nuclear-encoded mitochondrial ribosomal genes, reducing mitochondrial translation and oxidative respiration.  It also inhibited the expression of receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor-α (PDGFR-α), reducing signaling flux through the AKT, extracellular-signal-regulated kinase 1/2 (ERK1/2) and signal transducer and activator of transcription 3 (STAT3) downstream pathways.  Finally, THZ1 disrupted nucleolar, Cajal body and nuclear speckle formation, resulting in reduced cytosolic translation and malfunction of the spliceosome and thus leading to aberrant mRNA processing.  These findings indicate that CDK7 is crucial for gliomagenesis, validate CDK7 as a therapeutic target and provide new insight into the cellular processes that are affected by THZ1 and induce antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsiQ1SulsDprVg90H21EOLACvtfcHk0ligwcNXIH66JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKmurk%253D&md5=90176bafe1f4adeac3c0032d22aa96a3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Foncsis.2017.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foncsis.2017.33%26sid%3Dliteratum%253Aachs%26aulast%3DGreenall%26aufirst%3DS.%2BA.%26aulast%3DLim%26aufirst%3DY.%26aulast%3DMitchell%26aufirst%3DC.%26aulast%3DEnsbey%26aufirst%3DK.%2BS.%26aulast%3DStringer%26aufirst%3DB.%2BW.%26aulast%3DWilding%26aufirst%3DA.%2BL.%26aulast%3DO%25E2%2580%2599neill%26aufirst%3DG.%26aulast%3DMcDonald%26aufirst%3DK.%26aulast%3DGough%26aufirst%3DD.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DJohns%26aufirst%3DT.%2BG.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Is%2520a%2520Therapeutic%2520Target%2520in%2520High-Grade%2520Glioma%26jtitle%3DOncogenesis%26date%3D2017%26volume%3D6%26issue%3D5%26doi%3D10.1038%2Foncsis.2017.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guarducci, C.</span>; <span class="NLM_string-name">Nardone, A.</span>; <span class="NLM_string-name">Feiglin, A.</span>; <span class="NLM_string-name">Migliaccio, I.</span>; <span class="NLM_string-name">Malorni, L.</span>; <span class="NLM_string-name">Bonechi, M.</span>; <span class="NLM_string-name">Benelli, M.</span>; <span class="NLM_string-name">Di Leo, A.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Brown, M.</span>; <span class="NLM_string-name">Jeselsohn, R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CDK7 Overcomes Resistance to CDK4/6 Inhibitors in Hormone Receptor Positive Breast Cancer Cells</span>.  <i>Proceedings of the 2018 SABCS</i>; <span class="NLM_publisher-loc">San Antonio, TX</span>, Dec 4–8, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Guarducci&author=A.+Nardone&author=A.+Feiglin&author=I.+Migliaccio&author=L.+Malorni&author=M.+Bonechi&author=M.+Benelli&author=A.+Di+Leo&author=G.+Hodgson&author=G.+Shapiro&author=M.+Brown&author=R.+Jeselsohn&title=Proceedings+of+the+2018+SABCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGuarducci%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520CDK7%2520Overcomes%2520Resistance%2520to%2520CDK4%252F6%2520Inhibitors%2520in%2520Hormone%2520Receptor%2520Positive%2520Breast%2520Cancer%2520Cells%26btitle%3DProceedings%2520of%2520the%25202018%2520SABCS%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, H.-B.</span></span> <span> </span><span class="NLM_article-title">THZ1 Suppresses Human Non-Small-Cell Lung Cancer Cells in Vitro Through Interference with Cancer Metabolism</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0187-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41401-018-0187-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30446732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1eiu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=814-822&issue=6&author=Z.-J.+Chengauthor=D.-L.+Miaoauthor=Q.-Y.+Suauthor=X.-L.+Tangauthor=X.-L.+Wangauthor=L.-B.+Dengauthor=H.-D.+Shiauthor=H.-B.+Xin&title=THZ1+Suppresses+Human+Non-Small-Cell+Lung+Cancer+Cells+in+Vitro+Through+Interference+with+Cancer+Metabolism&doi=10.1038%2Fs41401-018-0187-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism</span></div><div class="casAuthors">Cheng, Zhu-Jun; Miao, Du-Ling; Su, Qiu-Yun; Tang, Xiao-Li; Wang, Xiao-Lei; Deng, Li-Bin; Shi, Hui-Dong; Xin, Hong-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">814-822</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer cells always require more nutrients, energy, and biosynthetic activity to sustain their rapid proliferation than normal cells.  Previous studies have shown the impact of THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), on transcription regulation and cell-cycle arrest in numerous cancers, but its effects on cellular metab. in cancer cells remain unknown.  In this study we elucidated the anticancer mechanism of THZ1 in human non-small-cell lung cancer (NSCLC) cells.  We showed that treatment with THZ1 (10-1000 nM) dose-dependently suppressed the proliferation of human NSCLC cell lines H1299, A549, H292, and H23, and markedly inhibited the migration of these NSCLC cells.  Furthermore, treatment with THZ1 (50 nM) arrested cell cycle at G2/M phase and induced apoptosis in these NSCLC cell lines.  More importantly, we revealed that treatment with THZ1 (50 nM) blocked the glycolysis pathway but had no effect on glutamine metab.  We further demonstrated that THZ1 treatment altered the expression pattern of glutaminase 1 (GLS1) isoforms through promoting the ubiquitination and degrdn. of NUDT21.  Combined treatment of THZ1 with a glutaminase inhibitor CB-839 (500 nM) exerted a more potent anti-proliferative effect in these NSCLC cell lines than treatment with THZ1 or CB-839 alone.  Our results demonstrate that the inhibitory effect of THZ1 on the growth of human NSCLC cells is partially attributed to interfering with cancer metab.  Thus, we provide a new potential therapeutic strategy for NSCLC treatment by combining THZ1 with the inhibitors of glutamine metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFRTyHkOgGpLVg90H21EOLACvtfcHk0ligwcNXIH66JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1eiu7rO&md5=70999bac41f6f734dfecf980b5013f3e</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0187-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0187-3%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.-J.%26aulast%3DMiao%26aufirst%3DD.-L.%26aulast%3DSu%26aufirst%3DQ.-Y.%26aulast%3DTang%26aufirst%3DX.-L.%26aulast%3DWang%26aufirst%3DX.-L.%26aulast%3DDeng%26aufirst%3DL.-B.%26aulast%3DShi%26aufirst%3DH.-D.%26aulast%3DXin%26aufirst%3DH.-B.%26atitle%3DTHZ1%2520Suppresses%2520Human%2520Non-Small-Cell%2520Lung%2520Cancer%2520Cells%2520in%2520Vitro%2520Through%2520Interference%2520with%2520Cancer%2520Metabolism%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26issue%3D6%26spage%3D814%26epage%3D822%26doi%3D10.1038%2Fs41401-018-0187-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibition as a Promising Therapeutic Strategy for Lung Squamous Cell Carcinomas with a SOX2 Amplification</span>. <i>Cell. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1007/s13402-019-00434-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1007%2Fs13402-019-00434-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVals7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=449-458&issue=4&author=J.+Y.+Hurauthor=H.+R.+Kimauthor=J.+Y.+Leeauthor=S.+Parkauthor=J.+A.+Hwangauthor=W.+S.+Kimauthor=S.+Yoonauthor=C.-M.+Choiauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=CDK7+Inhibition+as+a+Promising+Therapeutic+Strategy+for+Lung+Squamous+Cell+Carcinomas+with+a+SOX2+Amplification&doi=10.1007%2Fs13402-019-00434-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification</span></div><div class="casAuthors">Hur, Jae Young; Kim, Hyeong Ryul; Lee, Jung Yeon; Park, Sojung; Hwang, Ji An; Kim, Woo Sung; Yoon, Shinkyo; Choi, Chang-Min; Rho, Jin Kyung; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-458</span>CODEN:
                <span class="NLM_cas:coden">COENGH</span>;
        ISSN:<span class="NLM_cas:issn">2211-3436</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Here, we investigated the effects of THZ1, a potent cyclin-dependent kinase 7 (CDK7) inhibitor that plays a key role in gene transcription, in SCC.  Lung SCC-derived cell viabilities were assessed using a CCK-8 assay.  SOX2 expression and RNAPII-CTD phosphorylation levels after THZ1 treatment were detd. by Western blotting.  The effect of SOX2 suppression using shRNA was assessed by flow cytometry.  Gene expression patterns after THZ1 treatment of lung SCC-derived cells were identified using microarray-based mRNA profiling.  We found that THZ1 treatment led to suppression of cell growth and apoptotic cell death in SOX2-amplified SCC-derived cells only, whereas the modest growth-inhibitory effect of cisplatin did not differ according to SOX2 amplification status.  We also found that THZ1 decreased the phosphorylation of the carboxyl-terminal domain of RNA polymerase II and the expression of several genes.  Specifically, we found that the expression of transcription-assocd. genes, including SOX2, was down-regulated by THZ1 in SOX2-amplified SCC cells.  This inhibition of SOX2 expression resulted in suppression of the growth of these cells.  From our data, we conclude that THZ1 may effectively control the proliferation and survival of SOX2-amplified SCC cells through a decrease in global transcriptional activity, suggesting that CDK7 inhibition leading to transcription suppression may be a promising therapeutic option for lung SCC with a SOX2 amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtayG3PDD7TrVg90H21EOLACvtfcHk0ligwcNXIH66JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVals7s%253D&md5=18b68fba372e0fa5edc5830369ba3899</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs13402-019-00434-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13402-019-00434-2%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DC.-M.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DCDK7%2520Inhibition%2520as%2520a%2520Promising%2520Therapeutic%2520Strategy%2520for%2520Lung%2520Squamous%2520Cell%2520Carcinomas%2520with%2520a%2520SOX2%2520Amplification%26jtitle%3DCell.%2520Oncol.%26date%3D2019%26volume%3D42%26issue%3D4%26spage%3D449%26epage%3D458%26doi%3D10.1007%2Fs13402-019-00434-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span> <span> </span><span class="NLM_article-title">Interaction with Cyclin H/Cyclin-Dependent Kinase 7 (CCNH/CDK7) Stabilizes C-Terminal Binding Protein 2 (CtBP2) and Promotes Cancer Cell Migration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">9028</span>– <span class="NLM_lpage">9034</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.432005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1074%2Fjbc.M112.432005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=23393140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2murc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=9028-9034&issue=13&author=Y.+Wangauthor=F.+Liuauthor=F.+Maoauthor=Q.+Hangauthor=X.+Huangauthor=S.+Heauthor=Y.+Wangauthor=C.+Chengauthor=H.+Wangauthor=G.+Xuauthor=T.+Zhangauthor=A.+Shen&title=Interaction+with+Cyclin+H%2FCyclin-Dependent+Kinase+7+%28CCNH%2FCDK7%29+Stabilizes+C-Terminal+Binding+Protein+2+%28CtBP2%29+and+Promotes+Cancer+Cell+Migration&doi=10.1074%2Fjbc.M112.432005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction with Cyclin H/Cyclin-dependent Kinase 7 (CCNH/CDK7) Stabilizes C-terminal Binding Protein 2 (CtBP2) and Promotes Cancer Cell Migration</span></div><div class="casAuthors">Wang, Yuchan; Liu, Fang; Mao, Feng; Hang, Qinlei; Huang, Xiaodong; He, Song; Wang, Yingying; Cheng, Chun; Wang, Huijie; Xu, Guangfei; Zhang, Tianyi; Shen, Aiguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9028-9034</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">CtBP2 has been demonstrated to possess tumor-promoting capacities by virtue of up-regulating epithelial-mesenchymal transition (EMT) and down-regulating apoptosis in cancer cells.  As a result, cellular CtBP2 levels are considered a key factor detg. the outcome of oncogenic transformation.  How pro-tumorigenic and anti-tumorigenic factors compete for fine-tuning CtBP2 levels is incompletely understood.  Here we report that the cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) complex interacted with CtBP2 in vivo and in vitro.  Depletion of either CCNH or CDK7 decreased CtBP2 protein levels by accelerating proteasome-dependent CtBP2 clearance.  Further anal. revealed that CCNH/CDK7 competed with the tumor repressor HIPK2 for CtBP2 binding and consequently inhibited phosphorylation and dimerization of CtBP2.  Phosphorylation-defective CtBP2 interacted more strongly with CCNH/CDK7 and was more resistant to degrdn.  Finally, overexpression of CtBP2 increased whereas depletion of CtBP2 dampened the invasive and migratory potential of breast cancer cells.  CtBP2 promoted the invasion and migration of breast cancer cells in a CCNH-dependent manner.  Taken together, our data have delineated a novel pathway that regulates CtBP2 stability, suggesting that targeting the CCNH/CDK7-CtBP2 axis may yield a viable anti-tumor strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTiSrV9eLwN7Vg90H21EOLACvtfcHk0ljpgH9u_MIB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2murc%253D&md5=cf7b41da65dc786cf42df524b2eb0914</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.432005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.432005%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DHang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DA.%26atitle%3DInteraction%2520with%2520Cyclin%2520H%252FCyclin-Dependent%2520Kinase%25207%2520%2528CCNH%252FCDK7%2529%2520Stabilizes%2520C-Terminal%2520Binding%2520Protein%25202%2520%2528CtBP2%2529%2520and%2520Promotes%2520Cancer%2520Cell%2520Migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D13%26spage%3D9028%26epage%3D9034%26doi%3D10.1074%2Fjbc.M112.432005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span> <span> </span><span class="NLM_article-title">Interaction with CCNH/CDK7 Facilitates CtBP2 Promoting Esophageal Squamous Cell Carcinoma (ESCC) Metastasis via Upregulating Epithelial-Mesenchymal Transition (EMT) Progression</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">6701</span>– <span class="NLM_lpage">6714</span>, <span class="refDoi"> DOI: 10.1007/s13277-015-3354-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1007%2Fs13277-015-3354-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=6701-6714&issue=9&author=J.+Zhangauthor=J.+Zhuauthor=L.+Yangauthor=C.+Guanauthor=R.+Niauthor=Y.+Wangauthor=L.+Jiauthor=Y.+Tian&title=Interaction+with+CCNH%2FCDK7+Facilitates+CtBP2+Promoting+Esophageal+Squamous+Cell+Carcinoma+%28ESCC%29+Metastasis+via+Upregulating+Epithelial-Mesenchymal+Transition+%28EMT%29+Progression&doi=10.1007%2Fs13277-015-3354-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression</span></div><div class="casAuthors">Zhang, Jianguo; Zhu, Junya; Yang, Lei; Guan, Chengqi; Ni, Runzhou; Wang, Yuchan; Ji, Lili; Tian, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6701-6714</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">CtBP2, as a transcriptional corepressor of epithelial-specific genes, has been reported to promote tumor due to upregulating epithelial-mesenchymal transition (EMT) in cancer cells.  CtBP2 was also demonstrated to contribute to the proliferation of esophageal squamous cell carcinoma (ESCC) cells through a neg. transcriptional regulation of p16INK4A.  In this study, for the first time, we reported that CtBP2 expression, along with CCNH/CDK7, was higher in ESCC tissues with lymph node metastases than in those without lymph node metastases.  Moreover, both CtBP2 and CCNH/CDK7 were pos. correlated with E-cadherin, tumor grade, and tumor metastasis.  However, the concrete mechanism of CtBP2's role in enhancing ESCC migration remains incompletely understood.  We confirmed that CCNH/CDK7 could directly interact with CtBP2 in ESCC cells in vivo and in vitro.  Furthermore, our data demonstrate for the first time that CtBP2 enhanced the migration of ESCC cells in a CCNH/CDK7-dependent manner.  Our results indicated that CCNH/CDK7-CtBP2 axis may augment ESCC cell migration, and targeting the interaction of both may provide a novel therapeutic target of ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyjvsAojbLO7Vg90H21EOLACvtfcHk0ljpgH9u_MIB7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslCgsbc%253D&md5=aa3b5fefbb66ee69a6839003001bb1eb</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs13277-015-3354-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-015-3354-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DC.%26aulast%3DNi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DY.%26atitle%3DInteraction%2520with%2520CCNH%252FCDK7%2520Facilitates%2520CtBP2%2520Promoting%2520Esophageal%2520Squamous%2520Cell%2520Carcinoma%2520%2528ESCC%2529%2520Metastasis%2520via%2520Upregulating%2520Epithelial-Mesenchymal%2520Transition%2520%2528EMT%2529%2520Progression%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26issue%3D9%26spage%3D6701%26epage%3D6714%26doi%3D10.1007%2Fs13277-015-3354-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, C.</span></span> <span> </span><span class="NLM_article-title">Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3149</span>– <span class="NLM_lpage">3155</span>, <span class="refDoi"> DOI: 10.7150/jca.25395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.7150%2Fjca.25395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30210638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otlGqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3149-3155&issue=17&author=X.+Maauthor=X.+Kuangauthor=Q.+Xiaauthor=Z.+Huangauthor=Y.+Fanauthor=J.+Ningauthor=J.+Wenauthor=H.+Zhangauthor=J.+Yanauthor=Q.+Zhangauthor=H.+Shenauthor=C.+Long&title=Covalent+CDK7+Inhibitor+THZ1+Inhibits+Myogenic+Differentiation&doi=10.7150%2Fjca.25395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation</span></div><div class="casAuthors">Ma Xinqi; Kuang Xielan; Xia Qing; Huang Zixin; Fan Yuting; Ning Jie; Wen Jiajie; Zhang Han; Yan Jianhua; Zhang Qingjiong; Shen Huangxuan; Long Chongde; Kuang Xielan; Shen Huangxuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3149-3155</span>
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    </div><div class="casAbstract">Covalent CDK7 inhibitor THZ1 is a newly discovered anti-tumor drug.THZ1 affects the function of transcription factor TFIIH by inhibiting CDK7, which in turn affects RNA polymerase II, and ultimately affects transcription initiation.  Study found that THZ1 could inhibit proliferation and promote apoptosis of several tumor cell lines.  However, there is no report of the potential side effect of THZ1 in normal tissues.  In the course of cancer, the muscle consumption of cachexia needs to be supplemented by the differentiation of muscle cells.  However, the effect of THZ1 on myogenic differentiation remains unclear.  Our study in this article found that THZ1 could both inhibit the differentiation of C2C12 cells and mouse primary myoblasts, also repressing the expression of differentiation-related transcription factors and muscle structural proteins, such as and myogenin, myh3 and MCK.  Moreover, THZ1 could inhibit C2C12 cell proliferation and migration, increase its oxidative stress and promote its apoptosis.  Our data indicates that THZ1 inhibits myogenic differentiation, suggesting that therapies based on THZ1 might have potential side effects on muscle functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvVmaBIAg3KRJ5E29YNGvQfW6udTcc2ebSr8svpe58Bbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otlGqtQ%253D%253D&md5=5f904b5e7aa2158d3f3410381344b38a</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.7150%2Fjca.25395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.25395%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DKuang%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DNing%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DC.%26atitle%3DCovalent%2520CDK7%2520Inhibitor%2520THZ1%2520Inhibits%2520Myogenic%2520Differentiation%26jtitle%3DJ.%2520Cancer%26date%3D2018%26volume%3D9%26issue%3D17%26spage%3D3149%26epage%3D3155%26doi%3D10.7150%2Fjca.25395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Ke, N.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Lopez, J.</span>; <span class="NLM_string-name">Milijovska, S.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Schmidt, D.</span>; <span class="NLM_string-name">Bradley, M.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">Olson, E.</span></span> <span> </span><span class="NLM_article-title">First-in-Class CDK7 Inhibitor, Induces Robust Apoptosis in Acute Myeloid Leukemia and Demonstrates Durable in Vivo Efficacy</span>.  <i>Proceedings of the EHA 21st congress</i>; <span class="NLM_publisher-loc">Copenhagen</span>, Jun 8–12, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Choi&author=S.+Hu&author=N.+Ke&author=Y.+Ren&author=J.+Lopez&author=S.+Milijovska&author=D.+Orlando&author=D.+Schmidt&author=M.+Bradley&author=K.+Sprott&author=C.+Fritz&author=E.+Olson&title=Proceedings+of+the+EHA+21st+congress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DFirst-in-Class%2520CDK7%2520Inhibitor%252C%2520Induces%2520Robust%2520Apoptosis%2520in%2520Acute%2520Myeloid%2520Leukemia%2520and%2520Demonstrates%2520Durable%2520in%2520Vivo%2520Efficacy%26btitle%3DProceedings%2520of%2520the%2520EHA%252021st%2520congress%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Precision Retargeting: A Selective Covalent Inhibitor Illuminates CDK7 Biology</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.chembiol.2019.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31226310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wqu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=779-780&issue=6&author=L.+H.+Jones&title=Precision+Retargeting%3A+A+Selective+Covalent+Inhibitor+Illuminates+CDK7+Biology&doi=10.1016%2Fj.chembiol.2019.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Precision Retargeting: A Selective Covalent Inhibitor Illuminates CDK7 Biology</span></div><div class="casAuthors">Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-780</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  In this issue of Cell Chem. Biol., Olson et al. (2019) develop the first selective CDK7 irreversible inhibitor.  Elegant cell-based studies using a CDK7 mutant that is not covalently engaged by the probe helped decipher the effects of inhibiting the kinase on the cell cycle and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUOGGohvuYlbVg90H21EOLACvtfcHk0li2YIE-5S8N3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wqu7fK&md5=ab6ffe4eae4bc407ca8e99d7e25bcfee</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DPrecision%2520Retargeting%253A%2520A%2520Selective%2520Covalent%2520Inhibitor%2520Illuminates%2520CDK7%2520Biology%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D779%26epage%3D780%26doi%3D10.1016%2Fj.chembiol.2019.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, L.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Ke, N.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Alnemy, S.</span>; <span class="NLM_string-name">Carulli, J.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">di Tomaso, E.</span></span> <span> </span><span class="NLM_article-title">SY-1365, a Selective CDK7 Inhibitor, Enhances Carboplatin Activity in Ovarian Cancer Cell Lines and Xenografts, and Transcriptionally Inhibits Homologous Recombination Repair (HRR) Genes</span>.  <i>Proceedings of the 30th EORTC-NCI-AACR Symposium</i>; <span class="NLM_publisher-loc">Dublin, Ireland</span>, Nov 13–16, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Johannessen&author=S.+Hu&author=N.+Ke&author=N.+Rajagopal&author=D.+Orlando&author=S.+Alnemy&author=J.+Carulli&author=G.+Hodgson&author=E.+di+Tomaso&title=Proceedings+of+the+30th+EORTC-NCI-AACR+Symposium"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJohannessen%26aufirst%3DL.%26atitle%3DSY-1365%252C%2520a%2520Selective%2520CDK7%2520Inhibitor%252C%2520Enhances%2520Carboplatin%2520Activity%2520in%2520Ovarian%2520Cancer%2520Cell%2520Lines%2520and%2520Xenografts%252C%2520and%2520Transcriptionally%2520Inhibits%2520Homologous%2520Recombination%2520Repair%2520%2528HRR%2529%2520Genes%26btitle%3DProceedings%2520of%2520the%252030th%2520EORTC-NCI-AACR%2520Symposium%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buczkowski, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockorny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poudel-Neupane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudianto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span> <span> </span><span class="NLM_article-title">Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F2159-8290.CD-17-0461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29054992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslSjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=59-73&issue=1&author=M.+Rusanauthor=K.+Liauthor=Y.+Liauthor=C.+L.+Christensenauthor=B.+J.+Abrahamauthor=N.+Kwiatkowskiauthor=K.+A.+Buczkowskiauthor=B.+Bockornyauthor=T.+Chenauthor=S.+Liauthor=K.+Rheeauthor=H.+Zhangauthor=W.+Chenauthor=H.+Teraiauthor=T.+Tavaresauthor=A.+L.+Leggettauthor=T.+Liauthor=Y.+Wangauthor=T.+Zhangauthor=T.+J.+Kimauthor=S.+H.+Hongauthor=N.+Poudel-Neupaneauthor=M.+Silkesauthor=T.+Mudiantoauthor=L.+Tanauthor=T.+Shimamuraauthor=M.+Meyersonauthor=A.+J.+Bassauthor=H.+Watanabeauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=K.+K.+Wongauthor=P.+S.+Hammerman&title=Suppression+of+Adaptive+Responses+to+Targeted+Cancer+Therapy+by+Transcriptional+Repression&doi=10.1158%2F2159-8290.CD-17-0461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression</span></div><div class="casAuthors">Rusan, Maria; Li, Kapsok; Li, Yvonne; Christensen, Camilla L.; Abraham, Brian J.; Kwiatkowski, Nicholas; Buczkowski, Kevin A.; Bockorny, Bruno; Chen, Ting; Li, Shuai; Rhee, Kevin; Zhang, Haikuo; Chen, Wankun; Terai, Hideki; Tavares, Tiffany; Leggett, Alan L.; Li, Tianxia; Wang, Yichen; Zhang, Tinghu; Kim, Tae-Jung; Hong, Sook-Hee; Poudel-Neupane, Neermala; Silkes, Michael; Mudianto, Tenny; Tan, Li; Shimamura, Takeshi; Meyerson, Matthew; Bass, Adam J.; Watanabe, Hideo; Gray, Nathanael S.; Young, Richard A.; Wong, Kwok-Kin; Hammerman, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-73</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer therapies.  Targeting tumors with kinase inhibitors induces complex adaptive programs that promote the persistence of a fraction of the original cell population, facilitating the eventual outgrowth of inhibitor-resistant tumor clones.  We show that the addn. of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models.  We propose that targeted therapy induces a state of transcriptional dependency in a subpopulation of cells poised to become drug tolerant, which THZ1 can exploit by blocking dynamic transcriptional responses, promoting remodeling of enhancers and key signaling outputs required for tumor cell survival in the setting of targeted therapy.  These findings suggest that the addn. of THZ1 to targeted therapies is a promising broad-based strategy to hinder the emergence of drug-resistant cancer cell populations.  Significance: CDK7/12 inhibition prevents active enhancer formation at genes, promoting resistance emergence in response to targeted therapy, and impedes the engagement of transcriptional programs required for tumor cell survival.  CDK7/12 inhibition in combination with targeted cancer therapies may serve as a therapeutic paradigm for enhancing the effectiveness of targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ZQwuLLgYC7Vg90H21EOLACvtfcHk0li2YIE-5S8N3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslSjtQ%253D%253D&md5=e0ac792dc39965a556ab66676c344397</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0461%26sid%3Dliteratum%253Aachs%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DBuczkowski%26aufirst%3DK.%2BA.%26aulast%3DBockorny%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DTerai%26aufirst%3DH.%26aulast%3DTavares%26aufirst%3DT.%26aulast%3DLeggett%26aufirst%3DA.%2BL.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DT.%2BJ.%26aulast%3DHong%26aufirst%3DS.%2BH.%26aulast%3DPoudel-Neupane%26aufirst%3DN.%26aulast%3DSilkes%26aufirst%3DM.%26aulast%3DMudianto%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26atitle%3DSuppression%2520of%2520Adaptive%2520Responses%2520to%2520Targeted%2520Cancer%2520Therapy%2520by%2520Transcriptional%2520Repression%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D1%26spage%3D59%26epage%3D73%26doi%3D10.1158%2F2159-8290.CD-17-0461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazard, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Transcriptional Kinase CDK7 Overcomes Therapeutic Resistance in HER2-Positive Breast Cancers</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-0953-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41388-019-0953-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31462705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Krs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=50-63&issue=1&author=B.+Sunauthor=S.+Masonauthor=R.+C.+Wilsonauthor=S.+E.+Hazardauthor=Y.+Wangauthor=R.+Fangauthor=Q.+Wangauthor=E.+S.+Yehauthor=M.+Yangauthor=T.+M.+Robertsauthor=J.+J.+Zhaoauthor=Q.+Wang&title=Inhibition+of+the+Transcriptional+Kinase+CDK7+Overcomes+Therapeutic+Resistance+in+HER2-Positive+Breast+Cancers&doi=10.1038%2Fs41388-019-0953-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers</span></div><div class="casAuthors">Sun, Bowen; Mason, Seth; Wilson, Robert C.; Hazard, Starr E.; Wang, Yubao; Fang, Rong; Wang, Qiwei; Yeh, Elizabeth S.; Yang, Meixiang; Roberts, Thomas M.; Zhao, Jean J.; Wang, Qi</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-63</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Resistance of breast cancer to human epidermal growth factor receptor 2 (HER2) inhibitors involves reprogramming of the kinome through HER2/HER3 signaling via the activation of multiple tyrosine kinases and transcriptional upregulation.  The heterogeneity of induced kinases prevents kinase targeting by a single kinase inhibitor and presents a major challenge to the treatment of therapeutically recalcitrant HER2-pos. breast cancers (HER2+ BCs).  As a result, there is a crit. need for effective treatment that attacks the aberrant kinome activation assocd. with resistance to HER2-targeted therapy.  Here, we describe a novel treatment strategy that targets cyclin-dependent kinase 7 (CDK7) in HER2 inhibitor-resistant (HER2iR) breast cancer.  We show that both HER2 inhibitor-sensitive (HER2iS) and HER2iR breast cancer cell lines exhibit high sensitivity to THZ1, a newly identified covalent inhibitor of the transcription regulatory kinase CDK7.  CDK7 promotes cell cycle progression through inhibition of transcription, rather than via direct phosphorylation of classical CDK targets.  The transcriptional kinase activity of CDK7 is regulated by HER2, and by the receptor tyrosine kinases activated in response to HER2 inhibition, as well as by the downstream SHP2 and PI3K/AKT pathways.  A low dose of THZ1 displayed potent synergy with the HER2 inhibitor lapatinib in HER2iR BC cells in vitro.  Dual HER2 and CDK7 inhibition induced tumor regression in two HER2iR BC xenograft models in vivo.  Our data support the utilization of CDK7 inhibition as an addnl. therapeutic avenue that blocks the activation of genes engaged by multiple HER2iR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOhWJoycnIULVg90H21EOLACvtfcHk0lhcwLh_wLVbTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Krs7zN&md5=fd8c4b665351ba3df05252a18db2b53d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-0953-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-0953-9%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%2BC.%26aulast%3DHazard%26aufirst%3DS.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYeh%26aufirst%3DE.%2BS.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DInhibition%2520of%2520the%2520Transcriptional%2520Kinase%2520CDK7%2520Overcomes%2520Therapeutic%2520Resistance%2520in%2520HER2-Positive%2520Breast%2520Cancers%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26issue%3D1%26spage%3D50%26epage%3D63%26doi%3D10.1038%2Fs41388-019-0953-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Fang, S.</span>; <span class="NLM_string-name">Lee, M.</span>; <span class="NLM_string-name">Zeng, H.</span>; <span class="NLM_string-name">Li, T.</span>; <span class="NLM_string-name">Han, W.</span>; <span class="NLM_string-name">Sun, D.</span>; <span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthetic Lethality of Combinatory Inhibition of BET and CDK7 in BET(i) Resistant Leukemia Cells</span>.  <i>Proceedings of the 60th ASH Annual Meeting</i>; <span class="NLM_publisher-loc">San Diego, CA</span>, Nov 29, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Guo&author=J.+Li&author=S.+Fang&author=M.+Lee&author=H.+Zeng&author=T.+Li&author=W.+Han&author=D.+Sun&author=Y.+Huang&title=Synthetic+Lethality+of+Combinatory+Inhibition+of+BET+and+CDK7+in+BET%28i%29+Resistant+Leukemia+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26atitle%3DSynthetic%2520Lethality%2520of%2520Combinatory%2520Inhibition%2520of%2520BET%2520and%2520CDK7%2520in%2520BET%2528i%2529%2520Resistant%2520Leukemia%2520Cells%26jtitle%3DProceedings%2520of%2520the%252060th%2520ASH%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span> <span> </span><span class="NLM_article-title">Combinational Therapeutic Targeting of BRD4 and CDK7 Synergistically Induces Anticancer Effects in Head and Neck Squamous Cell Carcinoma</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.11.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.canlet.2019.11.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31765738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12jt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2020&pages=510-523&author=W.+Zhangauthor=H.+Geauthor=Y.+Jiangauthor=R.+Huangauthor=Y.+Wuauthor=D.+Wangauthor=S.+Guoauthor=S.+Liauthor=Y.+Wangauthor=H.+Jiangauthor=J.+Cheng&title=Combinational+Therapeutic+Targeting+of+BRD4+and+CDK7+Synergistically+Induces+Anticancer+Effects+in+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1016%2Fj.canlet.2019.11.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Zhang, Wei; Ge, Han; Jiang, Yue; Huang, Rong; Wu, Yaping; Wang, Dongmiao; Guo, Songsong; Li, Sheng; Wang, Yanling; Jiang, Hongbing; Cheng, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">510-523</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal domain protein BRD4 has been recognized as a key oncogenic driver and a druggable target against cancer.  However, these BRD4 inhibitors as monotherapy were moderate in efficacy in preclin. models.  Here we utilized a small-scale drug synergy screen that combined the BRD4 inhibitor (JQ1) with 8 epigenetic or transcriptional targeted chems. and identified THZ1 (a CDK7 inhibitor) acting synergistically with JQ1 against head neck squamous cell carcinoma (HNSCC).  Combinational JQ1 and THZ1 treatment impaired cell proliferation, induced apoptosis and senescence, which were largely recapitulated by dual BRD4 and CDK7 knockdown.  Combinational treatment inhibited tumor growth and progression in 4NQO-induced HNSCC and xenograft animal models.  RNA-sequencing analyses identified hundreds of differentially expressed genes modulated by JQ1 and THZ1, which were significantly enriched in categories including cell cycle and apoptosis.  Mechanistically, combinational treatment reduced H3K27ac enrichment in the super-enhancer region of YAP1, which inactivated its transcription and in turn induced anti-proliferative and pro-apoptotic effects.  Combined BRD4 and CDK7 upregulation assocd. with worst prognosis in HNSCC patients.  Collectively, our findings reveal a novel therapeutic strategy of pharmacol. inhibitions of BRD4 and CDK7 against HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXMfxOO0V8crVg90H21EOLACvtfcHk0lhcwLh_wLVbTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12jt77J&md5=afdf6a2b4b789bc7f2745dc84eec7355</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.11.027%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%26atitle%3DCombinational%2520Therapeutic%2520Targeting%2520of%2520BRD4%2520and%2520CDK7%2520Synergistically%2520Induces%2520Anticancer%2520Effects%2520in%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DCancer%2520Lett.%26date%3D2020%26volume%3D469%26spage%3D510%26epage%3D523%26doi%3D10.1016%2Fj.canlet.2019.11.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posternak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M. D.</span></span> <span> </span><span class="NLM_article-title">Strategically Targeting MYC in Cancer</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">408</span>, <span class="refDoi"> DOI: 10.12688/f1000research.7879.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.12688%2Ff1000research.7879.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVOhtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=408&author=V.+Posternakauthor=M.+D.+Cole&title=Strategically+Targeting+MYC+in+Cancer&doi=10.12688%2Ff1000research.7879.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Strategically targeting MYC in cancer[version 1; referees: 2 approved]</span></div><div class="casAuthors">Posternak, Valeriya; Cole, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">408/1-408/7</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">MYC is a major driver of cancer cell growth and mediates a transcriptional program spanning cell growth, the cell cycle, metab., and cell survival.  Many efforts have been made to deliberately target MYC for cancer therapy.  A variety of compds. have been generated to inhibit MYC function or stability, either directly or indirectly.  The most direct inhibitors target the interaction between MYC and MAX, which is required for DNA binding.  Unfortunately, these compds. do not have the desired pharmacokinetics and pharmacodynamics for in vivo application.  Recent studies report the indirect inhibition of MYC through the development of two compds., JQ1 and THZ1, which target factors involved in unique stages of transcription.  These compds. appear to have significant therapeutic value for cancers with high levels of MYC, although some effects are MYC-independent.  These approaches serve as a foundation for developing novel compds. to pharmacol. target MYC-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7C9GXC2g647Vg90H21EOLACvtfcHk0linMI7b0TSXFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVOhtb4%253D&md5=978b38c80f91751343fb3df5c77cab76</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.7879.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.7879.1%26sid%3Dliteratum%253Aachs%26aulast%3DPosternak%26aufirst%3DV.%26aulast%3DCole%26aufirst%3DM.%2BD.%26atitle%3DStrategically%2520Targeting%2520MYC%2520in%2520Cancer%26jtitle%3DF1000Research%26date%3D2016%26volume%3D5%26spage%3D408%26doi%3D10.12688%2Ff1000research.7879.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span>; <span class="NLM_string-name">Siddiquee, Z.</span>; <span class="NLM_string-name">Ganesh, S.</span>; <span class="NLM_string-name">Shui, S.</span>; <span class="NLM_string-name">Shah, A.</span>; <span class="NLM_string-name">Kim, B.</span>; <span class="NLM_string-name">Chen, D.</span>; <span class="NLM_string-name">Pandya, P.</span>; <span class="NLM_string-name">Storr, R.</span>; <span class="NLM_string-name">Wang, W.</span>; <span class="NLM_string-name">Dudek, H.</span>; <span class="NLM_string-name">Lai, C.</span>; <span class="NLM_string-name">Abrams, M.</span>; <span class="NLM_string-name">Brown, B.</span></span> <span> </span><span class="NLM_article-title">Anti-Tumor Activity of a MYC-Targeting Dicer Substrate siRNA in Combination with BRD4/CDK7 Inhibitors</span>.  <i>Proceedings of the AACR 107th Annual Meeting</i>; <span class="NLM_publisher-loc">New Orleans, LA</span>, Apr 16–20, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Chipumuro&author=Z.+Siddiquee&author=S.+Ganesh&author=S.+Shui&author=A.+Shah&author=B.+Kim&author=D.+Chen&author=P.+Pandya&author=R.+Storr&author=W.+Wang&author=H.+Dudek&author=C.+Lai&author=M.+Abrams&author=B.+Brown&title=Anti-Tumor+Activity+of+a+MYC-Targeting+Dicer+Substrate+siRNA+in+Combination+with+BRD4%2FCDK7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DChipumuro%26aufirst%3DE.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520a%2520MYC-Targeting%2520Dicer%2520Substrate%2520siRNA%2520in%2520Combination%2520with%2520BRD4%252FCDK7%2520Inhibitors%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520107th%2520Annual%2520Meeting%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Sayaka, O.</span>; <span class="NLM_string-name">Umezaki, S.</span>; <span class="NLM_string-name">Kojima, M.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Shiraishi, Y.</span>; <span class="NLM_string-name">Okudo, M.</span>; <span class="NLM_string-name">Kimura, T.</span></span> <span> </span><span class="NLM_article-title">Substituted Dihydropyrrolopyrazole Derivative</span>. <span class="NLM_patent">US20190256531A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=N.+Iwase&author=Y.+Aga&author=S.+Ushiyama&author=S.+Kono&author=H.+Sunamoto&author=T.+Matsushita&author=O.+Sayaka&author=S.+Umezaki&author=M.+Kojima&author=K.+Onuma&author=Y.+Shiraishi&author=M.+Okudo&author=T.+Kimura&title=Substituted+Dihydropyrrolopyrazole+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIwase%26aufirst%3DN.%26atitle%3DSubstituted%2520Dihydropyrrolopyrazole%2520Derivative%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span>; <span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Sayaka, O.</span>; <span class="NLM_string-name">Tanaka, M.</span>; <span class="NLM_string-name">Matoyama, M.</span>; <span class="NLM_string-name">Umezaki, S.</span>; <span class="NLM_string-name">Shiraishi, Y.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Kojima, M.</span>; <span class="NLM_string-name">Nishiyama, H.</span>; <span class="NLM_string-name">Kimura, T.</span></span> <span> </span><span class="NLM_article-title">Substituted Dihydropyrrolopyrazole Compound</span>. <span class="NLM_patent">US20170313727A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Aga&author=S.+Ushiyama&author=N.+Iwase&author=S.+Kono&author=H.+Sunamoto&author=T.+Matsushita&author=O.+Sayaka&author=M.+Tanaka&author=M.+Matoyama&author=S.+Umezaki&author=Y.+Shiraishi&author=K.+Onuma&author=M.+Kojima&author=H.+Nishiyama&author=T.+Kimura&title=Substituted+Dihydropyrrolopyrazole+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAga%26aufirst%3DY.%26atitle%3DSubstituted%2520Dihydropyrrolopyrazole%2520Compound%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-O.</span>; <span class="NLM_string-name">Yoo, J.</span>; <span class="NLM_string-name">Lee, M. J.</span>; <span class="NLM_string-name">Lee, K. W.</span>; <span class="NLM_string-name">Min, J. E.</span>; <span class="NLM_string-name">Kim, J.</span>; <span class="NLM_string-name">Min, K.-N.</span>; <span class="NLM_string-name">Roh, T. C.</span>; <span class="NLM_string-name">Seo, K.-S.</span>; <span class="NLM_string-name">Rhee, H. I.</span>; <span class="NLM_string-name">Lee, J. H.</span>; <span class="NLM_string-name">Jeon, D.-H.</span>; <span class="NLM_string-name">Lim, D. S.</span></span> <span> </span><span class="NLM_article-title">YPN005, an Oral CDK7 Inhibitor, Exhibits a Significant Antitumor Activity in Myc-Driven Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 3, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.-O.+Lee&author=J.+Yoo&author=M.+J.+Lee&author=K.+W.+Lee&author=J.+E.+Min&author=J.+Kim&author=K.-N.+Min&author=T.+C.+Roh&author=K.-S.+Seo&author=H.+I.+Rhee&author=J.+H.+Lee&author=D.-H.+Jeon&author=D.+S.+Lim&title=YPN005%2C+an+Oral+CDK7+Inhibitor%2C+Exhibits+a+Significant+Antitumor+Activity+in+Myc-Driven+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.-O.%26atitle%3DYPN005%252C%2520an%2520Oral%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520a%2520Significant%2520Antitumor%2520Activity%2520in%2520Myc-Driven%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satyam, L. K.</span>; <span class="NLM_string-name">Poddutoori, R.</span>; <span class="NLM_string-name">Mukherjee, S.</span>; <span class="NLM_string-name">Marappan, S.</span>; <span class="NLM_string-name">Gopinath, S.</span>; <span class="NLM_string-name">Ramachandra, R.</span>; <span class="NLM_string-name">Pothuganti, M. K.</span>; <span class="NLM_string-name">Nayak, S. S.</span>; <span class="NLM_string-name">Nandish, C.</span>; <span class="NLM_string-name">Naik, C.</span>; <span class="NLM_string-name">Ravindra, M. V.</span>; <span class="NLM_string-name">Dabbeeru, M. B.</span>; <span class="NLM_string-name">Nagaraju, A.</span>; <span class="NLM_string-name">Mahankali, B.</span>; <span class="NLM_string-name">Antony, T.</span>; <span class="NLM_string-name">Pandit, C.</span>; <span class="NLM_string-name">Chelur, S.</span>; <span class="NLM_string-name">Daginakatte, G.</span>; <span class="NLM_string-name">Samajdar, S.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Inhibition of CDK7 by Novel Covalent Inhibitors</span>.  <i>Proceedings of the AACR 107th Annual Meeting</i>; <span class="NLM_publisher-loc">New Orleans, LA</span>, Apr 16–20, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+K.+Satyam&author=R.+Poddutoori&author=S.+Mukherjee&author=S.+Marappan&author=S.+Gopinath&author=R.+Ramachandra&author=M.+K.+Pothuganti&author=S.+S.+Nayak&author=C.+Nandish&author=C.+Naik&author=M.+V.+Ravindra&author=M.+B.+Dabbeeru&author=A.+Nagaraju&author=B.+Mahankali&author=T.+Antony&author=C.+Pandit&author=S.+Chelur&author=G.+Daginakatte&author=S.+Samajdar&author=M.+Ramachandra&title=Potent+and+Selective+Inhibition+of+CDK7+by+Novel+Covalent+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSatyam%26aufirst%3DL.%2BK.%26atitle%3DPotent%2520and%2520Selective%2520Inhibition%2520of%2520CDK7%2520by%2520Novel%2520Covalent%2520Inhibitors%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520107th%2520Annual%2520Meeting%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samajdar, S.</span>; <span class="NLM_string-name">Poddutoori, R.</span>; <span class="NLM_string-name">Pandit, C.</span>; <span class="NLM_string-name">Mukherjee, S.</span>; <span class="NLM_string-name">Goswami, R.</span></span> <span> </span><span class="NLM_article-title">Substituted Heterocyclyl Derivatives as CDK Inhibitors</span>. <span class="NLM_patent">US20180362471A9</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Samajdar&author=R.+Poddutoori&author=C.+Pandit&author=S.+Mukherjee&author=R.+Goswami&title=Substituted+Heterocyclyl+Derivatives+as+CDK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSamajdar%26aufirst%3DS.%26atitle%3DSubstituted%2520Heterocyclyl%2520Derivatives%2520as%2520CDK%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samajdar, S.</span>; <span class="NLM_string-name">Poddutoori, R.</span>; <span class="NLM_string-name">Mukherjee, S.</span>; <span class="NLM_string-name">Goswami, R.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>][1,3,5]triazine and Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as CDK Inhibitors</span>. <span class="NLM_patent">US20180258092A9</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Samajdar&author=R.+Poddutoori&author=S.+Mukherjee&author=R.+Goswami&title=Pyrazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazine+and+Pyrazolo%5B1%2C5-a%5Dpyrimidine+Derivatives+as+CDK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSamajdar%26aufirst%3DS.%26atitle%3DPyrazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazine%2520and%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520Derivatives%2520as%2520CDK%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thode, T.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Weston, A.</span>; <span class="NLM_string-name">Soldi, R.</span>; <span class="NLM_string-name">Kaadige, M. R.</span>; <span class="NLM_string-name">Vankayalapti, H.</span>; <span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK7-Dependent Transcriptional Addiction with Novel, Orally Available Small Molecule Inhibitor Shows Efficacy in Pancreatic Cancer Models</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 3, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Thode&author=Z.+Li&author=A.+Weston&author=R.+Soldi&author=M.+R.+Kaadige&author=H.+Vankayalapti&author=S.+Sharma&title=Targeting+CDK7-Dependent+Transcriptional+Addiction+with+Novel%2C+Orally+Available+Small+Molecule+Inhibitor+Shows+Efficacy+in+Pancreatic+Cancer+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DThode%26aufirst%3DT.%26atitle%3DTargeting%2520CDK7-Dependent%2520Transcriptional%2520Addiction%2520with%2520Novel%252C%2520Orally%2520Available%2520Small%2520Molecule%2520Inhibitor%2520Shows%2520Efficacy%2520in%2520Pancreatic%2520Cancer%2520Models%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of the Novel CDK7 Inhibitor QS1189 in Mantle Cell Lymphoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7193</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-43760-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41598-019-43760-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31076643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ksFKqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7193&issue=1&author=Y.+J.+Choiauthor=D.+H.+Kimauthor=D.+H.+Yoonauthor=C.+Suhauthor=C.-M.+Choiauthor=J.+C.+Leeauthor=J.+Y.+Hongauthor=J.+K.+Rho&title=Efficacy+of+the+Novel+CDK7+Inhibitor+QS1189+in+Mantle+Cell+Lymphoma&doi=10.1038%2Fs41598-019-43760-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma</span></div><div class="casAuthors">Choi Yun Jung; Kim Dong Ha; Yoon Dok Hyun; Suh Cheolwon; Choi Chang-Min; Choi Chang-Min; Lee Jae Cheol; Hong Jung Yong; Rho Jin Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7193</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mantle cell lymphoma (MCL) is typically an aggressive and rare form of non-Hodgkin lymphoma (NHL) with a poor prognosis despite recent advances in immunochemotherapy and targeted therapeutics against NHL.  New therapeutic agents are needed for MCL.  In this study, we generated a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated QS1189, and confirmed its anti-cancer effects towards MCL and other lymphomas.  QS1189 was highly selective for CDK7 and showed potent anticancer effects in MCL compared to other targeted therapeutic agents, such as ibrutinib and venetoclax.  Consistent with a conventional CDK7 inhibitor, QS1189 treatment significantly decreased phosphorylation of the carboxyl-terminal domain of RNA polymerase II and transcription-associated genes.  QS1189 induced cell cycle arrest at the G2/M phase and apoptosis.  Interestingly, QS1189 overcame the acquired resistance to venetoclax, which is mediated by Bcl-xL.  Similarly, QS1189 showed potent tumour cell growth inhibition of various lymphomas.  Thus, CDK7 might be a suitable therapeutic target for inhibiting lymphoma, and QS1189 is a promising therapeutic option for various lymphomas and cells with acquired resistance to targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRiZBZakKAD6qcneEtCi92fW6udTcc2ebbTQyjXNEDpLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ksFKqsA%253D%253D&md5=c4a0d995b5c52084965c50659a50c15a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-43760-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-43760-z%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DYoon%26aufirst%3DD.%2BH.%26aulast%3DSuh%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DC.-M.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DHong%26aufirst%3DJ.%2BY.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26atitle%3DEfficacy%2520of%2520the%2520Novel%2520CDK7%2520Inhibitor%2520QS1189%2520in%2520Mantle%2520Cell%2520Lymphoma%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D7193%26doi%3D10.1038%2Fs41598-019-43760-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coates, D. A.</span>; <span class="NLM_string-name">Montero, C.</span>; <span class="NLM_string-name">Patel, B. K. R.</span>; <span class="NLM_string-name">Remick, D. M.</span>; <span class="NLM_string-name">Yadav, V.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful for Inhibiting CDK7</span>. <span class="NLM_patent">WO2019099298A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+A.+Coates&author=C.+Montero&author=B.+K.+R.+Patel&author=D.+M.+Remick&author=V.+Yadav&title=Compounds+Useful+for+Inhibiting+CDK7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoates%26aufirst%3DD.%2BA.%26atitle%3DCompounds%2520Useful%2520for%2520Inhibiting%2520CDK7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span> <span> </span><span class="NLM_article-title">(<i>E</i>)-1-(4-(Dimethylamino)but-2-enoyl)pyrrolidin-3-yl-4-((3-isopropyl-5-methylpyrazolo[1,5-<i>a</i>]pyrimidin-7-yl)amino)piperidine-1-carboxylate for Inhibiting CDK7</span>. <span class="NLM_patent">US20190144456</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Montero&title=%28E%29-1-%284-%28Dimethylamino%29but-2-enoyl%29pyrrolidin-3-yl-4-%28%283-isopropyl-5-methylpyrazolo%5B1%2C5-a%5Dpyrimidin-7-yl%29amino%29piperidine-1-carboxylate+for+Inhibiting+CDK7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DC.%26atitle%3D%2528E%2529-1-%25284-%2528Dimethylamino%2529but-2-enoyl%2529pyrrolidin-3-yl-4-%2528%25283-isopropyl-5-methylpyrazolo%255B1%252C5-a%255Dpyrimidin-7-yl%2529amino%2529piperidine-1-carboxylate%2520for%2520Inhibiting%2520CDK7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref116"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref116'); return false;" data-citation="" class="refNumLink">116</a></strong><div class="NLM_citation" id="cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, K.</span>; <span class="NLM_string-name">Kim, J.</span>; <span class="NLM_string-name">Jeon, Y.</span>; <span class="NLM_string-name">Yu, D.</span>; <span class="NLM_string-name">Seo, M.</span>; <span class="NLM_string-name">Park, D.</span>; <span class="NLM_string-name">Eickhoff, J.</span>; <span class="NLM_string-name">Zischinsky, G.</span>; <span class="NLM_string-name">Koch, U.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutically Active Pyrazolo-Triazine and/or Pyrazolo-Pyrimidine Derivatives</span>. <span class="NLM_patent">WO2019197546A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.+Nam&author=J.+Kim&author=Y.+Jeon&author=D.+Yu&author=M.+Seo&author=D.+Park&author=J.+Eickhoff&author=G.+Zischinsky&author=U.+Koch&title=Pharmaceutically+Active+Pyrazolo-Triazine+and%2For+Pyrazolo-Pyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DK.%26atitle%3DPharmaceutically%2520Active%2520Pyrazolo-Triazine%2520and%252For%2520Pyrazolo-Pyrimidine%2520Derivatives%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref117"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref117'); return false;" data-citation="" class="refNumLink">117</a></strong><div class="NLM_citation" id="cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a Novel Oral Multi-Kinase Inhibitor of CDKs, JAK2 and FLT3 with Potent Anti-Leukemic Properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&issue=2&author=K.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+Ongauthor=Y.+Lohauthor=A.+Cheongauthor=Y.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+Novel+Oral+Multi-Kinase+Inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+Potent+Anti-Leukemic+Properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0linx0JHcaFpfA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%26aulast%3DLoh%26aufirst%3DY.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520Novel%2520Oral%2520Multi-Kinase%2520Inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520Potent%2520Anti-Leukemic%2520Properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D2%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref118"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref118'); return false;" data-citation="" class="refNumLink">118</a></strong><div class="NLM_citation" id="cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Lou, Y.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibitors of CDK-7</span>. <span class="NLM_patent">US20180008604A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Chen&author=Y.+Lou&title=Covalent+Inhibitors+of+CDK-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCovalent%2520Inhibitors%2520of%2520CDK-7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref119"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref119'); return false;" data-citation="" class="refNumLink">119</a></strong><div class="NLM_citation" id="cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciblat, S.</span>; <span class="NLM_string-name">Kabro, A.</span>; <span class="NLM_string-name">Leblanc, M.</span>; <span class="NLM_string-name">Leger, S.</span>; <span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Miller, T.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Schmidt, D.</span>; <span class="NLM_string-name">Siddiqui, A. M.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Winter, D. K.</span>; <span class="NLM_string-name">Ripka, A.</span>; <span class="NLM_string-name">Li, D.</span>; <span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">WO2016058544A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ciblat&author=A.+Kabro&author=M.+Leblanc&author=S.+Leger&author=J.+J.+Marineau&author=T.+Miller&author=S.+Roy&author=D.+Schmidt&author=A.+M.+Siddiqui&author=K.+Sprott&author=D.+K.+Winter&author=A.+Ripka&author=D.+Li&author=G.+Zhang&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCiblat%26aufirst%3DS.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref120"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref120'); return false;" data-citation="" class="refNumLink">120</a></strong><div class="NLM_citation" id="cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Chuaqui, C.</span>; <span class="NLM_string-name">Ciblat, S.</span>; <span class="NLM_string-name">Kabro, A.</span>; <span class="NLM_string-name">Piras, H.</span>; <span class="NLM_string-name">Whitmore, K. Matthew</span>; <span class="NLM_string-name">Lund, K.-L.</span>; <span class="NLM_string-name">Bradley, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">WO2019143730</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+J.+Marineau&author=C.+Chuaqui&author=S.+Ciblat&author=A.+Kabro&author=H.+Piras&author=K.+Matthew+Whitmore&author=K.-L.+Lund&author=M.+Bradley&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref121"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref121'); return false;" data-citation="" class="refNumLink">121</a></strong><div class="NLM_citation" id="cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Chuaqui, C.</span>; <span class="NLM_string-name">Ciblat, S.</span>; <span class="NLM_string-name">Kabro, A.</span>; <span class="NLM_string-name">Piras, H.</span>; <span class="NLM_string-name">Whitmore, K. M.</span>; <span class="NLM_string-name">Lund, K.-L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">WO2019143719</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+J.+Marineau&author=C.+Chuaqui&author=S.+Ciblat&author=A.+Kabro&author=H.+Piras&author=K.+M.+Whitmore&author=K.-L.+Lund&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref122"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref122'); return false;" data-citation="" class="refNumLink">122</a></strong><div class="NLM_citation" id="cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Schmidt, D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">US20190330218A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+J.+Marineau&author=K.+Sprott&author=D.+Schmidt&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115'],'ref116':['cit116'],'ref117':['cit117'],'ref118':['cit118'],'ref119':['cit119'],'ref120':['cit120'],'ref121':['cit121'],'ref122':['cit122']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 10 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingyu  Peng</span>, <span class="hlFld-ContribAuthor ">Ming  Yang</span>, <span class="hlFld-ContribAuthor ">Ran  Bi</span>, <span class="hlFld-ContribAuthor ">Yueyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Chunxi  Wang</span>, <span class="hlFld-ContribAuthor ">Xue  Wei</span>, <span class="hlFld-ContribAuthor ">Zhihao  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiao  Xie</span>, <span class="hlFld-ContribAuthor ">Wei  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Mutated p53 Dependency in Triple-Negative Breast Cancer Cells Through CDK7 Inhibition. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.664848" title="DOI URL">https://doi.org/10.3389/fonc.2021.664848</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.664848&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.664848%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DTargeting%252BMutated%252Bp53%252BDependency%252Bin%252BTriple-Negative%252BBreast%252BCancer%252BCells%252BThrough%252BCDK7%252BInhibition%26aulast%3DPeng%26aufirst%3DJingyu%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ranadip  Mandal</span>, <span class="hlFld-ContribAuthor ">Sven  Becker</span>, <span class="hlFld-ContribAuthor ">Klaus  Strebhardt</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting CDK9 for Anti-Cancer Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2021,</strong> <em>13 </em>
                                    (9)
                                     , 2181. <a href="https://doi.org/10.3390/cancers13092181" title="DOI URL">https://doi.org/10.3390/cancers13092181</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers13092181&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers13092181%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DTargeting%252BCDK9%252Bfor%252BAnti-Cancer%252BTherapeutics%26aulast%3DMandal%26aufirst%3DRanadip%26date%3D2021%26date%3D2021%26volume%3D13%26issue%3D9%26spage%3D2181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yiting  Lin</span>, <span class="hlFld-ContribAuthor ">Ke  Xue</span>, <span class="hlFld-ContribAuthor ">Qingyang  Li</span>, <span class="hlFld-ContribAuthor ">Zhenhua  Liu</span>, <span class="hlFld-ContribAuthor ">Zhenlai  Zhu</span>, <span class="hlFld-ContribAuthor ">Jiaoling  Chen</span>, <span class="hlFld-ContribAuthor ">Erle  Dang</span>, <span class="hlFld-ContribAuthor ">Lei  Wang</span>, <span class="hlFld-ContribAuthor ">Weigang  Zhang</span>, <span class="hlFld-ContribAuthor ">Gang  Wang</span>, <span class="hlFld-ContribAuthor ">Bing  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-Dependent Kinase 7 Promotes Th17/Th1 Cell Differentiation in Psoriasis by Modulating Glycolytic Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Journal of Investigative Dermatology</span><span> <strong>2021,</strong> <em>9 </em><a href="https://doi.org/10.1016/j.jid.2021.04.018" title="DOI URL">https://doi.org/10.1016/j.jid.2021.04.018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jid.2021.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jid.2021.04.018%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Investigative%2520Dermatology%26atitle%3DCyclin-Dependent%252BKinase%252B7%252BPromotes%252BTh17%25252FTh1%252BCell%252BDifferentiation%252Bin%252BPsoriasis%252Bby%252BModulating%252BGlycolytic%252BMetabolism%26aulast%3DLin%26aufirst%3DYiting%26date%3D2021%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tuersunayi  Abudureheman</span>, <span class="hlFld-ContribAuthor ">Jing  Xia</span>, <span class="hlFld-ContribAuthor ">Ming-Hao  Li</span>, <span class="hlFld-ContribAuthor ">Hang  Zhou</span>, <span class="hlFld-ContribAuthor ">Wei-Wei  Zheng</span>, <span class="hlFld-ContribAuthor ">Neng  Zhou</span>, <span class="hlFld-ContribAuthor ">Rong-Yi  Shi</span>, <span class="hlFld-ContribAuthor ">Jian-Min  Zhu</span>, <span class="hlFld-ContribAuthor ">Li-Ting  Yang</span>, <span class="hlFld-ContribAuthor ">Li  Chen</span>, <span class="hlFld-ContribAuthor ">Liang  Zheng</span>, <span class="hlFld-ContribAuthor ">Kai  Xue</span>, <span class="hlFld-ContribAuthor ">Kai  Qing</span>, <span class="hlFld-ContribAuthor ">Cai-Wen  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fonc.2021.663360" title="DOI URL">https://doi.org/10.3389/fonc.2021.663360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2021.663360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2021.663360%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DCDK7%252BInhibitor%252BTHZ1%252BInduces%252Bthe%252BCell%252BApoptosis%252Bof%252BB-Cell%252BAcute%252BLymphocytic%252BLeukemia%252Bby%252BPerturbing%252BCellular%252BMetabolism%26aulast%3DAbudureheman%26aufirst%3DTuersunayi%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christin  Riess</span>, <span class="hlFld-ContribAuthor ">Nina  Irmscher</span>, <span class="hlFld-ContribAuthor ">Inken  Salewski</span>, <span class="hlFld-ContribAuthor ">Daniel  Strüder</span>, <span class="hlFld-ContribAuthor ">Carl-Friedrich  Classen</span>, <span class="hlFld-ContribAuthor ">Christina  Große-Thie</span>, <span class="hlFld-ContribAuthor ">Christian  Junghanss</span>, <span class="hlFld-ContribAuthor ">Claudia  Maletzki</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?. </span><span class="cited-content_cbyCitation_journal-name">Cancer and Metastasis Reviews</span><span> <strong>2021,</strong> <em>40 </em>
                                    (1)
                                     , 153-171. <a href="https://doi.org/10.1007/s10555-020-09940-4" title="DOI URL">https://doi.org/10.1007/s10555-020-09940-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10555-020-09940-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10555-020-09940-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520and%2520Metastasis%2520Reviews%26atitle%3DCyclin-dependent%252Bkinase%252Binhibitors%252Bin%252Bhead%252Band%252Bneck%252Bcancer%252Band%252Bglioblastoma%2525E2%252580%252594backbone%252Bor%252Badd-on%252Bin%252Bimmune-oncology%25253F%26aulast%3DRiess%26aufirst%3DChristin%26date%3D2021%26date%3D2020%26volume%3D40%26issue%3D1%26spage%3D153%26epage%3D171" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Wu</span>, <span class="hlFld-ContribAuthor ">Zhaoyan  Zhang</span>, <span class="hlFld-ContribAuthor ">Xing  Chen</span>, <span class="hlFld-ContribAuthor ">Yaoyao  Yan</span>, <span class="hlFld-ContribAuthor ">Xinhua  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Angel or Devil ? - CDK8 as the new drug target. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113043. <a href="https://doi.org/10.1016/j.ejmech.2020.113043" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.113043</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.113043&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.113043%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DAngel%252Bor%252BDevil%252B%25253F%252B-%252BCDK8%252Bas%252Bthe%252Bnew%252Bdrug%252Btarget%26aulast%3DWu%26aufirst%3DDan%26date%3D2021%26volume%3D213%26spage%3D113043" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lucia  Gutierrez-Chamorro</span>, <span class="hlFld-ContribAuthor ">Eudald  Felip</span>, <span class="hlFld-ContribAuthor ">Ifeanyi Jude  Ezeonwumelu</span>, <span class="hlFld-ContribAuthor ">Mireia  Margelí</span>, <span class="hlFld-ContribAuthor ">Ester  Ballana</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-dependent Kinases as Emerging Targets for Developing Novel Antiviral Therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Trends in Microbiology</span><span> <strong>2021,</strong> <em>37 </em><a href="https://doi.org/10.1016/j.tim.2021.01.014" title="DOI URL">https://doi.org/10.1016/j.tim.2021.01.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tim.2021.01.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tim.2021.01.014%26sid%3Dliteratum%253Aachs%26jtitle%3DTrends%2520in%2520Microbiology%26atitle%3DCyclin-dependent%252BKinases%252Bas%252BEmerging%252BTargets%252Bfor%252BDeveloping%252BNovel%252BAntiviral%252BTherapeutics%26aulast%3DGutierrez-Chamorro%26aufirst%3DLucia%26date%3D2021%26volume%3D37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hangzhan  Ma</span>, <span class="hlFld-ContribAuthor ">Dylan C.  Dean</span>, <span class="hlFld-ContribAuthor ">Ran  Wei</span>, <span class="hlFld-ContribAuthor ">Francis J.  Hornicek</span>, <span class="hlFld-ContribAuthor ">Zhenfeng  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Cyclin-dependent kinase 7 (CDK7) is an emerging prognostic biomarker and therapeutic target in osteosarcoma. </span><span class="cited-content_cbyCitation_journal-name">Therapeutic Advances in Musculoskeletal Disease</span><span> <strong>2021,</strong> <em>13 </em>, 1759720X2199506. <a href="https://doi.org/10.1177/1759720X21995069" title="DOI URL">https://doi.org/10.1177/1759720X21995069</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1759720X21995069&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1759720X21995069%26sid%3Dliteratum%253Aachs%26jtitle%3DTherapeutic%2520Advances%2520in%2520Musculoskeletal%2520Disease%26atitle%3DCyclin-dependent%252Bkinase%252B7%252B%252528CDK7%252529%252Bis%252Ban%252Bemerging%252Bprognostic%252Bbiomarker%252Band%252Btherapeutic%252Btarget%252Bin%252Bosteosarcoma%26aulast%3DMa%26aufirst%3DHangzhan%26date%3D2021%26date%3D2021%26volume%3D13%26spage%3D1759720X2199506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia A.  Elkina</span>, <span class="hlFld-ContribAuthor ">Yanina V.  Burgart</span>, <span class="hlFld-ContribAuthor ">Evgeny V.  Shchegolkov</span>, <span class="hlFld-ContribAuthor ">Olga P.  Krasnykh</span>, <span class="hlFld-ContribAuthor ">Vera V.  Maslova</span>, <span class="hlFld-ContribAuthor ">Galina A.  Triandafilova</span>, <span class="hlFld-ContribAuthor ">Sergey S.  Solodnikov</span>, <span class="hlFld-ContribAuthor ">Anna A.  Muryleva</span>, <span class="hlFld-ContribAuthor ">Maria A.  Misiurina</span>, <span class="hlFld-ContribAuthor ">Alexander V.  Slita</span>, <span class="hlFld-ContribAuthor ">Vladimir V.  Zarubaev</span>, <span class="hlFld-ContribAuthor ">Victor I.  Saloutin</span>. </span><span class="cited-content_cbyCitation_article-title">Competitive routes to cyclizations of polyfluoroalkyl-containing 2-tolylhydrazinylidene-1,3-diketones with 3-aminopyrazoles into bioactive pyrazoloazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2020,</strong> <em>240 </em>, 109648. <a href="https://doi.org/10.1016/j.jfluchem.2020.109648" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2020.109648</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2020.109648&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2020.109648%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DCompetitive%252Broutes%252Bto%252Bcyclizations%252Bof%252Bpolyfluoroalkyl-containing%252B2-tolylhydrazinylidene-1%25252C3-diketones%252Bwith%252B3-aminopyrazoles%252Binto%252Bbioactive%252Bpyrazoloazines%26aulast%3DElkina%26aufirst%3DNatalia%2BA.%26date%3D2020%26volume%3D240%26spage%3D109648" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Lin</span>, <span class="hlFld-ContribAuthor ">Xiaoyang  Lin</span>, <span class="hlFld-ContribAuthor ">Tianlin  He</span>, <span class="hlFld-ContribAuthor ">Guoqun  Xie</span>. </span><span class="cited-content_cbyCitation_article-title"><p>Gambogic Acid Inhibits the Progression of Gastric Cancer via circRNA_ASAP2/miR-33a-5p/CDK7 Axis</p>. </span><span class="cited-content_cbyCitation_journal-name">Cancer Management and Research</span><span> <strong>2020,</strong> <em>Volume 12 </em>, 9221-9233. <a href="https://doi.org/10.2147/CMAR.S269768" title="DOI URL">https://doi.org/10.2147/CMAR.S269768</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2147/CMAR.S269768&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2147%2FCMAR.S269768%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Management%2520and%2520Research%26atitle%3D%25253Cp%25253EGambogic%252BAcid%252BInhibits%252Bthe%252BProgression%252Bof%252BGastric%252BCancer%252Bvia%252BcircRNA_ASAP2%25252FmiR-33a-5p%25252FCDK7%252BAxis%25253C%25252Fp%25253E%26aulast%3DLin%26aufirst%3DDan%26date%3D2020%26date%3D2020%26volume%3DVolume%252012%26spage%3D9221%26epage%3D9233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0009.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Roles of CDK7 in mRNA transcription (A) and cell cycle progression (B). (A) CDK7, as part of TFIIH, phosphorylates Ser5 at the CTD of RNAP II for the initiation of transcription and subsequently affects the phosphorylation of CDK9 to release the pause and further prompt the productive elongation. (B) CDK7, as the key component of CAK, phosphorylates CDK1/2/4/6 to regulate cell cycle progression.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. (A) Superposition of the crystal structures of CDK7 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2">1UA2</a>) in cyan and CDK2 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HCK">1HCK</a>) in light purple. (B) Crystal structure of ATP-bound CDK7 (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2">1UA2</a>). The hinge region of CDK7 is colored in yellow and the ATP in pink. The hinge region of CDK2 is colored in green and ATP in gold. Hydrogen bonds are shown as black dashed lines. The figure was generated using Pymol v.1.7.0.1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. (A) Structures of roscovitine, LDC3140, and LDC4297. (B) Optimization of CDK7 inhibition of pyrazolo[1,5-<i>a</i>]pyrimidine analogues; R′ = H unless specified otherwise. IC<sub>50</sub> refers to the inhibitory potency against CDK7 unless specified otherwise.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Cocrystal structure of CT7001 (yellow) with CDK2 in light purple (PDB ID: <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JQ5">5JQ5</a>). The hinge region and selected amino acid residues are illustrated in green. Hydrogen bonds are shown as black dashed lines. The figure was generated using Pymol v.1.7.0.1.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Chemical structures and enzymatic potency of covalent CDK7 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Schematic representations of the predicted modes of binding of SY-1365 (A) or YKL-5-124 (B) to CDK7. Hydrogen bonds are shown as red dashed lines and covalent bonds as red solid lines.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/medium/jm9b01985_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Structures of new CDK7 inhibitors under development.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2020/jmcmar.2020.63.issue-14/acs.jmedchem.9b01985/20200716/images/large/jm9b01985_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b01985&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_74027" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_74027" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 122 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">CDK7: a Kinase at the Core of Transcription and in the Crosshairs of Cancer Drug Discovery</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">47</span>– <span class="NLM_lpage">56</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1553483</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1080%2F21541264.2018.1553483" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30488763" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisVKit7jJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=47-56&issue=2&author=R.+P.+Fisher&title=CDK7%3A+a+Kinase+at+the+Core+of+Transcription+and+in+the+Crosshairs+of+Cancer+Drug+Discovery&doi=10.1080%2F21541264.2018.1553483"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Cdk7: a kinase at the core of transcription and in the crosshairs of cancer drug discovery</span></div><div class="casAuthors">Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">47-56</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">The transcription cycle of RNA polymerase II (Pol II) is regulated by a set of cyclin-dependent kinases (CDKs).  Cdk7, assocd. with the transcription initiation factor TFIIH, is both an effector CDK that phosphorylates Pol II and other targets within the transcriptional machinery, and a CDK-activating kinase (CAK) for at least one other essential CDK involved in transcription.  Recent studies have illuminated Cdk7 functions that are executed throughout the Pol II transcription cycle, from promoter clearance and promoter-proximal pausing, to co-transcriptional chromatin modification in gene bodies, to mRNA 3'-end formation and termination.  Cdk7 has also emerged as a target of small-mol. inhibitors that show promise in the treatment of cancer and inflammation.  The challenges now are to identify the relevant targets of Cdk7 at each step of the transcription cycle, and to understand how heightened dependence on an essential CDK emerges in cancer, and might be exploited therapeutically.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGofoFEzSkAQxLVg90H21EOLACvtfcHk0lg6Rcq12L52bw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisVKit7jJ&md5=b6344f44b27d777d4fb7aad3a609d087</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1553483&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1553483%26sid%3Dliteratum%253Aachs%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DCDK7%253A%2520a%2520Kinase%2520at%2520the%2520Core%2520of%2520Transcription%2520and%2520in%2520the%2520Crosshairs%2520of%2520Cancer%2520Drug%2520Discovery%26jtitle%3DTranscription%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D47%26epage%3D56%26doi%3D10.1080%2F21541264.2018.1553483" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Whittaker, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mallinger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Workman, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Clarke, P. A.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinases as Cancer Therapeutics</span>. <i>Pharmacol. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>173</i></span>,  <span class="NLM_fpage">83</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1016/j.pharmthera.2017.02.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.pharmthera.2017.02.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28174091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=173&publication_year=2017&pages=83-105&author=S.+R.+Whittakerauthor=A.+Mallingerauthor=P.+Workmanauthor=P.+A.+Clarke&title=Inhibitors+of+Cyclin-Dependent+Kinases+as+Cancer+Therapeutics&doi=10.1016%2Fj.pharmthera.2017.02.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of cyclin-dependent kinases as cancer therapeutics</span></div><div class="casAuthors">Whittaker, Steven R.; Mallinger, Aurelie; Workman, Paul; Clarke, Paul A.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacology & Therapeutics</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">173</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-105</span>CODEN:
                <span class="NLM_cas:coden">PHTHDT</span>;
        ISSN:<span class="NLM_cas:issn">0163-7258</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Over the past two decades there has been a great deal of interest in the development of inhibitors of the cyclin-dependent kinases (CDKs).  This attention initially stemmed from observations that different CDK isoforms have key roles in cancer cell proliferation through loss of regulation of the cell cycle, a hallmark feature of cancer.  CDKs have now been shown to regulate other processes, particularly various aspects of transcription.  The early non-selective CDK inhibitors exhibited considerable toxicity and proved to be insufficiently active in most cancers.  The lack of patient selection biomarkers and an absence of understanding of the inhibitory profile required for efficacy hampered the development of these inhibitors.  However, the advent of potent isoform-selective inhibitors with accompanying biomarkers has re-ignited interest.  Palbociclib, a selective CDK4/6 inhibitor, is now approved for the treatment of ER +/HER2- advanced breast cancer.  Current developments in the field include the identification of potent and selective inhibitors of the transcriptional CDKs; these include tool compds. that have allowed exploration of individual CDKs as cancer targets and the detn. of their potential therapeutic windows.  Biomarkers that allow the selection of patients likely to respond are now being discovered.  Drug resistance has emerged as a major hurdle in the clinic for most protein kinase inhibitors and resistance mechanism are beginning to be identified for CDK inhibitors.  This suggests that the selective inhibitors may be best used combined with std. of care or other molecularly targeted agents now in development rather than in isolation as monotherapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5gsvVBhpMEbVg90H21EOLACvtfcHk0liVy8ohrMwRhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXis1yrtb0%253D&md5=933364a96089bc4c47e15bddb412bd53</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.pharmthera.2017.02.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pharmthera.2017.02.008%26sid%3Dliteratum%253Aachs%26aulast%3DWhittaker%26aufirst%3DS.%2BR.%26aulast%3DMallinger%26aufirst%3DA.%26aulast%3DWorkman%26aufirst%3DP.%26aulast%3DClarke%26aufirst%3DP.%2BA.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinases%2520as%2520Cancer%2520Therapeutics%26jtitle%3DPharmacol.%2520Ther.%26date%3D2017%26volume%3D173%26spage%3D83%26epage%3D105%26doi%3D10.1016%2Fj.pharmthera.2017.02.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Devault, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fesquet, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Labbe, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morin, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tassan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nigg, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavadore, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Doree, M.</span></span> <span> </span><span class="NLM_article-title">MAT1 (‘Menage à Trois’) a New RING Finger Protein Subunit Stabilizing Cyclin H-CDK7 Complexes in Starfish and Xenopus CAK</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">5027</span>– <span class="NLM_lpage">5036</span>, <span class="refDoi"> DOI: 10.1002/j.1460-2075.1995.tb00185.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fj.1460-2075.1995.tb00185.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=7588631" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADyaK2MXptFyju7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=1995&pages=5027-5036&issue=20&author=A.+Devaultauthor=A.+Martinezauthor=D.+Fesquetauthor=J.+Labbeauthor=N.+Morinauthor=J.+Tassanauthor=E.+Niggauthor=J.+Cavadoreauthor=M.+Doree&title=MAT1+%28%E2%80%98Menage+%C3%A0+Trois%E2%80%99%29+a+New+RING+Finger+Protein+Subunit+Stabilizing+Cyclin+H-CDK7+Complexes+in+Starfish+and+Xenopus+CAK&doi=10.1002%2Fj.1460-2075.1995.tb00185.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">MAT1 ('menage a trois') a new RING finger protein subunit stabilizing cyclin H-cdk7 complexes in starfish and Xenopus CAK</span></div><div class="casAuthors">Devault, Alain; Martinez, Anne-Marie; Fesquet, Didier; Labbe, Jean-Claude; Morin, Nathalie; Tassan, Jean-Pierre; Nigg, Erich A.; Cavadore, Jean-Claude; Doree, Marcel</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">5027-36</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Oxford University Press</span>)
        </div><div class="casAbstract">The kinase responsible for Thr161-Thr160 phosphorylation and activation of cdc2/cdk2 (CAK:cdk-activating kinase) has been shown previously to comprise at least two subunits, cdk7 and cyclin H.  An addnl. protein co-purified with CAK in starfish oocytes, but its sequencing did not reveal any similarity with any known protein.  In the present work, a cDNA encoding this protein is cloned and sequenced in both starfish and Xenopus oocytes.  It is shown to encode a new member of the RING finger family of proteins with a characteristic C3HC4 motif located in the N-terminal domain.  The authors demonstrate that the RING finger protein (MAT1: 'menage a trois') is a new subunit of CAK in both vertebrate and invertebrates.  However, CAK may also exist in oocytes as heterodimeric complexes between cyclin H and cdk7 only.  Stable heterotrimeric CAK complexes were generated in reticulocyte lysates programmed with mRNAs encoding Xenopus cdk7, cyclin H and MAT1.  In contrast, no heterodimeric cyclin H-cdk7 complex be immunopptd. from reticulocyte lysates programmed with cdk7 and cyclin H mRNAs only.  Stabilization of CAK complexes by MAT1 does not involve phosphorylation of Thr176, as the Thr176 → Ala mutant of Xenopus cdk7 could engage as efficiently as wild-type cdk7 in ternary complexes.  Even though starfish MAT1 is almost identical to Xenopus MAT1 in the RING finger domain, the starfish subunit could not replace the Xenopus subunit and stabilize cyclin H-cdk7 in reticulocyte lysate, suggesting that the MAT1 subunit does not (or not only) interact with cyclin H-cdk7 through the RING finger domain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpgk12ErxosA7Vg90H21EOLACvtfcHk0liVy8ohrMwRhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXptFyju7k%253D&md5=8abb5e85707d591651677780b5ceff0b</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1002%2Fj.1460-2075.1995.tb00185.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fj.1460-2075.1995.tb00185.x%26sid%3Dliteratum%253Aachs%26aulast%3DDevault%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DA.%26aulast%3DFesquet%26aufirst%3DD.%26aulast%3DLabbe%26aufirst%3DJ.%26aulast%3DMorin%26aufirst%3DN.%26aulast%3DTassan%26aufirst%3DJ.%26aulast%3DNigg%26aufirst%3DE.%26aulast%3DCavadore%26aufirst%3DJ.%26aulast%3DDoree%26aufirst%3DM.%26atitle%3DMAT1%2520%2528%25E2%2580%2598Menage%2520%25C3%25A0%2520Trois%25E2%2580%2599%2529%2520a%2520New%2520RING%2520Finger%2520Protein%2520Subunit%2520Stabilizing%2520Cyclin%2520H-CDK7%2520Complexes%2520in%2520Starfish%2520and%2520Xenopus%2520CAK%26jtitle%3DEMBO%2520J.%26date%3D1995%26volume%3D14%26issue%3D20%26spage%3D5027%26epage%3D5036%26doi%3D10.1002%2Fj.1460-2075.1995.tb00185.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Garrett, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barton, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knights, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Morgan, D. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Reciprocal Activation by Cyclin-Dependent Kinases 2 and 7 Is Directed by Substrate Specificity Determinants Outside the T Loop</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">99</span>, <span class="refDoi"> DOI: 10.1128/MCB.21.1.88-99.2001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FMCB.21.1.88-99.2001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=11113184" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD3MXovFyh" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2001&pages=88-99&issue=1&author=S.+Garrettauthor=W.+A.+Bartonauthor=R.+Knightsauthor=P.+Jinauthor=D.+O.+Morganauthor=R.+P.+Fisher&title=Reciprocal+Activation+by+Cyclin-Dependent+Kinases+2+and+7+Is+Directed+by+Substrate+Specificity+Determinants+Outside+the+T+Loop&doi=10.1128%2FMCB.21.1.88-99.2001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Reciprocal activation by cyclin-dependent kinases 2 and 7 is directed by substrate specificity determinants outside the T loop</span></div><div class="casAuthors">Garrett, Sarah; Barton, William A.; Knights, Ronald; Jin, Pei; Morgan, David O.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">88-99</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) is the catalytic subunit of the metazoan CDK-activating kinase (CAK), which activates CDKs, such as CDC2 and CDK2, through phosphorylation of a conserved threonine residue in the T loop.  Full activation of CDK7 requires assocn. with a pos. regulatory subunit, cyclin H, and phosphorylation of a conserved threonine residue at position 170 in its own T loop.  We show that threonine-170 of CDK7 is phosphorylated in vitro by its targets, CDC2 and CDK2, which also phosphorylate serine-164 in the CDK7 T loop, a site that perfectly matches their consensus phosphorylation site.  In contrast, neither CDK4 nor CDK7 itself can phosphorylate the CDK7 T loop in vitro.  The ability of CDC2 or CDK2 and CDK7 to phosphorylate each other but not themselves implies that each kinase can discriminate among closely related sequences and can recognize a substrate site that diverges from its usual preferred site.  To understand the basis for this paradoxical substrate specificity, we constructed a chimeric CDK with the T loop of CDK7 grafted onto the body of CDK2.  Surprisingly, the hybrid enzyme, CDK2-7, was efficiently activated in cyclin A-dependent fashion by CDK7 but not at all by CDK2.  CDK2-7, moreover, phosphorylated wild-type CDK7 but not CDK2.  Our results suggest that the primary amino acid sequence of the T loop plays only a minor role, if any, in detg. the specificity of cyclin-dependent CAKs for their CDK substrates and that protein-protein interactions involving sequences outside the T loop can influence substrate specificity both pos. and neg.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpHZCqCtS5KpbVg90H21EOLACvtfcHk0lgnEG2iLmUAwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXovFyh&md5=a55831bd5cb8f80b2658edf177c4cb2d</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1128%2FMCB.21.1.88-99.2001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.21.1.88-99.2001%26sid%3Dliteratum%253Aachs%26aulast%3DGarrett%26aufirst%3DS.%26aulast%3DBarton%26aufirst%3DW.%2BA.%26aulast%3DKnights%26aufirst%3DR.%26aulast%3DJin%26aufirst%3DP.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DReciprocal%2520Activation%2520by%2520Cyclin-Dependent%2520Kinases%25202%2520and%25207%2520Is%2520Directed%2520by%2520Substrate%2520Specificity%2520Determinants%2520Outside%2520the%2520T%2520Loop%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2001%26volume%3D21%26issue%3D1%26spage%3D88%26epage%3D99%26doi%3D10.1128%2FMCB.21.1.88-99.2001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Long, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leresche, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kriwacki, R. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gottesfeld, J. M.</span></span> <span> </span><span class="NLM_article-title">Repression of TFIIH Transcriptional Activity and TFIIH-Associated CDK7 Kinase Activity at Mitosis</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">1467</span>– <span class="NLM_lpage">1476</span>, <span class="refDoi"> DOI: 10.1128/MCB.18.3.1467</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FMCB.18.3.1467" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=9488463" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADyaK1cXhtleiu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=1998&pages=1467-1476&issue=3&author=J.+J.+Longauthor=A.+Lerescheauthor=R.+W.+Kriwackiauthor=J.+M.+Gottesfeld&title=Repression+of+TFIIH+Transcriptional+Activity+and+TFIIH-Associated+CDK7+Kinase+Activity+at+Mitosis&doi=10.1128%2FMCB.18.3.1467"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Repression of TFIIH transcriptional activity and TFIIH-associated cdk7 kinase activity at mitosis</span></div><div class="casAuthors">Long, John J.; Leresche, Anne; Kriwacki, Richard W.; Gottesfeld, Joel M.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1467-1476</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Nuclear transcription is repressed when eukaryotic cells enter mitosis.  Mitotic repression of transcription of various cellular and viral gene promoters by RNA polymerase II can be reproduced in vitro either with exts. prepd. from cells arrested at mitosis with the microtubule polymn. inhibitor nocodazole or with nuclear exts. prepd. from asynchronous cells and the mitotic protein kinase cdc2/cyclin B.  Purified cdc2/cyclin B kinase is also sufficient to inhibit transcription in reconstituted transcription reactions with biochem. purified and recombinant basal transcription factors and RNA polymerase II.  The cyclin-dependent kinase inhibitor p21Waf1/Cip1/Sdi1 can reverse the effect of cdc2/cyclin B kinase, indicating that repression of transcription is due to protein phosphorylation.  Transcription rescue and inhibition expts. with each of the basal factors and the polymerase suggest that multiple components of the transcription machinery are inactivated by cdc2/cyclin B kinase.  For an activated promoter, targets of repression are TFIID and TFIIH, while for a basal promoter, TFIIH is the major target for mitotic inactivation of transcription.  Protein labeling expts. indicate that the p62 and p36 subunits of TFIIH are in vitro substrates for mitotic phosphorylation.  Using the carboxy-terminal domain of the large subunit of RNA polymerase II as a test substrate for phosphorylation, the TFIIH-assocd. kinase, cdk7/cyclin H, is inhibited concomitant with inhibition of transcription activity.  Our results suggest that there exist multiple phosphorylation targets for the global shutdown of transcription at mitosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoJcoMMr5slibVg90H21EOLACvtfcHk0lgnEG2iLmUAwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXhtleiu7c%253D&md5=b487a7a93040f77478eed2a403387f3f</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1128%2FMCB.18.3.1467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.18.3.1467%26sid%3Dliteratum%253Aachs%26aulast%3DLong%26aufirst%3DJ.%2BJ.%26aulast%3DLeresche%26aufirst%3DA.%26aulast%3DKriwacki%26aufirst%3DR.%2BW.%26aulast%3DGottesfeld%26aufirst%3DJ.%2BM.%26atitle%3DRepression%2520of%2520TFIIH%2520Transcriptional%2520Activity%2520and%2520TFIIH-Associated%2520CDK7%2520Kinase%2520Activity%2520at%2520Mitosis%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1998%26volume%3D18%26issue%3D3%26spage%3D1467%26epage%3D1476%26doi%3D10.1128%2FMCB.18.3.1467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nilson, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turek, M. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brogie, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luse, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Price, D. H.</span></span> <span> </span><span class="NLM_article-title">THZ1 Reveals Roles for CDK7 in Co-transcriptional Capping and Pausing</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">576</span>– <span class="NLM_lpage">587</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.06.032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2015.06.032" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=26257281" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlSju7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=576-587&issue=4&author=K.+A.+Nilsonauthor=J.+Guoauthor=M.+E.+Turekauthor=J.+E.+Brogieauthor=E.+Delaneyauthor=D.+S.+Luseauthor=D.+H.+Price&title=THZ1+Reveals+Roles+for+CDK7+in+Co-transcriptional+Capping+and+Pausing&doi=10.1016%2Fj.molcel.2015.06.032"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 Reveals Roles for Cdk7 in Co-transcriptional Capping and Pausing</span></div><div class="casAuthors">Nilson, Kyle A.; Guo, Jiannan; Turek, Michael E.; Brogie, John E.; Delaney, Elizabeth; Luse, Donal S.; Price, David H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">576-587</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">The Cdk7 subunit of TFIIH phosphorylates RNA polymerase II (Pol II) during initiation, and, while recent studies show that inhibition of human Cdk7 neg. influences transcription, the mechanisms involved are unclear.  Using in vitro transcription with nuclear ext., we demonstrate that THZ1, a covalent Cdk7 inhibitor, causes defects in Pol II phosphorylation, co-transcriptional capping, promoter proximal pausing, and productive elongation.  THZ1 does not affect initiation but blocks essentially all Pol II large subunit C-terminal domain (CTD) phosphorylation.  We found that guanylylation of nascent RNAs is length dependent and modulated by a THZ1-sensitive factor present in nuclear ext.  THZ1 impacts pausing through a capping-independent block of DSIF and NELF loading.  The P-TEFb-dependent transition into productive elongation was also inhibited by THZ1, likely due to loss of DSIF.  Capping and pausing were also reduced in THZ1-treated cells.  Our results provide mechanistic insights into THZ1 action and how Cdk7 broadly influences transcription and capping.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6vyXXJUmAULVg90H21EOLACvtfcHk0lgnEG2iLmUAwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlSju7bP&md5=6a38991e587b7e0c199627b0f5ea6696</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.06.032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.06.032%26sid%3Dliteratum%253Aachs%26aulast%3DNilson%26aufirst%3DK.%2BA.%26aulast%3DGuo%26aufirst%3DJ.%26aulast%3DTurek%26aufirst%3DM.%2BE.%26aulast%3DBrogie%26aufirst%3DJ.%2BE.%26aulast%3DDelaney%26aufirst%3DE.%26aulast%3DLuse%26aufirst%3DD.%2BS.%26aulast%3DPrice%26aufirst%3DD.%2BH.%26atitle%3DTHZ1%2520Reveals%2520Roles%2520for%2520CDK7%2520in%2520Co-transcriptional%2520Capping%2520and%2520Pausing%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D59%26issue%3D4%26spage%3D576%26epage%3D587%26doi%3D10.1016%2Fj.molcel.2015.06.032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coin, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egly, J.-M.</span></span> <span> </span><span class="NLM_article-title">Revisiting the Function of CDK7 in Transcription by Virtue of a Recently Described TFIIH Kinase Inhibitor</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">513</span>– <span class="NLM_lpage">514</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2015.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2015.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=26295956" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhtlymtLvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=513-514&issue=4&author=F.+Coinauthor=J.-M.+Egly&title=Revisiting+the+Function+of+CDK7+in+Transcription+by+Virtue+of+a+Recently+Described+TFIIH+Kinase+Inhibitor&doi=10.1016%2Fj.molcel.2015.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Revisiting the function of CDK7 in transcription by virtue of a recently described TFIIH kinase inhibitor</span></div><div class="casAuthors">Coin, Frederic; Egly, Jean-Marc</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">513-514</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">A review.  In this issue of Mol. Cell, Nilson et al. (2015) took advantage of THZ1, a recently described covalent inhibitor of the TFIIH kinase CDK7, to further characterize the role of this enzyme in the early stages of transcription and postprocessing events.  They unveiled an unexpected function of CDK7 in RNA polymerase II pausing and mRNA capping.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqh76M4cZqjzLVg90H21EOLACvtfcHk0lgnEG2iLmUAwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhtlymtLvK&md5=360b4bf4d63a7c2a8e9f0e77f083ca9c</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2015.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2015.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DCoin%26aufirst%3DF.%26aulast%3DEgly%26aufirst%3DJ.-M.%26atitle%3DRevisiting%2520the%2520Function%2520of%2520CDK7%2520in%2520Transcription%2520by%2520Virtue%2520of%2520a%2520Recently%2520Described%2520TFIIH%2520Kinase%2520Inhibitor%26jtitle%3DMol.%2520Cell%26date%3D2015%26volume%3D59%26issue%3D4%26spage%3D513%26epage%3D514%26doi%3D10.1016%2Fj.molcel.2015.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Glover-Cutter, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sansó, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bentley, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Control of the Initiation-to-Elongation Switch of RNA Polymerase II</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>19</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1108</span>– <span class="NLM_lpage">1115</span>, <span class="refDoi"> DOI: 10.1038/nsmb.2399</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnsmb.2399" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=23064645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2012&pages=1108-1115&issue=11&author=S.+Larochelleauthor=R.+Amatauthor=K.+Glover-Cutterauthor=M.+Sans%C3%B3author=C.+Zhangauthor=J.+J.+Allenauthor=K.+M.+Shokatauthor=D.+L.+Bentleyauthor=R.+P.+Fisher&title=Cyclin-Dependent+Kinase+Control+of+the+Initiation-to-Elongation+Switch+of+RNA+Polymerase+II&doi=10.1038%2Fnsmb.2399"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II</span></div><div class="casAuthors">Larochelle, Stephane; Amat, Ramon; Glover-Cutter, Kira; Sanso, Miriam; Zhang, Chao; Allen, Jasmina J.; Shokat, Kevan M.; Bentley, David L.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1108-1115</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Promoter-proximal pausing by RNA polymerase II (Pol II) ensures gene-specific regulation and RNA quality control.  Structural considerations suggested a requirement for initiation-factor eviction in elongation-factor engagement and pausing of transcription complexes.  Here we show that selective inhibition of Cdk7-part of TFIIH-increases TFIIE retention, prevents DRB sensitivity-inducing factor (DSIF) recruitment and attenuates pausing in human cells.  Pause release depends on Cdk9-cyclin T1 (P-TEFb); Cdk7 is also required for Cdk9-activating phosphorylation and Cdk9-dependent downstream events-Pol II C-terminal domain Ser2 phosphorylation and histone H2B ubiquitylation-in vivo.  Cdk7 inhibition, moreover, impairs Pol II transcript 3'-end formation.  Cdk7 thus acts through TFIIE and DSIF to establish, and through P-TEFb to relieve, barriers to elongation: incoherent feedforward that might create a window to recruit RNA-processing machinery.  Therefore, cyclin-dependent kinases govern Pol II handoff from initiation to elongation factors and cotranscriptional RNA maturation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUhQtYIcdjLbVg90H21EOLACvtfcHk0lgad8_8Smeb3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhsV2rsLvI&md5=e483e572df1f8645db9da40800dffe4d</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1038%2Fnsmb.2399&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnsmb.2399%26sid%3Dliteratum%253Aachs%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DAmat%26aufirst%3DR.%26aulast%3DGlover-Cutter%26aufirst%3DK.%26aulast%3DSans%25C3%25B3%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DAllen%26aufirst%3DJ.%2BJ.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DBentley%26aufirst%3DD.%2BL.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DCyclin-Dependent%2520Kinase%2520Control%2520of%2520the%2520Initiation-to-Elongation%2520Switch%2520of%2520RNA%2520Polymerase%2520II%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2012%26volume%3D19%26issue%3D11%26spage%3D1108%26epage%3D1115%26doi%3D10.1038%2Fnsmb.2399" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cho, W.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spille, J.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hecht, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grube, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisse, I. I.</span></span> <span> </span><span class="NLM_article-title">Mediator and RNA Polymerase II Clusters Associate in Transcription-Dependent Condensates</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>),  <span class="NLM_fpage">412</span>– <span class="NLM_lpage">415</span>, <span class="refDoi"> DOI: 10.1126/science.aar4199</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aar4199" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29930094" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlyitrrJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&pages=412-415&issue=6400&author=W.-K.+Choauthor=J.-H.+Spilleauthor=M.+Hechtauthor=C.+Leeauthor=C.+Liauthor=V.+Grubeauthor=I.+I.+Cisse&title=Mediator+and+RNA+Polymerase+II+Clusters+Associate+in+Transcription-Dependent+Condensates&doi=10.1126%2Fscience.aar4199"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Mediator and RNA polymerase II clusters associate in transcription-dependent condensates</span></div><div class="casAuthors">Cho, Won-Ki; Spille, Jan-Hendrik; Hecht, Micca; Lee, Choongman; Li, Charles; Grube, Valentin; Cisse, Ibrahim I.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6400</span>),
    <span class="NLM_cas:pages">412-415</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Models of gene control have emerged from genetic and biochem. studies, with limited consideration of the spatial organization and dynamics of key components in living cells.  Here, we used live-cell super-resoln. and light-sheet imaging to study the organization and dynamics of the Mediator coactivator and RNA polymerase II (Pol II) directly.  Mediator and Pol II each formed small transient and large stable clusters in living embryonic stem cells.  Mediator and Pol II were colocalized in the stable clusters, which assocd. with chromatin, have properties of phase-sepd. condensates, and are sensitive to transcriptional inhibitors.  We suggest that large clusters of Mediator, recruited by transcription factors at large or clustered enhancer elements, interact with large Pol II clusters in transcriptional condensates in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrryxgv6U-HA7Vg90H21EOLACvtfcHk0lgad8_8Smeb3A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlyitrrJ&md5=02ade395f3f4df7f9d85662c8a6e5677</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar4199&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar4199%26sid%3Dliteratum%253Aachs%26aulast%3DCho%26aufirst%3DW.-K.%26aulast%3DSpille%26aufirst%3DJ.-H.%26aulast%3DHecht%26aufirst%3DM.%26aulast%3DLee%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DGrube%26aufirst%3DV.%26aulast%3DCisse%26aufirst%3DI.%2BI.%26atitle%3DMediator%2520and%2520RNA%2520Polymerase%2520II%2520Clusters%2520Associate%2520in%2520Transcription-Dependent%2520Condensates%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26spage%3D412%26epage%3D415%26doi%3D10.1126%2Fscience.aar4199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugast-Darzacq, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dong, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dailey, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cattoglio, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Banala, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lavis, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tjian, R.</span></span> <span> </span><span class="NLM_article-title">Imaging Dynamic and Selective Low-Complexity Domain Interactions that Control Gene Transcription</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>), <span class="NLM_elocation-id">eaar2555</span> <span class="refDoi"> DOI: 10.1126/science.aar2555</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aar2555" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29930090" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&issue=6400&author=S.+Chongauthor=C.+Dugast-Darzacqauthor=Z.+Liuauthor=P.+Dongauthor=G.+M.+Daileyauthor=C.+Cattoglioauthor=A.+Heckertauthor=S.+Banalaauthor=L.+Lavisauthor=X.+Darzacqauthor=R.+Tjian&title=Imaging+Dynamic+and+Selective+Low-Complexity+Domain+Interactions+that+Control+Gene+Transcription&doi=10.1126%2Fscience.aar2555"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar2555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar2555%26sid%3Dliteratum%253Aachs%26aulast%3DChong%26aufirst%3DS.%26aulast%3DDugast-Darzacq%26aufirst%3DC.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DDong%26aufirst%3DP.%26aulast%3DDailey%26aufirst%3DG.%2BM.%26aulast%3DCattoglio%26aufirst%3DC.%26aulast%3DHeckert%26aufirst%3DA.%26aulast%3DBanala%26aufirst%3DS.%26aulast%3DLavis%26aufirst%3DL.%26aulast%3DDarzacq%26aufirst%3DX.%26aulast%3DTjian%26aufirst%3DR.%26atitle%3DImaging%2520Dynamic%2520and%2520Selective%2520Low-Complexity%2520Domain%2520Interactions%2520that%2520Control%2520Gene%2520Transcription%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26doi%3D10.1126%2Fscience.aar2555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Plys, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingston, R. E.</span></span> <span> </span><span class="NLM_article-title">Dynamic Condensates Activate Transcription</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>),  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">330</span>, <span class="refDoi"> DOI: 10.1126/science.aau4795</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aau4795" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30049863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsVKlsbfF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&pages=329-330&issue=6400&author=A.+J.+Plysauthor=R.+E.+Kingston&title=Dynamic+Condensates+Activate+Transcription&doi=10.1126%2Fscience.aau4795"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Dynamic condensates activate transcription</span></div><div class="casAuthors">Plys, Aaron J.; Kingston, Robert E.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">361</span>
        (<span class="NLM_cas:issue">6400</span>),
    <span class="NLM_cas:pages">329-330</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">
                There is no expanded citation for this reference.
            </div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-W9HQuyn2u7Vg90H21EOLACvtfcHk0lj_JFpMPCmOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsVKlsbfF&md5=6c61a3593836e3918894c976b17cbd83</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1126%2Fscience.aau4795&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aau4795%26sid%3Dliteratum%253Aachs%26aulast%3DPlys%26aufirst%3DA.%2BJ.%26aulast%3DKingston%26aufirst%3DR.%2BE.%26atitle%3DDynamic%2520Condensates%2520Activate%2520Transcription%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26spage%3D329%26epage%3D330%26doi%3D10.1126%2Fscience.aau4795" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sabari, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dall’Agnese, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boija, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, I. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coffey, E. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shrinivas, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zamudio, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manteiga, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, Y. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, D. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schuijers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vasile, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malik, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hnisz, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cisse, I. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roeder, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharp, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chakraborty, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span> <span> </span><span class="NLM_article-title">Coactivator Condensation at Super-Enhancers Links Phase Separation and Gene Control</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>361</i></span> (<span class="NLM_issue">6400</span>), <span class="NLM_elocation-id">eaar3958</span> <span class="refDoi"> DOI: 10.1126/science.aar3958</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1126%2Fscience.aar3958" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29930091" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=361&publication_year=2018&issue=6400&author=B.+R.+Sabariauthor=A.+Dall%E2%80%99Agneseauthor=A.+Boijaauthor=I.+A.+Kleinauthor=E.+L.+Coffeyauthor=K.+Shrinivasauthor=B.+J.+Abrahamauthor=N.+M.+Hannettauthor=A.+V.+Zamudioauthor=J.+C.+Manteigaauthor=C.+H.+Liauthor=Y.+E.+Guoauthor=D.+S.+Dayauthor=J.+Schuijersauthor=E.+Vasileauthor=S.+Malikauthor=D.+Hniszauthor=T.+I.+Leeauthor=I.+I.+Cisseauthor=R.+G.+Roederauthor=R.+A.+Sharpauthor=A.+K.+Chakrabortyauthor=R.+A.+Young&title=Coactivator+Condensation+at+Super-Enhancers+Links+Phase+Separation+and+Gene+Control&doi=10.1126%2Fscience.aar3958"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1126%2Fscience.aar3958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.aar3958%26sid%3Dliteratum%253Aachs%26aulast%3DSabari%26aufirst%3DB.%2BR.%26aulast%3DDall%25E2%2580%2599Agnese%26aufirst%3DA.%26aulast%3DBoija%26aufirst%3DA.%26aulast%3DKlein%26aufirst%3DI.%2BA.%26aulast%3DCoffey%26aufirst%3DE.%2BL.%26aulast%3DShrinivas%26aufirst%3DK.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DZamudio%26aufirst%3DA.%2BV.%26aulast%3DManteiga%26aufirst%3DJ.%2BC.%26aulast%3DLi%26aufirst%3DC.%2BH.%26aulast%3DGuo%26aufirst%3DY.%2BE.%26aulast%3DDay%26aufirst%3DD.%2BS.%26aulast%3DSchuijers%26aufirst%3DJ.%26aulast%3DVasile%26aufirst%3DE.%26aulast%3DMalik%26aufirst%3DS.%26aulast%3DHnisz%26aufirst%3DD.%26aulast%3DLee%26aufirst%3DT.%2BI.%26aulast%3DCisse%26aufirst%3DI.%2BI.%26aulast%3DRoeder%26aufirst%3DR.%2BG.%26aulast%3DSharp%26aufirst%3DR.%2BA.%26aulast%3DChakraborty%26aufirst%3DA.%2BK.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26atitle%3DCoactivator%2520Condensation%2520at%2520Super-Enhancers%2520Links%2520Phase%2520Separation%2520and%2520Gene%2520Control%26jtitle%3DScience%26date%3D2018%26volume%3D361%26issue%3D6400%26doi%3D10.1126%2Fscience.aar3958" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Boehning, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dugast-Darzacq, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marie-Nelly, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McSwiggen, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kokic, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dailey, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cramer, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zweckstetter, M.</span></span> <span> </span><span class="NLM_article-title">RNA Polymerase II Clustering Through Carboxy-Terminal Domain Phase Separation</span>. <i>Nat. Struct. Mol. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">833</span>– <span class="NLM_lpage">840</span>, <span class="refDoi"> DOI: 10.1038/s41594-018-0112-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41594-018-0112-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30127355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFGjtLvF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=833-840&issue=9&author=M.+Boehningauthor=C.+Dugast-Darzacqauthor=M.+Rankovicauthor=A.+S.+Hansenauthor=T.+Yuauthor=H.+Marie-Nellyauthor=D.+T.+McSwiggenauthor=G.+Kokicauthor=G.+M.+Daileyauthor=P.+Cramerauthor=X.+Darzacqauthor=M.+Zweckstetter&title=RNA+Polymerase+II+Clustering+Through+Carboxy-Terminal+Domain+Phase+Separation&doi=10.1038%2Fs41594-018-0112-y"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">RNA polymerase II clustering through carboxy-terminal domain phase separation</span></div><div class="casAuthors">Boehning, Marc; Dugast-Darzacq, Claire; Rankovic, Marija; Hansen, Anders S.; Yu, Taekyung; Marie-Nelly, Herve; McSwiggen, David T.; Kokic, Goran; Dailey, Gina M.; Cramer, Patrick; Darzacq, Xavier; Zweckstetter, Markus</div><div class="citationInfo"><span class="NLM_cas:title">Nature Structural & Molecular Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">833-840</span>CODEN:
                <span class="NLM_cas:coden">NSMBCU</span>;
        ISSN:<span class="NLM_cas:issn">1545-9993</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">The carboxy-terminal domain (CTD) of RNA polymerase (Pol) II is an intrinsically disordered low-complexity region that is crit. for pre-mRNA transcription and processing.  The CTD consists of hepta-amino acid repeats varying in no. from 52 in humans to 26 in yeast.  Here we report that human and yeast CTDs undergo cooperative liq. phase sepn., with the shorter yeast CTD forming less-stable droplets.  In human cells, truncation of the CTD to the length of the yeast CTD decreases Pol II clustering and chromatin assocn., whereas CTD extension has the opposite effect.  CTD droplets can incorporate intact Pol II and are dissolved by CTD phosphorylation with the transcription initiation factor IIH kinase CDK7.  Together with published data, our results suggest that Pol II forms clusters or hubs at active genes through interactions between CTDs and with activators and that CTD phosphorylation liberates Pol II enzymes from hubs for promoter escape and transcription elongation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJaIan4V-y0LVg90H21EOLACvtfcHk0lj_JFpMPCmOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFGjtLvF&md5=eea3ebfe4634197a90a513a72b71621e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fs41594-018-0112-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41594-018-0112-y%26sid%3Dliteratum%253Aachs%26aulast%3DBoehning%26aufirst%3DM.%26aulast%3DDugast-Darzacq%26aufirst%3DC.%26aulast%3DRankovic%26aufirst%3DM.%26aulast%3DHansen%26aufirst%3DA.%2BS.%26aulast%3DYu%26aufirst%3DT.%26aulast%3DMarie-Nelly%26aufirst%3DH.%26aulast%3DMcSwiggen%26aufirst%3DD.%2BT.%26aulast%3DKokic%26aufirst%3DG.%26aulast%3DDailey%26aufirst%3DG.%2BM.%26aulast%3DCramer%26aufirst%3DP.%26aulast%3DDarzacq%26aufirst%3DX.%26aulast%3DZweckstetter%26aufirst%3DM.%26atitle%3DRNA%2520Polymerase%2520II%2520Clustering%2520Through%2520Carboxy-Terminal%2520Domain%2520Phase%2520Separation%26jtitle%3DNat.%2520Struct.%2520Mol.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D9%26spage%3D833%26epage%3D840%26doi%3D10.1038%2Fs41594-018-0112-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Balanced Between Order and Disorder: a New Phase in Transcription Elongation Control and Beyond</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">157</span>– <span class="NLM_lpage">163</span>, <span class="refDoi"> DOI: 10.1080/21541264.2019.1570812</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1080%2F21541264.2019.1570812" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30663929" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlCquro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=157-163&issue=3&author=H.+Luauthor=R.+Liuauthor=Q.+Zhou&title=Balanced+Between+Order+and+Disorder%3A+a+New+Phase+in+Transcription+Elongation+Control+and+Beyond&doi=10.1080%2F21541264.2019.1570812"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Balanced between order and disorder: a new phase in transcription elongation control and beyond</span></div><div class="casAuthors">Lu, Huasong; Liu, Rongdiao; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">157-163</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  We recently reported that the cyclin T1 histidine-rich domain creates a phase-sepd. environment to promote hyperphosphorylation of RNA polymerase II C-terminal domain and robust transcriptional elongation by P-TEFb.  Here, we discuss this and several other recent discoveries to demonstrate that phase sepn. is important for controlling various aspects of transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrDO99TGC9RyLVg90H21EOLACvtfcHk0lj_JFpMPCmOIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlCquro%253D&md5=06e87862905ef912c3fb2f1aa19a8a74</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1080%2F21541264.2019.1570812&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2019.1570812%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DBalanced%2520Between%2520Order%2520and%2520Disorder%253A%2520a%2520New%2520Phase%2520in%2520Transcription%2520Elongation%2520Control%2520and%2520Beyond%26jtitle%3DTranscription%26date%3D2019%26volume%3D10%26issue%3D3%26spage%3D157%26epage%3D163%26doi%3D10.1080%2F21541264.2019.1570812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hansen, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ganguly, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heckert, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darzacq, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Q.</span></span> <span> </span><span class="NLM_article-title">Phase-Separation Mechanism for C-Terminal Hyperphosphorylation of RNA Polymerase II</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>558</i></span> (<span class="NLM_issue">7709</span>),  <span class="NLM_fpage">318</span>– <span class="NLM_lpage">323</span>, <span class="refDoi"> DOI: 10.1038/s41586-018-0174-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41586-018-0174-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29849146" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVGitLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=558&publication_year=2018&pages=318-323&issue=7709&author=H.+Luauthor=D.+Yuauthor=A.+S.+Hansenauthor=S.+Gangulyauthor=R.+Liuauthor=A.+Heckertauthor=X.+Darzacqauthor=Q.+Zhou&title=Phase-Separation+Mechanism+for+C-Terminal+Hyperphosphorylation+of+RNA+Polymerase+II&doi=10.1038%2Fs41586-018-0174-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Phase-separation mechanism for C-terminal hyperphosphorylation of RNA polymerase II</span></div><div class="casAuthors">Lu, Huasong; Yu, Dan; Hansen, Anders S.; Ganguly, Sourav; Liu, Rongdiao; Heckert, Alec; Darzacq, Xavier; Zhou, Qiang</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">558</span>
        (<span class="NLM_cas:issue">7709</span>),
    <span class="NLM_cas:pages">318-323</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Hyperphosphorylation of the C-terminal domain (CTD) of the RPB1 subunit of human RNA polymerase (Pol) II is essential for transcriptional elongation and mRNA processing.  The CTD contains 52 heptapeptide repeats of the consensus sequence YSPTSPS.  The highly repetitive nature and abundant possible phosphorylation sites of the CTD exert special constraints on the kinases that catalyze its hyperphosphorylation.  Pos. transcription elongation factor b (P-TEFb) - which consists of CDK9 and cyclin T1 - is known to hyperphosphorylate the CTD and neg. elongation factors to stimulate Pol II elongation.  The sequence determinant on P-TEFb that facilitates this action is currently unknown.  Here we identify a histidine-rich domain in cyclin T1 that promotes the hyperphosphorylation of the CTD and stimulation of transcription by CDK9.  The histidine-rich domain markedly enhances the binding of P-TEFb to the CTD and functional engagement with target genes in cells.  In addn. to cyclin T1, at least one other kinase - DYRK1A - also uses a histidine-rich domain to target and hyperphosphorylate the CTD.  As a low-complexity domain, the histidine-rich domain also promotes the formation of phase-sepd. liq. droplets in vitro, and the localization of P-TEFb to nuclear speckles that display dynamic liq. properties and are sensitive to the disruption of weak hydrophobic interactions.  The CTD - which in isolation does not phase sep., despite being a low-complexity domain - is trapped within the cyclin T1 droplets, and this process is enhanced upon pre-phosphorylation by CDK7 of transcription initiation factor TFIIH.  By using multivalent interactions to create a phase-sepd. functional compartment, the histidine-rich domain in kinases targets the CTD into this environment to ensure hyperphosphorylation and efficient elongation of Pol II.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrpWrNiDYPH0bVg90H21EOLACvtfcHk0liOGp9JdOqyxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVGitLrN&md5=d05bcba86158d961de0834c86adab64c</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fs41586-018-0174-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41586-018-0174-3%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DH.%26aulast%3DYu%26aufirst%3DD.%26aulast%3DHansen%26aufirst%3DA.%2BS.%26aulast%3DGanguly%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DR.%26aulast%3DHeckert%26aufirst%3DA.%26aulast%3DDarzacq%26aufirst%3DX.%26aulast%3DZhou%26aufirst%3DQ.%26atitle%3DPhase-Separation%2520Mechanism%2520for%2520C-Terminal%2520Hyperphosphorylation%2520of%2520RNA%2520Polymerase%2520II%26jtitle%3DNature%26date%3D2018%26volume%3D558%26issue%3D7709%26spage%3D318%26epage%3D323%26doi%3D10.1038%2Fs41586-018-0174-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Galbraith, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bender, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espinosa, J. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Targeting of Transcriptional Cyclin-Dependent Kinases</span>. <i>Transcription</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">118</span>– <span class="NLM_lpage">136</span>, <span class="refDoi"> DOI: 10.1080/21541264.2018.1539615</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1080%2F21541264.2018.1539615" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30409083" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=118-136&issue=2&author=M.+D.+Galbraithauthor=H.+Benderauthor=J.+M.+Espinosa&title=Therapeutic+Targeting+of+Transcriptional+Cyclin-Dependent+Kinases&doi=10.1080%2F21541264.2018.1539615"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic targeting of transcriptional cyclin-dependent kinases</span></div><div class="casAuthors">Galbraith, Matthew D.; Bender, Heather; Espinosa, Joaquin M.</div><div class="citationInfo"><span class="NLM_cas:title">Transcription</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">118-136</span>CODEN:
                <span class="NLM_cas:coden">TRANH2</span>;
        ISSN:<span class="NLM_cas:issn">2154-1272</span>.
    
            (<span class="NLM_cas:orgname">Taylor & Francis, Inc.</span>)
        </div><div class="casAbstract">A review.  The fact that many cancer types display transcriptional addiction driven by dysregulation of oncogenic enhancers and transcription factors has led to increased interest in a group of protein kinases, known as transcriptional cyclin dependent kinases (tCDKs), as potential therapeutic targets.  Despite early reservations about targeting a process that is essential to healthy cell types, there is now evidence that targeting tCDKs could provide enough therapeutic window to be effective in the clinic.  Here, we discuss recent developments in this field, with an emphasis on highly-selective inhibitors and the challenges to be addressed before these inhibitors could be used for therapeutic purposes.: CAK: CDK-activating kinase;CDK: cyclin-dependent kinase;CMGC group: CDK-, MAPK-, GSK3-, and CLK-like;CTD: C-terminal repeat domain of the RPB1 subunit of RNA polymerase II;DRB: 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole;mCRPC: metastatic castration-resistant prostate cancer;NSCLC: non-small cell lung cancer;P-TEFb: pos. elongation factor b;RNAPII: RNA polymerase II;S2: serine-2 of CTD repeats;S5: serine-5 of CTD repeats;S7: serine-7 of CTD repeats;SEC: super elongation complex;tCDK: transcriptional cyclin-dependent kinase;TNBC: triple-neg. breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptgAOjkQMqqbVg90H21EOLACvtfcHk0liOGp9JdOqyxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitFKjs7vP&md5=1700138890acfc08ad2ab2a81f62c476</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1080%2F21541264.2018.1539615&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1080%252F21541264.2018.1539615%26sid%3Dliteratum%253Aachs%26aulast%3DGalbraith%26aufirst%3DM.%2BD.%26aulast%3DBender%26aufirst%3DH.%26aulast%3DEspinosa%26aufirst%3DJ.%2BM.%26atitle%3DTherapeutic%2520Targeting%2520of%2520Transcriptional%2520Cyclin-Dependent%2520Kinases%26jtitle%3DTranscription%26date%3D2019%26volume%3D10%26issue%3D2%26spage%3D118%26epage%3D136%26doi%3D10.1080%2F21541264.2018.1539615" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terret, M.-E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wohlbold, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barboza, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jallepalli, P. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Requirements for CDK7 in the Assembly of CDK1/Cyclin B and Activation of CDK2 Revealed by Chemical Genetics in Human Cells</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">839</span>– <span class="NLM_lpage">850</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2007.02.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2007.02.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=17386261" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXktFCgsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2007&pages=839-850&issue=6&author=S.+Larochelleauthor=K.+A.+Merrickauthor=M.-E.+Terretauthor=L.+Wohlboldauthor=N.+M.+Barbozaauthor=C.+Zhangauthor=K.+M.+Shokatauthor=P.+V.+Jallepalliauthor=R.+P.+Fisher&title=Requirements+for+CDK7+in+the+Assembly+of+CDK1%2FCyclin+B+and+Activation+of+CDK2+Revealed+by+Chemical+Genetics+in+Human+Cells&doi=10.1016%2Fj.molcel.2007.02.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Requirements for Cdk7 in the assembly of Cdk1/cyclin B and activation of Cdk2 revealed by chemical genetics in human cells</span></div><div class="casAuthors">Larochelle, Stephane; Merrick, Karl A.; Terret, Marie-Emilie; Wohlbold, Lara; Barboza, Nora M.; Zhang, Chao; Shokat, Kevan M.; Jallepalli, Prasad V.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">839-850</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cell division is controlled by cyclin-dependent kinases (CDKs).  In metazoans, S phase onset coincides with activation of Cdk2, whereas Cdk1 triggers mitosis.  Both Cdk1 and -2 require cyclin binding and T loop phosphorylation for full activity.  The only known CDK-activating kinase (CAK) in metazoans is Cdk7, which is also part of the transcription machinery.  To test the requirements for Cdk7 in vivo, we replaced wild-type Cdk7 with a version sensitive to bulky ATP analogs in human cancer cells.  Selective inhibition of Cdk7 in G1 prevents activation (but not formation) of Cdk2/cyclin complexes and delays S phase.  Inhibiting Cdk7 in G2 blocks entry to mitosis and disrupts Cdk1/cyclin B complex assembly, indicating that the two steps of Cdk1 activation-cyclin binding and T loop phosphorylation-are mutually dependent.  Therefore, by combining chem. genetics and homologous gene replacement in somatic cells, we reveal different modes of CDK activation by Cdk7 at two distinct execution points in the cell cycle.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGptnQJb6qpSabVg90H21EOLACvtfcHk0liOGp9JdOqyxw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXktFCgsbo%253D&md5=fe003624658619167adf3429e04cf58f</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2007.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2007.02.003%26sid%3Dliteratum%253Aachs%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DTerret%26aufirst%3DM.-E.%26aulast%3DWohlbold%26aufirst%3DL.%26aulast%3DBarboza%26aufirst%3DN.%2BM.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DJallepalli%26aufirst%3DP.%2BV.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DRequirements%2520for%2520CDK7%2520in%2520the%2520Assembly%2520of%2520CDK1%252FCyclin%2520B%2520and%2520Activation%2520of%2520CDK2%2520Revealed%2520by%2520Chemical%2520Genetics%2520in%2520Human%2520Cells%26jtitle%3DMol.%2520Cell%26date%3D2007%26volume%3D25%26issue%3D6%26spage%3D839%26epage%3D850%26doi%3D10.1016%2Fj.molcel.2007.02.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merrick, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirschi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rubin, S. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">A CDK7-CDK4 T-Loop Phosphorylation Cascade Promotes G1 Progression</span>. <i>Mol. Cell</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>50</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">250</span>– <span class="NLM_lpage">260</span>, <span class="refDoi"> DOI: 10.1016/j.molcel.2013.04.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.molcel.2013.04.003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=23622515" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXmvVWitb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=50&publication_year=2013&pages=250-260&issue=2&author=M.+M.+Schachterauthor=K.+A.+Merrickauthor=S.+Larochelleauthor=A.+Hirschiauthor=C.+Zhangauthor=K.+M.+Shokatauthor=S.+M.+Rubinauthor=R.+P.+Fisher&title=A+CDK7-CDK4+T-Loop+Phosphorylation+Cascade+Promotes+G1+Progression&doi=10.1016%2Fj.molcel.2013.04.003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression</span></div><div class="casAuthors">Schachter, Miriam Merzel; Merrick, Karl A.; Larochelle, Stephane; Hirschi, Alexander; Zhang, Chao; Shokat, Kevan M.; Rubin, Seth M.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cell</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">50</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">250-260</span>CODEN:
                <span class="NLM_cas:coden">MOCEFL</span>;
        ISSN:<span class="NLM_cas:issn">1097-2765</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Eukaryotic cell division is controlled by cyclin-dependent kinases (CDKs), which require phosphorylation by a CDK-activating kinase (CAK) for full activity.  Chem. genetics uncovered requirements for the metazoan CAK Cdk7 in detg. cyclin specificity and activation order of Cdk2 and Cdk1 during S and G2 phases.  It was unknown if Cdk7 also activates Cdk4 and Cdk6 to promote passage of the restriction (R) point, when continued cell-cycle progression becomes mitogen independent, or if CDK-activating phosphorylation regulates G1 progression.  Here we show that Cdk7 is a Cdk4- and Cdk6-activating kinase in human cells, required to maintain activity, not just to establish the active state, as is the case for Cdk1 and Cdk2.  Activating phosphorylation of Cdk7 rises concurrently with that of Cdk4 as cells exit quiescence and accelerates Cdk4 activation in vitro.  Therefore, mitogen signaling drives a CDK-activation cascade during G1 progression, and CAK might be rate-limiting for R point passage.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp5WwOfxdUtXbVg90H21EOLACvtfcHk0lhBiAgIjqKl8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXmvVWitb8%253D&md5=5a5f10c30bd6c9ff5d8e6bfb5c3c8b6e</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.molcel.2013.04.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.molcel.2013.04.003%26sid%3Dliteratum%253Aachs%26aulast%3DSchachter%26aufirst%3DM.%2BM.%26aulast%3DMerrick%26aufirst%3DK.%2BA.%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DHirschi%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DRubin%26aufirst%3DS.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DA%2520CDK7-CDK4%2520T-Loop%2520Phosphorylation%2520Cascade%2520Promotes%2520G1%2520Progression%26jtitle%3DMol.%2520Cell%26date%3D2013%26volume%3D50%26issue%3D2%26spage%3D250%26epage%3D260%26doi%3D10.1016%2Fj.molcel.2013.04.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">The CDK-Activating Kinase CDK7: Taking Yes for an Answer</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3239</span>– <span class="NLM_lpage">3240</span>, <span class="refDoi"> DOI: 10.4161/cc.26355</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.4161%2Fcc.26355" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=24036541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvVWhuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=3239-3240&issue=20&author=M.+M.+Schachterauthor=R.+P.+Fisher&title=The+CDK-Activating+Kinase+CDK7%3A+Taking+Yes+for+an+Answer&doi=10.4161%2Fcc.26355"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The CDK-activating kinase Cdk7: taking yes for an answer</span></div><div class="casAuthors">Schachter, Miriam Merzel; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3239-3240</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  This article discusses about role of human cyclin-dependent kinase 7 in cell division, proliferation and activation of Cdk1, Cdk2, Cdk4, Cdk6 and effect of Cdk7 inhibition on phosphorylation of G1, S phase and mitotic cyclin-dependent kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpaZHU-gaVkMLVg90H21EOLACvtfcHk0lhBiAgIjqKl8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvVWhuro%253D&md5=dad0ee8b9477ff235ab6feaeea1da85e</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.4161%2Fcc.26355&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.26355%26sid%3Dliteratum%253Aachs%26aulast%3DSchachter%26aufirst%3DM.%2BM.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DThe%2520CDK-Activating%2520Kinase%2520CDK7%253A%2520Taking%2520Yes%2520for%2520an%2520Answer%26jtitle%3DCell%2520Cycle%26date%3D2013%26volume%3D12%26issue%3D20%26spage%3D3239%26epage%3D3240%26doi%3D10.4161%2Fcc.26355" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ganuza, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sáiz-Ladera, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cañamero, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gómez, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schneider, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blasco, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pisano, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paramio, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santamaría, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbacid, M.</span></span> <span> </span><span class="NLM_article-title">Genetic Inactivation of CDK7 Leads to Cell Cycle Arrest and Induces Premature Aging Due to Adult Stem Cell Exhaustion</span>. <i>EMBO J.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>31</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2498</span>– <span class="NLM_lpage">2510</span>, <span class="refDoi"> DOI: 10.1038/emboj.2012.94</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Femboj.2012.94" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=22505032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=2498-2510&issue=11&author=M.+Ganuzaauthor=C.+S%C3%A1iz-Laderaauthor=M.+Ca%C3%B1ameroauthor=G.+G%C3%B3mezauthor=R.+Schneiderauthor=M.+A.+Blascoauthor=D.+Pisanoauthor=J.+M.+Paramioauthor=D.+Santamar%C3%ADaauthor=M.+Barbacid&title=Genetic+Inactivation+of+CDK7+Leads+to+Cell+Cycle+Arrest+and+Induces+Premature+Aging+Due+to+Adult+Stem+Cell+Exhaustion&doi=10.1038%2Femboj.2012.94"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Genetic inactivation of Cdk7 leads to cell cycle arrest and induces premature aging due to adult stem cell exhaustion</span></div><div class="casAuthors">Ganuza, Miguel; Saiz-Ladera, Cristina; Canamero, Marta; Gomez, Gonzalo; Schneider, Ralph; Blasco, Maria A.; Pisano, David; Paramio, Jesus M.; Santamaria, David; Barbacid, Mariano</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2498-2510</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase (Cdk)7, the catalytic subunit of the Cdk-activating kinase (CAK) complex has been implicated in the control of cell cycle progression and of RNA polymerase II (RNA pol II)-mediated transcription.  Genetic inactivation of the Cdk7 locus revealed that whereas Cdk7 is completely dispensable for global transcription, is essential for the cell cycle via phosphorylation of Cdk1 and Cdk2.  In vivo, Cdk7 is also indispensable for cell proliferation except during the initial stages of embryonic development.  Interestingly, widespread elimination of Cdk7 in adult tissues with low proliferative indexes had no phenotypic consequences.  However, ablation of conditional Cdk7 alleles in tissues with elevated cellular turnover led to the efficient repopulation of these tissues with Cdk7-expressing cells most likely derived from adult stem cells that may have escaped the inactivation of their targeted Cdk7 alleles.  This process, a physiol. attempt to maintain tissue homeostasis, led to the attrition of adult stem cell pools and to the appearance of age-related phenotypes, including telomere shortening and early death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmsIzd_tP1b7Vg90H21EOLACvtfcHk0lhBiAgIjqKl8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlsFWjsbk%253D&md5=c12ca2a3563a387e1edd95d443cd405b</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.94&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.94%26sid%3Dliteratum%253Aachs%26aulast%3DGanuza%26aufirst%3DM.%26aulast%3DS%25C3%25A1iz-Ladera%26aufirst%3DC.%26aulast%3DCa%25C3%25B1amero%26aufirst%3DM.%26aulast%3DG%25C3%25B3mez%26aufirst%3DG.%26aulast%3DSchneider%26aufirst%3DR.%26aulast%3DBlasco%26aufirst%3DM.%2BA.%26aulast%3DPisano%26aufirst%3DD.%26aulast%3DParamio%26aufirst%3DJ.%2BM.%26aulast%3DSantamar%25C3%25ADa%26aufirst%3DD.%26aulast%3DBarbacid%26aufirst%3DM.%26atitle%3DGenetic%2520Inactivation%2520of%2520CDK7%2520Leads%2520to%2520Cell%2520Cycle%2520Arrest%2520and%2520Induces%2520Premature%2520Aging%2520Due%2520to%2520Adult%2520Stem%2520Cell%2520Exhaustion%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D31%26issue%3D11%26spage%3D2498%26epage%3D2510%26doi%3D10.1038%2Femboj.2012.94" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fu, D.-R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Q.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, M.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xing, Z.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, M.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Inhibitor THZ2 Inhibits the Growth of Human Gastric Cancer in Vitro and in Vivo</span>. <i>Am. J. Transl. Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">3664</span>– <span class="NLM_lpage">3676</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30662617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFCmu7zK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2018&pages=3664-3676&issue=11&author=J.-R.+Huangauthor=W.-M.+Qinauthor=K.+Wangauthor=D.-R.+Fuauthor=W.-J.+Zhangauthor=Q.-W.+Jiangauthor=Y.+Yangauthor=M.-L.+Yuanauthor=Z.-H.+Xingauthor=M.-N.+Weiauthor=Y.+Liauthor=Z.+Shi&title=Cyclin-Dependent+Kinase+7+Inhibitor+THZ2+Inhibits+the+Growth+of+Human+Gastric+Cancer+in+Vitro+and+in+Vivo"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 inhibitor THZ2 inhibits the growth of human gastric cancer in vitro and in vivo</span></div><div class="casAuthors">Huang, Jia-Rong; Qin, Wu-Ming; Wang, Kun; Fu, Deng-Rui; Zhang, Wen-Ji; Jiang, Qi-Wei; Yang, Yang; Yuan, Meng-Ling; Xing, Zi-Hao; Wei, Meng-Ning; Li, Yao; Shi, Zhi</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Translational Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">3664-3676</span>CODEN:
                <span class="NLM_cas:coden">AJTRA7</span>;
        ISSN:<span class="NLM_cas:issn">1943-8141</span>.
    
            (<span class="NLM_cas:orgname">e-Century Publishing Corp.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) is a member of the CDK family, which forms the CDK activating kinase complex with Cyclin H and RING finger protein Mat1 to control cell cycle progression and transcription by phosphorylating other CDKs and RNA polymerase II.  In this study, we analyzed TCGA data and found that upregulation of CDK7 frequently occurred in human gastric cancer.  A potent and selective irreversible CDK7 inhibitor THZ2 was able to induce cell growth inhibition, cell cycle arrest at G2/M phase and apoptosis with the increasing intracellular reactive oxidative species (ROS) levels in gastric cancer cells.  Pretreatment with ROS scavenger N-acety-L-cysteine partially reversed cell apoptosis induced by THZ2.  In the nude mice, THZ2 also suppressed the growth of xenograft tumors of gastric cancer.  Overall, our data showed that inhibition of CDK7 with THZ2 in gastric cancer presented outstanding anticancer effect in vitro and in vivo, suggesting that CDK7 is a potential therapeutic target for gastric cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoIxSbm1DrtsrVg90H21EOLACvtfcHk0ljhVEJytU_tLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFCmu7zK&md5=b59e672e5665e3fc20fd0ad0577b634a</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DJ.-R.%26aulast%3DQin%26aufirst%3DW.-M.%26aulast%3DWang%26aufirst%3DK.%26aulast%3DFu%26aufirst%3DD.-R.%26aulast%3DZhang%26aufirst%3DW.-J.%26aulast%3DJiang%26aufirst%3DQ.-W.%26aulast%3DYang%26aufirst%3DY.%26aulast%3DYuan%26aufirst%3DM.-L.%26aulast%3DXing%26aufirst%3DZ.-H.%26aulast%3DWei%26aufirst%3DM.-N.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DZ.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Inhibitor%2520THZ2%2520Inhibits%2520the%2520Growth%2520of%2520Human%2520Gastric%2520Cancer%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DAm.%2520J.%2520Transl.%2520Res.%26date%3D2018%26volume%3D10%26issue%3D11%26spage%3D3664%26epage%3D3676" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Evers, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jin, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lieftink, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Beijersbergen, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bernards, R.</span></span> <span> </span><span class="NLM_article-title">A CRISPR Screen Identifies CDK7 as a Therapeutic Target in Hepatocellular Carcinoma</span>. <i>Cell Res.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>28</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">690</span>– <span class="NLM_lpage">692</span>, <span class="refDoi"> DOI: 10.1038/s41422-018-0020-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41422-018-0020-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29507396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXht1ektb7J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2018&pages=690-692&issue=6&author=C.+Wangauthor=H.+Jinauthor=D.+Gaoauthor=L.+Wangauthor=B.+Eversauthor=Z.+Xueauthor=G.+Jinauthor=C.+Lieftinkauthor=R.+L.+Beijersbergenauthor=W.+Qinauthor=R.+Bernards&title=A+CRISPR+Screen+Identifies+CDK7+as+a+Therapeutic+Target+in+Hepatocellular+Carcinoma&doi=10.1038%2Fs41422-018-0020-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma</span></div><div class="casAuthors">Wang, Cun; Jin, Haojie; Gao, Dongmei; Wang, Liqin; Evers, Bastiaan; Xue, Zheng; Jin, Guangzhi; Lieftink, Cor; Beijersbergen, Roderick L.; Qin, Wenxin; Bernards, Rene</div><div class="citationInfo"><span class="NLM_cas:title">Cell Research</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">690-692</span>CODEN:
                <span class="NLM_cas:coden">CREEB6</span>;
        ISSN:<span class="NLM_cas:issn">1001-0602</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Liver cancer is one of the most frequent malignancies and the second leading cause of cancer-related mortality worldwide.  We analyzed CDK7 expression using a tissue microarray (TMA) contg. 80 HCC specimens by immunochem. anal.  Kaplan- Meier anal. indicated that HCC patients with high expression of CDK7 exhibited worse overall survival as compared to patients with low expression of CDK7 (n = 80, P = 0.048, log-rank test, Fig. 1d).  We also analyzed the growth inhibitory effects of shCDK7 in five addnl. cell lines (SNU398, JHH1, SNU449, PLC/PRF/5 and MHCC97H).  We found that SNU398 and JHH1 are also very sensitive to CDK7 knockdown, whereas SNU449, PLC/PRF/5 and MHCC97H cells are resistant to CDK7 knockdown (Supplementary information, Figure S2a, b).  To test the sensitivity of HCC cells to THZ1, we treated the panel of 10 HCC cell lines with increasing concns. of THZ1 for about 2 wk in colony formation assays.  Together, our data indicate that there may be a subgroup of liver cancer cells with a profound dependence on CDK7 for survival and CDK7 may represent a novel therapeutic target in this subgroup.  MYC deregulation is a common event in liver cancer.  We analyzed the correlation between CDK7 and MYC mRNA levels in two clin. HCC cohorts (GSE14520 n = 225 and TCGA database n= 371).  As shown in Supplementary information, Figure S5, we obsd. a significant correlation between CDK7 and MYC mRNA expression in both GSE14520 (R = 0.274, P < 0.001) and TCGA database (R = 0.348, P < 0.001).  Our work now identifies CDK7 inhibition as vulnerability of HCC tumors having high MYC expression.  The recent start of a clin. study with a CDK7 inhibitor (NCT03134638) may enable clin. validation of this notion in the near future.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrvRikdDFXhbVg90H21EOLACvtfcHk0ljhVEJytU_tLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXht1ektb7J&md5=4b113b9a72ad206d52e91b176ffe4fc7</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1038%2Fs41422-018-0020-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41422-018-0020-z%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DC.%26aulast%3DJin%26aufirst%3DH.%26aulast%3DGao%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DEvers%26aufirst%3DB.%26aulast%3DXue%26aufirst%3DZ.%26aulast%3DJin%26aufirst%3DG.%26aulast%3DLieftink%26aufirst%3DC.%26aulast%3DBeijersbergen%26aufirst%3DR.%2BL.%26aulast%3DQin%26aufirst%3DW.%26aulast%3DBernards%26aufirst%3DR.%26atitle%3DA%2520CRISPR%2520Screen%2520Identifies%2520CDK7%2520as%2520a%2520Therapeutic%2520Target%2520in%2520Hepatocellular%2520Carcinoma%26jtitle%3DCell%2520Res.%26date%3D2018%26volume%3D28%26issue%3D6%26spage%3D690%26epage%3D692%26doi%3D10.1038%2Fs41422-018-0020-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">An, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Du, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK7 Increases the Stability of Snail to Promote the Dissemination of Colorectal Cancer</span>. <i>Cell Death Differ.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1442</span>– <span class="NLM_lpage">1452</span>, <span class="refDoi"> DOI: 10.1038/s41418-018-0222-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41418-018-0222-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30451989" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=1442-1452&issue=8&author=Y.+Zhouauthor=L.+Luauthor=G.+Jiangauthor=Z.+Chenauthor=J.+Liauthor=P.+Anauthor=L.+Chenauthor=J.+Duauthor=H.+Wang&title=Targeting+CDK7+Increases+the+Stability+of+Snail+to+Promote+the+Dissemination+of+Colorectal+Cancer&doi=10.1038%2Fs41418-018-0222-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting CDK7 increases the stability of Snail to promote the dissemination of colorectal cancer</span></div><div class="casAuthors">Zhou, Yan; Lu, Linlin; Jiang, Guanmin; Chen, Zhuojia; Li, Jiexin; An, Panpan; Chen, Likun; Du, Jun; Wang, Hongsheng</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Differentiation</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1442-1452</span>CODEN:
                <span class="NLM_cas:coden">CDDIEK</span>;
        ISSN:<span class="NLM_cas:issn">1350-9047</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Targeted inhibition of cyclin-dependent kinase 7 (CDK7) via its covalent inhibitor THZ1 can suppress the growth of various cancers, while its roles on colorectal cancer (CRC) remain obscure.  Here we report that the expression of CDK7 is upregulated in CRC cells and tissues.  THZ1 exhibits high potency and selectivity against CRC cells both in vitro and in vivo via induction of cell apoptosis rather than cell cycle disruption.  Intriguingly, THZ1 treatment increases the ability of epithelial mesenchymal transition (EMT) and in vivo metastasis to liver of CRC cells.  Mechanistical studies reveal that THZ1 increases the expression of Snail, while not other EMT-transcription factors, via enhancing its protein stability rather than mRNA expression or translation.  By screening Snail stability related factors via qRT-PCR, results indicate THZ1 and si-CDK7 decrease the expression of protein kinase D1 (PKD1) in CRC cells.  Down regulation of PKD1 mediates THZ1 up regulated Snail via dephosphorylation of Snail Ser 11 and prevention of proteasome mediated degrdn.  Clin. anal. confirms that CDK7 is significantly (p < 0.05) neg. correlated with the expression of mesenchymal markers including FN1, VIM, and MMP2.  CRC patients whose tumors expressing less CDK7/SNAI1 or PKD1/SNAI1 showed significant (p < 0.05) poorer overall survival (OS) rate as compared with those with greater levels.  Collectively, our data suggest that targeted inhibition of CDK7 can trigger the metastasis of CRC during cancer development via PKD1/Snail axis, which imposes great challenge that inhibition of CDK7 is a potential approach for cancer treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpy89Fkw4m-F7Vg90H21EOLACvtfcHk0ljhVEJytU_tLA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXitlegtrzJ&md5=6674d36ade83d70a05060d69632d3737</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1038%2Fs41418-018-0222-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41418-018-0222-4%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DL.%26aulast%3DJiang%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DAn%26aufirst%3DP.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DDu%26aufirst%3DJ.%26aulast%3DWang%26aufirst%3DH.%26atitle%3DTargeting%2520CDK7%2520Increases%2520the%2520Stability%2520of%2520Snail%2520to%2520Promote%2520the%2520Dissemination%2520of%2520Colorectal%2520Cancer%26jtitle%3DCell%2520Death%2520Differ.%26date%3D2019%26volume%3D26%26issue%3D8%26spage%3D1442%26epage%3D1452%26doi%3D10.1038%2Fs41418-018-0222-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xiao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shan, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span> <span> </span><span class="NLM_article-title">Upregulation of CDK7 in Gastric Cancer Cell Promotes Tumor Cell Proliferation and Predicts Poor Prognosis</span>. <i>Exp. Mol. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>100</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">514</span>– <span class="NLM_lpage">521</span>, <span class="refDoi"> DOI: 10.1016/j.yexmp.2016.05.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.yexmp.2016.05.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27155449" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XosVWisLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2016&pages=514-521&issue=3&author=Q.+Wangauthor=M.+Liauthor=X.+Zhangauthor=H.+Huangauthor=J.+Huangauthor=J.+Keauthor=H.+Dingauthor=J.+Xiaoauthor=X.+Shanauthor=Q.+Liuauthor=B.+Baoauthor=L.+Yang&title=Upregulation+of+CDK7+in+Gastric+Cancer+Cell+Promotes+Tumor+Cell+Proliferation+and+Predicts+Poor+Prognosis&doi=10.1016%2Fj.yexmp.2016.05.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Upregulation of CDK7 in gastric cancer cell promotes tumor cell proliferation and predicts poor prognosis</span></div><div class="casAuthors">Wang, Qiuhong; Li, Manhua; Zhang, Xunlei; Huang, Hua; Huang, Jianfei; Ke, Jing; Ding, Haifang; Xiao, Jinzhang; Shan, Xiaohang; Liu, Qingqing; Bao, Bojun; Yang, Lei</div><div class="citationInfo"><span class="NLM_cas:title">Experimental and Molecular Pathology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">514-521</span>CODEN:
                <span class="NLM_cas:coden">EXMPA6</span>;
        ISSN:<span class="NLM_cas:issn">0014-4800</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">CDK7 has been known as a component of CDK activating kinase (CAK) complex, the complex was composed of CDK7, Cyclin H and RING finger protein Mat1 that contribute to cell cycle progression by phosphorylating other CDKs.  In addn., the complex is also an essential component of general transcription factor TFIIH which controls transcription via activating RNA polymerase II by serines 5 and 7 phosphorylation of the carboxyl-terminal domain (CTD) of its largest subunit.  However, the role of CDK7 in the pathogenesis of gastric cancer has not been identified.  Our study showed that CDK7 was significantly upregulated and pos. correlated with tumor grade, infiltration depth, lymph node, Ki-67, and predicted poor prognosis in 173 gastric cancer specimens by immunohistochemistrical analyses.  Furthermore, in vitro results indicated that CDK7 promoted proliferation of gastric cancer cells by CCK8, clone formation analyses and flow cytometric analyses, while CDK7 knockdown led to decreased cell proliferation.  Our study will provide a theor. basis for the study of CDK7 in gastric cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq7kTib1JYcwrVg90H21EOLACvtfcHk0liBmpMM4LJuFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XosVWisLw%253D&md5=fca329fa2cd174bc1837bc32168e2e19</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1016%2Fj.yexmp.2016.05.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.yexmp.2016.05.001%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DM.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DH.%26aulast%3DHuang%26aufirst%3DJ.%26aulast%3DKe%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DH.%26aulast%3DXiao%26aufirst%3DJ.%26aulast%3DShan%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DL.%26atitle%3DUpregulation%2520of%2520CDK7%2520in%2520Gastric%2520Cancer%2520Cell%2520Promotes%2520Tumor%2520Cell%2520Proliferation%2520and%2520Predicts%2520Poor%2520Prognosis%26jtitle%3DExp.%2520Mol.%2520Pathol.%26date%3D2016%26volume%3D100%26issue%3D3%26spage%3D514%26epage%3D521%26doi%3D10.1016%2Fj.yexmp.2016.05.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Diao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span> <span> </span><span class="NLM_article-title">Overexpression of CDK7 Is Associated with Unfavourable Prognosis in Oral Squamous Cell Carcinoma</span>. <i>Pathology</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>51</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">74</span>– <span class="NLM_lpage">80</span>, <span class="refDoi"> DOI: 10.1016/j.pathol.2018.10.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.pathol.2018.10.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30473182" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1yls7rP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2019&pages=74-80&issue=1&author=L.+Jiangauthor=R.+Huangauthor=Y.+Wuauthor=P.+Diaoauthor=W.+Zhangauthor=J.+Liauthor=Z.+Liauthor=Y.+Wangauthor=J.+Chengauthor=J.+Yang&title=Overexpression+of+CDK7+Is+Associated+with+Unfavourable+Prognosis+in+Oral+Squamous+Cell+Carcinoma&doi=10.1016%2Fj.pathol.2018.10.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Overexpression of CDK7 is associated with unfavourable prognosis in oral squamous cell carcinoma</span></div><div class="casAuthors">Jiang, Lei; Huang, Rong; Wu, Yaping; Diao, Pengfei; Zhang, Wei; Li, Jin; Li, Zhongwu; Wang, Yanling; Cheng, Jie; Yang, Jianrong</div><div class="citationInfo"><span class="NLM_cas:title">Pathology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">74-80</span>CODEN:
                <span class="NLM_cas:coden">PTLGAX</span>;
        ISSN:<span class="NLM_cas:issn">0031-3025</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Increased expression of cyclin-dependent kinase 7 (CDK7), an ubiquitous kinase assocd. with cell cycle and transcription, contributes to human tumorigenesis and assocs. with patient's prognosis.  In the present study, we sought to investigate the expression pattern of CDK7 and its clinicopathol. significance in primary oral squamous cell carcinoma (OSCC).  The expression of CDK7 mRNA in OSCC was detd. by data mining and interrogation using the Oncomine database.  Its protein expression was measured by immunohistochem. in clin. samples from a retrospective cohort of 113 patients with primary OSCC which were treated at our institution from Jan. 2006 to Dec. 2016.  The potential assocns. between CDK7 abundance and multiple clinicopathol. parameters as well as patient's survival were assessed.  The 4-nitroquinoline 1-oxide (4NQO)-induced OSCC mouse model was developed to monitor CDK7 expression during cancer initiation and progression.  The bioinformatics analyses revealed higher CDK7 mRNA in OSCC samples compared to normal counterparts.  Our immunohistochem. staining data revealed significant aberrant overexpression of CDK7 in a large subset of OSCC.  Elevated CDK7 expression was found to be significantly assocd. with higher T-stage (p = 0.009) and reduced overall and disease-free survival (Log-rank test, p = 0.022, 0.010, resp.).  Both univariate and multivariate Cox regression anal. identified the expression status of CDK7 as an important independent prognostic factor for patient's survival.  Increased CDK7 expression was parallel with OSCC development in the 4NQO-induced animal model.  Our findings indicate that aberrant CDK7 overexpression assocs. with T-stage and reduced survival in OSCC, thus suggesting that it might play crit. roles underlying oral tumorigenesis and also serve as a novel biomarker with diagnostic and prognostic significance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrGDjIhULb497Vg90H21EOLACvtfcHk0liBmpMM4LJuFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1yls7rP&md5=2ce562a61569b6ff111c070d805d9b54</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1016%2Fj.pathol.2018.10.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pathol.2018.10.004%26sid%3Dliteratum%253Aachs%26aulast%3DJiang%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DDiao%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DJ.%26atitle%3DOverexpression%2520of%2520CDK7%2520Is%2520Associated%2520with%2520Unfavourable%2520Prognosis%2520in%2520Oral%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DPathology%26date%3D2019%26volume%3D51%26issue%3D1%26spage%3D74%26epage%3D80%26doi%3D10.1016%2Fj.pathol.2018.10.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abduljabbar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, C.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gemma, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steel, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Busonero, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jerjees, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Remenyi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gomm, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Magnani, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Győrffy, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuller-Pace, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shousha, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buluwela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rakha, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ellis, I. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor–Positive Breast Cancer</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>22</i></span> (<span class="NLM_issue">23</span>),  <span class="NLM_fpage">5929</span>– <span class="NLM_lpage">5938</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-15-1104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1078-0432.CCR-15-1104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27301701" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XitVegt7zP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2016&pages=5929-5938&issue=23&author=H.+Patelauthor=R.+Abduljabbarauthor=C.-F.+Laiauthor=M.+Periyasamyauthor=A.+Harrodauthor=C.+Gemmaauthor=J.+H.+Steelauthor=N.+Patelauthor=C.+Busoneroauthor=D.+Jerjeesauthor=J.+Remenyiauthor=S.+Smithauthor=J.+J.+Gommauthor=L.+Magnaniauthor=B.+Gy%C5%91rffyauthor=L.+J.+Jonesauthor=F.+Fuller-Paceauthor=S.+Shoushaauthor=L.+Buluwelaauthor=E.+A.+Rakhaauthor=I.+O.+Ellisauthor=R.+C.+Coombesauthor=S.+Ali&title=Expression+of+CDK7%2C+Cyclin+H%2C+and+MAT1+Is+Elevated+in+Breast+Cancer+and+Is+Prognostic+in+Estrogen+Receptor%E2%80%93Positive+Breast+Cancer&doi=10.1158%2F1078-0432.CCR-15-1104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Expression of CDK7, Cyclin H, and MAT1 Is Elevated in Breast Cancer and Is Prognostic in Estrogen Receptor-Positive Breast Cancer</span></div><div class="casAuthors">Patel, Hetal; Abduljabbar, Rezvan; Lai, Chun-Fui; Periyasamy, Manikandan; Harrod, Alison; Gemma, Carolina; Steel, Jennifer H.; Patel, Naina; Busonero, Claudia; Jerjees, Dena; Remenyi, Judit; Smith, Sally; Gomm, Jennifer J.; Magnani, Luca; Gyaorffy, Balazs; Jones, Louise J.; Fuller-Pace, Frances; Shousha, Sami; Buluwela, Laki; Rakha, Emad A.; Ellis, Ian O.; Coombes, R. Charles; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5929-5938</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: CDK-activating kinase (CAK) is required for the regulation of the cell cycle and is a trimeric complex consisting of cyclin-dependent kinase 7 (CDK7), Cyclin H, and the accessory protein, MAT1.  CDK7 also plays a crit. role in regulating transcription, primarily by phosphorylating RNA polymerase II, as well as transcription factors such as estrogen receptor-α (ER).  Deregulation of cell cycle and transcriptional control are general features of tumor cells, highlighting the potential for the use of CDK7 inhibitors as novel cancer therapeutics.  Exptl. Design: mRNA and protein expression of CDK7 and its essential cofactors cyclin H and MAT1 were evaluated in breast cancer samples to det. if their levels are altered in cancer.  Immunohistochem. staining of >900 breast cancers was used to det. the assocn. with clinicopathol. features and patient outcome.  Results: We show that expressions of CDK7, cyclin H, and MAT1 are all closely linked at the mRNA and protein level, and their expression is elevated in breast cancer compared with the normal breast tissue.  Intriguingly, CDK7 expression was inversely proportional to tumor grade and size, and outcome anal. showed an assocn. between CAK levels and better outcome.  Moreover, CDK7 expression was pos. assocd. with ER expression and in particular with phosphorylation of ER at serine 118, a site important for ER transcriptional activity.  Conclusions: Expressions of components of the CAK complex, CDK7, MAT1, and Cyclin H are elevated in breast cancer and correlate with ER.  Like ER, CDK7 expression is inversely proportional to poor prognostic factors and survival.  Clin Cancer Res; 22(23); 5929-38. 2016 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpH0KlK2HCGsrVg90H21EOLACvtfcHk0liBmpMM4LJuFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XitVegt7zP&md5=14eebdf0a0f46cc759def88fdcc3d74b</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-15-1104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-15-1104%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DAbduljabbar%26aufirst%3DR.%26aulast%3DLai%26aufirst%3DC.-F.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DHarrod%26aufirst%3DA.%26aulast%3DGemma%26aufirst%3DC.%26aulast%3DSteel%26aufirst%3DJ.%2BH.%26aulast%3DPatel%26aufirst%3DN.%26aulast%3DBusonero%26aufirst%3DC.%26aulast%3DJerjees%26aufirst%3DD.%26aulast%3DRemenyi%26aufirst%3DJ.%26aulast%3DSmith%26aufirst%3DS.%26aulast%3DGomm%26aufirst%3DJ.%2BJ.%26aulast%3DMagnani%26aufirst%3DL.%26aulast%3DGy%25C5%2591rffy%26aufirst%3DB.%26aulast%3DJones%26aufirst%3DL.%2BJ.%26aulast%3DFuller-Pace%26aufirst%3DF.%26aulast%3DShousha%26aufirst%3DS.%26aulast%3DBuluwela%26aufirst%3DL.%26aulast%3DRakha%26aufirst%3DE.%2BA.%26aulast%3DEllis%26aufirst%3DI.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DExpression%2520of%2520CDK7%252C%2520Cyclin%2520H%252C%2520and%2520MAT1%2520Is%2520Elevated%2520in%2520Breast%2520Cancer%2520and%2520Is%2520Prognostic%2520in%2520Estrogen%2520Receptor%25E2%2580%2593Positive%2520Breast%2520Cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2016%26volume%3D22%26issue%3D23%26spage%3D5929%26epage%3D5938%26doi%3D10.1158%2F1078-0432.CCR-15-1104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chonghaile, T. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Madden, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klinger, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, A. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walsh, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Hurley, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Udupi, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Joseph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tarrant, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Conroy, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaber, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chin, S. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bardwell, H. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Provenzano, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crown, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dubois, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Linn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jirstrom, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Caldas, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Connor, D. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gallagher, W. M.</span></span> <span> </span><span class="NLM_article-title">Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>77</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">3834</span>– <span class="NLM_lpage">3845</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-16-2546</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F0008-5472.CAN-16-2546" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28455421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=77&publication_year=2017&pages=3834-3845&issue=14&author=B.+Liauthor=T.+N.+Chonghaileauthor=Y.+Fanauthor=S.+F.+Maddenauthor=R.+Klingerauthor=A.+E.+O%E2%80%99Connorauthor=L.+Walshauthor=G.+O%E2%80%99Hurleyauthor=G.+M.+Udupiauthor=J.+Josephauthor=F.+Tarrantauthor=E.+Conroyauthor=A.+Gaberauthor=S.+F.+Chinauthor=H.+A.+Bardwellauthor=E.+Provenzanoauthor=J.+Crownauthor=T.+Duboisauthor=S.+Linnauthor=K.+Jirstromauthor=C.+Caldasauthor=D.+P.+O%E2%80%99Connorauthor=W.+M.+Gallagher&title=Therapeutic+Rationale+to+Target+Highly+Expressed+CDK7+Conferring+Poor+Outcomes+in+Triple-Negative+Breast+Cancer&doi=10.1158%2F0008-5472.CAN-16-2546"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Rationale to Target Highly Expressed CDK7 Conferring Poor Outcomes in Triple-Negative Breast Cancer</span></div><div class="casAuthors">Li, Bo; Ni Chonghaile, Triona; Fan, Yue; Madden, Stephen F.; Klinger, Rut; O'Connor, Aisling E.; Walsh, Louise; O'Hurley, Gillian; Mallya Udupi, Girish; Joseph, Jesuchristopher; Tarrant, Finbarr; Conroy, Emer; Gaber, Alexander; Chin, Suet-Feung; Bardwell, Helen A.; Provenzano, Elena; Crown, John; Dubois, Thierry; Linn, Sabine; Jirstrom, Karin; Caldas, Carlos; O'Connor, Darran P.; Gallagher, William M.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">77</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">3834-3845</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but there remains a lack of biomarkers and effective targeted therapies for this disease.  Here, we report evidence highlighting the cell-cycle-related kinase CDK7 as a driver and candidate therapeutic target in TNBC.  Using publicly available transcriptomic data from a collated set of TNBC patients (n = 383) and the METABRIC TNBC dataset (n = 217), we found CDK7 mRNA levels to be correlated with patient prognosis.  High CDK7 protein expression was assocd. with poor prognosis within the RATHER TNBC cohort (n = 109) and the METABRIC TNBC cohort (n = 203).  The highly specific CDK7 kinase inhibitors, BS-181 and THZ1, each downregulated CDK7-mediated phosphorylation of RNA polymerase II, indicative of transcriptional inhibition, with THZ1 exhibiting 500-fold greater potency than BS-181.  Mechanistic investigations revealed that the survival of MDA-MB-231 TNBC cells relied heavily on the BCL-2/BCL-XL signaling axes in cells.  Accordingly, we found that combining the BCL-2/BCL-XL inhibitors ABT-263/ABT199 with the CDK7 inhibitor THZ1 synergized in producing growth inhibition and apoptosis of human TNBC cells.  Collectively, our results highlight elevated CDK7 expression as a candidate biomarker of poor prognosis in TNBC, and they offer a preclin. proof of concept for combining CDK7 and BCL-2/BCL-XL inhibitors as a mechanism-based therapeutic strategy to improve TNBC treatment.  Cancer Res; 77(14); 3834-45. ©2017 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnxGf2Y8smdbVg90H21EOLACvtfcHk0lh_qSSWxEzJEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhtFKiurvE&md5=af2710f8621b18c53f616f27967b061a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-16-2546&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-16-2546%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.%26aulast%3DChonghaile%26aufirst%3DT.%2BN.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DMadden%26aufirst%3DS.%2BF.%26aulast%3DKlinger%26aufirst%3DR.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DA.%2BE.%26aulast%3DWalsh%26aufirst%3DL.%26aulast%3DO%25E2%2580%2599Hurley%26aufirst%3DG.%26aulast%3DUdupi%26aufirst%3DG.%2BM.%26aulast%3DJoseph%26aufirst%3DJ.%26aulast%3DTarrant%26aufirst%3DF.%26aulast%3DConroy%26aufirst%3DE.%26aulast%3DGaber%26aufirst%3DA.%26aulast%3DChin%26aufirst%3DS.%2BF.%26aulast%3DBardwell%26aufirst%3DH.%2BA.%26aulast%3DProvenzano%26aufirst%3DE.%26aulast%3DCrown%26aufirst%3DJ.%26aulast%3DDubois%26aufirst%3DT.%26aulast%3DLinn%26aufirst%3DS.%26aulast%3DJirstrom%26aufirst%3DK.%26aulast%3DCaldas%26aufirst%3DC.%26aulast%3DO%25E2%2580%2599Connor%26aufirst%3DD.%2BP.%26aulast%3DGallagher%26aufirst%3DW.%2BM.%26atitle%3DTherapeutic%2520Rationale%2520to%2520Target%2520Highly%2520Expressed%2520CDK7%2520Conferring%2520Poor%2520Outcomes%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DCancer%2520Res.%26date%3D2017%26volume%3D77%26issue%3D14%26spage%3D3834%26epage%3D3845%26doi%3D10.1158%2F0008-5472.CAN-16-2546" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuzugullu, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Von, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stover, D. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Z. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iglehart, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span> <span> </span><span class="NLM_article-title">CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>163</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">174</span>– <span class="NLM_lpage">186</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2015.08.063</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.cell.2015.08.063" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=26406377" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrjP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=163&publication_year=2015&pages=174-186&issue=1&author=Y.+Wangauthor=T.+Zhangauthor=N.+Kwiatkowskiauthor=B.+J.+Abrahamauthor=T.+I.+Leeauthor=S.+Xieauthor=H.+Yuzugulluauthor=T.+Vonauthor=H.+Liauthor=Z.+Linauthor=D.+G.+Stoverauthor=E.+Limauthor=Z.+C.+Wangauthor=J.+D.+Iglehartauthor=R.+A.+Youngauthor=N.+S.+Grayauthor=J.+J.+Zhao&title=CDK7-Dependent+Transcriptional+Addiction+in+Triple-Negative+Breast+Cancer&doi=10.1016%2Fj.cell.2015.08.063"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7-dependent transcriptional addiction in triple-negative breast cancer</span></div><div class="casAuthors">Wang, Yubao; Zhang, Tinghu; Kwiatkowski, Nicholas; Abraham, Brian J.; Lee, Tong Ihn; Xie, Shaozhen; Yuzugullu, Haluk; Von, Thanh; Li, Heyuan; Lin, Ziao; Stover, Daniel G.; Lim, Elgene; Wang, Zhigang C.; Iglehart, J. Dirk; Young, Richard A.; Gray, Nathanael S.; Zhao, Jean J.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">163</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">174-186</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Triple-neg. breast cancer (TNBC) is a highly aggressive form of breast cancer that exhibits extremely high levels of genetic complexity and yet a relatively uniform transcriptional program.  We postulate that TNBC might be highly dependent on uninterrupted transcription of a key set of genes within this gene expression program and might therefore be exceptionally sensitive to inhibitors of transcription.  Utilizing kinase inhibitors and CRISPR/Cas9-mediated gene editing, we show here that triple-neg. but not hormone receptor-pos. breast cancer cells are exceptionally dependent on CDK7, a transcriptional cyclin-dependent kinase.  TNBC cells are unique in their dependence on this transcriptional CDK and suffer apoptotic cell death upon CDK7 inhibition.  An "Achilles cluster" of TNBC-specific genes is esp. sensitive to CDK7 inhibition and frequently assocd. with super-enhancers.  We conclude that CDK7 mediates transcriptional addiction to a vital cluster of genes in TNBC and CDK7 inhibition may be a useful therapy for this challenging cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqEe3LZxVCwWLVg90H21EOLACvtfcHk0lh_qSSWxEzJEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKqtrjP&md5=34441125e931816d29e419f3f7dc0346</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2015.08.063&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2015.08.063%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DLee%26aufirst%3DT.%2BI.%26aulast%3DXie%26aufirst%3DS.%26aulast%3DYuzugullu%26aufirst%3DH.%26aulast%3DVon%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DH.%26aulast%3DLin%26aufirst%3DZ.%26aulast%3DStover%26aufirst%3DD.%2BG.%26aulast%3DLim%26aufirst%3DE.%26aulast%3DWang%26aufirst%3DZ.%2BC.%26aulast%3DIglehart%26aufirst%3DJ.%2BD.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26atitle%3DCDK7-Dependent%2520Transcriptional%2520Addiction%2520in%2520Triple-Negative%2520Breast%2520Cancer%26jtitle%3DCell%26date%3D2015%26volume%3D163%26issue%3D1%26spage%3D174%26epage%3D186%26doi%3D10.1016%2Fj.cell.2015.08.063" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kanin, E. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kipp, R. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slattery, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Viale, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hahn, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shokat, K. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ansari, A. Z.</span></span> <span> </span><span class="NLM_article-title">Chemical Inhibition of the TFIIH-Associated Kinase CDK7/Kin28 Does Not Impair Global mRNA Synthesis</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>104</i></span> (<span class="NLM_issue">14</span>),  <span class="NLM_fpage">5812</span>– <span class="NLM_lpage">5817</span>, <span class="refDoi"> DOI: 10.1073/pnas.0611505104</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1073%2Fpnas.0611505104" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=17392431" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2sXkt1Kgtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=104&publication_year=2007&pages=5812-5817&issue=14&author=E.+I.+Kaninauthor=R.+T.+Kippauthor=C.+Kungauthor=M.+Slatteryauthor=A.+Vialeauthor=S.+Hahnauthor=K.+M.+Shokatauthor=A.+Z.+Ansari&title=Chemical+Inhibition+of+the+TFIIH-Associated+Kinase+CDK7%2FKin28+Does+Not+Impair+Global+mRNA+Synthesis&doi=10.1073%2Fpnas.0611505104"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Chemical inhibition of TFIIH-associated kinase Cdk7/Kin28 does not impair global mRNA synthesis</span></div><div class="casAuthors">Kanin, Elenita I.; Kipp, Ryan T.; Kung, Charles; Slattery, Matthew; Viale, Agnes; Hahn, Steven; Shokat, Kevan M.; Ansari, Aseem Z.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">104</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">5812-5817</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">The process of gene transcription requires the recruitment of a hypophosphorylated form of RNA polymerase II (Pol II) to a gene promoter.  The TFIIH-assocd. kinase Cdk7/Kin28 hyperphosphorylates the promoter-bound polymerase; this event is thought to play a crucial role in transcription initiation and promoter clearance.  Studies using temp.-sensitive mutants of Kin28 have provided the most compelling evidence for an essential role of its kinase activity in global mRNA synthesis.  In contrast, using a small mol. inhibitor that specifically inhibits Kin28 in vivo, we find that the kinase activity is not essential for global transcription.  Unlike the temp.-sensitive alleles, the small-mol. inhibitor does not perturb protein-protein interactions nor does it provoke the disassocn. of TFIIH from gene promoters.  These results lead us to conclude that other functions of TFIIH, rather than the kinase activity, are crit. for global gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo-64JGuvGdl7Vg90H21EOLACvtfcHk0lgAkrkmsHf6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXkt1Kgtro%253D&md5=f6c870b29f092771809b9b5759d01072</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0611505104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0611505104%26sid%3Dliteratum%253Aachs%26aulast%3DKanin%26aufirst%3DE.%2BI.%26aulast%3DKipp%26aufirst%3DR.%2BT.%26aulast%3DKung%26aufirst%3DC.%26aulast%3DSlattery%26aufirst%3DM.%26aulast%3DViale%26aufirst%3DA.%26aulast%3DHahn%26aufirst%3DS.%26aulast%3DShokat%26aufirst%3DK.%2BM.%26aulast%3DAnsari%26aufirst%3DA.%2BZ.%26atitle%3DChemical%2520Inhibition%2520of%2520the%2520TFIIH-Associated%2520Kinase%2520CDK7%252FKin28%2520Does%2520Not%2520Impair%2520Global%2520mRNA%2520Synthesis%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2007%26volume%3D104%26issue%3D14%26spage%3D5812%26epage%3D5817%26doi%3D10.1073%2Fpnas.0611505104" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zuo, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span> <span> </span><span class="NLM_article-title">Recent Progress of Cyclin-Dependent Kinase Inhibitors as Potential Anticancer Agents</span>. <i>Future Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">2047</span>– <span class="NLM_lpage">2076</span>, <span class="refDoi"> DOI: 10.4155/fmc-2016-0129</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.4155%2Ffmc-2016-0129" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27774795" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XhslGisbnJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2016&pages=2047-2076&issue=17&author=T.+Liauthor=T.+Wengauthor=M.+Zuoauthor=Z.+Weiauthor=M.+Chenauthor=Z.+Li&title=Recent+Progress+of+Cyclin-Dependent+Kinase+Inhibitors+as+Potential+Anticancer+Agents&doi=10.4155%2Ffmc-2016-0129"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Recent progress of cyclin-dependent kinase inhibitors as potential anticancer agents</span></div><div class="casAuthors">Li, Tinghan; Weng, Tianwei; Zuo, Minzan; Wei, Zhihui; Chen, Ming; Li, Zhiyu</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2047-2076</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">Deregulation of the cell cycle is a common feature in human cancer.  The inhibition of cyclin-dependent kinases (CDKs), which play a crucial role in control of the cell cycle, has always been one of the most promising areas in cancer chemotherapy.  This review first summarizes the biol. of CDKs and then focuses on the recent advances in both broad-range and selective CDK inhibitors during the last 5 years.  The design rationale, structural optimization and structure-activity relationships anal. of these small mols. have been discussed in detail and the key interactions with the amino-acid residues of the most important compds. are highlighted.  Future perspectives for CDKs inhibitors will be defined in the development of highly selective CDK inhibitors, an accurate knowledge of gene control mechanism and further predictive biomarker research.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKW1A5UEVYeLVg90H21EOLACvtfcHk0lgAkrkmsHf6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhslGisbnJ&md5=90331b2b80a383eaee6483a6e6e6e1e6</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.4155%2Ffmc-2016-0129&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc-2016-0129%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWeng%26aufirst%3DT.%26aulast%3DZuo%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DChen%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DZ.%26atitle%3DRecent%2520Progress%2520of%2520Cyclin-Dependent%2520Kinase%2520Inhibitors%2520as%2520Potential%2520Anticancer%2520Agents%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2016%26volume%3D8%26issue%3D17%26spage%3D2047%26epage%3D2076%26doi%3D10.4155%2Ffmc-2016-0129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Asghar, U.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Witkiewicz, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Turner, N. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knudsen, E. S.</span></span> <span> </span><span class="NLM_article-title">The History and Future of Targeting Cyclin-Dependent Kinases in Cancer Therapy</span>. <i>Nat. Rev. Drug Discovery</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>14</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">130</span>– <span class="NLM_lpage">146</span>, <span class="refDoi"> DOI: 10.1038/nrd4504</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnrd4504" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25633797" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2015&pages=130-146&issue=2&author=U.+Asgharauthor=A.+K.+Witkiewiczauthor=N.+C.+Turnerauthor=E.+S.+Knudsen&title=The+History+and+Future+of+Targeting+Cyclin-Dependent+Kinases+in+Cancer+Therapy&doi=10.1038%2Fnrd4504"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">The history and future of targeting cyclin-dependent kinases in cancer therapy</span></div><div class="casAuthors">Asghar, Uzma; Witkiewicz, Agnieszka K.; Turner, Nicholas C.; Knudsen, Erik S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">130-146</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Cancer represents a pathol. manifestation of uncontrolled cell division; therefore, it has long been anticipated that our understanding of the basic principles of cell cycle control would result in effective cancer therapies.  In particular, cyclin-dependent kinases (CDKs) that promote transition through the cell cycle were expected to be key therapeutic targets because many tumorigenic events ultimately drive proliferation by impinging on CDK4 or CDK6 complexes in the G1 phase of the cell cycle.  Moreover, perturbations in chromosomal stability and aspects of S phase and G2/M control mediated by CDK2 and CDK1 are pivotal tumorigenic events.  Translating this knowledge into successful clin. development of CDK inhibitors has historically been challenging, and numerous CDK inhibitors have demonstrated disappointing results in clin. trials.  Here, we review the biol. of CDKs, the rationale for therapeutically targeting discrete kinase complexes and historical clin. results of CDK inhibitors.  We also discuss how CDK inhibitors with high selectivity (particularly for both CDK4 and CDK6), in combination with patient stratification, have resulted in more substantial clin. activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqJ_utd-yiEZLVg90H21EOLACvtfcHk0lgAkrkmsHf6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXjvVCrtLc%253D&md5=113bcd2e99a8267119d180670d3c7761</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1038%2Fnrd4504&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd4504%26sid%3Dliteratum%253Aachs%26aulast%3DAsghar%26aufirst%3DU.%26aulast%3DWitkiewicz%26aufirst%3DA.%2BK.%26aulast%3DTurner%26aufirst%3DN.%2BC.%26aulast%3DKnudsen%26aufirst%3DE.%2BS.%26atitle%3DThe%2520History%2520and%2520Future%2520of%2520Targeting%2520Cyclin-Dependent%2520Kinases%2520in%2520Cancer%2520Therapy%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2015%26volume%3D14%26issue%3D2%26spage%3D130%26epage%3D146%26doi%3D10.1038%2Fnrd4504" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sánchez-Martínez, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lallena, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanfeliciano, S. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Dios, A.</span></span> <span> </span><span class="NLM_article-title">Cyclin Dependent Kinase (CDK) Inhibitors as Anticancer Drugs: Recent Advances (2015–2019)</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>29</i></span>,  <span class="NLM_fpage">126637</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2019.126637</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.bmcl.2019.126637" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31477350" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2019&pages=126637&author=C.+S%C3%A1nchez-Mart%C3%ADnezauthor=M.+J.+Lallenaauthor=S.+G.+Sanfelicianoauthor=A.+de+Dios&title=Cyclin+Dependent+Kinase+%28CDK%29+Inhibitors+as+Anticancer+Drugs%3A+Recent+Advances+%282015%E2%80%932019%29&doi=10.1016%2Fj.bmcl.2019.126637"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin dependent kinase (CDK) inhibitors as anticancer drugs: Recent advances (2015-2019)</span></div><div class="casAuthors">Sanchez-Martinez, Concepcion; Lallena, Maria Jose; Sanfeliciano, Sonia Gutierrez; de Dios, Alfonso</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">126637</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Sustained proliferative capacity and gene dysregulation are hallmarks of cancer.  In mammalian cells, cyclin-dependent kinases (CDKs) control crit. cell cycle checkpoints and key transcriptional events in response to extracellular and intracellular signals leading to proliferation.  Significant clin. activity for the treatment of hormone receptor pos. metastatic breast cancer has been demonstrated by palbociclib, ribociclib and abemaciclib, dual CDK4/6 inhibitors recently FDA-approved.  SY-1365, a CDK7 inhibitor has shown initial encouraging data in phase I for solid tumors treatment.  These results have rejuvenated the CDKs research field.  This review provides an overview of relevant advances on CDK inhibitor research since 2015 to 2019, with special emphasis on transcriptional CDK inhibitors, new emerging strategies such as target protein degrdn. and compds. under clin. evaluation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcZ4sKIv0DfrVg90H21EOLACvtfcHk0lgAkrkmsHf6rQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslWjs73N&md5=2808e04d5c09daad462133bcf9b9cb3d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2019.126637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2019.126637%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A1nchez-Mart%25C3%25ADnez%26aufirst%3DC.%26aulast%3DLallena%26aufirst%3DM.%2BJ.%26aulast%3DSanfeliciano%26aufirst%3DS.%2BG.%26aulast%3Dde%2BDios%26aufirst%3DA.%26atitle%3DCyclin%2520Dependent%2520Kinase%2520%2528CDK%2529%2520Inhibitors%2520as%2520Anticancer%2520Drugs%253A%2520Recent%2520Advances%2520%25282015%25E2%2580%25932019%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2019%26volume%3D29%26spage%3D126637%26doi%3D10.1016%2Fj.bmcl.2019.126637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Teng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingarra, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Galons, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oumata, N.</span></span> <span> </span><span class="NLM_article-title">Recent Advances in the Development of Cyclin-Dependent Kinase 7 Inhibitors</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>183</i></span>,  <span class="NLM_fpage">111641</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2019.111641</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.ejmech.2019.111641" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31514062" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhslGmsrrP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=183&publication_year=2019&pages=111641&author=Y.+Tengauthor=K.+Luauthor=Q.+Zhangauthor=L.+Zhaoauthor=Y.+Huangauthor=A.+M.+Ingarraauthor=H.+Galonsauthor=T.+Liauthor=S.+Cuiauthor=P.+Yuauthor=N.+Oumata&title=Recent+Advances+in+the+Development+of+Cyclin-Dependent+Kinase+7+Inhibitors&doi=10.1016%2Fj.ejmech.2019.111641"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">Recent advances in the development of cyclin-dependent kinase 7 inhibitors</span></div><div class="casAuthors">Teng, Yuou; Lu, Kui; Zhang, Qian; Zhao, Lianbo; Huang, Yuna; Ingarra, Angela Maria; Galons, Herve; Li, Tingshen; Cui, Shanshan; Yu, Peng; Oumata, Nassima</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">183</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">111641</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A review.  Cyclin dependent kinase 7 (CDK7) plays a double role as it activates several other cyclin dependent kinases and participates to the initiation of transcription.  This kinase is overexpressed in various types of tumors.  Relatively few selective CDK7 inhibitors have been up to now disclosed.  Most of these inhibitors belong to two chem. families: pyrazolopyrimidines and pyrazolotriazines on one side and pyrimidines on another side.  They also differ by their mol. mechanism of action.  Some are acting as competitive inhibitors and some others are covalent inhibitors.  With these tools, the understanding of the potential therapeutic interest of CDK7 inhibitors in cancer is rapidly growing.  They display antiproliferative activity against various types of tumors and leukemia and synergies have been identified.  Two inhibitors are undergoing clin. testing.  The most potent compds. inhibit a large no. of cell-lines with IC50 < 200 nM.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqvrYOLV98iBLVg90H21EOLACvtfcHk0ljNaLsQH5qPIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhslGmsrrP&md5=b9610495cc6fb3e1aafc621cb18fe292</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2019.111641&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2019.111641%26sid%3Dliteratum%253Aachs%26aulast%3DTeng%26aufirst%3DY.%26aulast%3DLu%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DZhao%26aufirst%3DL.%26aulast%3DHuang%26aufirst%3DY.%26aulast%3DIngarra%26aufirst%3DA.%2BM.%26aulast%3DGalons%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DCui%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DOumata%26aufirst%3DN.%26atitle%3DRecent%2520Advances%2520in%2520the%2520Development%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520Inhibitors%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2019%26volume%3D183%26spage%3D111641%26doi%3D10.1016%2Fj.ejmech.2019.111641" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lowe, E. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johnson, L. N.</span></span> <span> </span><span class="NLM_article-title">The Crystal Structure of Human CDK7 and its Protein Recognition Properties</span>. <i>Structure</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">2067</span>– <span class="NLM_lpage">2079</span>, <span class="refDoi"> DOI: 10.1016/j.str.2004.08.013</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.str.2004.08.013" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=15530371" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD2cXpsVOrs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2004&pages=2067-2079&issue=11&author=G.+Lolliauthor=E.+D.+Loweauthor=N.+R.+Brownauthor=L.+N.+Johnson&title=The+Crystal+Structure+of+Human+CDK7+and+its+Protein+Recognition+Properties&doi=10.1016%2Fj.str.2004.08.013"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">The Crystal Structure of Human CDK7 and Its Protein Recognition Properties</span></div><div class="casAuthors">Lolli, Graziano; Lowe, Edward D.; Brown, Nick R.; Johnson, Louise N.</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2067-2079</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">CDK7, a member of the cyclin-dependent protein kinase family, regulates the activities of other CDKs through phosphorylation on their activation segment and hence contributes to control of the eukaryotic cell cycle.  CDK7 also assists in the regulation of transcription as part of the transcription factor TFIIH complex.  For max. activity and stability, CDK7 requires phosphorylation, assocn. with cyclin H, and assocn. with a third protein, MAT1.  We have detd. the crystal structure of human CDK7 in complex with ATP at 3Å resoln.  The kinase is in the inactive conformation, similar to that obsd. for inactive CDK2.  The activation segment is phosphorylated at Thr170 and is in a defined conformation that differs from that in phospho-CDK2 and phospho-CDK2/cyclin A.  The functional properties of the enzyme against CDK2 and CTD as substrates are characterized through kinase assays.  Expts. confirm that CDK7 is not a substrate for kinase-assocd. phosphatase.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCpKkVuAvQ7LVg90H21EOLACvtfcHk0ljNaLsQH5qPIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXpsVOrs7Y%253D&md5=b090d554993e8968c64d28fabaf6a507</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2004.08.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2004.08.013%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DG.%26aulast%3DLowe%26aufirst%3DE.%2BD.%26aulast%3DBrown%26aufirst%3DN.%2BR.%26aulast%3DJohnson%26aufirst%3DL.%2BN.%26atitle%3DThe%2520Crystal%2520Structure%2520of%2520Human%2520CDK7%2520and%2520its%2520Protein%2520Recognition%2520Properties%26jtitle%3DStructure%26date%3D2004%26volume%3D12%26issue%3D11%26spage%3D2067%26epage%3D2079%26doi%3D10.1016%2Fj.str.2004.08.013" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lolli, G.</span></span> <span> </span><span class="NLM_article-title">Structural Dissection of Cyclin Dependent Kinases Regulation and Protein Recognition Properties</span>. <i>Cell Cycle</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1551</span>– <span class="NLM_lpage">1561</span>, <span class="refDoi"> DOI: 10.4161/cc.9.8.11195</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.4161%2Fcc.9.8.11195" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=20372077" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1551-1561&issue=8&author=G.+Lolli&title=Structural+Dissection+of+Cyclin+Dependent+Kinases+Regulation+and+Protein+Recognition+Properties&doi=10.4161%2Fcc.9.8.11195"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Structural dissection of cyclin dependent kinases regulation and protein recognition properties</span></div><div class="casAuthors">Lolli, Graziano</div><div class="citationInfo"><span class="NLM_cas:title">Cell Cycle</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1551-1561</span>CODEN:
                <span class="NLM_cas:coden">CCEYAS</span>;
        ISSN:<span class="NLM_cas:issn">1538-4101</span>.
    
            (<span class="NLM_cas:orgname">Landes Bioscience</span>)
        </div><div class="casAbstract">A review.  Cyclin Dependent Kinases (CDKs) regulate the cell division cycle, apoptosis, transcription and differentiation in addn. to functions in the nervous system.  They are regulated by their cyclin partners and by a variety of addnl. protein effectors (inhibitors, kinases, phosphatases).  Each CDK serves its function by means of specific protein recognition properties.  These are also responsible for the differential regulation of CDKs/Cyclin couples involved in processes as different as cell cycle and transcription.  The structural features detg. general and specific properties for CDKs/Cyclin complexes are analyzed.  They reside in an overall conserved architecture with divergent spots used by the complexes to present themselves to specific substrates or other protein effectors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq28MAQ6SOxDLVg90H21EOLACvtfcHk0ljNaLsQH5qPIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXht12qsL%252FP&md5=34d193f3e930ba5043f152a252063f36</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.4161%2Fcc.9.8.11195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4161%252Fcc.9.8.11195%26sid%3Dliteratum%253Aachs%26aulast%3DLolli%26aufirst%3DG.%26atitle%3DStructural%2520Dissection%2520of%2520Cyclin%2520Dependent%2520Kinases%2520Regulation%2520and%2520Protein%2520Recognition%2520Properties%26jtitle%3DCell%2520Cycle%26date%3D2010%26volume%3D9%26issue%3D8%26spage%3D1551%26epage%3D1561%26doi%3D10.4161%2Fcc.9.8.11195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wood, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span> <span> </span><span class="NLM_article-title">Structural Insights into the Functional Diversity of the CDK–Cyclin Family</span>. <i>Open Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">180112</span>, <span class="refDoi"> DOI: 10.1098/rsob.180112</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1098%2Frsob.180112" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30185601" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXjvVajsrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=180112&issue=9&author=D.+J.+Woodauthor=J.+A.+Endicott&title=Structural+Insights+into+the+Functional+Diversity+of+the+CDK%E2%80%93Cyclin+Family&doi=10.1098%2Frsob.180112"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Structural insights into the functional diversity of the CDK - cyclin family</span></div><div class="casAuthors">Wood, Daniel J.; Endicott, Jane A.</div><div class="citationInfo"><span class="NLM_cas:title">Open Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">180112/1-180112/26</span>CODEN:
                <span class="NLM_cas:coden">OBPICQ</span>;
        ISSN:<span class="NLM_cas:issn">2046-2441</span>.
    
            (<span class="NLM_cas:orgname">Royal Society</span>)
        </div><div class="casAbstract">A review.  Since their characterization as conserved modules that regulate progression through the eukaryotic cell cycle, cyclin-dependent protein kinases (CDKs) in higher eukaryotic cells are now also emerging as significant regulators of transcription, metab. and cell differentiation.  The cyclins, though originally characterized as CDK partners, also have CDK-independent roles that include the regulation of DNA damage repair and transcriptional programs that direct cell differentiation, apoptosis and metabolic flux.  This review compares the structures of the members of the CDK and cyclin families detd. by X-ray crystallog., and considers what mechanistic insights they provide to guide functional studies and distinguish CDK- and cyclin-specific activities.  Aberrant CDK activity is a hallmark of a no. of diseases, and structural studies can provide important insights to identify novel routes to therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrOkS3eVCOYErVg90H21EOLACvtfcHk0ljYCMbIFqhmSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXjvVajsrc%253D&md5=f3ae7b31eb93ebe607a68f46b1a7bf58</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1098%2Frsob.180112&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1098%252Frsob.180112%26sid%3Dliteratum%253Aachs%26aulast%3DWood%26aufirst%3DD.%2BJ.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26atitle%3DStructural%2520Insights%2520into%2520the%2520Functional%2520Diversity%2520of%2520the%2520CDK%25E2%2580%2593Cyclin%2520Family%26jtitle%3DOpen%2520Biol.%26date%3D2018%26volume%3D8%26issue%3D9%26spage%3D180112%26doi%3D10.1098%2Frsob.180112" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolhurst, R. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span> <span> </span><span class="NLM_article-title">The Development of a Selective Cyclin-Dependent Kinase Inhibitor that Shows Antitumor Activity</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>69</i></span> (<span class="NLM_issue">15</span>),  <span class="NLM_fpage">6208</span>– <span class="NLM_lpage">6215</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-0301</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F0008-5472.CAN-09-0301" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=19638587" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BD1MXpt1Cgtbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6208-6215&issue=15&author=S.+Aliauthor=D.+A.+Heathcoteauthor=S.+H.+Krollauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=H.+Patelauthor=J.+Brackowauthor=A.+Siwickaauthor=M.+J.+Fuchterauthor=M.+Periyasamyauthor=R.+S.+Tolhurstauthor=S.+K.+Kannegantiauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=E.+O.+Aboagyeauthor=A.+G.+Barrettauthor=R.+C.+Coombes&title=The+Development+of+a+Selective+Cyclin-Dependent+Kinase+Inhibitor+that+Shows+Antitumor+Activity&doi=10.1158%2F0008-5472.CAN-09-0301"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity</span></div><div class="casAuthors">Ali, Simak; Heathcote, Dean A.; Kroll, Sebastian H. B.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Patel, Hetal; Brackow, Jan; Siwicka, Alekasandra; Fuchter, Matthew J.; Periyasamy, Manikandan; Tolhurst, Robert S.; Kanneganti, Seshu K.; Snyder, James P.; Liotta, Dennis C.; Aboagye, Eric O.; Barrett, Anthony G. M.; Coombes, R. Charles</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">6208-6215</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Normal progression through the cell cycle requires the sequential action of cyclin-dependent kinases CDK1, CDK2, CDK4, and CDK6.  Direct or indirect deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents.  The CDK-activating kinase (CAK) plays a crit. role in regulating cell cycle by mediating the activating phosphorylation of CDK1, CDK2, CDK4, and CDK6.  As such, CDK7, which also regulates transcription as part of the TFIIH basal transcription factor, is an attractive target for the development of anticancer drugs.  Computer modeling of the CDK7 structure was used to design potential potent CDK7 inhibitors.  Here, we show that a pyrazolo[1,5-a]pyrimidine-derived compd., BS-181, inhibited CAK activity with an IC50 of 21 nmol/L.  Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concns. lower than 1 μmol/L, with CDK2 being inhibited 35-fold less potently (IC50 880 nmol/L) than CDK7.  In MCF-7 cells, BS-181 inhibited the phosphorylation of CDK7 substrates, promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines, and showed antitumor effects in vivo.  The drug was stable in vivo with a plasma elimination half-life in mice of 405 min after i.p. administration of 10 mg/kg.  The same dose of drug inhibited the growth of MCF-7 human xenografts in nude mice.  BS-181 therefore provides the first example of a potent and selective CDK7 inhibitor with potential as an anticancer agent.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqID6wwGAnx6LVg90H21EOLACvtfcHk0ljYCMbIFqhmSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXpt1Cgtbs%253D&md5=9a6fa4d9871a203ee3ba27fd971ceb98</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-0301&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-0301%26sid%3Dliteratum%253Aachs%26aulast%3DAli%26aufirst%3DS.%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DTolhurst%26aufirst%3DR.%2BS.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26atitle%3DThe%2520Development%2520of%2520a%2520Selective%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%2520that%2520Shows%2520Antitumor%2520Activity%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26issue%3D15%26spage%3D6208%26epage%3D6215%26doi%3D10.1158%2F0008-5472.CAN-09-0301" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span>; <span class="NLM_string-name">Kroll, S.</span>; <span class="NLM_string-name">Barrett, A.</span>; <span class="NLM_string-name">Fuchter, M.</span>; <span class="NLM_string-name">Slafer, B.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, C.</span>; <span class="NLM_string-name">Snyder, J. P.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>]pyrimidine-5,7-diamine Compounds as CDK Inhibitors and their Therapeutic Use</span>. <span class="NLM_patent">US20160362410A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=A.+Bondke&author=S.+Kroll&author=A.+Barrett&author=M.+Fuchter&author=B.+Slafer&author=S.+Ali&author=C.+Coombes&author=J.+P.+Snyder&title=Pyrazolo%5B1%2C5-a%5Dpyrimidine-5%2C7-diamine+Compounds+as+CDK+Inhibitors+and+their+Therapeutic+Use"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DBondke%26aufirst%3DA.%26atitle%3DPyrazolo%255B1%252C5-a%255Dpyrimidine-5%252C7-diamine%2520Compounds%2520as%2520CDK%2520Inhibitors%2520and%2520their%2520Therapeutic%2520Use%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Slafer, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Starkey, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ottaviani, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harrod, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buluwela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment</span>. <i>Mol. Cancer Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>17</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">1156</span>– <span class="NLM_lpage">1166</span>, <span class="refDoi"> DOI: 10.1158/1535-7163.MCT-16-0847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1535-7163.MCT-16-0847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29545334" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2018&pages=1156-1166&issue=6&author=H.+Patelauthor=M.+Periyasamyauthor=G.+P.+Savaauthor=A.+Bondkeauthor=B.+W.+Slaferauthor=S.+H.+Krollauthor=M.+Barbazangesauthor=R.+Starkeyauthor=S.+Ottavianiauthor=A.+Harrodauthor=E.+O.+Aboagyeauthor=L.+Buluwelaauthor=M.+J.+Fuchterauthor=A.+G.+M.+Barrettauthor=R.+C.+Coombesauthor=S.+Ali&title=ICEC0942%2C+an+Orally+Bioavailable+Selective+Inhibitor+of+CDK7+for+Cancer+Treatment&doi=10.1158%2F1535-7163.MCT-16-0847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment</span></div><div class="casAuthors">Patel, Hetal; Periyasamy, Manikandan; Sava, Georgina P.; Bondke, Alexander; Slafer, Brian W.; Kroll, Sebastian H. B.; Barbazanges, Marion; Starkey, Richard; Ottaviani, Silvia; Harrod, Alison; Aboagye, Eric O.; Buluwela, Laki; Fuchter, Matthew J.; Barrett, Anthony G. M.; Coombes, R. Charles; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1156-1166</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Recent reports indicate that some cancer types are esp. sensitive to transcription inhibition, suggesting that targeting the transcriptional machinery provides new approaches to cancer treatment.  Cyclin-dependent kinase (CDK)7 is necessary for transcription, and acts by phosphorylating the C-terminal domain (CTD) of RNA polymerase II (PolII) to enable transcription initiation.  CDK7 addnl. regulates the activities of a no. of transcription factors, including estrogen receptor (ER)-α.  Here we describe a new, orally bioavailable CDK7 inhibitor, ICEC0942.  It selectively inhibits CDK7, with an IC50 of 40 nmol/L; IC50 values for CDK1, CDK2, CDK5, and CDK9 were 45-, 15-, 230-, and 30-fold higher.  In vitro studies show that a wide range of cancer types are sensitive to CDK7 inhibition with GI50 values ranging between 0.2 and 0.3 μmol/L.  In xenografts of both breast and colorectal cancers, the drug has substantial antitumor effects.  In addn., combination therapy with tamoxifen showed complete growth arrest of ER-pos. tumor xenografts.  Our findings reveal that CDK7 inhibition provides a new approach, esp. for ER-pos. breast cancer and identify ICEC0942 as a prototype drug with potential utility as a single agent or in combination with hormone therapies for breast cancer.  ICEC0942 may also be effective in other cancers that display characteristics of transcription factor addiction, such as acute leukemia and small-cell lung cancer.  Mol Cancer Ther; 17(6); 1156-66. ©2018 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq5aOnz0_JSSbVg90H21EOLACvtfcHk0ljYCMbIFqhmSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtVKjsL3M&md5=097bb6632e5c57b5e0a128385b319d7d</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-16-0847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-16-0847%26sid%3Dliteratum%253Aachs%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DSava%26aufirst%3DG.%2BP.%26aulast%3DBondke%26aufirst%3DA.%26aulast%3DSlafer%26aufirst%3DB.%2BW.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DStarkey%26aufirst%3DR.%26aulast%3DOttaviani%26aufirst%3DS.%26aulast%3DHarrod%26aufirst%3DA.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DBuluwela%26aufirst%3DL.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%2BM.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DICEC0942%252C%2520an%2520Orally%2520Bioavailable%2520Selective%2520Inhibitor%2520of%2520CDK7%2520for%2520Cancer%2520Treatment%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2018%26volume%3D17%26issue%3D6%26spage%3D1156%26epage%3D1166%26doi%3D10.1158%2F1535-7163.MCT-16-0847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kelso, T. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumgart, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Albert, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Antrecht, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lemcke, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meisterernst, M.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Controls mRNA Synthesis by Affecting Stability of Preinitiation Complexes, Leading to Altered Gene Expression, Cell Cycle Progression, and Survival of Tumor Cells</span>. <i>Mol. Cell. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>34</i></span> (<span class="NLM_issue">19</span>),  <span class="NLM_fpage">3675</span>– <span class="NLM_lpage">3688</span>, <span class="refDoi"> DOI: 10.1128/MCB.00595-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FMCB.00595-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25047832" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhs12jsL%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2014&pages=3675-3688&issue=19&author=T.+W.+Kelsoauthor=K.+Baumgartauthor=J.+Eickhoffauthor=T.+Albertauthor=C.+Antrechtauthor=S.+Lemckeauthor=B.+Kleblauthor=M.+Meisterernst&title=Cyclin-Dependent+Kinase+7+Controls+mRNA+Synthesis+by+Affecting+Stability+of+Preinitiation+Complexes%2C+Leading+to+Altered+Gene+Expression%2C+Cell+Cycle+Progression%2C+and+Survival+of+Tumor+Cells&doi=10.1128%2FMCB.00595-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 controls mRNA synthesis by affecting stability of preinitiation complexes, leading to altered gene expression, cell cycle progression and survival of tumor cells</span></div><div class="casAuthors">Kelso, Timothy W. R.; Baumgart, Karen; Eickhoff, Jan; Albert, Thomas; Antrecht, Claudia; Lemcke, Sarah; Klebl, Bert; Meisterernst, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">3675-3688, 15 pp.</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">1098-5549</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) activates cell cycle CDKs and is a member of the general transcription factor TFIIH.  Although there is substantial evidence for an active role of CDK7 in mRNA synthesis and assocd. processes, the degree of its influence on global and gene-specific transcription in mammalian species is unclear.  In the current study, we utilize two novel inhibitors with high specificity for CDK7 to demonstrate a restricted but robust impact of CDK7 on gene transcription in vivo and in in vitro-reconstituted reactions.  We distinguish between relative low- and high-dose responses and relate them to distinct mol. mechanisms and altered physiol. responses.  Low inhibitor doses cause rapid clearance of paused RNA polymerase II (RNAPII) mols. and sufficed to cause genome-wide alterations in gene expression, delays in cell cycle progression at both the G1/S and G2/M checkpoints and diminished survival of human tumor cells.  Higher doses and prolonged inhibition led to strong redns. in RNAPII carboxyl-terminal domain (CTD) phosphorylation, eventual activation of the p53 program and increased cell death.  Together, our data reason for a quant. contribution of CDK7 to mRNA synthesis, which is crit. for cellular homeostasis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcBXPoLwf8YLVg90H21EOLACvtfcHk0liGV8Oph1ntoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhs12jsL%252FL&md5=69cdab044f79f1e71b9fe30dedda717c</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.1128%2FMCB.00595-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.00595-14%26sid%3Dliteratum%253Aachs%26aulast%3DKelso%26aufirst%3DT.%2BW.%26aulast%3DBaumgart%26aufirst%3DK.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DAlbert%26aufirst%3DT.%26aulast%3DAntrecht%26aufirst%3DC.%26aulast%3DLemcke%26aufirst%3DS.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMeisterernst%26aufirst%3DM.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Controls%2520mRNA%2520Synthesis%2520by%2520Affecting%2520Stability%2520of%2520Preinitiation%2520Complexes%252C%2520Leading%2520to%2520Altered%2520Gene%2520Expression%252C%2520Cell%2520Cycle%2520Progression%252C%2520and%2520Survival%2520of%2520Tumor%2520Cells%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D2014%26volume%3D34%26issue%3D19%26spage%3D3675%26epage%3D3688%26doi%3D10.1128%2FMCB.00595-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nekardová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vymĕtalová, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Khirsariya, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kováčová, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hylsová, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kryštof, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fanfrlík, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hobza, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span> <span> </span><span class="NLM_article-title">Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and its Analogues Having Bioisosteric Central Heterocycles</span>. <i>ChemPhysChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">785</span>– <span class="NLM_lpage">795</span>, <span class="refDoi"> DOI: 10.1002/cphc.201601319</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fcphc.201601319" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28128514" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXislOgt78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2017&pages=785-795&issue=7&author=M.+Nekardov%C3%A1author=L.+Vym%C4%95talov%C3%A1author=P.+Khirsariyaauthor=S.+Kov%C3%A1%C4%8Dov%C3%A1author=M.+Hylsov%C3%A1author=R.+Jordaauthor=V.+Kry%C5%A1tofauthor=J.+Fanfrl%C3%ADkauthor=P.+Hobzaauthor=K.+Paruch&title=Structural+Basis+of+the+Interaction+of+Cyclin-Dependent+Kinase+2+with+Roscovitine+and+its+Analogues+Having+Bioisosteric+Central+Heterocycles&doi=10.1002%2Fcphc.201601319"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles</span></div><div class="casAuthors">Nekardova, Michaela; Vymetalova, Ladislava; Khirsariya, Prashant; Kovacova, Silvia; Hylsova, Michaela; Jorda, Radek; Krystof, Vladimir; Fanfrlik, Jindrich; Hobza, Pavel; Paruch, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">ChemPhysChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">785-795</span>CODEN:
                <span class="NLM_cas:coden">CPCHFT</span>;
        ISSN:<span class="NLM_cas:issn">1439-4235</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The structural basis for the interaction of roscovitine and analogs contg. 13 different bioisosteric central heterocycles with the enzyme cyclin-dependent kinase 2 (CDK2) is elucidated.  Although all the central scaffolds are very similar to the purine core of roscovitine, the exptl. detd. IC50 values of the inhibitors span three orders of magnitude.  By using an extensive computational chem. approach, the affinities of the inhibitors to CDK2 are detd. as calcd. binding scores of complexes of the inhibitors with the protein.  The interactions of the inhibitors with CDK2 are computationally described by using a hybrid quantum mechanics/semi-empirical quantum mechanics method (QM/SQM), which combines the DFT-D method for the QM part and the PM6-D3H4X method for the SQM part.  The solvent effect is described by the COSMO implicit solvation model at the SQM level for the whole system.  The contributions of the scaffolds and the individual substituents, quantified and evaluated in relation to conformations of optimized protein-inhibitor complexes, are found not to be simply additive.  The inhibitory activity of the selected candidates, including two newly prepd. compds., is tested against CDK2.  The results of the calcns. are in close agreement with the exptl. data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqHTqWv47eXK7Vg90H21EOLACvtfcHk0liGV8Oph1ntoA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXislOgt78%253D&md5=222a27e05756ada8610ba14c87fa4627</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1002%2Fcphc.201601319&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcphc.201601319%26sid%3Dliteratum%253Aachs%26aulast%3DNekardov%25C3%25A1%26aufirst%3DM.%26aulast%3DVym%25C4%2595talov%25C3%25A1%26aufirst%3DL.%26aulast%3DKhirsariya%26aufirst%3DP.%26aulast%3DKov%25C3%25A1%25C4%258Dov%25C3%25A1%26aufirst%3DS.%26aulast%3DHylsov%25C3%25A1%26aufirst%3DM.%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DKry%25C5%25A1tof%26aufirst%3DV.%26aulast%3DFanfrl%25C3%25ADk%26aufirst%3DJ.%26aulast%3DHobza%26aufirst%3DP.%26aulast%3DParuch%26aufirst%3DK.%26atitle%3DStructural%2520Basis%2520of%2520the%2520Interaction%2520of%2520Cyclin-Dependent%2520Kinase%25202%2520with%2520Roscovitine%2520and%2520its%2520Analogues%2520Having%2520Bioisosteric%2520Central%2520Heterocycles%26jtitle%3DChemPhysChem%26date%3D2017%26volume%3D18%26issue%3D7%26spage%3D785%26epage%3D795%26doi%3D10.1002%2Fcphc.201601319" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span>; <span class="NLM_string-name">Snyder, J. P.</span>; <span class="NLM_string-name">Liotta, D. C.</span>; <span class="NLM_string-name">Barrett, A. G.</span>; <span class="NLM_string-name">Coombes, R. C. D. S.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Siwicka, A.</span>; <span class="NLM_string-name">Brackow, J.</span>; <span class="NLM_string-name">Scheiper, B.</span></span> <span> </span><span class="NLM_article-title">Selective Inhibitors for Cyclin-Dependent Kinases</span>. CA<span class="NLM_patent">CA2688616A1</span>, <span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&author=A.+S.+Jogalekar&author=J.+P.+Snyder&author=D.+C.+Liotta&author=A.+G.+Barrett&author=R.+C.+D.+S.+Coombes&author=S.+Ali&author=A.+Siwicka&author=J.+Brackow&author=B.+Scheiper&title=Selective+Inhibitors+for+Cyclin-Dependent+Kinases"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26atitle%3DSelective%2520Inhibitors%2520for%2520Cyclin-Dependent%2520Kinases%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jorda, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Paruch, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Krystof, V.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase Inhibitors Inspired by Roscovitine: Purine Bioisosteres</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>18</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">2974</span>– <span class="NLM_lpage">2980</span>, <span class="refDoi"> DOI: 10.2174/138161212800672804</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.2174%2F138161212800672804" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=22571665" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XovFalt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2012&pages=2974-2980&issue=20&author=R.+Jordaauthor=K.+Paruchauthor=V.+Krystof&title=Cyclin-Dependent+Kinase+Inhibitors+Inspired+by+Roscovitine%3A+Purine+Bioisosteres&doi=10.2174%2F138161212800672804"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase inhibitors inspired by roscovitine: purine bioisosteres</span></div><div class="casAuthors">Jorda, Radek; Paruch, Kamil; Krystof, Vladimir</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">2974-2980</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Roscovitine is a synthetic inhibitor of cyclin-dependent kinases that is currently undergoing clin. trials as a candidate drug for some oncol. indications.  Its discovery prompted many research teams to further optimize its structure or to initiate their own related but independent studies.  This article reviews known roscovitine bioisosteres that have been prepd. as CDK inhibitors using different core heterocycles.  The individual bioisostere types have been described and explored to a different extent, which complicates direct comparisons of their biochem. activity - only six direct analogs contg. different purine bioisosteres have been prepd. and evaluated side by side with roscovitine.  Only four types of bioisosteres have demonstrated improved biol. properties, namely pyrazolo[1,5-a]-1,3,5-triazines, pyrazolo[1,5-a]pyrimidines, pyrazolo[1,5-a]pyridines and pyrazolo[4,3-d]pyrimidines.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGotYtawOBwFJLVg90H21EOLACvtfcHk0lgxYntTfWza1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XovFalt74%253D&md5=f5a2841359f53407dbbb667cb7b5772d</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.2174%2F138161212800672804&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161212800672804%26sid%3Dliteratum%253Aachs%26aulast%3DJorda%26aufirst%3DR.%26aulast%3DParuch%26aufirst%3DK.%26aulast%3DKrystof%26aufirst%3DV.%26atitle%3DCyclin-Dependent%2520Kinase%2520Inhibitors%2520Inspired%2520by%2520Roscovitine%253A%2520Purine%2520Bioisosteres%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2012%26volume%3D18%26issue%3D20%26spage%3D2974%26epage%3D2980%26doi%3D10.2174%2F138161212800672804" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Periyasamy, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alikian, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kanneganti, S. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jogalekar, A. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiper, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Blum, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brackow, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siwicka, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pace, R. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liotta, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemont, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">A Novel Pyrazolo[1,5-<i>a</i>]pyrimidine Is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>53</i></span> (<span class="NLM_issue">24</span>),  <span class="NLM_fpage">8508</span>– <span class="NLM_lpage">8522</span>, <span class="refDoi"> DOI: 10.1021/jm100732t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm100732t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2010&pages=8508-8522&issue=24&author=D.+A.+Heathcoteauthor=H.+Patelauthor=S.+H.+Krollauthor=P.+Hazelauthor=M.+Periyasamyauthor=M.+Alikianauthor=S.+K.+Kannegantiauthor=A.+S.+Jogalekarauthor=B.+Scheiperauthor=M.+Barbazangesauthor=A.+Blumauthor=J.+Brackowauthor=A.+Siwickaauthor=R.+D.+Paceauthor=M.+J.+Fuchterauthor=J.+P.+Snyderauthor=D.+C.+Liottaauthor=P.+S.+Freemontauthor=E.+O.+Aboagyeauthor=R.+C.+Coombesauthor=A.+G.+Barrettauthor=S.+Ali&title=A+Novel+Pyrazolo%5B1%2C5-a%5Dpyrimidine+Is+a+Potent+Inhibitor+of+Cyclin-Dependent+Protein+Kinases+1%2C+2%2C+and+9%2C+Which+Demonstrates+Antitumor+Effects+in+Human+Tumor+Xenografts+Following+Oral+Administration&doi=10.1021%2Fjm100732t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">A Novel Pyrazolo[1,5-a]pyrimidine is a Potent Inhibitor of Cyclin-Dependent Protein Kinases 1, 2, and 9, Which Demonstrates Antitumor Effects in Human Tumor Xenografts Following Oral Administration</span></div><div class="casAuthors">Heathcote, Dean A.; Patel, Hetal; Kroll, Sebastian H. B.; Hazel, Pascale; Periyasamy, Manikandan; Alikian, Mary; Kanneganti, Seshu K.; Jogalekar, Ashutosh S.; Scheiper, Bodo; Barbazanges, Marion; Blum, Andreas; Brackow, Jan; Siwicka, Alekasandra; Pace, Robert D. M.; Fuchter, Matthew J.; Snyder, James P.; Liotta, Dennis C.; Freemont, Paul. S.; Aboagye, Eric O.; Coombes, R. Charles; Barrett, Anthony G. M.; Ali, Simak</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">24</span>),
    <span class="NLM_cas:pages">8508-8522</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cyclin-dependent protein kinases (CDKs) are central to the appropriate regulation of cell proliferation, apoptosis, and gene expression.  Abnormalities in CDK activity and regulation are common features of cancer, making CDK family members attractive targets for the development of anticancer drugs.  Here, we report the identification of a pyrazolo[1,5-a]pyrimidine derived compd., 4k (BS-194, I), as a selective and potent CDK inhibitor, which inhibits CDK2, CDK1, CDK5, CDK7, and CDK9 (IC50 = 3, 30, 30, 250, and 90 nmol/L, resp.).  Cell-based studies showed inhibition of the phosphorylation of CDK substrates, Rb and the RNA polymerase II C-terminal domain, down-regulation of cyclins A, E, and D1, and cell cycle block in the S and G2/M phases.  Consistent with these findings, 4k demonstrated potent antiproliferative activity in 60 cancer cell lines tested (mean GI50 = 280 nmol/L).  Pharmacokinetic studies showed that 4k is orally bioavailable, with an elimination half-life of 178 min following oral dosing in mice.  When administered at a concn. of 25 mg/kg orally, 4k inhibited human tumor xenografts and suppressed CDK substrate phosphorylation.  These findings identify 4k as a novel, potent CDK selective inhibitor with potential for oral delivery in cancer patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUJPhLKEWwBLVg90H21EOLACvtfcHk0lgxYntTfWza1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVeksL%252FJ&md5=b84f41ab0cbf298a9ac248bc0a9d0d73</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1021%2Fjm100732t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm100732t%26sid%3Dliteratum%253Aachs%26aulast%3DHeathcote%26aufirst%3DD.%2BA.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DPeriyasamy%26aufirst%3DM.%26aulast%3DAlikian%26aufirst%3DM.%26aulast%3DKanneganti%26aufirst%3DS.%2BK.%26aulast%3DJogalekar%26aufirst%3DA.%2BS.%26aulast%3DScheiper%26aufirst%3DB.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DBlum%26aufirst%3DA.%26aulast%3DBrackow%26aufirst%3DJ.%26aulast%3DSiwicka%26aufirst%3DA.%26aulast%3DPace%26aufirst%3DR.%2BD.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DSnyder%26aufirst%3DJ.%2BP.%26aulast%3DLiotta%26aufirst%3DD.%2BC.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DA%2520Novel%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Cyclin-Dependent%2520Protein%2520Kinases%25201%252C%25202%252C%2520and%25209%252C%2520Which%2520Demonstrates%2520Antitumor%2520Effects%2520in%2520Human%2520Tumor%2520Xenografts%2520Following%2520Oral%2520Administration%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2010%26volume%3D53%26issue%3D24%26spage%3D8508%26epage%3D8522%26doi%3D10.1021%2Fjm100732t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kaliszczak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carroll, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delaney, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heathcote, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aboagye, E. O.</span></span> <span> </span><span class="NLM_article-title">Development of a Cyclin-Dependent Kinase Inhibitor Devoid of ABC Transporter-Dependent Drug Resistance</span>. <i>Br. J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>109</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">2356</span>– <span class="NLM_lpage">2367</span>, <span class="refDoi"> DOI: 10.1038/bjc.2013.584</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fbjc.2013.584" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=24071597" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsFeqt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=109&publication_year=2013&pages=2356-2367&issue=9&author=M.+Kaliszczakauthor=H.+Patelauthor=S.+Krollauthor=L.+Carrollauthor=G.+Smithauthor=S.+Delaneyauthor=D.+Heathcoteauthor=A.+Bondkeauthor=M.+Fuchterauthor=R.+Coombesauthor=A.+G.+Barrettauthor=S.+Aliauthor=E.+O.+Aboagye&title=Development+of+a+Cyclin-Dependent+Kinase+Inhibitor+Devoid+of+ABC+Transporter-Dependent+Drug+Resistance&doi=10.1038%2Fbjc.2013.584"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance</span></div><div class="casAuthors">Kaliszczak, M.; Patel, H.; Kroll, S. H. B.; Carroll, L.; Smith, G.; Delaney, S.; Heathcote, D. A.; Bondke, A.; Fuchter, M. J.; Coombes, R. C.; Barrett, A. G. M.; Ali, S.; Aboagye, E. O.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">109</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2356-2367</span>CODEN:
                <span class="NLM_cas:coden">BJCAAI</span>;
        ISSN:<span class="NLM_cas:issn">0007-0920</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background: Cyclin-dependent kinases (CDKs) control cell cycle progression, RNA transcription and apoptosis, making them attractive targets for anticancer drug development.  Unfortunately, CDK inhibitors developed to date have demonstrated variable efficacy.  Methods: We generated drug-resistant cells by continuous low-dose exposure to a model pyrazolo[1,5-a]pyrimidine CDK inhibitor and investigated potential structural alterations for optimal efficacy.  Results: We identified induction of the ATP-binding cassette (ABC) transporters, ABCB1 and ABCG2, in resistant cells.  Assessment of features involved in the ABC transporter substrate specificity from a compd. library revealed high polar surface area (>100 Å2) as a key determinant of transporter interaction.  We developed ICEC-0782 that preferentially inhibited CDK2, CDK7 and CDK9 in the nanomolar range.  The compd. inhibited phosphorylation of CDK substrates and downregulated the short-lived proteins, Mcl-1 and cyclin D1.  ICEC-0782 induced G2/M arrest and apoptosis.  The permeability and cytotoxicity of ICEC-0782 were unaffected by ABC transporter expression.  Following daily oral dosing, the compd. inhibited growth of human colon HCT-116 and human breast MCF7 tumor xenografts in vivo by 84% and 94%, resp.  Conclusion: We identified a promising pyrazolo[1,5-a]pyrimidine compd. devoid of ABC transporter interaction, highly suitable for further preclin. and clin. evaluation for the treatment of cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpi1gofdYFccrVg90H21EOLACvtfcHk0liGoFpib42G7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsFeqt7bP&md5=ebc44722d641bd567b7899f10de4c137</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1038%2Fbjc.2013.584&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fbjc.2013.584%26sid%3Dliteratum%253Aachs%26aulast%3DKaliszczak%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DKroll%26aufirst%3DS.%26aulast%3DCarroll%26aufirst%3DL.%26aulast%3DSmith%26aufirst%3DG.%26aulast%3DDelaney%26aufirst%3DS.%26aulast%3DHeathcote%26aufirst%3DD.%26aulast%3DBondke%26aufirst%3DA.%26aulast%3DFuchter%26aufirst%3DM.%26aulast%3DCoombes%26aufirst%3DR.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DAboagye%26aufirst%3DE.%2BO.%26atitle%3DDevelopment%2520of%2520a%2520Cyclin-Dependent%2520Kinase%2520Inhibitor%2520Devoid%2520of%2520ABC%2520Transporter-Dependent%2520Drug%2520Resistance%26jtitle%3DBr.%2520J.%2520Cancer%26date%3D2013%26volume%3D109%26issue%3D9%26spage%3D2356%26epage%3D2367%26doi%3D10.1038%2Fbjc.2013.584" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sava, G. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lusvarghi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pancholi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ambudkar, S. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, L.-A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buluwela, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span> <span> </span><span class="NLM_article-title">ABC-Transporter Upregulation Mediates Resistance to the CDK7 Inhibitors THZ1 and ICEC0942</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">13</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-1008-y</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41388-019-1008-y" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31462710" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=1-13&author=G.+P.+Savaauthor=H.+Fanauthor=R.+A.+Fisherauthor=S.+Lusvarghiauthor=S.+Pancholiauthor=S.+V.+Ambudkarauthor=L.-A.+Martinauthor=R.+C.+Coombesauthor=L.+Buluwelaauthor=S.+Ali&title=ABC-Transporter+Upregulation+Mediates+Resistance+to+the+CDK7+Inhibitors+THZ1+and+ICEC0942&doi=10.1038%2Fs41388-019-1008-y"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-1008-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-1008-y%26sid%3Dliteratum%253Aachs%26aulast%3DSava%26aufirst%3DG.%2BP.%26aulast%3DFan%26aufirst%3DH.%26aulast%3DFisher%26aufirst%3DR.%2BA.%26aulast%3DLusvarghi%26aufirst%3DS.%26aulast%3DPancholi%26aufirst%3DS.%26aulast%3DAmbudkar%26aufirst%3DS.%2BV.%26aulast%3DMartin%26aufirst%3DL.-A.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DBuluwela%26aufirst%3DL.%26aulast%3DAli%26aufirst%3DS.%26atitle%3DABC-Transporter%2520Upregulation%2520Mediates%2520Resistance%2520to%2520the%2520CDK7%2520Inhibitors%2520THZ1%2520and%2520ICEC0942%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26spage%3D1%26epage%3D13%26doi%3D10.1038%2Fs41388-019-1008-y" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hazel, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kroll, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bondke, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbazanges, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fuchter, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coombes, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ali, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barrett, A. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freemont, P. S.</span></span> <span> </span><span class="NLM_article-title">Inhibitor Selectivity for Cyclin-Dependent Kinase 7: a Structural, Thermodynamic, and Modelling Study</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">372</span>– <span class="NLM_lpage">380</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201600535</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fcmdc.201600535" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28125165" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitFegsb8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2017&pages=372-380&issue=5&author=P.+Hazelauthor=S.+H.+Krollauthor=A.+Bondkeauthor=M.+Barbazangesauthor=H.+Patelauthor=M.+J.+Fuchterauthor=R.+C.+Coombesauthor=S.+Aliauthor=A.+G.+Barrettauthor=P.+S.+Freemont&title=Inhibitor+Selectivity+for+Cyclin-Dependent+Kinase+7%3A+a+Structural%2C+Thermodynamic%2C+and+Modelling+Study&doi=10.1002%2Fcmdc.201600535"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitor selectivity for cyclin-dependent kinase 7: A structural, thermodynamic, and modeling study</span></div><div class="casAuthors">Hazel, Pascale; Kroll, Sebastian H. B.; Bondke, Alexander; Barbazanges, Marion; Patel, Hetal; Fuchter, Matthew J.; Coombes, R. Charles; Ali, Simak; Barrett, Anthony G. M.; Freemont, Paul S.</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">372-380</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">Deregulation of the cell cycle by mechanisms that lead to elevated activities of cyclin-dependent kinases (CDKs) is a feature of many human diseases, cancer in particular.  Here, we identified small-mol.-wt. inhibitors that selectively inhibit CDK7, the kinase that phosphorylates cell-cycle CDKs to promote their activities.  To investigate the selectivity of these inhibitors, we used a combination of structural, biophys., and modeling approaches.  We detd. the crystal structures of CDK7-selective compds. ICEC 0942 and ICEC 0943 bound to CDK2, and used these to build models of inhibitor binding to CDK7.  Mol. dynamics (MD) simulations of inhibitors bound to CDK2 and CDK7 generated possible models of inhibitor binding.  To exptl. validate these models, we gathered isothermal titrn. calorimetry (ITC) binding data for recombinant wild-type and binding site mutants of CDK7 and CDK2.  We identified specific residues of CDK7, notably Asp-155, that were involved in detg. inhibitor selectivity.  The MD simulations also showed that the flexibility of the G-rich and activation loops of CDK7 is likely an important determinant of inhibitor specificity similar to CDK2.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkKGwMKK6Xb7Vg90H21EOLACvtfcHk0liGoFpib42G7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitFegsb8%253D&md5=7fb792661b58d7e3d0859c2630dccdae</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201600535&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201600535%26sid%3Dliteratum%253Aachs%26aulast%3DHazel%26aufirst%3DP.%26aulast%3DKroll%26aufirst%3DS.%2BH.%26aulast%3DBondke%26aufirst%3DA.%26aulast%3DBarbazanges%26aufirst%3DM.%26aulast%3DPatel%26aufirst%3DH.%26aulast%3DFuchter%26aufirst%3DM.%2BJ.%26aulast%3DCoombes%26aufirst%3DR.%2BC.%26aulast%3DAli%26aufirst%3DS.%26aulast%3DBarrett%26aufirst%3DA.%2BG.%26aulast%3DFreemont%26aufirst%3DP.%2BS.%26atitle%3DInhibitor%2520Selectivity%2520for%2520Cyclin-Dependent%2520Kinase%25207%253A%2520a%2520Structural%252C%2520Thermodynamic%252C%2520and%2520Modelling%2520Study%26jtitle%3DChemMedChem%26date%3D2017%26volume%3D12%26issue%3D5%26spage%3D372%26epage%3D380%26doi%3D10.1002%2Fcmdc.201600535" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hutterer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eickhoff, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milbradt, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korn, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeitträger, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bahsi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wagner, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zischinsky, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wolf, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Degenhart, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Unger, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klebl, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marschall, M.</span></span> <span> </span><span class="NLM_article-title">A Novel CDK7 Inhibitor of the Pyrazolotriazine Class Exerts Broad-Spectrum Antiviral Activity at Nanomolar Concentrations</span>. <i>Antimicrob. Agents Chemother.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>59</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">2062</span>– <span class="NLM_lpage">2071</span>, <span class="refDoi"> DOI: 10.1128/AAC.04534-14</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1128%2FAAC.04534-14" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25624324" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2015&pages=2062-2071&issue=4&author=C.+Huttererauthor=J.+Eickhoffauthor=J.+Milbradtauthor=K.+Kornauthor=I.+Zeittr%C3%A4gerauthor=H.+Bahsiauthor=S.+Wagnerauthor=G.+Zischinskyauthor=A.+Wolfauthor=C.+Degenhartauthor=A.+Ungerauthor=M.+Baumannauthor=B.+Kleblauthor=M.+Marschall&title=A+Novel+CDK7+Inhibitor+of+the+Pyrazolotriazine+Class+Exerts+Broad-Spectrum+Antiviral+Activity+at+Nanomolar+Concentrations&doi=10.1128%2FAAC.04534-14"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">A novel CDK7 inhibitor of the Pyrazolotriazine class exerts broad-spectrum antiviral activity at nanomolar concentrations</span></div><div class="casAuthors">Hutterer Corina; Milbradt Jens; Korn Klaus; Zeittrager Isabel; Bahsi Hanife; Wagner Sabrina; Marschall Manfred; Eickhoff Jan; Zischinsky Gunther; Wolf Alexander; Degenhart Carsten; Unger Anke; Baumann Matthias; Klebl Bert</div><div class="citationInfo"><span class="NLM_cas:title">Antimicrobial agents and chemotherapy</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">2062-71</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Protein kinases represent central and multifunctional regulators of a balanced virus-host interaction.  Cyclin-dependent protein kinase 7 (CDK7) plays crucial regulatory roles in cell cycle and transcription, both connected with the replication of many viruses.  Previously, we developed a CDK7 inhibitor, LDC4297, that inhibits CDK7 in vitro in the nano-picomolar range.  Novel data from a kinome-wide evaluation (>330 kinases profiled in vitro) demonstrate a kinase selectivity.  Importantly, we provide first evidence for the antiviral potential of the CDK7 inhibitor LDC4297, i.e., in exerting a block of the replication of human cytomegalovirus (HCMV) in primary human fibroblasts at nanomolar concentrations (50% effective concentration, 24.5 ± 1.3 nM).  As a unique feature compared to approved antiherpesviral drugs, inhibition occurred already at the immediate-early level of HCMV gene expression.  The mode of antiviral action was considered multifaceted since CDK7-regulated cellular factors that are supportive of HCMV replication were substantially affected by the inhibitors.  An effect of LDC4297 was identified in the interference with HCMV-driven inactivation of retinoblastoma protein (Rb), a regulatory step generally considered a hallmark of herpesviral replication.  In line with this finding, a broad inhibitory activity of the drug could be demonstrated against a selection of human and animal herpesviruses and adenoviruses, whereas other viruses only showed intermediate drug sensitivity.  Summarized, the CDK7 inhibitor LDC4297 is a promising candidate for further antiviral drug development, possibly offering new options for a comprehensive approach to antiviral therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTZOhFUzosBFOdfST00W0BcfW6udTcc2eZYjb4GA4rJWbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2MvpvVemtg%253D%253D&md5=57c36db4aa7415d9023016868151ba3f</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1128%2FAAC.04534-14&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FAAC.04534-14%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DMilbradt%26aufirst%3DJ.%26aulast%3DKorn%26aufirst%3DK.%26aulast%3DZeittr%25C3%25A4ger%26aufirst%3DI.%26aulast%3DBahsi%26aufirst%3DH.%26aulast%3DWagner%26aufirst%3DS.%26aulast%3DZischinsky%26aufirst%3DG.%26aulast%3DWolf%26aufirst%3DA.%26aulast%3DDegenhart%26aufirst%3DC.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DBaumann%26aufirst%3DM.%26aulast%3DKlebl%26aufirst%3DB.%26aulast%3DMarschall%26aufirst%3DM.%26atitle%3DA%2520Novel%2520CDK7%2520Inhibitor%2520of%2520the%2520Pyrazolotriazine%2520Class%2520Exerts%2520Broad-Spectrum%2520Antiviral%2520Activity%2520at%2520Nanomolar%2520Concentrations%26jtitle%3DAntimicrob.%2520Agents%2520Chemother.%26date%3D2015%26volume%3D59%26issue%3D4%26spage%3D2062%26epage%3D2071%26doi%3D10.1128%2FAAC.04534-14" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rahl, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reddy, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dastur, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amzallag, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramaswamy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tesar, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jenkins, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McMillin, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sanda, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, N. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Look, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitsiades, C. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Weng, A. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benes, C. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting Transcription Regulation in Cancer with a Covalent CDK7 Inhibitor</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>511</i></span> (<span class="NLM_issue">7511</span>),  <span class="NLM_fpage">616</span>– <span class="NLM_lpage">620</span>, <span class="refDoi"> DOI: 10.1038/nature13393</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnature13393" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25043025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=511&publication_year=2014&pages=616-620&issue=7511&author=N.+Kwiatkowskiauthor=T.+Zhangauthor=P.+B.+Rahlauthor=B.+J.+Abrahamauthor=J.+Reddyauthor=S.+B.+Ficarroauthor=A.+Dasturauthor=A.+Amzallagauthor=S.+Ramaswamyauthor=B.+Tesarauthor=C.+E.+Jenkinsauthor=N.+M.+Hannettauthor=D.+McMillinauthor=T.+Sandaauthor=T.+Simauthor=N.+D.+Kimauthor=T.+Lookauthor=C.+S.+Mitsiadesauthor=A.+P.+Wengauthor=J.+R.+Brownauthor=C.+H.+Benesauthor=J.+A.+Martoauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Targeting+Transcription+Regulation+in+Cancer+with+a+Covalent+CDK7+Inhibitor&doi=10.1038%2Fnature13393"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting transcription regulation in cancer with a covalent CDK7 inhibitor</span></div><div class="casAuthors">Kwiatkowski, Nicholas; Zhang, Tinghu; Rahl, Peter B.; Abraham, Brian J.; Reddy, Jessica; Ficarro, Scott B.; Dastur, Anahita; Amzallag, Arnaud; Ramaswamy, Sridhar; Tesar, Bethany; Jenkins, Catherine E.; Hannett, Nancy M.; McMillin, Douglas; Sanda, Takaomi; Sim, Taebo; Kim, Nam Doo; Look, Thomas; Mitsiades, Constantine S.; Weng, Andrew P.; Brown, Jennifer R.; Benes, Cyril H.; Marto, Jarrod A.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">511</span>
        (<span class="NLM_cas:issue">7511</span>),
    <span class="NLM_cas:pages">616-620</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Tumor oncogenes include transcription factors that co-opt the general transcriptional machinery to sustain the oncogenic state, but direct pharmacol. inhibition of transcription factors has so far proven difficult.  However, the transcriptional machinery contains various enzymic cofactors that can be targeted for the development of new therapeutic candidates, including cyclin-dependent kinases (CDKs).  Here the authors present the discovery and characterization of a covalent CDK7 inhibitor, THZ1, which has the unprecedented ability to target a remote cysteine residue located outside of the canonical kinase domain, providing an unanticipated means of achieving selectivity for CDK7.  Cancer cell-line profiling indicates that a subset of cancer cell lines, including human T-cell acute lymphoblastic leukemia (T-ALL), have exceptional sensitivity to THZ1.  Genome-wide anal. in Jurkat T-ALL cells shows that THZ1 disproportionally affects transcription of RUNX1 and suggests that sensitivity to THZ1 may be due to vulnerability conferred by the RUNX1 super-enhancer and the key role of RUNX1 in the core transcriptional regulatory circuitry of these tumor cells.  Pharmacol. modulation of CDK7 kinase activity may thus provide an approach to identify and treat tumor types that are dependent on transcription for maintenance of the oncogenic state.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrVD-DeTAQCqrVg90H21EOLACvtfcHk0lhmuRk7uvBvNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1ChurnF&md5=895a28fb536663a31e7558fe79ce628b</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1038%2Fnature13393&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature13393%26sid%3Dliteratum%253Aachs%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DRahl%26aufirst%3DP.%2BB.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DReddy%26aufirst%3DJ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DDastur%26aufirst%3DA.%26aulast%3DAmzallag%26aufirst%3DA.%26aulast%3DRamaswamy%26aufirst%3DS.%26aulast%3DTesar%26aufirst%3DB.%26aulast%3DJenkins%26aufirst%3DC.%2BE.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DMcMillin%26aufirst%3DD.%26aulast%3DSanda%26aufirst%3DT.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DN.%2BD.%26aulast%3DLook%26aufirst%3DT.%26aulast%3DMitsiades%26aufirst%3DC.%2BS.%26aulast%3DWeng%26aufirst%3DA.%2BP.%26aulast%3DBrown%26aufirst%3DJ.%2BR.%26aulast%3DBenes%26aufirst%3DC.%2BH.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520Transcription%2520Regulation%2520in%2520Cancer%2520with%2520a%2520Covalent%2520CDK7%2520Inhibitor%26jtitle%3DNature%26date%3D2014%26volume%3D511%26issue%3D7511%26spage%3D616%26epage%3D620%26doi%3D10.1038%2Fnature13393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shao, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hole, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abbas, A. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baumli, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lam, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Foley, D. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fischer, P. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Noble, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Endicott, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepper, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, S.</span></span> <span> </span><span class="NLM_article-title">Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>56</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">640</span>– <span class="NLM_lpage">659</span>, <span class="refDoi"> DOI: 10.1021/jm301475f</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm301475f" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXms1Oqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=640-659&issue=3&author=H.+Shaoauthor=S.+Shiauthor=S.+Huangauthor=A.+J.+Holeauthor=A.+Y.+Abbasauthor=S.+Baumliauthor=X.+Liuauthor=F.+Lamauthor=D.+W.+Foleyauthor=P.+M.+Fischerauthor=M.+Nobleauthor=J.+A.+Endicottauthor=C.+Pepperauthor=S.+Wang&title=Substituted+4-%28Thiazol-5-yl%29-2-%28phenylamino%29pyrimidines+Are+Highly+Active+CDK9+Inhibitors%3A+Synthesis%2C+X-ray+Crystal+Structures%2C+Structure%E2%80%93Activity+Relationship%2C+and+Anticancer+Activities&doi=10.1021%2Fjm301475f"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure-Activity Relationship, and Anticancer Activities</span></div><div class="casAuthors">Shao, Hao; Shi, Shenhua; Huang, Shiliang; Hole, Alison J.; Abbas, Abdullahi Y.; Baumli, Sonja; Liu, Xiangrui; Lam, Frankie; Foley, David W.; Fischer, Peter M.; Noble, Martin; Endicott, Jane A.; Pepper, Chris; Wang, Shudong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">640-659</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Cancer cells often have a high demand for antiapoptotic proteins in order to resist programmed cell death.  CDK9 inhibition selectively targets survival proteins and reinstates apoptosis in cancer cells.  We designed a series of 4-thiazol-2-anilinopyrimidine derivs. with functional groups attached to the C5-position of the pyrimidine or to the C4-thiazol moiety and investigated their effects on CDK9 potency and selectivity.  One of the most selective compds., 12u (I) inhibits CDK9 with IC50 = 7 nM and shows over 80-fold selectivity for CDK9 vs. CDK2.  X-ray crystal structures of 12u bound to CDK9 and CDK2 provide insights into the binding modes.  This work, together with crystal structures of selected inhibitors in complex with both enzymes described in a companion paper, provides a rationale for the obsd. SAR.  12U demonstrates potent anticancer activity against primary chronic lymphocytic leukemia cells with a therapeutic window 31- and 107-fold over those of normal B- and T-cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUOOiqFBF6S7Vg90H21EOLACvtfcHk0lhmuRk7uvBvNw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXms1Oqsg%253D%253D&md5=5f490a79f72e445c8d8f9fcb23f5e917</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1021%2Fjm301475f&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm301475f%26sid%3Dliteratum%253Aachs%26aulast%3DShao%26aufirst%3DH.%26aulast%3DShi%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DS.%26aulast%3DHole%26aufirst%3DA.%2BJ.%26aulast%3DAbbas%26aufirst%3DA.%2BY.%26aulast%3DBaumli%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DLam%26aufirst%3DF.%26aulast%3DFoley%26aufirst%3DD.%2BW.%26aulast%3DFischer%26aufirst%3DP.%2BM.%26aulast%3DNoble%26aufirst%3DM.%26aulast%3DEndicott%26aufirst%3DJ.%2BA.%26aulast%3DPepper%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DS.%26atitle%3DSubstituted%25204-%2528Thiazol-5-yl%2529-2-%2528phenylamino%2529pyrimidines%2520Are%2520Highly%2520Active%2520CDK9%2520Inhibitors%253A%2520Synthesis%252C%2520X-ray%2520Crystal%2520Structures%252C%2520Structure%25E2%2580%2593Activity%2520Relationship%252C%2520and%2520Anticancer%2520Activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26issue%3D3%26spage%3D640%26epage%3D659%26doi%3D10.1021%2Fjm301475f" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K.-k.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">135</span>– <span class="NLM_lpage">142</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2017.11.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.chembiol.2017.11.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29276047" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVehtLzL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2018&pages=135-142&issue=2&author=Y.+Gaoauthor=T.+Zhangauthor=H.+Teraiauthor=S.+B.+Ficarroauthor=N.+Kwiatkowskiauthor=M.-F.+Haoauthor=B.+Sharmaauthor=C.+L.+Christensenauthor=E.+Chipumuroauthor=K.-k.+Wongauthor=J.+A.+Martoauthor=P.+S.+Hammermanauthor=N.+S.+Grayauthor=R.+E.+George&title=Overcoming+Resistance+to+the+THZ+Series+of+Covalent+Transcriptional+CDK+Inhibitors&doi=10.1016%2Fj.chembiol.2017.11.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">Overcoming Resistance to the THZ Series of Covalent Transcriptional CDK Inhibitors</span></div><div class="casAuthors">Gao, Yang; Zhang, Tinghu; Terai, Hideki; Ficarro, Scott B.; Kwiatkowski, Nicholas; Hao, Ming-Feng; Sharma, Bandana; Christensen, Camilla L.; Chipumuro, Edmond; Wong, Kwok-kin; Marto, Jarrod A.; Hammerman, Peter S.; Gray, Nathanael S.; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">135-142.e5</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Irreversible inhibition of transcriptional cyclin-dependent kinases (CDKs) provides a therapeutic strategy for cancers that rely on aberrant transcription; however, lack of understanding of resistance mechanisms to these agents will likely impede their clin. evolution.  Here, we demonstrate upregulation of multidrug transporters ABCB1 and ABCG2 as a major mode of resistance to THZ1, a covalent inhibitor of CDKs 7, 12, and 13 in neuroblastoma and lung cancer.  To counter this obstacle, we developed a CDK inhibitor, E9, that is not a substrate for ABC transporters, and by selecting for resistance, detd. that it exerts its cytotoxic effects through covalent modification of cysteine 1039 of CDK12.  These results highlight the importance of considering this common mode of resistance in the development of clin. analogs of THZ1, identify a covalent CDK12 inhibitor that is not susceptible to ABC transporter-mediated drug efflux, and demonstrate that target deconvolution can be accomplished through selection for resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrANNBJPMcYQbVg90H21EOLACvtfcHk0ljv8KOq0n8IZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVehtLzL&md5=2b579072d0f53f8381886149a31f4e18</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2017.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2017.11.007%26sid%3Dliteratum%253Aachs%26aulast%3DGao%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DTerai%26aufirst%3DH.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DHao%26aufirst%3DM.-F.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DChipumuro%26aufirst%3DE.%26aulast%3DWong%26aufirst%3DK.-k.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DOvercoming%2520Resistance%2520to%2520the%2520THZ%2520Series%2520of%2520Covalent%2520Transcriptional%2520CDK%2520Inhibitors%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2018%26volume%3D25%26issue%3D2%26spage%3D135%26epage%3D142%26doi%3D10.1016%2Fj.chembiol.2017.11.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hamman, K. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schmidt, D. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ke, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradley, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Orlando, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alnemy, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ren, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ciblat, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Winter, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kabro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sprott, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fritz, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carulli, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">di Tomaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, E. R.</span></span> <span> </span><span class="NLM_article-title">Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7</span>. <i>Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>79</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">3479</span>– <span class="NLM_lpage">3491</span>, <span class="refDoi"> DOI: 10.1158/0008-5472.CAN-19-0119</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F0008-5472.CAN-19-0119" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31064851" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3M7jtl2iug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=79&publication_year=2019&pages=3479-3491&issue=13&author=S.+Huauthor=J.+J.+Marineauauthor=N.+Rajagopalauthor=K.+B.+Hammanauthor=Y.+J.+Choiauthor=D.+R.+Schmidtauthor=N.+Keauthor=L.+Johannessenauthor=M.+J.+Bradleyauthor=D.+A.+Orlandoauthor=S.+R.+Alnemyauthor=Y.+Renauthor=S.+Ciblatauthor=D.+K.+Winterauthor=A.+Kabroauthor=K.+T.+Sprottauthor=J.+G.+Hodgsonauthor=C.+C.+Fritzauthor=J.+P.+Carulliauthor=E.+di+Tomasoauthor=E.+R.+Olson&title=Discovery+and+Characterization+of+SY-1365%2C+a+Selective%2C+Covalent+Inhibitor+of+CDK7&doi=10.1158%2F0008-5472.CAN-19-0119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery and Characterization of SY-1365, a Selective, Covalent Inhibitor of CDK7</span></div><div class="casAuthors">Hu Shanhu; Marineau Jason J; Rajagopal Nisha; Hamman Kristin B; Choi Yoon Jong; Schmidt Darby R; Ke Nan; Johannessen Liv; Bradley Michael J; Orlando David A; Alnemy Sydney R; Ren Yixuan; Sprott Kevin T; Hodgson J Graeme; Fritz Christian C; Carulli John P; di Tomaso Emmanuelle; Olson Eric R; Ciblat Stephane; Winter Dana K; Kabro Anzhelika</div><div class="citationInfo"><span class="NLM_cas:title">Cancer research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">79</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3479-3491</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Recent studies suggest that targeting transcriptional machinery can lead to potent and selective anticancer effects in cancers dependent on high and constant expression of certain transcription factors for growth and survival.  Cyclin-dependent kinase 7 (CDK7) is the catalytic subunit of the CDK-activating kinase complex.  Its function is required for both cell-cycle regulation and transcriptional control of gene expression.  CDK7 has recently emerged as an attractive cancer target because its inhibition leads to decreased transcript levels of oncogenic transcription factors, especially those associated with super-enhancers.  Here, we describe a selective CDK7 inhibitor SY-1365, which is currently in clinical trials in populations of patients with ovarian and breast cancer (NCT03134638).  In vitro, SY-1365 inhibited cell growth of many different cancer types at nanomolar concentrations.  SY-1365 treatment decreased MCL1 protein levels, and cancer cells with low BCL2L1 (BCL-XL) expression were found to be more sensitive to SY-1365.  Transcriptional changes in acute myeloid leukemia (AML) cell lines were distinct from those following treatment with other transcriptional inhibitors.  SY-1365 demonstrated substantial antitumor effects in multiple AML xenograft models as a single agent; SY-1365-induced growth inhibition was enhanced in combination with the BCL2 inhibitor venetoclax.  Antitumor activity was also observed in xenograft models of ovarian cancer, suggesting the potential for exploring SY-1365 in the clinic in both hematologic and solid tumors.  Our findings support targeting CDK7 as a new approach for treating transcriptionally addicted cancers.  SIGNIFICANCE: These findings demonstrate the molecular mechanism of action and potent antitumor activity of SY-1365, the first selective CDK7 inhibitor to enter clinical investigation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTAyWVFYyjv30kUaC_kzhvyfW6udTcc2eZ86AmzLrdi2Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7jtl2iug%253D%253D&md5=4fd24fb5eea04eb6e921f52206f69098</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-19-0119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-19-0119%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26aulast%3DRajagopal%26aufirst%3DN.%26aulast%3DHamman%26aufirst%3DK.%2BB.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DSchmidt%26aufirst%3DD.%2BR.%26aulast%3DKe%26aufirst%3DN.%26aulast%3DJohannessen%26aufirst%3DL.%26aulast%3DBradley%26aufirst%3DM.%2BJ.%26aulast%3DOrlando%26aufirst%3DD.%2BA.%26aulast%3DAlnemy%26aufirst%3DS.%2BR.%26aulast%3DRen%26aufirst%3DY.%26aulast%3DCiblat%26aufirst%3DS.%26aulast%3DWinter%26aufirst%3DD.%2BK.%26aulast%3DKabro%26aufirst%3DA.%26aulast%3DSprott%26aufirst%3DK.%2BT.%26aulast%3DHodgson%26aufirst%3DJ.%2BG.%26aulast%3DFritz%26aufirst%3DC.%2BC.%26aulast%3DCarulli%26aufirst%3DJ.%2BP.%26aulast%3Ddi%2BTomaso%26aufirst%3DE.%26aulast%3DOlson%26aufirst%3DE.%2BR.%26atitle%3DDiscovery%2520and%2520Characterization%2520of%2520SY-1365%252C%2520a%2520Selective%252C%2520Covalent%2520Inhibitor%2520of%2520CDK7%26jtitle%3DCancer%2520Res.%26date%3D2019%26volume%3D79%26issue%3D13%26spage%3D3479%26epage%3D3491%26doi%3D10.1158%2F0008-5472.CAN-19-0119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dixon-Clarke, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greifenberg, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elkins, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hannett, N. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Manz, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartkowiak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greenleaf, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Covalent Targeting of Remote Cysteine Residues to Develop CDK12 and CDK13 Inhibitors</span>. <i>Nat. Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>12</i></span> (<span class="NLM_issue">10</span>),  <span class="NLM_fpage">876</span>– <span class="NLM_lpage">884</span>, <span class="refDoi"> DOI: 10.1038/nchembio.2166</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fnchembio.2166" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27571479" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2016&pages=876-884&issue=10&author=T.+Zhangauthor=N.+Kwiatkowskiauthor=C.+M.+Olsonauthor=S.+E.+Dixon-Clarkeauthor=B.+J.+Abrahamauthor=A.+K.+Greifenbergauthor=S.+B.+Ficarroauthor=J.+M.+Elkinsauthor=Y.+Liangauthor=N.+M.+Hannettauthor=T.+Manzauthor=M.+Haoauthor=B.+Bartkowiakauthor=A.+L.+Greenleafauthor=J.+A.+Martoauthor=M.+Geyerauthor=A.+N.+Bullockauthor=R.+A.+Youngauthor=N.+S.+Gray&title=Covalent+Targeting+of+Remote+Cysteine+Residues+to+Develop+CDK12+and+CDK13+Inhibitors&doi=10.1038%2Fnchembio.2166"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent targeting of remote cysteine residues to develop CDK12 and CDK13 inhibitors</span></div><div class="casAuthors">Zhang, Tinghu; Kwiatkowski, Nicholas; Olson, Calla M.; Dixon-Clarke, Sarah E.; Abraham, Brian J.; Greifenberg, Ann K.; Ficarro, Scott B.; Elkins, Jonathan M.; Liang, Yanke; Hannett, Nancy M.; Manz, Theresa; Hao, Mingfeng; Bartkowiak, Bartlomiej; Greenleaf, Arno L.; Marto, Jarrod A.; Geyer, Matthias; Bullock, Alex N.; Young, Richard A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">876-884</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Cyclin-dependent kinases 12 and 13 (CDK12 and CDK13) play crit. roles in the regulation of gene transcription.  However, the absence of CDK12 and CDK13 inhibitors has hindered the ability to investigate the consequences of their inhibition in healthy cells and cancer cells.  Here we describe the rational design of a first-in-class CDK12 and CDK13 covalent inhibitor, THZ531.  Co-crystn. of THZ531 with CDK12-cyclin K indicates that THZ531 irreversibly targets a cysteine located outside the kinase domain.  THZ531 causes a loss of gene expression with concurrent loss of elongating and hyperphosphorylated RNA polymerase II.  In particular, THZ531 substantially decreases the expression of DNA damage response genes and key super-enhancer-assocd. transcription factor genes.  Coincident with transcriptional perturbation, THZ531 dramatically induced apoptotic cell death.  Small mols. capable of specifically targeting CDK12 and CDK13 may thus help identify cancer subtypes that are particularly dependent on their kinase activities.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXIyvy8vbjvrVg90H21EOLACvtfcHk0lgFaL2g7F_Sag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlyqsbbJ&md5=5ac265105d1654e129c3c1325572f389</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.2166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.2166%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DDixon-Clarke%26aufirst%3DS.%2BE.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DGreifenberg%26aufirst%3DA.%2BK.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DElkins%26aufirst%3DJ.%2BM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DHannett%26aufirst%3DN.%2BM.%26aulast%3DManz%26aufirst%3DT.%26aulast%3DHao%26aufirst%3DM.%26aulast%3DBartkowiak%26aufirst%3DB.%26aulast%3DGreenleaf%26aufirst%3DA.%2BL.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DBullock%26aufirst%3DA.%2BN.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DCovalent%2520Targeting%2520of%2520Remote%2520Cysteine%2520Residues%2520to%2520Develop%2520CDK12%2520and%2520CDK13%2520Inhibitors%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2016%26volume%3D12%26issue%3D10%26spage%3D876%26epage%3D884%26doi%3D10.1038%2Fnchembio.2166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, W. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mills, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Elsarrag, S. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ficarro, S. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Düster, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sim, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marto, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sorger, P. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westover, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">792</span>– <span class="NLM_lpage">803</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.02.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.chembiol.2019.02.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30905681" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXlvVWhtrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=792-803&issue=6&author=C.+M.+Olsonauthor=Y.+Liangauthor=A.+Leggettauthor=W.+D.+Parkauthor=L.+Liauthor=C.+E.+Millsauthor=S.+Z.+Elsarragauthor=S.+B.+Ficarroauthor=T.+Zhangauthor=R.+D%C3%BCsterauthor=M.+Geyerauthor=T.+Simauthor=J.+A.+Martoauthor=P.+K.+Sorgerauthor=K.+D.+Westoverauthor=C.+Y.+Linauthor=N.+Kwiatkowskiauthor=N.+S.+Gray&title=Development+of+a+Selective+CDK7+Covalent+Inhibitor+Reveals+Predominant+Cell-Cycle+Phenotype&doi=10.1016%2Fj.chembiol.2019.02.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Development of a Selective CDK7 Covalent Inhibitor Reveals Predominant Cell-Cycle Phenotype</span></div><div class="casAuthors">Olson, Calla M.; Liang, Yanke; Leggett, Alan; Park, Woojun D.; Li, Lianbo; Mills, Caitlin E.; Elsarrag, Selma Z.; Ficarro, Scott B.; Zhang, Tinghu; Duster, Robert; Geyer, Matthias; Sim, Taebo; Marto, Jarrod A.; Sorger, Peter K.; Westover, Ken D.; Lin, Charles Y.; Kwiatkowski, Nicholas; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">792-803.e10</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase 7 (CDK7) regulates both cell cycle and transcription, but its precise role remains elusive.  We previously described THZ1, a CDK7 inhibitor, which dramatically inhibits superenhancer-assocd. gene expression.  However, potent CDK12/13 off-target activity obscured CDK7s contribution to this phenotype.  Here, we describe the discovery of a highly selective covalent CDK7 inhibitor.  YKL-5-124 causes arrest at the G1/S transition and inhibition of E2F-driven gene expression; these effects are rescued by a CDK7 mutant unable to covalently engage YKL-5-124, demonstrating on-target specificity.  Unlike THZ1, treatment with YKL-5-124 resulted in no change to RNA polymerase II C-terminal domain phosphorylation; however, inhibition could be reconstituted by combining YKL-5-124 and THZ531, a selective CDK12/13 inhibitor, revealing potential redundancies in CDK control of gene transcription.  These findings highlight the importance of CDK7/12/13 polypharmacol. for anti-cancer activity of THZ1 and posit that selective inhibition of CDK7 may be useful for treatment of cancers marked by E2F misregulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpK2AujiJVqR7Vg90H21EOLACvtfcHk0lgFaL2g7F_Sag"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXlvVWhtrc%253D&md5=750541769d6848ebbc0dff10ddce8a0a</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.02.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.02.012%26sid%3Dliteratum%253Aachs%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DLeggett%26aufirst%3DA.%26aulast%3DPark%26aufirst%3DW.%2BD.%26aulast%3DLi%26aufirst%3DL.%26aulast%3DMills%26aufirst%3DC.%2BE.%26aulast%3DElsarrag%26aufirst%3DS.%2BZ.%26aulast%3DFicarro%26aufirst%3DS.%2BB.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DD%25C3%25BCster%26aufirst%3DR.%26aulast%3DGeyer%26aufirst%3DM.%26aulast%3DSim%26aufirst%3DT.%26aulast%3DMarto%26aufirst%3DJ.%2BA.%26aulast%3DSorger%26aufirst%3DP.%2BK.%26aulast%3DWestover%26aufirst%3DK.%2BD.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DDevelopment%2520of%2520a%2520Selective%2520CDK7%2520Covalent%2520Inhibitor%2520Reveals%2520Predominant%2520Cell-Cycle%2520Phenotype%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D792%26epage%3D803%26doi%3D10.1016%2Fj.chembiol.2019.02.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murray, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piraino, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Westwick, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamerdin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dagostino, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knighton, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zager, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraynov, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Popoff, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, J. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kephart, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marakovits, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karlicek, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bergqvist, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smeal, T.</span></span> <span> </span><span class="NLM_article-title">Small-Molecule p21-Activated Kinase Inhibitor PF-3758309 Is a Potent Inhibitor of Oncogenic Signaling and Tumor Growth</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">2010</span>,  <span class="NLM_volume"><i>107</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">9446</span>– <span class="NLM_lpage">9451</span>, <span class="refDoi"> DOI: 10.1073/pnas.0911863107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1073%2Fpnas.0911863107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=20439741" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3cXmslWqtrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=9446-9451&issue=20&author=B.+W.+Murrayauthor=C.+Guoauthor=J.+Pirainoauthor=J.+K.+Westwickauthor=C.+Zhangauthor=J.+Lamerdinauthor=E.+Dagostinoauthor=D.+Knightonauthor=C.-M.+Loiauthor=M.+Zagerauthor=E.+Kraynovauthor=I.+Popoffauthor=J.+G.+Christensenauthor=R.+Martinezauthor=S.+E.+Kephartauthor=J.+Marakovitsauthor=S.+Karlicekauthor=S.+Bergqvistauthor=T.+Smeal&title=Small-Molecule+p21-Activated+Kinase+Inhibitor+PF-3758309+Is+a+Potent+Inhibitor+of+Oncogenic+Signaling+and+Tumor+Growth&doi=10.1073%2Fpnas.0911863107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Small-molecule p21-activated kinase inhibitor PF3758309 is a potent inhibitor of oncogenic signaling and tumor growth</span></div><div class="casAuthors">Murray, Brion W.; Guo, Chuangxing; Piraino, Joseph; Westwick, John K.; Zhang, Cathy; Lamerdin, Jane; Dagostino, Eleanor; Knighton, Daniel; Loi, Cho-Ming; Zager, Michael; Kraynov, Eugenia; Popoff, Ian; Chrietensen, James G.; Martinez, Ricardo; Kephart, Susan E.; Marakovits, Joseph; Karlicek, Shannon; Bergqvist, Simon; Smeal, Tod</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">9446-9451, S9446/1-S9446/18</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Despite abundant evidence that aberrant Rho-family GTPase activation contributes to most steps of cancer initiation and progression, there is a dearth of inhibitors of their effectors (e.g.. p21-activated kinases).  Through high-throughput screening and structure-based design, the authors identify PF-3758309, a potent (Kd = 2.7 nM), ATP-competitive, pyrrolopyrazole inhibitor of PAK4.  In cells, PF-3758309 inhibits phosphorylation of the PAK4 substrate GEF-H1 (IC50 = 1.3 nM) and anchorage-independent growth of a panel of tumor cell lines (IC50 = 4.7±3 nM).  The mol. underpinnings of PF-3758309 biol. effects were characterized using an integration of traditional and emerging technologies.  Crystallog. characterization of the PF-3758309/PAK4 complex defined determinants of potency and kinase selectivity.  Global high-content cellular anal. confirms that PF-3758309 modulates known PAK4-dependent signaling nodes and identifies unexpected links to addnl. pathways (e.g., p53).  In tumor models, PF-3758309 inhibits PAK4-dependent pathways in proteomic studies and regulates functional activities related to cell proliferation and survival.  PF-3758309 blocks the growth of multiple human tumor xenografts, with a plasma EC50 value of 0.4 nM in the most sensitive model.  This study defines PAK4-related pathways, provides addnl. support for PAK4 as a therapeutic target with a unique combination of functions (apoptotic, cytoskeletal, cell-cycle), and identifies a potent, orally available small-mol. PAK inhibitor with significant promise for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWI0STMKt9dbVg90H21EOLACvtfcHk0lhZUiOQtc8dHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXmslWqtrw%253D&md5=0080659735ef51f84c00112e573b1c31</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0911863107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0911863107%26sid%3Dliteratum%253Aachs%26aulast%3DMurray%26aufirst%3DB.%2BW.%26aulast%3DGuo%26aufirst%3DC.%26aulast%3DPiraino%26aufirst%3DJ.%26aulast%3DWestwick%26aufirst%3DJ.%2BK.%26aulast%3DZhang%26aufirst%3DC.%26aulast%3DLamerdin%26aufirst%3DJ.%26aulast%3DDagostino%26aufirst%3DE.%26aulast%3DKnighton%26aufirst%3DD.%26aulast%3DLoi%26aufirst%3DC.-M.%26aulast%3DZager%26aufirst%3DM.%26aulast%3DKraynov%26aufirst%3DE.%26aulast%3DPopoff%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DMartinez%26aufirst%3DR.%26aulast%3DKephart%26aufirst%3DS.%2BE.%26aulast%3DMarakovits%26aufirst%3DJ.%26aulast%3DKarlicek%26aufirst%3DS.%26aulast%3DBergqvist%26aufirst%3DS.%26aulast%3DSmeal%26aufirst%3DT.%26atitle%3DSmall-Molecule%2520p21-Activated%2520Kinase%2520Inhibitor%2520PF-3758309%2520Is%2520a%2520Potent%2520Inhibitor%2520of%2520Oncogenic%2520Signaling%2520and%2520Tumor%2520Growth%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26issue%3D20%26spage%3D9446%26epage%3D9451%26doi%3D10.1073%2Fpnas.0911863107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rudolph, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crawford, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoeflich, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of p21-Activated Kinases (PAKs) Miniperspective</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>58</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">111</span>– <span class="NLM_lpage">129</span>, <span class="refDoi"> DOI: 10.1021/jm501613q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm501613q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2015&pages=111-129&issue=1&author=J.+Rudolphauthor=J.+J.+Crawfordauthor=K.+P.+Hoeflichauthor=W.+Wang&title=Inhibitors+of+p21-Activated+Kinases+%28PAKs%29+Miniperspective&doi=10.1021%2Fjm501613q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of p21-Activated Kinases (PAKs)</span></div><div class="casAuthors">Rudolph, Joachim; Crawford, James J.; Hoeflich, Klaus P.; Wang, Weiru</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">111-129</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The p21-activated kinase (PAK) family of serine/threonine protein kinases plays important roles in cytoskeletal organization, cellular morphogenesis, and survival, and members of this family have been implicated in many diseases including cancer, infectious diseases, and neurol. disorders.  Owing to their large and flexible ATP binding cleft, PAKs, particularly group I PAKs (PAK1, -2, and -3), are difficult to drug; hence, few PAK inhibitors with satisfactory kinase selectivity and druglike properties have been reported to date.  Examples are a recently discovered group II PAK (PAK4, -5, -6) selective inhibitor series based on a benzimidazole core, a group I PAK selective series based on a pyrido[2,3-d]pyrimidine-7-one core, and an allosteric dibenzodiazepine PAK1 inhibitor series.  Only one compd., an aminopyrazole based pan-PAK inhibitor, entered clin. trials but did not progress beyond phase I trials.  Clin. proof of concept for pan-group I, pan-group II, or PAK isoform selective inhibition has yet to be demonstrated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpILWqNpGwtFrVg90H21EOLACvtfcHk0lhZUiOQtc8dHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFOhsb7F&md5=f6f95e58da2de3262157f1b00e856b9b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1021%2Fjm501613q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm501613q%26sid%3Dliteratum%253Aachs%26aulast%3DRudolph%26aufirst%3DJ.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26aulast%3DHoeflich%26aufirst%3DK.%2BP.%26aulast%3DWang%26aufirst%3DW.%26atitle%3DInhibitors%2520of%2520p21-Activated%2520Kinases%2520%2528PAKs%2529%2520Miniperspective%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2015%26volume%3D58%26issue%3D1%26spage%3D111%26epage%3D129%26doi%3D10.1021%2Fjm501613q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kalan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amat, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schachter, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Olson, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Larochelle, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fisher, R. P.</span></span> <span> </span><span class="NLM_article-title">Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to CDK7 Inhibitors</span>. <i>Cell Rep.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>21</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">467</span>– <span class="NLM_lpage">481</span>, <span class="refDoi"> DOI: 10.1016/j.celrep.2017.09.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.celrep.2017.09.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29020632" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs77M" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2017&pages=467-481&issue=2&author=S.+Kalanauthor=R.+Amatauthor=M.+M.+Schachterauthor=N.+Kwiatkowskiauthor=B.+J.+Abrahamauthor=Y.+Liangauthor=T.+Zhangauthor=C.+M.+Olsonauthor=S.+Larochelleauthor=R.+A.+Youngauthor=N.+S.+Grayauthor=R.+P.+Fisher&title=Activation+of+the+p53+Transcriptional+Program+Sensitizes+Cancer+Cells+to+CDK7+Inhibitors&doi=10.1016%2Fj.celrep.2017.09.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the p53 Transcriptional Program Sensitizes Cancer Cells to Cdk7 Inhibitors</span></div><div class="casAuthors">Kalan, Sampada; Amat, Ramon; Schachter, Miriam Merzel; Kwiatkowski, Nicholas; Abraham, Brian J.; Liang, Yanke; Zhang, Tinghu; Olson, Calla M.; Larochelle, Stephane; Young, Richard A.; Gray, Nathanael S.; Fisher, Robert P.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Reports</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">467-481</span>CODEN:
                <span class="NLM_cas:coden">CREED8</span>;
        ISSN:<span class="NLM_cas:issn">2211-1247</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Cdk7, the CDK-activating kinase and transcription factor IIH component, is a target of inhibitors that kill cancer cells by exploiting tumor-specific transcriptional dependencies.  However, whereas selective inhibition of analog-sensitive (AS) Cdk7 in colon cancer-derived cells arrests division and disrupts transcription, it does not by itself trigger apoptosis efficiently.  Here, we show that p53 activation by 5-fluorouracil or nutlin-3 synergizes with a reversible Cdk7as inhibitor to induce cell death.  Synthetic lethality was recapitulated with covalent inhibitors of wild-type Cdk7, THZ1, or the more selective YKL-1-116.  The effects were allele specific; a CDK7as mutation conferred both sensitivity to bulky adenine analogs and resistance to covalent inhibitors.  Non-transformed colon epithelial cells were resistant to these combinations, as were cancer-derived cells with p53-inactivating mutations.  Apoptosis was dependent on death receptor DR5, a p53 transcriptional target whose expression was refractory to Cdk7 inhibition.  Therefore, p53 activation induces transcriptional dependency to sensitize cancer cells to Cdk7 inhibition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpc7h-ZFvFgBrVg90H21EOLACvtfcHk0liRuv-MI9lfWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhs1Chs77M&md5=c210b9906acfad945620fcace4040e77</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.celrep.2017.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.celrep.2017.09.056%26sid%3Dliteratum%253Aachs%26aulast%3DKalan%26aufirst%3DS.%26aulast%3DAmat%26aufirst%3DR.%26aulast%3DSchachter%26aufirst%3DM.%2BM.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DOlson%26aufirst%3DC.%2BM.%26aulast%3DLarochelle%26aufirst%3DS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DFisher%26aufirst%3DR.%2BP.%26atitle%3DActivation%2520of%2520the%2520p53%2520Transcriptional%2520Program%2520Sensitizes%2520Cancer%2520Cells%2520to%2520CDK7%2520Inhibitors%26jtitle%3DCell%2520Rep.%26date%3D2017%26volume%3D21%26issue%3D2%26spage%3D467%26epage%3D481%26doi%3D10.1016%2Fj.celrep.2017.09.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, J.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.-S.</span></span> <span> </span><span class="NLM_article-title">Selective CDK7 Inhibition with BS-181 Suppresses Cell Proliferation and Induces Cell Cycle Arrest and Apoptosis in Gastric Cancer</span>. <i>Drug Des., Dev. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">1181</span>– <span class="NLM_lpage">1189</span>, <span class="refDoi"> DOI: 10.2147/DDDT.S86317</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.2147%2FDDDT.S86317" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=27042010" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXmtFOltbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2016&pages=1181-1189&author=B.-Y.+Wangauthor=Q.-Y.+Liuauthor=J.+Caoauthor=J.-W.+Chenauthor=Z.-S.+Liu&title=Selective+CDK7+Inhibition+with+BS-181+Suppresses+Cell+Proliferation+and+Induces+Cell+Cycle+Arrest+and+Apoptosis+in+Gastric+Cancer&doi=10.2147%2FDDDT.S86317"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Selective CDK7 inhibition with BS-181 suppressescell proliferation and induces cell cycle arrest andapoptosis in gastric cancer</span></div><div class="casAuthors">Wang, Bo-Yong; Liu, Quan-Yan; Cao, Jun; Chen, Ji-Wei; Liu, Zhi-su</div><div class="citationInfo"><span class="NLM_cas:title">Drug Design, Development and Therapy</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1181-1189</span>CODEN:
                <span class="NLM_cas:coden">DDDTAQ</span>;
        ISSN:<span class="NLM_cas:issn">1177-8881</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Cyclin-dependent kinase (CDK) family members have been considered as attractive therapeutic targets for cancer.  In this study, we aim to investigate the anticancer effects of a selective CDK7 inhibitor, BS-181, in gastric cancer (GC) cell line.  Human GC cells (BGC823) were cultured with or without BS-181 at different concns. for 24 -72 h.  BS-181 significantly reduced the activity of CDK7 with downregulation of cyclin D1 and XIAP in GC cells.  Treatment with BS-181 induced cell cycle arrest and apoptosis.  The expression of Bax and caspase-3 was significantly increased, while Bcl-2 expression was decreased in cells treated with BS-181.  In addn., the inhibition of CDK7 with BS-181 resulted in reduced rates of proliferation, migration, and invasion of gastric cells.  Those results demonstrated the anticancer activities of selective CDK7 inhibitor BS-181 in BGC823 cells, suggesting that CDK7 may serve as a novel therapeutic target or the treatment of GC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPxGNtLVz75LVg90H21EOLACvtfcHk0liRuv-MI9lfWQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXmtFOltbk%253D&md5=5e45dc0a10b1eb473e10ad4d13801e62</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.2147%2FDDDT.S86317&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FDDDT.S86317%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DB.-Y.%26aulast%3DLiu%26aufirst%3DQ.-Y.%26aulast%3DCao%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DJ.-W.%26aulast%3DLiu%26aufirst%3DZ.-S.%26atitle%3DSelective%2520CDK7%2520Inhibition%2520with%2520BS-181%2520Suppresses%2520Cell%2520Proliferation%2520and%2520Induces%2520Cell%2520Cycle%2520Arrest%2520and%2520Apoptosis%2520in%2520Gastric%2520Cancer%26jtitle%3DDrug%2520Des.%252C%2520Dev.%2520Ther.%26date%3D2016%26volume%3D10%26spage%3D1181%26epage%3D1189%26doi%3D10.2147%2FDDDT.S86317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ainscow, E. K.</span>; <span class="NLM_string-name">Leishman, A.</span>; <span class="NLM_string-name">Sullivan, E.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Gallagher, W.</span>; <span class="NLM_string-name">Peall, A.</span>; <span class="NLM_string-name">Clark, K.</span>; <span class="NLM_string-name">Thomson, S.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, R. C.</span>; <span class="NLM_string-name">Bahl, A.</span></span> <span> </span><span class="NLM_article-title">CT7001: An Orally Bioavailable CDK7 Inhibitor Is a Potential Therapy for Breast, Small-Cell Lung and Haematological Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-name">AACR</span>: <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>;</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=E.+K.+Ainscow&author=A.+Leishman&author=E.+Sullivan&author=B.+Li&author=W.+Gallagher&author=A.+Peall&author=K.+Clark&author=S.+Thomson&author=S.+Ali&author=R.+C.+Coombes&author=A.+Bahl&title=CT7001%3A+An+Orally+Bioavailable+CDK7+Inhibitor+Is+a+Potential+Therapy+for+Breast%2C+Small-Cell+Lung+and+Haematological+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAinscow%26aufirst%3DE.%2BK.%26atitle%3DCT7001%253A%2520An%2520Orally%2520Bioavailable%2520CDK7%2520Inhibitor%2520Is%2520a%2520Potential%2520Therapy%2520for%2520Breast%252C%2520Small-Cell%2520Lung%2520and%2520Haematological%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26pub%3DAACR%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bahl, A.</span>; <span class="NLM_string-name">Einscow, E.</span>; <span class="NLM_string-name">Leishman, A.</span>; <span class="NLM_string-name">Sullivan, E.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, R.</span>; <span class="NLM_string-name">Barrett, A.</span>; <span class="NLM_string-name">Li, B.</span>; <span class="NLM_string-name">Gallagher, W.</span>; <span class="NLM_string-name">Carragher, N.</span>; <span class="NLM_string-name">Patel, T.</span></span> <span> </span><span class="NLM_article-title">Activity of CT7001 an Orally Bioavailable Cyclin-Dependent Kinase 7 Selective Inhibitor in Models of Triple Negative Breast Cancer</span>.  <i>Proceedings of the 2017 SABCS</i>; <span class="NLM_publisher-loc">San Antonio, TX</span>, Dec 5–9, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Bahl&author=E.+Einscow&author=A.+Leishman&author=E.+Sullivan&author=S.+Ali&author=R.+Coombes&author=A.+Barrett&author=B.+Li&author=W.+Gallagher&author=N.+Carragher&author=T.+Patel&title=Proceedings+of+the+2017+SABCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DBahl%26aufirst%3DA.%26atitle%3DActivity%2520of%2520CT7001%2520an%2520Orally%2520Bioavailable%2520Cyclin-Dependent%2520Kinase%25207%2520Selective%2520Inhibitor%2520in%2520Models%2520of%2520Triple%2520Negative%2520Breast%2520Cancer%26btitle%3DProceedings%2520of%2520the%25202017%2520SABCS%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Clark, K.</span>; <span class="NLM_string-name">Ainscow, E.</span>; <span class="NLM_string-name">Peall, A.</span>; <span class="NLM_string-name">Thomson, S.</span>; <span class="NLM_string-name">Leishman, A.</span>; <span class="NLM_string-name">Elaine, S.</span>; <span class="NLM_string-name">Ali, S.</span>; <span class="NLM_string-name">Coombes, R.</span>; <span class="NLM_string-name">Barrett, A.</span>; <span class="NLM_string-name">Bahl, A. K.</span></span> <span> </span><span class="NLM_article-title">CT7001, a Novel Orally Bioavailable CDK7 Inhibitor, Is Highly Active in in Vitro and in Vivo Models of AML</span>.  <i>Proceedings of the 59th ASH Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Dec 7, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=K.+Clark&author=E.+Ainscow&author=A.+Peall&author=S.+Thomson&author=A.+Leishman&author=S.+Elaine&author=S.+Ali&author=R.+Coombes&author=A.+Barrett&author=A.+K.+Bahl&title=CT7001%2C+a+Novel+Orally+Bioavailable+CDK7+Inhibitor%2C+Is+Highly+Active+in+in+Vitro+and+in+Vivo+Models+of+AML"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DClark%26aufirst%3DK.%26atitle%3DCT7001%252C%2520a%2520Novel%2520Orally%2520Bioavailable%2520CDK7%2520Inhibitor%252C%2520Is%2520Highly%2520Active%2520in%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Models%2520of%2520AML%26jtitle%3DProceedings%2520of%2520the%252059th%2520ASH%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Li, B.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, C.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qiu, M.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, Z.-R.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Inhibitor THZ1 in Cancer Therapy</span>. <i>Chronic Dis. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>5</i></span> (<span class="NLM_issue">3</span>),  <span class="NLM_fpage">155</span>– <span class="NLM_lpage">169</span>, <span class="refDoi"> DOI: 10.1016/j.cdtm.2019.08.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.cdtm.2019.08.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31891127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3MblsVKqsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2019&pages=155-169&issue=3&author=B.-B.+Liauthor=B.+Wangauthor=C.-M.+Zhuauthor=D.+Tangauthor=J.+Pangauthor=J.+Zhaoauthor=C.-H.+Sunauthor=M.-J.+Qiuauthor=Z.-R.+Qian&title=Cyclin-Dependent+Kinase+7+Inhibitor+THZ1+in+Cancer+Therapy&doi=10.1016%2Fj.cdtm.2019.08.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy</span></div><div class="casAuthors">Li Bin-Bin; Li Bin-Bin; Wang Bo; Zhu Cheng-Ming; Tang Di; Pang Jun; Zhao Jing; Sun Chun-Hui; Qiu Miao-Juan; Qian Zhi-Rong; Sun Chun-Hui</div><div class="citationInfo"><span class="NLM_cas:title">Chronic diseases and translational medicine</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">155-169</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Current cancer therapies have encountered adverse response due to poor therapeutic efficiency, severe side effects and acquired resistance to multiple drugs.  Thus, there are urgent needs for finding new cancer-targeted pharmacological strategies.  In this review, we summarized the current understanding with THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), which demonstrated promising anti-tumor activity against different cancer types.  By introducing the anti-tumor behaviors and the potential targets for different cancers, this review aims to provide more effective approaches to CDK7 inhibitor-based therapeutic agents and deeper insight into the diverse tumor proliferation mechanisms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTEv1qY9aiKatts4TFFB11gfW6udTcc2ea_ylys-bluzrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MblsVKqsg%253D%253D&md5=9e9b168b23b986c30540cdcd7c4a7d8f</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.cdtm.2019.08.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cdtm.2019.08.006%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DB.-B.%26aulast%3DWang%26aufirst%3DB.%26aulast%3DZhu%26aufirst%3DC.-M.%26aulast%3DTang%26aufirst%3DD.%26aulast%3DPang%26aufirst%3DJ.%26aulast%3DZhao%26aufirst%3DJ.%26aulast%3DSun%26aufirst%3DC.-H.%26aulast%3DQiu%26aufirst%3DM.-J.%26aulast%3DQian%26aufirst%3DZ.-R.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Inhibitor%2520THZ1%2520in%2520Cancer%2520Therapy%26jtitle%3DChronic%2520Dis.%2520Transl.%2520Med.%26date%3D2019%26volume%3D5%26issue%3D3%26spage%3D155%26epage%3D169%26doi%3D10.1016%2Fj.cdtm.2019.08.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bandyopadhyay, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Allen, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kmieciak, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">The Covalent CDK7 Inhibitor THZ1 Potently Induces Apoptosis in Multiple Myeloma Cells in Vitro and in Vivo</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>25</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">6195</span>– <span class="NLM_lpage">6205</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-18-3788</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1078-0432.CCR-18-3788" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31358538" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BB3cXovVSnurY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2019&pages=6195-6205&issue=20&author=Y.+Zhangauthor=L.+Zhouauthor=D.+Bandyopadhyayauthor=K.+Sharmaauthor=A.+J.+Allenauthor=M.+Kmieciakauthor=S.+Grant&title=The+Covalent+CDK7+Inhibitor+THZ1+Potently+Induces+Apoptosis+in+Multiple+Myeloma+Cells+in+Vitro+and+in+Vivo&doi=10.1158%2F1078-0432.CCR-18-3788"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">The covalent CDK7 inhibitor THZI potently induces apoptosis in multiple myeloma cells in vitro and in vivo</span></div><div class="casAuthors">Zhang, Yu; Zhou, Liang; Bandyopadhyay, Dipankar; Sharma, Kanika; Allen, Alexander Joseph; Kmieciak, Maciej; Grant, Steven</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">6195-6205</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The goal of this study was to characterize the activity of the covalent CDK7 inhibitor THZ1 in multiple myeloma models.  Exptl. Design: Multiple myeloma lines were exposed to varying THZ1 concns. alone or with carfilzomib or ABT-199, after which apoptosis was monitored by flow cytometry, protein expression by Western blot anal., mRNA by RT-PCR.  Analogous studies were performed in cells ectopically expressing c-MYC, MCL-1, or BCI-XI., or CRISPER-Cas CDK7 sgRNA knockout.  Primary multiple myeloma cells were exposed to THZ1 ± carfilzomib or ABT-199.  In vivo effects ofTHZ1 were examd. in a systemic U266 xenograft model.  Results: THZ1 markedly diminished multiple myeloma cell proliferation and survival despite bortezomib orstromal cell resistance in assocn. with G2-M arrest, inactivation of CTD RNAPol H, dephosphorylation ofCDKs 7 as well as 1, 2, and 9, and MCL-1, BCL-xL, and c-MYC mRNA or protein downregulation.  Ectopic MCL-1, c-MYC, or BCL-XL expression significantly protected cells from THZ1 lethality.  Both THZ1 and CRlSPR-Cas CDK7 knockout sharply diminished multiple myeloma cell proliferation and significantly increased carfilzomib and ABT-199 lethality.  Parallel effects and interactions were obsd. in primary CD1 38+ (N = 22) or primitive multiple myeloma cells (CD138-/CD19+/ CD20+/CD27+; N = 16).  THZ1 administration [10 mg/kg i.p. twice daily (BID), 5 days/wk] significantly improved survival in a systemic multiple myeloma xenograft model with minimal toxicity and induced similar events obsd. in vitro, for example, MCL-1 and c-MYC downregulation.  Conclusions: THZ1 potently reduces multiple myeloma cell proliferation through transcriptional downregulation of MCL-1, BCL-XL and c-MYC in vitro and in vivo.  It warrants further attention as a therapeutic agent in multiple myeloma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGprGqk86OMsXrVg90H21EOLACvtfcHk0lg6FX4Yqy7pdA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXovVSnurY%253D&md5=33e5094c26df8236e7697350abb08840</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-18-3788&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-18-3788%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DBandyopadhyay%26aufirst%3DD.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DAllen%26aufirst%3DA.%2BJ.%26aulast%3DKmieciak%26aufirst%3DM.%26aulast%3DGrant%26aufirst%3DS.%26atitle%3DThe%2520Covalent%2520CDK7%2520Inhibitor%2520THZ1%2520Potently%2520Induces%2520Apoptosis%2520in%2520Multiple%2520Myeloma%2520Cells%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2019%26volume%3D25%26issue%3D20%26spage%3D6195%26epage%3D6205%26doi%3D10.1158%2F1078-0432.CCR-18-3788" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, L.</span>; <span class="NLM_string-name">Zhang, Y.</span>; <span class="NLM_string-name">Sharma, K.</span>; <span class="NLM_string-name">McCarter, J.</span>; <span class="NLM_string-name">Craun, W.</span>; <span class="NLM_string-name">Grant, S.</span></span> <span> </span><span class="NLM_article-title">Targeting Transcriptional Regulation in Multiple Myeloma with a Covalent CDK7 Inhibitor THZ1</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Zhou&author=Y.+Zhang&author=K.+Sharma&author=J.+McCarter&author=W.+Craun&author=S.+Grant&title=Targeting+Transcriptional+Regulation+in+Multiple+Myeloma+with+a+Covalent+CDK7+Inhibitor+THZ1"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DL.%26atitle%3DTargeting%2520Transcriptional%2520Regulation%2520in%2520Multiple%2520Myeloma%2520with%2520a%2520Covalent%2520CDK7%2520Inhibitor%2520THZ1%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carretero, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Al-Shahrour, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herter-Sprie, G. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Akbay, E. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altabef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Capelletti, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reibel, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavanaugh, J. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gao, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Michaelsen, S. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poulsen, H. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aref, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbie, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradner, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span> <span> </span><span class="NLM_article-title">Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor</span>. <i>Cancer Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">909</span>– <span class="NLM_lpage">922</span>, <span class="refDoi"> DOI: 10.1016/j.ccell.2014.10.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.ccell.2014.10.019" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25490451" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFyhu7fL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2014&pages=909-922&issue=6&author=C.+L.+Christensenauthor=N.+Kwiatkowskiauthor=B.+J.+Abrahamauthor=J.+Carreteroauthor=F.+Al-Shahrourauthor=T.+Zhangauthor=E.+Chipumuroauthor=G.+S.+Herter-Sprieauthor=E.+A.+Akbayauthor=A.+Altabefauthor=J.+Zhangauthor=T.+Shimamuraauthor=M.+Capellettiauthor=J.+B.+Reibelauthor=J.+D.+Cavanaughauthor=P.+Gaoauthor=Y.+Liuauthor=S.+R.+Michaelsenauthor=H.+S.+Poulsenauthor=A.+R.+Arefauthor=D.+A.+Barbieauthor=J.+E.+Bradnerauthor=R.+E.+Georgeauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=K.+K.+Wong&title=Targeting+Transcriptional+Addictions+in+Small+Cell+Lung+Cancer+with+a+Covalent+CDK7+Inhibitor&doi=10.1016%2Fj.ccell.2014.10.019"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor</span></div><div class="casAuthors">Christensen, Camilla L.; Kwiatkowski, Nicholas; Abraham, Brian J.; Carretero, Julian; Al-Shahrour, Fatima; Zhang, Tinghu; Chipumuro, Edmond; Herter-Sprie, Grit S.; Akbay, Esra A.; Altabef, Abigail; Zhang, Jianming; Shimamura, Takeshi; Capelletti, Marzia; Reibel, Jakob B.; Cavanaugh, Jillian D.; Gao, Peng; Liu, Yan; Michaelsen, Signe R.; Poulsen, Hans S.; Aref, Amir R.; Barbie, David A.; Bradner, James E.; George, Rani E.; Gray, Nathanael S.; Young, Richard A.; Wong, Kwok-Kin</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">909-922</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Small cell lung cancer (SCLC) is an aggressive disease with high mortality, and the identification of effective pharmacol. strategies to target SCLC biol. represents an urgent need.  Using a high-throughput cellular screen of a diverse chem. library, we observe that SCLC is sensitive to transcription-targeting drugs, in particular to THZ1, a recently identified covalent inhibitor of cyclin-dependent kinase 7.  We find that expression of super-enhancer-assocd. transcription factor genes, including MYC family proto-oncogenes and neuroendocrine lineage-specific factors, is highly vulnerability to THZ1 treatment.  We propose that downregulation of these transcription factors contributes, in part, to SCLC sensitivity to transcriptional inhibitors and that THZ1 represents a prototype drug for tailored SCLC therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpxt0FHVPT1YbVg90H21EOLACvtfcHk0ljTozho89ELxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFyhu7fL&md5=997a05226adc37af5f4b85416cb6c73f</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2014.10.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2014.10.019%26sid%3Dliteratum%253Aachs%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DCarretero%26aufirst%3DJ.%26aulast%3DAl-Shahrour%26aufirst%3DF.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DChipumuro%26aufirst%3DE.%26aulast%3DHerter-Sprie%26aufirst%3DG.%2BS.%26aulast%3DAkbay%26aufirst%3DE.%2BA.%26aulast%3DAltabef%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DReibel%26aufirst%3DJ.%2BB.%26aulast%3DCavanaugh%26aufirst%3DJ.%2BD.%26aulast%3DGao%26aufirst%3DP.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DMichaelsen%26aufirst%3DS.%2BR.%26aulast%3DPoulsen%26aufirst%3DH.%2BS.%26aulast%3DAref%26aufirst%3DA.%2BR.%26aulast%3DBarbie%26aufirst%3DD.%2BA.%26aulast%3DBradner%26aufirst%3DJ.%2BE.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26atitle%3DTargeting%2520Transcriptional%2520Addictions%2520in%2520Small%2520Cell%2520Lung%2520Cancer%2520with%2520a%2520Covalent%2520CDK7%2520Inhibitor%26jtitle%3DCancer%2520Cell%26date%3D2014%26volume%3D26%26issue%3D6%26spage%3D909%26epage%3D922%26doi%3D10.1016%2Fj.ccell.2014.10.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jia, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lei, K.</span></span> <span> </span><span class="NLM_article-title">Inhibition of Cyclin-Dependent Kinase 7 Suppresses Human Hepatocellular Carcinoma by Inducing Apoptosis</span>. <i>J. Cell. Biochem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>119</i></span> (<span class="NLM_issue">12</span>),  <span class="NLM_fpage">9742</span>– <span class="NLM_lpage">9751</span>, <span class="refDoi"> DOI: 10.1002/jcb.27292</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1002%2Fjcb.27292" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30145799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhsFykurfN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=119&publication_year=2018&pages=9742-9751&issue=12&author=L.+Zhongauthor=S.+Yangauthor=Y.+Jiaauthor=K.+Lei&title=Inhibition+of+Cyclin-Dependent+Kinase+7+Suppresses+Human+Hepatocellular+Carcinoma+by+Inducing+Apoptosis&doi=10.1002%2Fjcb.27292"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of cyclin-dependent kinase 7 suppresses human hepatocellular carcinoma by inducing apoptosis</span></div><div class="casAuthors">Zhong, Liqiang; Yang, Sihao; Jia, Yuming; Lei, Kaijian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Biochemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">119</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">9742-9751</span>CODEN:
                <span class="NLM_cas:coden">JCEBD5</span>;
        ISSN:<span class="NLM_cas:issn">0730-2312</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">Increasing evidence has shown that THZ1, a covalent cyclin-dependent kinase 7 (CDK7) inhibitor, exhibits therapeutic effects in various tumors.  However, the possible effect of THZ1 on hepatocellular carcinoma (HCC) remains unknown.  Our study was to investigate the roles of THZ1 in HCC cells and in s.c. HCC model and illustrate the mol. mechanisms.  The phosphorylation levels of Ser2, Ser5, and Ser7 within RNA polymerase II (RNAPII) C-terminal domain (CTD) and the expression levels of Ki67, Mcl-1, survivin, XIAP, and p53 in HCC cells under different conditions were examd. by Western blot anal.  Cell growth and apoptosis were assessed via 3-(4,5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay and flow cytometry anal., resp.  Tumor vol. was assessed in HCC mice with THZ1 or vehicle treatment and immunohistochem. (IHC) anal. was conducted on excised tumors.  THZ1 significantly inhibited the phosphorylation of Ser2, Ser5, and Ser7 within RNAPII-CTD in the dose-dependent and irreversible manner.  MTT assay and flow cytometry anal. showed that THZ1 inhibited HCC cell proliferation and induced apoptosis, resp.  Western blot anal. indicated THZ1 significantly upregulated p53 expression and downregulated the expressions of Mcl-1, survivin, XIAP, and Ki67.  THZ1 suppressed tumor growth in Hep3B xenografted mice in a time-dependent manner.  IHC anal. indicated that tumors in THZ1 group had less Ki67+ cells and more cleaved caspase-3+ cells than those in vehicle group.  THZ1 exhibited anti-HCC effects through irreversibly inhibiting CDK7 activity, decreasing RNAPII-CTD phosphorylation, inducing p53 expression and inhibiting antiapoptotic gene expressions, which subsequently induced apoptosis and inhibited proliferation of HCC cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrc2X2FBXOiurVg90H21EOLACvtfcHk0ljTozho89ELxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhsFykurfN&md5=3bc1fd9a5563a0bf328737a8ff87aff8</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1002%2Fjcb.27292&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcb.27292%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DS.%26aulast%3DJia%26aufirst%3DY.%26aulast%3DLei%26aufirst%3DK.%26atitle%3DInhibition%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520Suppresses%2520Human%2520Hepatocellular%2520Carcinoma%2520by%2520Inducing%2520Apoptosis%26jtitle%3DJ.%2520Cell.%2520Biochem.%26date%3D2018%26volume%3D119%26issue%3D12%26spage%3D9742%26epage%3D9751%26doi%3D10.1002%2Fjcb.27292" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Eliades, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miller, D. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Njauw, C. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Taylor, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsao, H.</span></span> <span> </span><span class="NLM_article-title">High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma</span>. <i>J. Invest. Dermatol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>138</i></span> (<span class="NLM_issue">7</span>),  <span class="NLM_fpage">1582</span>– <span class="NLM_lpage">1590</span>, <span class="refDoi"> DOI: 10.1016/j.jid.2017.09.056</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.jid.2017.09.056" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29408204" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXks1yqtLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=138&publication_year=2018&pages=1582-1590&issue=7&author=P.+Eliadesauthor=B.+J.+Abrahamauthor=Z.+Jiauthor=D.+M.+Millerauthor=C.+L.+Christensenauthor=N.+Kwiatkowskiauthor=R.+Kumarauthor=C.+N.+Njauwauthor=M.+Taylorauthor=B.+Miaoauthor=T.+Zhangauthor=K.+K.+Wongauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=H.+Tsao&title=High+MITF+Expression+Is+Associated+with+Super-Enhancers+and+Suppressed+by+CDK7+Inhibition+in+Melanoma&doi=10.1016%2Fj.jid.2017.09.056"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">High MITF Expression Is Associated with Super-Enhancers and Suppressed by CDK7 Inhibition in Melanoma</span></div><div class="casAuthors">Eliades, Philip; Abraham, Brian J.; Ji, Zhenyu; Miller, David M.; Christensen, Camilla L.; Kwiatkowski, Nicholas; Kumar, Raj; Njauw, Ching Ni; Taylor, Michael; Miao, Benchun; Zhang, Tinghu; Wong, Kwok-Kin; Gray, Nathanael S.; Young, Richard A.; Tsao, Hensin</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Investigative Dermatology</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">138</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1582-1590</span>CODEN:
                <span class="NLM_cas:coden">JIDEAE</span>;
        ISSN:<span class="NLM_cas:issn">0022-202X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Cutaneous melanoma is an aggressive tumor that accounts for most skin cancer deaths.  Among the physiol. barriers against therapeutic success is a strong survival program driven by genes such as MITF that specify melanocyte identity, a phenomenon known in melanoma biol. as lineage dependency.  MITF overexpression is occasionally explained by gene amplification, but here we show that super-enhancers are also important determinants of MITF overexpression in some melanoma cell lines and tumors.  Although compds. that directly inhibit MITF are unavailable, a covalent CDK7 inhibitor, THZ1, has recently been shown to potently suppress the growth of various cancers through the depletion of master transcription-regulating oncogenes and the disruption of their attendant super-enhancers.  We also show that melanoma cells are highly sensitive to CDK7 inhibition both in vitro and in vivo and that THZ1 can dismantle the super-enhancer app. at MITF and SOX10 in some cell lines, thereby extinguishing their intracellular levels.  Our results show a dimension to MITF regulation in melanoma cells and point to CDK7 inhibition as a potential strategy to deprive oncogenic transcription and suppress tumor growth in melanoma.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqMvazXe7IUebVg90H21EOLACvtfcHk0ljTozho89ELxg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXks1yqtLw%253D&md5=4b2dcbccf777375608d21585727e772a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.jid.2017.09.056&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jid.2017.09.056%26sid%3Dliteratum%253Aachs%26aulast%3DEliades%26aufirst%3DP.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DJi%26aufirst%3DZ.%26aulast%3DMiller%26aufirst%3DD.%2BM.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DKumar%26aufirst%3DR.%26aulast%3DNjauw%26aufirst%3DC.%2BN.%26aulast%3DTaylor%26aufirst%3DM.%26aulast%3DMiao%26aufirst%3DB.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DTsao%26aufirst%3DH.%26atitle%3DHigh%2520MITF%2520Expression%2520Is%2520Associated%2520with%2520Super-Enhancers%2520and%2520Suppressed%2520by%2520CDK7%2520Inhibition%2520in%2520Melanoma%26jtitle%3DJ.%2520Invest.%2520Dermatol.%26date%3D2018%26volume%3D138%26issue%3D7%26spage%3D1582%26epage%3D1590%26doi%3D10.1016%2Fj.jid.2017.09.056" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marco, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hatheway, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharma, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeung, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Altabef, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perez-Atayde, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yuan, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">George, R. E.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer</span>. <i>Cell</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>159</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">1126</span>– <span class="NLM_lpage">1139</span>, <span class="refDoi"> DOI: 10.1016/j.cell.2014.10.024</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.cell.2014.10.024" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=25416950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7zO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=159&publication_year=2014&pages=1126-1139&issue=5&author=E.+Chipumuroauthor=E.+Marcoauthor=C.+L.+Christensenauthor=N.+Kwiatkowskiauthor=T.+Zhangauthor=C.+M.+Hathewayauthor=B.+J.+Abrahamauthor=B.+Sharmaauthor=C.+Yeungauthor=A.+Altabefauthor=A.+Perez-Ataydeauthor=K.+K.+Wongauthor=G.+C.+Yuanauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=R.+E.+George&title=CDK7+Inhibition+Suppresses+Super-Enhancer-Linked+Oncogenic+Transcription+in+MYCN-Driven+Cancer&doi=10.1016%2Fj.cell.2014.10.024"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer</span></div><div class="casAuthors">Chipumuro, Edmond; Marco, Eugenio; Christensen, Camilla L.; Kwiatkowski, Nicholas; Zhang, Tinghu; Hatheway, Clark M.; Abraham, Brian J.; Sharma, Bandana; Yeung, Caleb; Altabef, Abigail; Perez-Atayde, Antonio; Wong, Kwok-Kin; Yuan, Guo-Cheng; Gray, Nathanael S.; Young, Richard A.; George, Rani E.</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">159</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1126-1139</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The MYC oncoproteins are thought to stimulate tumor cell growth and proliferation through amplification of gene transcription, a mechanism that has thwarted most efforts to inhibit MYC function as potential cancer therapy.  Using a covalent inhibitor of cyclin-dependent kinase 7 (CDK7) to disrupt the transcription of amplified MYCN in neuroblastoma cells, the authors demonstrate downregulation of the oncoprotein with consequent massive suppression of MYCN-driven global transcriptional amplification.  This response translated to significant tumor regression in a mouse model of high-risk neuroblastoma, without the introduction of systemic toxicity.  The striking treatment selectivity of MYCN-overexpressing cells correlated with preferential downregulation of super-enhancer-assocd. genes, including MYCN and other known oncogenic drivers in neuroblastoma.  These results indicate that CDK7 inhibition, by selectively targeting the mechanisms that promote global transcriptional amplification in tumor cells, may be useful therapy for cancers that are driven by MYC family oncoproteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrx7Cu3MbB2zbVg90H21EOLACvtfcHk0lg3JOP3fc0JzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvV2nu7zO&md5=670596d985b3d2ef9a557bbbbb93993f</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2014.10.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2014.10.024%26sid%3Dliteratum%253Aachs%26aulast%3DChipumuro%26aufirst%3DE.%26aulast%3DMarco%26aufirst%3DE.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DHatheway%26aufirst%3DC.%2BM.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DSharma%26aufirst%3DB.%26aulast%3DYeung%26aufirst%3DC.%26aulast%3DAltabef%26aufirst%3DA.%26aulast%3DPerez-Atayde%26aufirst%3DA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DYuan%26aufirst%3DG.%2BC.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DGeorge%26aufirst%3DR.%2BE.%26atitle%3DCDK7%2520Inhibition%2520Suppresses%2520Super-Enhancer-Linked%2520Oncogenic%2520Transcription%2520in%2520MYCN-Driven%2520Cancer%26jtitle%3DCell%26date%3D2014%26volume%3D159%26issue%3D5%26spage%3D1126%26epage%3D1139%26doi%3D10.1016%2Fj.cell.2014.10.024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mei, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, Z.</span></span> <span> </span><span class="NLM_article-title">Antitumor Effects of a Covalent Cyclin-Dependent Kinase 7 Inhibitor in Colorectal Cancer</span>. <i>Anti-Cancer Drugs</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>30</i></span> (<span class="NLM_issue">5</span>),  <span class="NLM_fpage">466</span>– <span class="NLM_lpage">474</span>, <span class="refDoi"> DOI: 10.1097/CAD.0000000000000749</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1097%2FCAD.0000000000000749" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30694816" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXnt1Sgu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2019&pages=466-474&issue=5&author=J.+Wangauthor=Z.+Liauthor=H.+Meiauthor=D.+Zhangauthor=G.+Wuauthor=T.+Zhangauthor=Z.+Lin&title=Antitumor+Effects+of+a+Covalent+Cyclin-Dependent+Kinase+7+Inhibitor+in+Colorectal+Cancer&doi=10.1097%2FCAD.0000000000000749"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Antitumor effects of a covalent cyclin-dependent kinase 7 inhibitor in colorectal cancer</span></div><div class="casAuthors">Wang, Jian; Li, Zhenyu; Mei, Hong; Zhang, Dejun; Wu, Gang; Zhang, Tao; Lin, Zhenyu</div><div class="citationInfo"><span class="NLM_cas:title">Anti-Cancer Drugs</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">466-474</span>CODEN:
                <span class="NLM_cas:coden">ANTDEV</span>;
        ISSN:<span class="NLM_cas:issn">0959-4973</span>.
    
            (<span class="NLM_cas:orgname">Lippincott Williams & Wilkins</span>)
        </div><div class="casAbstract">Although both antiepidermal growth factor receptor and vascular endothelial growth factor therapies have been shown to be effective against colorectal cancer (CRC), their beneficial effects are limited to a small proportion of patients and are not sustainable.  Cyclin-dependent kinase 7 (CDK7) is an important regulator of the transcriptional machinery.  Use of small-mol. inhibitors of the transcriptional machinery has shown promising selectivity for cancer cells and potent antiproliferative effects.  In this study, the effects of a covalent CDK7 inhibitor THZ1 as a potent anti-CRC compd. were evaluated in vitro and in vivo.  THZ1 significantly inhibited cell growth and induced apoptosis of CRC cells in vitro.  In addn., it also decreased xenograft tumor growth in vivo.  RNA-Seq showed that THZ1 induced inhibition of a no. of oncogenic transcripts.  Taken together, our results indicate that pharmacol. modulation of CDK7 kinase activity by THZ1 may represent a potential strategy in the treatment of CRC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrrRw9_3bpukrVg90H21EOLACvtfcHk0lg3JOP3fc0JzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXnt1Sgu7o%253D&md5=945b1cd2145b82e9dd2102306009a72c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1097%2FCAD.0000000000000749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252FCAD.0000000000000749%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DZ.%26aulast%3DMei%26aufirst%3DH.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DWu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DLin%26aufirst%3DZ.%26atitle%3DAntitumor%2520Effects%2520of%2520a%2520Covalent%2520Cyclin-Dependent%2520Kinase%25207%2520Inhibitor%2520in%2520Colorectal%2520Cancer%26jtitle%3DAnti-Cancer%2520Drugs%26date%3D2019%26volume%3D30%26issue%3D5%26spage%3D466%26epage%3D474%26doi%3D10.1097%2FCAD.0000000000000749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhong, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di, W.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibitor Suppresses Tumor Progression Through Blocking the Cell Cycle at the G2/M Phase and Inhibiting Transcriptional Activity in Cervical Cancer</span>. <i>OncoTargets Ther.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">2137</span>– <span class="NLM_lpage">2147</span>, <span class="refDoi"> DOI: 10.2147/OTT.S195655</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.2147%2FOTT.S195655" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30962695" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXisVGrsLbJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2019&pages=2137-2147&author=S.+Zhongauthor=Y.+Zhangauthor=X.+Yinauthor=W.+Di&title=CDK7+Inhibitor+Suppresses+Tumor+Progression+Through+Blocking+the+Cell+Cycle+at+the+G2%2FM+Phase+and+Inhibiting+Transcriptional+Activity+in+Cervical+Cancer&doi=10.2147%2FOTT.S195655"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer</span></div><div class="casAuthors">Zhong, Shanshan; Zhang, Yi; Yin, Xia; Wen, Di-</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2137-2147</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">Background: The disordered cell cycle and dysregulated expression of numerous oncogenes involved in tumor-relevant processes are highly related to the tumorigenesis of cervical cancer.  Cyclin-dependent kinase 7 (CDK7) constitutes the indispensable catalytic subunit of CDKactivating kinase (CAK), which is required for both cell cycle transition and transcriptional regulation.  However, research regarding the antitumor effects of CDK7 inhibition in cervical cancer remains unclear.  Purpose: Our study aims to explore the antineoplastic effects of the CDK7 inhibitor THZ1 in cervical cancer cells and to find a potential agent for cervical cancer treatment.  Methods: The CRISPR-Cas9 system was used to knock down CDK7.  The Cell Counting Kit-8 (CCK-8) assay was used to detect the cell viability after CDK7 depletion and THZ1 treatment.  Western blot was employed to detect protein expression.  The expression levels of mRNA were assayed through qRT-PCR.  Flow cytometry anal. was used to assay the apoptotic cells and cell cycle distribution.  Gene expression microarray anal. was used to identify the differential expression of the genes.  S.c. xenograft mouse model was performed to test the antineoplastic effects of THZ1 in vivo.  Results: We revealed that the genetic depletion of CDK7 using the CRISPR-Cas9 system exhibited great cell growth inhibition in cervical cancer cell lines, consistent with the effects of CDK7 blocking using THZ1.  Cervical cancer cells were highly sensitive to THZ1 treatment, and a low concn. of THZ1 could induce substantial cell apoptosis.  THZ1 specifically perturbed the phosphorylation of cell cycle regulator CDK1 and decreased the expression of cyclin B1, leading to a cell cycle blockage at the G2/M phase and inducing cell growth inhibition.  The gene expression microarray anal. showed that massive oncogene transcripts, esp. those assocd. with tumorigenesis, were preferential suppressed after THZ1 treatment.  The qRT-PCR confirmed that several essential oncogenes in tumorigenesis (c-MYC, hTERT, RAD51, and BCL-2) and HPV viral oncogenes (E6 and E7) were preferentially repressed by THZ1.  Moreover, THZ1 exhibited substantial antineoplastic effects against cervical cancer in vivo without inducing obvious side effects.  Conclusion: These findings indicated that the CDK7 inhibitor THZ1 is a potential option in cervical cancer treatment owing to its ability to inhibit cell cycle progression and transcriptional activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrXsB5OOp0K87Vg90H21EOLACvtfcHk0lg3JOP3fc0JzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXisVGrsLbJ&md5=37ac3c921d08da0cb85a6bc871ee00ad</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.2147%2FOTT.S195655&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S195655%26sid%3Dliteratum%253Aachs%26aulast%3DZhong%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DYin%26aufirst%3DX.%26aulast%3DDi%26aufirst%3DW.%26atitle%3DCDK7%2520Inhibitor%2520Suppresses%2520Tumor%2520Progression%2520Through%2520Blocking%2520the%2520Cell%2520Cycle%2520at%2520the%2520G2%252FM%2520Phase%2520and%2520Inhibiting%2520Transcriptional%2520Activity%2520in%2520Cervical%2520Cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2019%26volume%3D12%26spage%3D2137%26epage%3D2147%26doi%3D10.2147%2FOTT.S195655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Huang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ding, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cao, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lv, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, X.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibitor THZ1 Inhibits MCL1 Synthesis and Drives Cholangiocarcinoma Apoptosis in Combination with BCL2/BCL-XL Inhibitor ABT-263</span>. <i>Cell Death Dis.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>10</i></span> (<span class="NLM_issue">8</span>),  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">14</span>, <span class="refDoi"> DOI: 10.1038/s41419-019-1831-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41419-019-1831-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2019&pages=1-14&issue=8&author=T.+Huangauthor=X.+Dingauthor=G.+Xuauthor=G.+Chenauthor=Y.+Caoauthor=C.+Pengauthor=S.+Shenauthor=Y.+Lvauthor=L.+Wangauthor=X.+Zou&title=CDK7+Inhibitor+THZ1+Inhibits+MCL1+Synthesis+and+Drives+Cholangiocarcinoma+Apoptosis+in+Combination+with+BCL2%2FBCL-XL+Inhibitor+ABT-263&doi=10.1038%2Fs41419-019-1831-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of STAT3 in tubular epithelial cells prevents kidney fibrosis and nephropathy in STZ-induced diabetic mice</span></div><div class="casAuthors">Zheng, Chao; Huang, Lan; Luo, Wu; Yu, Weihui; Hu, Xueting; Guan, Xinfu; Cai, Yan; Zou, Chunpeng; Yin, Haimin; Xu, Zheng; Liang, Guang; Wang, Yi</div><div class="citationInfo"><span class="NLM_cas:title">Cell Death & Disease</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1-14</span>CODEN:
                <span class="NLM_cas:coden">CDDEA4</span>;
        ISSN:<span class="NLM_cas:issn">2041-4889</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Recent evidences indicate that signal transducer and activator of transcription 3 (STAT3) is one of the crucial signaling pathways in the progression of diabetic nephropathy (DN).  Here, we investigated the hypothesis that pharmacol. blockade of STAT3 limits the progression of DN.  Treatment with selective STAT3 inhibitor, S3I-201 for 16 wk significantly attenuated kidney injuries in streptozotocin (STZ) induced diabetic mice, assocd. with downregulated expression of TGF-β1, ACE/AT1, and VEGF in diabetic mouse kidneys.  Similar results were confirmed using genetic knockdown of STAT3 in mouse kidneys by injections of AAV2 expressing STAT3 shRNA in diabetic mouse.  Further, STAT3 localization in kidney tissue was evaluated using immunofluorescent double-staining anal., which indicated that STAT3 expression was mainly in the tubular epithelial cells.  As expected, in renal tubular epithelial NRK-52E cells, high glucose (HG)-induced overexpression of TGF-β1, ACE/AT1, and VEGF were abrogated by S3I-201 pretreatment, as well as by genetic knockdown of STAT3 using specific siRNA sequence.  This study found that renal tubular epithelial cells contributed to STAT3-mediated progression of DN and provided the first evidence that pharmacol. inhibition of STAT3 attenuates DN.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpNeWGXpYwe97Vg90H21EOLACvtfcHk0lgSPgTFFIOZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitFWmsrvK&md5=541b619566f2d2bb80169c5ef0c7a2ac</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1038%2Fs41419-019-1831-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41419-019-1831-7%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DT.%26aulast%3DDing%26aufirst%3DX.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DChen%26aufirst%3DG.%26aulast%3DCao%26aufirst%3DY.%26aulast%3DPeng%26aufirst%3DC.%26aulast%3DShen%26aufirst%3DS.%26aulast%3DLv%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DZou%26aufirst%3DX.%26atitle%3DCDK7%2520Inhibitor%2520THZ1%2520Inhibits%2520MCL1%2520Synthesis%2520and%2520Drives%2520Cholangiocarcinoma%2520Apoptosis%2520in%2520Combination%2520with%2520BCL2%252FBCL-XL%2520Inhibitor%2520ABT-263%26jtitle%3DCell%2520Death%2520Dis.%26date%3D2019%26volume%3D10%26issue%3D8%26spage%3D1%26epage%3D14%26doi%3D10.1038%2Fs41419-019-1831-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rasool, R. u.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natesan, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aras, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lal, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sander Effron, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell-Velasquez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Posimo, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carskadon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baca, S. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pomerantz, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siddiqui, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schwartz, L. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, D. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palanisamy, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Narla, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Den, R. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freedman, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brady, D. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Asangani, I. A.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer Through MED1 Inactivation</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">11</span>),  <span class="NLM_fpage">1538</span>– <span class="NLM_lpage">1555</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-19-0189</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F2159-8290.CD-19-0189" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31466944" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3MrjtlOnsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=1538-1555&issue=11&author=R.+u.+Rasoolauthor=R.+Natesanauthor=Q.+Dengauthor=S.+Arasauthor=P.+Lalauthor=S.+Sander+Effronauthor=E.+Mitchell-Velasquezauthor=J.+M.+Posimoauthor=S.+Carskadonauthor=S.+C.+Bacaauthor=M.+M.+Pomerantzauthor=J.+Siddiquiauthor=L.+E.+Schwartzauthor=D.+J.+Leeauthor=N.+Palanisamyauthor=G.+Narlaauthor=R.+B.+Denauthor=M.+L.+Freedmanauthor=D.+C.+Bradyauthor=I.+A.+Asangani&title=CDK7+Inhibition+Suppresses+Castration-Resistant+Prostate+Cancer+Through+MED1+Inactivation&doi=10.1158%2F2159-8290.CD-19-0189"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation</span></div><div class="casAuthors">Rasool Reyaz Ur; Natesan Ramakrishnan; Deng Qu; Aras Shweta; Sander Effron Samuel; Mitchell-Velasquez Erick; Posimo Jessica M; Brady Donita C; Asangani Irfan A; Lal Priti; Schwartz Lauren E; Carskadon Shannon; Palanisamy Nallasivam; Baca Sylvan C; Pomerantz Mark M; Freedman Matthew L; Siddiqui Javed; Lee Daniel J; Narla Goutham; Den Robert B; Brady Donita C; Asangani Irfan A; Asangani Irfan A</div><div class="citationInfo"><span class="NLM_cas:title">Cancer discovery</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1538-1555</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Metastatic castration-resistant prostate cancer (CRPC) is a fatal disease, primarily resulting from the transcriptional addiction driven by androgen receptor (AR).  First-line CRPC treatments typically target AR signaling, but are rapidly bypassed, resulting in only a modest survival benefit with antiandrogens.  Therapeutic approaches that more effectively block the AR-transcriptional axis are urgently needed.  Here, we investigated the molecular mechanism underlying the association between the transcriptional coactivator MED1 and AR as a vulnerability in AR-driven CRPC.  MED1 undergoes CDK7-dependent phosphorylation at T1457 and physically engages AR at superenhancer sites, and is essential for AR-mediated transcription.  In addition, a CDK7-specific inhibitor, THZ1, blunts AR-dependent neoplastic growth by blocking AR/MED1 corecruitment genome-wide, as well as reverses the hyperphosphorylated MED1-associated enzalutamide-resistant phenotype.  In vivo, THZ1 induces tumor regression of AR-amplified human CRPC in a xenograft mouse model.  Together, we demonstrate that CDK7 inhibition selectively targets MED1-mediated, AR-dependent oncogenic transcriptional amplification, thus representing a potential new approach for the treatment of CRPC.  SIGNIFICANCE: Potent inhibition of AR signaling is critical to treat CRPC.  This study uncovers a driver role for CDK7 in regulating AR-mediated transcription through phosphorylation of MED1, thus revealing a therapeutically targetable potential vulnerability in AR-addicted CRPC.See related commentary by Russo et al., p. 1490.This article is highlighted in the In This Issue feature, p. 1469.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSzekStj1oHtMuCWE5mhx1RfW6udTcc2eaJy4Xme3aK-bntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3MrjtlOnsQ%253D%253D&md5=46aaa9c4a5aef7793444e97ac6faff4d</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-19-0189&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-19-0189%26sid%3Dliteratum%253Aachs%26aulast%3DRasool%26aufirst%3DR.%2Bu.%26aulast%3DNatesan%26aufirst%3DR.%26aulast%3DDeng%26aufirst%3DQ.%26aulast%3DAras%26aufirst%3DS.%26aulast%3DLal%26aufirst%3DP.%26aulast%3DSander%2BEffron%26aufirst%3DS.%26aulast%3DMitchell-Velasquez%26aufirst%3DE.%26aulast%3DPosimo%26aufirst%3DJ.%2BM.%26aulast%3DCarskadon%26aufirst%3DS.%26aulast%3DBaca%26aufirst%3DS.%2BC.%26aulast%3DPomerantz%26aufirst%3DM.%2BM.%26aulast%3DSiddiqui%26aufirst%3DJ.%26aulast%3DSchwartz%26aufirst%3DL.%2BE.%26aulast%3DLee%26aufirst%3DD.%2BJ.%26aulast%3DPalanisamy%26aufirst%3DN.%26aulast%3DNarla%26aufirst%3DG.%26aulast%3DDen%26aufirst%3DR.%2BB.%26aulast%3DFreedman%26aufirst%3DM.%2BL.%26aulast%3DBrady%26aufirst%3DD.%2BC.%26aulast%3DAsangani%26aufirst%3DI.%2BA.%26atitle%3DCDK7%2520Inhibition%2520Suppresses%2520Castration-Resistant%2520Prostate%2520Cancer%2520Through%2520MED1%2520Inactivation%26jtitle%3DCancer%2520Discovery%26date%3D2019%26volume%3D9%26issue%3D11%26spage%3D1538%26epage%3D1555%26doi%3D10.1158%2F2159-8290.CD-19-0189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lu, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geng, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niu, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Z.-G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, Y.-W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, L. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xue, J.</span></span> <span> </span><span class="NLM_article-title">THZ1 Reveals CDK7-Dependent Transcriptional Addictions in Pancreatic Cancer</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>38</i></span> (<span class="NLM_issue">20</span>),  <span class="NLM_fpage">3932</span>– <span class="NLM_lpage">3945</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-0701-1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41388-019-0701-1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30692639" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXmtVGgtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2019&pages=3932-3945&issue=20&author=P.+Luauthor=J.+Gengauthor=L.+Zhangauthor=Y.+Wangauthor=N.+Niuauthor=Y.+Fangauthor=F.+Liuauthor=J.+Shiauthor=Z.-G.+Zhangauthor=Y.-W.+Sunauthor=L.+W.+Wangauthor=Y.+Tangauthor=J.+Xue&title=THZ1+Reveals+CDK7-Dependent+Transcriptional+Addictions+in+Pancreatic+Cancer&doi=10.1038%2Fs41388-019-0701-1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 reveals CDK7-dependent transcriptional addictions in pancreatic cancer</span></div><div class="casAuthors">Lu, Ping; Geng, Jing; Zhang, Lei; Wang, Yu; Niu, Ningning; Fang, Yuan; Liu, Fang; Shi, Juanjuan; Zhang, Zhi-Gang; Sun, Yong-Wei; Wang, Li-Wei; Tang, Yujie; Xue, Jing</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">3932-3945</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with high mortality.  Lack of effective treatment makes novel therapeutic discovery an urgent demand in PDAC research.  By screening an epigenetic-related compd. library, we identified THZ1, a covalent inhibitor of CDK7, as a promising candidate.  Multiple long-established and patient-derived PDAC cell lines (PDC) were used to validate the efficacy of THZ1 in vitro.  In addn., patient-derived xenograft (PDX) models and animal models of PDAC were utilized for examg. THZ1 efficacy in vivo.  Furthermore, RNA-Seq analyze was performed to reveal the mol. mechanism of THZ1 treatment.  Finally, PDAC cell lines with primary or acquired resistance to THZ1 were investigated to explore the potential mechanism of THZ1 susceptibility.  CDK7 inhibition was identified as a selective and potent therapeutic strategy for PDAC progression in multiple preclin. models.  Mechanistic analyses revealed that CDK7 inhibition led to a pronounced downregulation of gene transcription, with a preferential repression of mitotic cell cycle and NF-κB signaling-related transcripts.  MYC transcriptional was found to be involved in susceptibility of PDAC cells to CDK7 inhibition.  In conclusion, Identification of CDK7-dependent transcriptional addiction in PDACs provides a potent therapeutic strategy that targets highly aggressive pancreatic cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpUteB_Lo01sLVg90H21EOLACvtfcHk0lgSPgTFFIOZKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXmtVGgtrg%253D&md5=86a9469f12f594c9cf42e8826ddd02f1</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-0701-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-0701-1%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DP.%26aulast%3DGeng%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DNiu%26aufirst%3DN.%26aulast%3DFang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DShi%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DZ.-G.%26aulast%3DSun%26aufirst%3DY.-W.%26aulast%3DWang%26aufirst%3DL.%2BW.%26aulast%3DTang%26aufirst%3DY.%26aulast%3DXue%26aufirst%3DJ.%26atitle%3DTHZ1%2520Reveals%2520CDK7-Dependent%2520Transcriptional%2520Addictions%2520in%2520Pancreatic%2520Cancer%26jtitle%3DOncogene%26date%3D2019%26volume%3D38%26issue%3D20%26spage%3D3932%26epage%3D3945%26doi%3D10.1038%2Fs41388-019-0701-1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabet, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hao, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Palakurthi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zeng, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kirschmeier, P. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meghani, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qi, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, J. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lin, C. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span> <span> </span><span class="NLM_article-title">Targeting MYC Dependency in Ovarian Cancer Through Inhibition of CDK7 and CDK12/13</span>. <i>eLife</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>7</i></span>, <span class="NLM_elocation-id">e39030</span> <span class="refDoi"> DOI: 10.7554/eLife.39030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.7554%2FeLife.39030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30422115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXitlyqsbvK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2018&author=M.+Zengauthor=N.+P.+Kwiatkowskiauthor=T.+Zhangauthor=B.+Nabetauthor=M.+Xuauthor=Y.+Liangauthor=C.+Quanauthor=J.+Wangauthor=M.+Haoauthor=S.+Palakurthiauthor=S.+Zhouauthor=Q.+Zengauthor=P.+T.+Kirschmeierauthor=K.+Meghaniauthor=A.+L.+Leggettauthor=J.+Qiauthor=G.+I.+Shapiroauthor=J.+F.+Liuauthor=U.+A.+Matulonisauthor=C.+Y.+Linauthor=P.+A.+Konstantinopoulosauthor=N.+S.+Gray&title=Targeting+MYC+Dependency+in+Ovarian+Cancer+Through+Inhibition+of+CDK7+and+CDK12%2F13&doi=10.7554%2FeLife.39030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13</span></div><div class="casAuthors">Zeng, Mei; Kwiatkowski, Nicholas P.; Zhang, Tinghu; Nabet, Behnam; Xu, Mousheng; Liang, Yanke; Quan, Chunshan; Wang, Jinhua; Hao, Mingfeng; Palakurthi, Sangeetha; Zhou, Shan; Zeng, Qing; Kirschmeier, Paul T.; Meghani, Khyati; Leggett, Alan L.; Qi, Jun; Shapiro, Geoffrey I.; Liu, Joyce F.; Matulonis, Ursula A.; Lin, Charles Y.; Konstantinopoulos, Panagiotis A.; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">eLife</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">e39030/1-e39030/20</span>CODEN:
                <span class="NLM_cas:coden">ELIFA8</span>;
        ISSN:<span class="NLM_cas:issn">2050-084X</span>.
    
            (<span class="NLM_cas:orgname">eLife Sciences Publications Ltd.</span>)
        </div><div class="casAbstract">High-grade serous ovarian cancer is characterized by extensive copy no. alterations, among which the amplification of MYC oncogene occurs in nearly half of tumors.  We demonstrate that ovarian cancer cells highly depend on MYC for maintaining their oncogenic growth, indicating MYC as a therapeutic target for this difficult-to-treat malignancy.  However, targeting MYC directly has proven difficult.  We screen small mols. targeting transcriptional and epigenetic regulation, and find that THZ1 - a chem. inhibiting CDK7, CDK12, and CDK13 - markedly downregulates MYC.  Notably, abolishing MYC expression cannot be achieved by targeting CDK7 alone, but requires the combined inhibition of CDK7, CDK12, and CDK13.  In 11 patient-derived xenografts models derived from heavily pre-treated ovarian cancer patients, administration of THZ1 induces significant tumor growth inhibition with concurrent abrogation of MYC expression.  Our study indicates that targeting these transcriptional CDKs with agents such as THZ1 may be an effective approach for MYC-dependent ovarian malignancies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrn2iDbCK3ukbVg90H21EOLACvtfcHk0ljA5T5BCf4brA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXitlyqsbvK&md5=40f9184065a1e4551f043ec7eb1cf30d</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.7554%2FeLife.39030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7554%252FeLife.39030%26sid%3Dliteratum%253Aachs%26aulast%3DZeng%26aufirst%3DM.%26aulast%3DKwiatkowski%26aufirst%3DN.%2BP.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DNabet%26aufirst%3DB.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DLiang%26aufirst%3DY.%26aulast%3DQuan%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DHao%26aufirst%3DM.%26aulast%3DPalakurthi%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DS.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DKirschmeier%26aufirst%3DP.%2BT.%26aulast%3DMeghani%26aufirst%3DK.%26aulast%3DLeggett%26aufirst%3DA.%2BL.%26aulast%3DQi%26aufirst%3DJ.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DLiu%26aufirst%3DJ.%2BF.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26aulast%3DLin%26aufirst%3DC.%2BY.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DTargeting%2520MYC%2520Dependency%2520in%2520Ovarian%2520Cancer%2520Through%2520Inhibition%2520of%2520CDK7%2520and%2520CDK12%252F13%26jtitle%3DeLife%26date%3D2018%26volume%3D7%26doi%3D10.7554%2FeLife.39030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zou, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xie, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yin, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, J.</span></span> <span> </span><span class="NLM_article-title">Targeting Super-Enhancer-Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor</span>. <i>Clin. Cancer Res.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>, <span class="refDoi"> DOI: 10.1158/1078-0432.CCR-19-1418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F1078-0432.CCR-19-1418" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2020&author=J.+Zhangauthor=W.+Liuauthor=C.+Zouauthor=Z.+Zhaoauthor=Y.+Laiauthor=Z.+Shiauthor=X.+Xieauthor=G.+Huangauthor=Y.+Wangauthor=X.+Zhangauthor=Z.+Fanauthor=Q.+Suauthor=J.+Yinauthor=J.+Shen&title=Targeting+Super-Enhancer-Associated+Oncogenes+in+Osteosarcoma+with+THZ2%2C+a+Covalent+CDK7+Inhibitor&doi=10.1158%2F1078-0432.CCR-19-1418"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-19-1418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-19-1418%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DW.%26aulast%3DZou%26aufirst%3DC.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLai%26aufirst%3DY.%26aulast%3DShi%26aufirst%3DZ.%26aulast%3DXie%26aufirst%3DX.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DX.%26aulast%3DFan%26aufirst%3DZ.%26aulast%3DSu%26aufirst%3DQ.%26aulast%3DYin%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DJ.%26atitle%3DTargeting%2520Super-Enhancer-Associated%2520Oncogenes%2520in%2520Osteosarcoma%2520with%2520THZ2%252C%2520a%2520Covalent%2520CDK7%2520Inhibitor%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2020%26doi%3D10.1158%2F1078-0432.CCR-19-1418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Johannessen, L.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Eaton, M.</span>; <span class="NLM_string-name">McKeown, M.</span>; <span class="NLM_string-name">Tyner, J. W.</span>; <span class="NLM_string-name">Kurtz, S. E.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">di Tomaso, E.</span></span> <span> </span><span class="NLM_article-title">Sy-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Anti-Tumor Activity in Preclinical Models of Hematologic Malignancies, and Demonstrates Interactions with the BCL-XL/BCL2 Mitochondrial Apoptosis Signaling Pathway in Leukemia</span>.  <i>Proceedings of the 59th ASH Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Dec 7, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=G.+Hodgson&author=L.+Johannessen&author=N.+Rajagopal&author=S.+Hu&author=D.+Orlando&author=M.+Eaton&author=M.+McKeown&author=J.+W.+Tyner&author=S.+E.+Kurtz&author=K.+Sprott&author=C.+Fritz&author=E.+di+Tomaso&title=Sy-1365%2C+a+Potent+and+Selective+CDK7+Inhibitor%2C+Exhibits+Anti-Tumor+Activity+in+Preclinical+Models+of+Hematologic+Malignancies%2C+and+Demonstrates+Interactions+with+the+BCL-XL%2FBCL2+Mitochondrial+Apoptosis+Signaling+Pathway+in+Leukemia"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHodgson%26aufirst%3DG.%26atitle%3DSy-1365%252C%2520a%2520Potent%2520and%2520Selective%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520Anti-Tumor%2520Activity%2520in%2520Preclinical%2520Models%2520of%2520Hematologic%2520Malignancies%252C%2520and%2520Demonstrates%2520Interactions%2520with%2520the%2520BCL-XL%252FBCL2%2520Mitochondrial%2520Apoptosis%2520Signaling%2520Pathway%2520in%2520Leukemia%26jtitle%3DProceedings%2520of%2520the%252059th%2520ASH%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Johannessen, L.</span>; <span class="NLM_string-name">Liu, J. F.</span>; <span class="NLM_string-name">Kirschmeier, P. T.</span>; <span class="NLM_string-name">Zhou, S.</span>; <span class="NLM_string-name">Tran, C. A.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">di Tomaso, E.</span>; <span class="NLM_string-name">Matulonis, U. A.</span></span> <span> </span><span class="NLM_article-title">SY-1365, a Selective CDK7 Inhibitor, Exhibits Potent Antitumor Activity Against Ovarian Cancer Models in Vitro and in Vivo</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=P.+A.+Konstantinopoulos&author=G.+Hodgson&author=N.+Rajagopal&author=L.+Johannessen&author=J.+F.+Liu&author=P.+T.+Kirschmeier&author=S.+Zhou&author=C.+A.+Tran&author=D.+Orlando&author=C.+Fritz&author=E.+di+Tomaso&author=U.+A.+Matulonis&title=SY-1365%2C+a+Selective+CDK7+Inhibitor%2C+Exhibits+Potent+Antitumor+Activity+Against+Ovarian+Cancer+Models+in+Vitro+and+in+Vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26atitle%3DSY-1365%252C%2520a%2520Selective%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520Potent%2520Antitumor%2520Activity%2520Against%2520Ovarian%2520Cancer%2520Models%2520in%2520Vitro%2520and%2520in%2520Vivo%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Ke, N.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Miljovska, S.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">McKeown, M.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Choi, Y. J.</span>; <span class="NLM_string-name">Olson, E.</span>; <span class="NLM_string-name">Fritz, C. C.</span></span> <span> </span><span class="NLM_article-title">SY-1365, a Potent and Selective CDK7 Inhibitor, Exhibits Promising Anti-Tumor Activity in Multiple Preclinical Models of Aggressive Solid Tumors</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Apr 1–5, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=S.+Hu&author=N.+Ke&author=Y.+Ren&author=S.+Miljovska&author=N.+Rajagopal&author=M.+McKeown&author=D.+Orlando&author=K.+Sprott&author=Y.+J.+Choi&author=E.+Olson&author=C.+C.+Fritz&title=SY-1365%2C+a+Potent+and+Selective+CDK7+Inhibitor%2C+Exhibits+Promising+Anti-Tumor+Activity+in+Multiple+Preclinical+Models+of+Aggressive+Solid+Tumors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26atitle%3DSY-1365%252C%2520a%2520Potent%2520and%2520Selective%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520Promising%2520Anti-Tumor%2520Activity%2520in%2520Multiple%2520Preclinical%2520Models%2520of%2520Aggressive%2520Solid%2520Tumors%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">McKeown, M.</span>; <span class="NLM_string-name">Bush, A.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Olson, E.</span>; <span class="NLM_string-name">di Tomaso, E.</span></span> <span> </span><span class="NLM_article-title">BCL2L1 (BCL-XL) Expression and MYC Super-Enhancer Positivity Predict Sensitivity to the Covalent CDK7 Inhibitor SY-1365 in Triple Negative Breast Cancer (TNBC) Cell Lines</span>.  <i>Proceedings of the 2017 SABCS</i>; <span class="NLM_publisher-loc">San Antonio, TX</span>, Dec 5–9, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=N.+Rajagopal&author=G.+Hodgson&author=S.+Hu&author=M.+McKeown&author=A.+Bush&author=C.+Fritz&author=D.+Orlando&author=E.+Olson&author=E.+di+Tomaso&title=Proceedings+of+the+2017+SABCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DRajagopal%26aufirst%3DN.%26atitle%3DBCL2L1%2520%2528BCL-XL%2529%2520Expression%2520and%2520MYC%2520Super-Enhancer%2520Positivity%2520Predict%2520Sensitivity%2520to%2520the%2520Covalent%2520CDK7%2520Inhibitor%2520SY-1365%2520in%2520Triple%2520Negative%2520Breast%2520Cancer%2520%2528TNBC%2529%2520Cell%2520Lines%26btitle%3DProceedings%2520of%2520the%25202017%2520SABCS%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span>; <span class="NLM_string-name">Papadopoulos, K.</span>; <span class="NLM_string-name">Tolcher, A.</span>; <span class="NLM_string-name">Do, K.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Zamboni, W.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">di Tomaso, E.</span>; <span class="NLM_string-name">Stephens, K.</span>; <span class="NLM_string-name">Roth, D.</span>; <span class="NLM_string-name">Shapiro, G.</span></span> <span> </span><span class="NLM_article-title">Proof-of-Mechanism Based on Target Engagement and Modulation of Gene Expression Following Treatment with SY-1365, a First-in-Class Selective CDK7 Inhibitor in Phase 1 Patients with Advanced Cancer</span>.  <i>Proceedings of the 30th EORTC-NCI-AACR Symposium</i>; <span class="NLM_publisher-loc">Dublin, Ireland</span>, Nov 13–16, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=D.+Juric&author=K.+Papadopoulos&author=A.+Tolcher&author=K.+Do&author=D.+Orlando&author=W.+Zamboni&author=G.+Hodgson&author=E.+di+Tomaso&author=K.+Stephens&author=D.+Roth&author=G.+Shapiro&title=Proceedings+of+the+30th+EORTC-NCI-AACR+Symposium"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJuric%26aufirst%3DD.%26atitle%3DProof-of-Mechanism%2520Based%2520on%2520Target%2520Engagement%2520and%2520Modulation%2520of%2520Gene%2520Expression%2520Following%2520Treatment%2520with%2520SY-1365%252C%2520a%2520First-in-Class%2520Selective%2520CDK7%2520Inhibitor%2520in%2520Phase%25201%2520Patients%2520with%2520Advanced%2520Cancer%26btitle%3DProceedings%2520of%2520the%252030th%2520EORTC-NCI-AACR%2520Symposium%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Shapiro, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Papadopoulos, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Do, K. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Juric, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jeseslsohn, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Konstantinopoulos, P. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matulonis, U. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodgson, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">DiTomaso, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stephens, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roth, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A. W.</span></span> <span> </span><span class="NLM_article-title">Trial Design of a First-in-Human Phase 1 Evaluation of SY-1365, a First-in-Class Selective CDK7 Inhibitor, with Initial Expansions in Ovarian and Breast Cancer</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">15_suppl</span>),  <span class="NLM_fpage">TPS2600</span>– <span class="NLM_lpage">TPS2600</span>, <span class="refDoi"> DOI: 10.1200/JCO.2018.36.15_suppl.TPS2600</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1200%2FJCO.2018.36.15_suppl.TPS2600" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2018&pages=TPS2600-TPS2600&issue=15_suppl&author=G.+Shapiroauthor=K.+P.+Papadopoulosauthor=K.+T.+Doauthor=D.+Juricauthor=R.+Jeseslsohnauthor=P.+A.+Konstantinopoulosauthor=U.+A.+Matulonisauthor=G.+Hodgsonauthor=E.+DiTomasoauthor=K.+Stephensauthor=D.+A.+Rothauthor=A.+W.+Tolcher&title=Trial+Design+of+a+First-in-Human+Phase+1+Evaluation+of+SY-1365%2C+a+First-in-Class+Selective+CDK7+Inhibitor%2C+with+Initial+Expansions+in+Ovarian+and+Breast+Cancer&doi=10.1200%2FJCO.2018.36.15_suppl.TPS2600"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1200%2FJCO.2018.36.15_suppl.TPS2600&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2018.36.15_suppl.TPS2600%26sid%3Dliteratum%253Aachs%26aulast%3DShapiro%26aufirst%3DG.%26aulast%3DPapadopoulos%26aufirst%3DK.%2BP.%26aulast%3DDo%26aufirst%3DK.%2BT.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DJeseslsohn%26aufirst%3DR.%26aulast%3DKonstantinopoulos%26aufirst%3DP.%2BA.%26aulast%3DMatulonis%26aufirst%3DU.%2BA.%26aulast%3DHodgson%26aufirst%3DG.%26aulast%3DDiTomaso%26aufirst%3DE.%26aulast%3DStephens%26aufirst%3DK.%26aulast%3DRoth%26aufirst%3DD.%2BA.%26aulast%3DTolcher%26aufirst%3DA.%2BW.%26atitle%3DTrial%2520Design%2520of%2520a%2520First-in-Human%2520Phase%25201%2520Evaluation%2520of%2520SY-1365%252C%2520a%2520First-in-Class%2520Selective%2520CDK7%2520Inhibitor%252C%2520with%2520Initial%2520Expansions%2520in%2520Ovarian%2520and%2520Breast%2520Cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2018%26volume%3D36%26issue%3D15_suppl%26spage%3DTPS2600%26epage%3DTPS2600%26doi%3D10.1200%2FJCO.2018.36.15_suppl.TPS2600" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tolcher, A.</span>; <span class="NLM_string-name">Do, K.</span>; <span class="NLM_string-name">di Tomaso, E.</span>; <span class="NLM_string-name">Waters, N.</span>; <span class="NLM_string-name">Stephens, K.</span>; <span class="NLM_string-name">Roth, D.</span>; <span class="NLM_string-name">Shapiro, G.</span></span> <span> </span><span class="NLM_article-title">A Phase 1 Study of SY-1365, a Selective CDK7 Inhibitor, in Adult Patients with Advanced Solid Tumors</span>.  <i>Proceedings of the ESMO 2017 Conference</i>; <span class="NLM_publisher-loc">Madrid, Spain</span>, Sep 8–12, <span class="NLM_year">2017</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1093%2Fannonc%2Fmdx367.058" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=A.+Tolcher&author=K.+Do&author=E.+di+Tomaso&author=N.+Waters&author=K.+Stephens&author=D.+Roth&author=G.+Shapiro&title=Proceedings+of+the+ESMO+2017+Conference"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1093%2Fannonc%2Fmdx367.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1093%252Fannonc%252Fmdx367.058%26sid%3Dliteratum%253Aachs%26aulast%3DTolcher%26aufirst%3DA.%26atitle%3DA%2520Phase%25201%2520Study%2520of%2520SY-1365%252C%2520a%2520Selective%2520CDK7%2520Inhibitor%252C%2520in%2520Adult%2520Patients%2520with%2520Advanced%2520Solid%2520Tumors%26btitle%3DProceedings%2520of%2520the%2520ESMO%25202017%2520Conference%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Marineau, J.</span>; <span class="NLM_string-name">Hamman, K.</span>; <span class="NLM_string-name">Bradley, M.</span>; <span class="NLM_string-name">Savinainen, A.</span>; <span class="NLM_string-name">Alnemy, S.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Chuaqui, C.</span>; <span class="NLM_string-name">Olson, E.</span></span> <span> </span><span class="NLM_article-title">SY-5609, an Orally Available Selective CDK7 Inhibitor Demonstrates Broad Anti-Tumor Activity in Vivo</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 3, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=S.+Hu&author=J.+Marineau&author=K.+Hamman&author=M.+Bradley&author=A.+Savinainen&author=S.+Alnemy&author=N.+Rajagopal&author=D.+Orlando&author=C.+Chuaqui&author=E.+Olson&title=SY-5609%2C+an+Orally+Available+Selective+CDK7+Inhibitor+Demonstrates+Broad+Anti-Tumor+Activity+in+Vivo"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DS.%26atitle%3DSY-5609%252C%2520an%2520Orally%2520Available%2520Selective%2520CDK7%2520Inhibitor%2520Demonstrates%2520Broad%2520Anti-Tumor%2520Activity%2520in%2520Vivo%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Hasegawa, T.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">In Vitro Anti-Cancer Activity of UD-017, a Novel Potent and Highly Selective CDK7 Reversible Inhibitor</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Apr 1–5, <span class="NLM_year">2017</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=T.+Matsushita&author=K.+Onuma&author=H.+Sunamoto&author=A.+Ogawa&author=S.+Ogi&author=T.+Hasegawa&author=S.+Kono&author=N.+Iwase&author=Y.+Aga&author=S.+Ushiyama&title=In+Vitro+Anti-Cancer+Activity+of+UD-017%2C+a+Novel+Potent+and+Highly+Selective+CDK7+Reversible+Inhibitor"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushita%26aufirst%3DT.%26atitle%3DIn%2520Vitro%2520Anti-Cancer%2520Activity%2520of%2520UD-017%252C%2520a%2520Novel%2520Potent%2520and%2520Highly%2520Selective%2520CDK7%2520Reversible%2520Inhibitor%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Tokunaga, Y.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Hasegawa, T.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">In Vivo Anti-Tumor Efficacy of UD-017, a Novel Highly Selective and Orally Available CDK7 Inhibitor, in Colorectal Cancer Cells Xenograft Models</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Washington, DC</span>, Apr 1–5, <span class="NLM_year">2017</span>; 2017.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&author=Y.+Aga&author=S.+Ogi&author=Y.+Tokunaga&author=A.+Ogawa&author=K.+Onuma&author=T.+Matsushita&author=H.+Sunamoto&author=T.+Hasegawa&author=S.+Ushiyama&title=In+Vivo+Anti-Tumor+Efficacy+of+UD-017%2C+a+Novel+Highly+Selective+and+Orally+Available+CDK7+Inhibitor%2C+in+Colorectal+Cancer+Cells+Xenograft+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAga%26aufirst%3DY.%26atitle%3DIn%2520Vivo%2520Anti-Tumor%2520Efficacy%2520of%2520UD-017%252C%2520a%2520Novel%2520Highly%2520Selective%2520and%2520Orally%2520Available%2520CDK7%2520Inhibitor%252C%2520in%2520Colorectal%2520Cancer%2520Cells%2520Xenograft%2520Models%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Hasegawa, T.</span>; <span class="NLM_string-name">Tokunaga, Y.</span>; <span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">UD-017, a Novel Highly Selective and Orally Active CDK7 Inhibitor, Shows a Significant Anticancer Activity in Patient-Derived Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=T.+Matsushita&author=S.+Ogi&author=K.+Onuma&author=H.+Sunamoto&author=A.+Ogawa&author=T.+Hasegawa&author=Y.+Tokunaga&author=Y.+Aga&author=S.+Ushiyama&title=UD-017%2C+a+Novel+Highly+Selective+and+Orally+Active+CDK7+Inhibitor%2C+Shows+a+Significant+Anticancer+Activity+in+Patient-Derived+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DMatsushita%26aufirst%3DT.%26atitle%3DUD-017%252C%2520a%2520Novel%2520Highly%2520Selective%2520and%2520Orally%2520Active%2520CDK7%2520Inhibitor%252C%2520Shows%2520a%2520Significant%2520Anticancer%2520Activity%2520in%2520Patient-Derived%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Onuma, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsushita, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sunamoto, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ogawa, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tokunaga, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">Preclinical in Vitro and in Vivo Study of UD-017, a Novel Highly Selective and Orally Available CDK7 Inhibitor, in a Variety of Cancers</span>. <i>J. Clin. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>35</i></span> (<span class="NLM_issue">15_suppl</span>), <span class="NLM_elocation-id">e14086-e14086</span> <span class="refDoi"> DOI: 10.1200/JCO.2017.35.15_suppl.e14086</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1200%2FJCO.2017.35.15_suppl.e14086" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2017&issue=15_suppl&author=K.+Onumaauthor=Y.+Agaauthor=S.+Ogiauthor=T.+Matsushitaauthor=H.+Sunamotoauthor=A.+Ogawaauthor=Y.+Tokunagaauthor=S.+Ushiyama&title=Preclinical+in+Vitro+and+in+Vivo+Study+of+UD-017%2C+a+Novel+Highly+Selective+and+Orally+Available+CDK7+Inhibitor%2C+in+a+Variety+of+Cancers&doi=10.1200%2FJCO.2017.35.15_suppl.e14086"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1200%2FJCO.2017.35.15_suppl.e14086&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2017.35.15_suppl.e14086%26sid%3Dliteratum%253Aachs%26aulast%3DOnuma%26aufirst%3DK.%26aulast%3DAga%26aufirst%3DY.%26aulast%3DOgi%26aufirst%3DS.%26aulast%3DMatsushita%26aufirst%3DT.%26aulast%3DSunamoto%26aufirst%3DH.%26aulast%3DOgawa%26aufirst%3DA.%26aulast%3DTokunaga%26aufirst%3DY.%26aulast%3DUshiyama%26aufirst%3DS.%26atitle%3DPreclinical%2520in%2520Vitro%2520and%2520in%2520Vivo%2520Study%2520of%2520UD-017%252C%2520a%2520Novel%2520Highly%2520Selective%2520and%2520Orally%2520Available%2520CDK7%2520Inhibitor%252C%2520in%2520a%2520Variety%2520of%2520Cancers%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2017%26volume%3D35%26issue%3D15_suppl%26doi%3D10.1200%2FJCO.2017.35.15_suppl.e14086" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ogi, S.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Ogawa, A.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Ushiyama, S.</span></span> <span> </span><span class="NLM_article-title">Evaluation of Anticancer Activities of UD-017, a Novel Selective and Orally Available CDK7 Inhibitor, in Blood Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Chicago, IL</span>, Apr 14–18, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Aga&author=S.+Ogi&author=K.+Onuma&author=H.+Sunamoto&author=T.+Matsushita&author=A.+Ogawa&author=S.+Kono&author=N.+Iwase&author=S.+Ushiyama&title=Evaluation+of+Anticancer+Activities+of+UD-017%2C+a+Novel+Selective+and+Orally+Available+CDK7+Inhibitor%2C+in+Blood+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DAga%26aufirst%3DY.%26atitle%3DEvaluation%2520of%2520Anticancer%2520Activities%2520of%2520UD-017%252C%2520a%2520Novel%2520Selective%2520and%2520Orally%2520Available%2520CDK7%2520Inhibitor%252C%2520in%2520Blood%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cayrol, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Praditsuktavorn, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernando, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marullo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calvo-Vidal, M. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Phillip, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pera, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, S. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takpradit, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roman, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaudiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Crescenzo, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ruan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Inghirami, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cremaschi, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cerchietti, L.</span></span> <span> </span><span class="NLM_article-title">THZ1 Targeting CDK7 Suppresses STAT Transcriptional Activity and Sensitizes T-cell Lymphomas to BCL2 Inhibitors</span>. <i>Nat. Commun.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">14290</span>, <span class="refDoi"> DOI: 10.1038/ncomms14290</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fncomms14290" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28134252" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXitVGltr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2017&pages=14290&author=F.+Cayrolauthor=P.+Praditsuktavornauthor=T.+M.+Fernandoauthor=N.+Kwiatkowskiauthor=R.+Marulloauthor=M.+N.+Calvo-Vidalauthor=J.+Phillipauthor=B.+Peraauthor=S.+N.+Yangauthor=K.+Takpraditauthor=L.+Romanauthor=M.+Gaudianoauthor=R.+Crescenzoauthor=J.+Ruanauthor=G.+Inghiramiauthor=T.+Zhangauthor=G.+Cremaschiauthor=N.+S.+Grayauthor=L.+Cerchietti&title=THZ1+Targeting+CDK7+Suppresses+STAT+Transcriptional+Activity+and+Sensitizes+T-cell+Lymphomas+to+BCL2+Inhibitors&doi=10.1038%2Fncomms14290"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors</span></div><div class="casAuthors">Cayrol, Florencia; Praditsuktavorn, Pannee; Fernando, Tharu M.; Kwiatkowski, Nicholas; Marullo, Rosella; Calvo-Vidal, M. Nieves; Phillip, Jude; Pera, Benet; Yang, Shao Ning; Takpradit, Kaipol; Roman, Lidia; Gaudiano, Marcello; Crescenzo, Ramona; Ruan, Jia; Inghirami, Giorgio; Zhang, Tinghu; Cremaschi, Graciela; Gray, Nathanael S.; Cerchietti, Leandro</div><div class="citationInfo"><span class="NLM_cas:title">Nature Communications</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">14290</span>CODEN:
                <span class="NLM_cas:coden">NCAOBW</span>;
        ISSN:<span class="NLM_cas:issn">2041-1723</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Peripheral T-cell lymphomas (PTCL) are aggressive diseases with poor response to chemotherapy and dismal survival.  Identification of effective strategies to target PTCL biol. represents an urgent need.  Here we report that PTCL are sensitive to transcription-targeting drugs, and, in particular, to THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7).  The STAT-signalling pathway is highly vulnerable to THZ1 even in PTCL cells that carry the activating STAT3 mutation Y640F.  In mutant cells, CDK7 inhibition decreases STAT3 chromatin binding and expression of highly transcribed target genes like MYC, PIM1, MCL1, CD30, IL2RA, CDC25A and IL4R.  In surviving cells, THZ1 decreases the expression of STAT-regulated anti-apoptotic BH3 family members MCL1 and BCL-XL sensitizing PTCL cells to BH3 mimetic drugs.  Accordingly, the combination of THZ1 and the BH3 mimetic obatoclax improves lymphoma growth control in a primary PTCL ex vivo culture and in two STAT3-mutant PTCL xenografts, delineating a potential targeted agent-based therapeutic option for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrBQbPpwOfLObVg90H21EOLACvtfcHk0lhHfBPOjIaDpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXitVGltr4%253D&md5=55b436fd7c4427da0005b735bea7e622</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1038%2Fncomms14290&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fncomms14290%26sid%3Dliteratum%253Aachs%26aulast%3DCayrol%26aufirst%3DF.%26aulast%3DPraditsuktavorn%26aufirst%3DP.%26aulast%3DFernando%26aufirst%3DT.%2BM.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DMarullo%26aufirst%3DR.%26aulast%3DCalvo-Vidal%26aufirst%3DM.%2BN.%26aulast%3DPhillip%26aufirst%3DJ.%26aulast%3DPera%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DS.%2BN.%26aulast%3DTakpradit%26aufirst%3DK.%26aulast%3DRoman%26aufirst%3DL.%26aulast%3DGaudiano%26aufirst%3DM.%26aulast%3DCrescenzo%26aufirst%3DR.%26aulast%3DRuan%26aufirst%3DJ.%26aulast%3DInghirami%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DCremaschi%26aufirst%3DG.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DCerchietti%26aufirst%3DL.%26atitle%3DTHZ1%2520Targeting%2520CDK7%2520Suppresses%2520STAT%2520Transcriptional%2520Activity%2520and%2520Sensitizes%2520T-cell%2520Lymphomas%2520to%2520BCL2%2520Inhibitors%26jtitle%3DNat.%2520Commun.%26date%3D2017%26volume%3D8%26spage%3D14290%26doi%3D10.1038%2Fncomms14290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greenall, S. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lim, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mitchell, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ensbey, K. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stringer, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilding, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’neill, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McDonald, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gough, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Day, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Johns, T. G.</span></span> <span> </span><span class="NLM_article-title">Cyclin-Dependent Kinase 7 Is a Therapeutic Target in High-Grade Glioma</span>. <i>Oncogenesis</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>6</i></span> (<span class="NLM_issue">5</span>), <span class="NLM_elocation-id">e336</span> <span class="refDoi"> DOI: 10.1038/oncsis.2017.33</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Foncsis.2017.33" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=28504693" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2sXnslKmurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2017&issue=5&author=S.+A.+Greenallauthor=Y.+Limauthor=C.+Mitchellauthor=K.+S.+Ensbeyauthor=B.+W.+Stringerauthor=A.+L.+Wildingauthor=G.+O%E2%80%99neillauthor=K.+McDonaldauthor=D.+Goughauthor=B.+W.+Dayauthor=T.+G.+Johns&title=Cyclin-Dependent+Kinase+7+Is+a+Therapeutic+Target+in+High-Grade+Glioma&doi=10.1038%2Foncsis.2017.33"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Cyclin-dependent kinase 7 is a therapeutic target in high-grade glioma</span></div><div class="casAuthors">Greenall, S. A.; Lim, Y. C.; Mitchell, C. B.; Ensbey, K. S.; Stringer, B. W.; Wilding, A. L.; O'Neill, G. M.; McDonald, K. L.; Gough, D. J.; Day, B. W.; Johns, T. G.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogenesis</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">e336</span>CODEN:
                <span class="NLM_cas:coden">ONCOCT</span>;
        ISSN:<span class="NLM_cas:issn">2157-9024</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">High-grade glioma (HGG) is an incurable brain cancer.  The transcriptomes of cells within HGG tumors are highly heterogeneous.  This renders the tumors unresponsive or able to adapt to therapeutics targeted at single pathways, thereby causing treatment failure.  To overcome this, we focused on cyclin-dependent kinase 7 (CDK7), a ubiquitously expressed mol. involved in two major drivers of HGG pathogenesis: cell cycle progression and RNA polymerase-II-based transcription.  We tested the activity of THZ1, an irreversible CDK7 inhibitor, on patient-derived primary HGG cell lines and ex vivo HGG patient tissue slices, using proliferation assays, microarray anal., high-resoln. respirometry, cell cycle anal. and in vivo tumor orthografts.  The cellular processes affected by CDK7 inhibition were analyzed by reverse transcriptase-quant. PCR, western blot, flow cytometry and immunofluorescence.  THZ1 perturbed the transcriptome and disabled CDK activation, leading to cell cycle arrest at G2 and DNA damage.  THZ1 halted transcription of the nuclear-encoded mitochondrial ribosomal genes, reducing mitochondrial translation and oxidative respiration.  It also inhibited the expression of receptor tyrosine kinases such as epidermal growth factor receptor (EGFR) and platelet-derived growth factor receptor-α (PDGFR-α), reducing signaling flux through the AKT, extracellular-signal-regulated kinase 1/2 (ERK1/2) and signal transducer and activator of transcription 3 (STAT3) downstream pathways.  Finally, THZ1 disrupted nucleolar, Cajal body and nuclear speckle formation, resulting in reduced cytosolic translation and malfunction of the spliceosome and thus leading to aberrant mRNA processing.  These findings indicate that CDK7 is crucial for gliomagenesis, validate CDK7 as a therapeutic target and provide new insight into the cellular processes that are affected by THZ1 and induce antitumor activity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqsiQ1SulsDprVg90H21EOLACvtfcHk0li4qHjR0L3GGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXnslKmurk%253D&md5=90176bafe1f4adeac3c0032d22aa96a3</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1038%2Foncsis.2017.33&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Foncsis.2017.33%26sid%3Dliteratum%253Aachs%26aulast%3DGreenall%26aufirst%3DS.%2BA.%26aulast%3DLim%26aufirst%3DY.%26aulast%3DMitchell%26aufirst%3DC.%26aulast%3DEnsbey%26aufirst%3DK.%2BS.%26aulast%3DStringer%26aufirst%3DB.%2BW.%26aulast%3DWilding%26aufirst%3DA.%2BL.%26aulast%3DO%25E2%2580%2599neill%26aufirst%3DG.%26aulast%3DMcDonald%26aufirst%3DK.%26aulast%3DGough%26aufirst%3DD.%26aulast%3DDay%26aufirst%3DB.%2BW.%26aulast%3DJohns%26aufirst%3DT.%2BG.%26atitle%3DCyclin-Dependent%2520Kinase%25207%2520Is%2520a%2520Therapeutic%2520Target%2520in%2520High-Grade%2520Glioma%26jtitle%3DOncogenesis%26date%3D2017%26volume%3D6%26issue%3D5%26doi%3D10.1038%2Foncsis.2017.33" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guarducci, C.</span>; <span class="NLM_string-name">Nardone, A.</span>; <span class="NLM_string-name">Feiglin, A.</span>; <span class="NLM_string-name">Migliaccio, I.</span>; <span class="NLM_string-name">Malorni, L.</span>; <span class="NLM_string-name">Bonechi, M.</span>; <span class="NLM_string-name">Benelli, M.</span>; <span class="NLM_string-name">Di Leo, A.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">Shapiro, G.</span>; <span class="NLM_string-name">Brown, M.</span>; <span class="NLM_string-name">Jeselsohn, R.</span></span> <span> </span><span class="NLM_article-title">Inhibition of CDK7 Overcomes Resistance to CDK4/6 Inhibitors in Hormone Receptor Positive Breast Cancer Cells</span>.  <i>Proceedings of the 2018 SABCS</i>; <span class="NLM_publisher-loc">San Antonio, TX</span>, Dec 4–8, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=C.+Guarducci&author=A.+Nardone&author=A.+Feiglin&author=I.+Migliaccio&author=L.+Malorni&author=M.+Bonechi&author=M.+Benelli&author=A.+Di+Leo&author=G.+Hodgson&author=G.+Shapiro&author=M.+Brown&author=R.+Jeselsohn&title=Proceedings+of+the+2018+SABCS"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DGuarducci%26aufirst%3DC.%26atitle%3DInhibition%2520of%2520CDK7%2520Overcomes%2520Resistance%2520to%2520CDK4%252F6%2520Inhibitors%2520in%2520Hormone%2520Receptor%2520Positive%2520Breast%2520Cancer%2520Cells%26btitle%3DProceedings%2520of%2520the%25202018%2520SABCS%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Z.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miao, D.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, Q.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tang, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, X.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Deng, L.-B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shi, H.-D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xin, H.-B.</span></span> <span> </span><span class="NLM_article-title">THZ1 Suppresses Human Non-Small-Cell Lung Cancer Cells in Vitro Through Interference with Cancer Metabolism</span>. <i>Acta Pharmacol. Sin.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>40</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">814</span>– <span class="NLM_lpage">822</span>, <span class="refDoi"> DOI: 10.1038/s41401-018-0187-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41401-018-0187-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30446732" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1eiu7rO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=40&publication_year=2019&pages=814-822&issue=6&author=Z.-J.+Chengauthor=D.-L.+Miaoauthor=Q.-Y.+Suauthor=X.-L.+Tangauthor=X.-L.+Wangauthor=L.-B.+Dengauthor=H.-D.+Shiauthor=H.-B.+Xin&title=THZ1+Suppresses+Human+Non-Small-Cell+Lung+Cancer+Cells+in+Vitro+Through+Interference+with+Cancer+Metabolism&doi=10.1038%2Fs41401-018-0187-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">THZ1 suppresses human non-small-cell lung cancer cells in vitro through interference with cancer metabolism</span></div><div class="casAuthors">Cheng, Zhu-Jun; Miao, Du-Ling; Su, Qiu-Yun; Tang, Xiao-Li; Wang, Xiao-Lei; Deng, Li-Bin; Shi, Hui-Dong; Xin, Hong-Bo</div><div class="citationInfo"><span class="NLM_cas:title">Acta Pharmacologica Sinica</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">40</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">814-822</span>CODEN:
                <span class="NLM_cas:coden">APSCG5</span>;
        ISSN:<span class="NLM_cas:issn">1671-4083</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Cancer cells always require more nutrients, energy, and biosynthetic activity to sustain their rapid proliferation than normal cells.  Previous studies have shown the impact of THZ1, a covalent inhibitor of cyclin-dependent kinase 7 (CDK7), on transcription regulation and cell-cycle arrest in numerous cancers, but its effects on cellular metab. in cancer cells remain unknown.  In this study we elucidated the anticancer mechanism of THZ1 in human non-small-cell lung cancer (NSCLC) cells.  We showed that treatment with THZ1 (10-1000 nM) dose-dependently suppressed the proliferation of human NSCLC cell lines H1299, A549, H292, and H23, and markedly inhibited the migration of these NSCLC cells.  Furthermore, treatment with THZ1 (50 nM) arrested cell cycle at G2/M phase and induced apoptosis in these NSCLC cell lines.  More importantly, we revealed that treatment with THZ1 (50 nM) blocked the glycolysis pathway but had no effect on glutamine metab.  We further demonstrated that THZ1 treatment altered the expression pattern of glutaminase 1 (GLS1) isoforms through promoting the ubiquitination and degrdn. of NUDT21.  Combined treatment of THZ1 with a glutaminase inhibitor CB-839 (500 nM) exerted a more potent anti-proliferative effect in these NSCLC cell lines than treatment with THZ1 or CB-839 alone.  Our results demonstrate that the inhibitory effect of THZ1 on the growth of human NSCLC cells is partially attributed to interfering with cancer metab.  Thus, we provide a new potential therapeutic strategy for NSCLC treatment by combining THZ1 with the inhibitors of glutamine metab.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoFRTyHkOgGpLVg90H21EOLACvtfcHk0li4qHjR0L3GGg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1eiu7rO&md5=70999bac41f6f734dfecf980b5013f3e</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1038%2Fs41401-018-0187-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41401-018-0187-3%26sid%3Dliteratum%253Aachs%26aulast%3DCheng%26aufirst%3DZ.-J.%26aulast%3DMiao%26aufirst%3DD.-L.%26aulast%3DSu%26aufirst%3DQ.-Y.%26aulast%3DTang%26aufirst%3DX.-L.%26aulast%3DWang%26aufirst%3DX.-L.%26aulast%3DDeng%26aufirst%3DL.-B.%26aulast%3DShi%26aufirst%3DH.-D.%26aulast%3DXin%26aufirst%3DH.-B.%26atitle%3DTHZ1%2520Suppresses%2520Human%2520Non-Small-Cell%2520Lung%2520Cancer%2520Cells%2520in%2520Vitro%2520Through%2520Interference%2520with%2520Cancer%2520Metabolism%26jtitle%3DActa%2520Pharmacol.%2520Sin.%26date%3D2019%26volume%3D40%26issue%3D6%26spage%3D814%26epage%3D822%26doi%3D10.1038%2Fs41401-018-0187-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hur, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, H. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Park, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hwang, J. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span> <span> </span><span class="NLM_article-title">CDK7 Inhibition as a Promising Therapeutic Strategy for Lung Squamous Cell Carcinomas with a SOX2 Amplification</span>. <i>Cell. Oncol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>42</i></span> (<span class="NLM_issue">4</span>),  <span class="NLM_fpage">449</span>– <span class="NLM_lpage">458</span>, <span class="refDoi"> DOI: 10.1007/s13402-019-00434-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1007%2Fs13402-019-00434-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BB3cXlsVals7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2019&pages=449-458&issue=4&author=J.+Y.+Hurauthor=H.+R.+Kimauthor=J.+Y.+Leeauthor=S.+Parkauthor=J.+A.+Hwangauthor=W.+S.+Kimauthor=S.+Yoonauthor=C.-M.+Choiauthor=J.+K.+Rhoauthor=J.+C.+Lee&title=CDK7+Inhibition+as+a+Promising+Therapeutic+Strategy+for+Lung+Squamous+Cell+Carcinomas+with+a+SOX2+Amplification&doi=10.1007%2Fs13402-019-00434-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">CDK7 inhibition as a promising therapeutic strategy for lung squamous cell carcinomas with a SOX2 amplification</span></div><div class="casAuthors">Hur, Jae Young; Kim, Hyeong Ryul; Lee, Jung Yeon; Park, Sojung; Hwang, Ji An; Kim, Woo Sung; Yoon, Shinkyo; Choi, Chang-Min; Rho, Jin Kyung; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cellular Oncology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">449-458</span>CODEN:
                <span class="NLM_cas:coden">COENGH</span>;
        ISSN:<span class="NLM_cas:issn">2211-3436</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Here, we investigated the effects of THZ1, a potent cyclin-dependent kinase 7 (CDK7) inhibitor that plays a key role in gene transcription, in SCC.  Lung SCC-derived cell viabilities were assessed using a CCK-8 assay.  SOX2 expression and RNAPII-CTD phosphorylation levels after THZ1 treatment were detd. by Western blotting.  The effect of SOX2 suppression using shRNA was assessed by flow cytometry.  Gene expression patterns after THZ1 treatment of lung SCC-derived cells were identified using microarray-based mRNA profiling.  We found that THZ1 treatment led to suppression of cell growth and apoptotic cell death in SOX2-amplified SCC-derived cells only, whereas the modest growth-inhibitory effect of cisplatin did not differ according to SOX2 amplification status.  We also found that THZ1 decreased the phosphorylation of the carboxyl-terminal domain of RNA polymerase II and the expression of several genes.  Specifically, we found that the expression of transcription-assocd. genes, including SOX2, was down-regulated by THZ1 in SOX2-amplified SCC cells.  This inhibition of SOX2 expression resulted in suppression of the growth of these cells.  From our data, we conclude that THZ1 may effectively control the proliferation and survival of SOX2-amplified SCC cells through a decrease in global transcriptional activity, suggesting that CDK7 inhibition leading to transcription suppression may be a promising therapeutic option for lung SCC with a SOX2 amplification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqtayG3PDD7TrVg90H21EOLACvtfcHk0liRsYFOmxKGjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BB3cXlsVals7s%253D&md5=18b68fba372e0fa5edc5830369ba3899</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1007%2Fs13402-019-00434-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13402-019-00434-2%26sid%3Dliteratum%253Aachs%26aulast%3DHur%26aufirst%3DJ.%2BY.%26aulast%3DKim%26aufirst%3DH.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BY.%26aulast%3DPark%26aufirst%3DS.%26aulast%3DHwang%26aufirst%3DJ.%2BA.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DYoon%26aufirst%3DS.%26aulast%3DChoi%26aufirst%3DC.-M.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DCDK7%2520Inhibition%2520as%2520a%2520Promising%2520Therapeutic%2520Strategy%2520for%2520Lung%2520Squamous%2520Cell%2520Carcinomas%2520with%2520a%2520SOX2%2520Amplification%26jtitle%3DCell.%2520Oncol.%26date%3D2019%26volume%3D42%26issue%3D4%26spage%3D449%26epage%3D458%26doi%3D10.1007%2Fs13402-019-00434-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mao, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">He, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, A.</span></span> <span> </span><span class="NLM_article-title">Interaction with Cyclin H/Cyclin-Dependent Kinase 7 (CCNH/CDK7) Stabilizes C-Terminal Binding Protein 2 (CtBP2) and Promotes Cancer Cell Migration</span>. <i>J. Biol. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>288</i></span> (<span class="NLM_issue">13</span>),  <span class="NLM_fpage">9028</span>– <span class="NLM_lpage">9034</span>, <span class="refDoi"> DOI: 10.1074/jbc.M112.432005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1074%2Fjbc.M112.432005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=23393140" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC3sXkvF2murc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=288&publication_year=2013&pages=9028-9034&issue=13&author=Y.+Wangauthor=F.+Liuauthor=F.+Maoauthor=Q.+Hangauthor=X.+Huangauthor=S.+Heauthor=Y.+Wangauthor=C.+Chengauthor=H.+Wangauthor=G.+Xuauthor=T.+Zhangauthor=A.+Shen&title=Interaction+with+Cyclin+H%2FCyclin-Dependent+Kinase+7+%28CCNH%2FCDK7%29+Stabilizes+C-Terminal+Binding+Protein+2+%28CtBP2%29+and+Promotes+Cancer+Cell+Migration&doi=10.1074%2Fjbc.M112.432005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction with Cyclin H/Cyclin-dependent Kinase 7 (CCNH/CDK7) Stabilizes C-terminal Binding Protein 2 (CtBP2) and Promotes Cancer Cell Migration</span></div><div class="casAuthors">Wang, Yuchan; Liu, Fang; Mao, Feng; Hang, Qinlei; Huang, Xiaodong; He, Song; Wang, Yingying; Cheng, Chun; Wang, Huijie; Xu, Guangfei; Zhang, Tianyi; Shen, Aiguo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">288</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">9028-9034</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">CtBP2 has been demonstrated to possess tumor-promoting capacities by virtue of up-regulating epithelial-mesenchymal transition (EMT) and down-regulating apoptosis in cancer cells.  As a result, cellular CtBP2 levels are considered a key factor detg. the outcome of oncogenic transformation.  How pro-tumorigenic and anti-tumorigenic factors compete for fine-tuning CtBP2 levels is incompletely understood.  Here we report that the cyclin H/cyclin-dependent kinase 7 (CCNH/CDK7) complex interacted with CtBP2 in vivo and in vitro.  Depletion of either CCNH or CDK7 decreased CtBP2 protein levels by accelerating proteasome-dependent CtBP2 clearance.  Further anal. revealed that CCNH/CDK7 competed with the tumor repressor HIPK2 for CtBP2 binding and consequently inhibited phosphorylation and dimerization of CtBP2.  Phosphorylation-defective CtBP2 interacted more strongly with CCNH/CDK7 and was more resistant to degrdn.  Finally, overexpression of CtBP2 increased whereas depletion of CtBP2 dampened the invasive and migratory potential of breast cancer cells.  CtBP2 promoted the invasion and migration of breast cancer cells in a CCNH-dependent manner.  Taken together, our data have delineated a novel pathway that regulates CtBP2 stability, suggesting that targeting the CCNH/CDK7-CtBP2 axis may yield a viable anti-tumor strategy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTiSrV9eLwN7Vg90H21EOLACvtfcHk0liRsYFOmxKGjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXkvF2murc%253D&md5=cf7b41da65dc786cf42df524b2eb0914</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M112.432005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M112.432005%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DY.%26aulast%3DLiu%26aufirst%3DF.%26aulast%3DMao%26aufirst%3DF.%26aulast%3DHang%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DHe%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DCheng%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DG.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DShen%26aufirst%3DA.%26atitle%3DInteraction%2520with%2520Cyclin%2520H%252FCyclin-Dependent%2520Kinase%25207%2520%2528CCNH%252FCDK7%2529%2520Stabilizes%2520C-Terminal%2520Binding%2520Protein%25202%2520%2528CtBP2%2529%2520and%2520Promotes%2520Cancer%2520Cell%2520Migration%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2013%26volume%3D288%26issue%3D13%26spage%3D9028%26epage%3D9034%26doi%3D10.1074%2Fjbc.M112.432005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guan, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ni, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ji, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tian, Y.</span></span> <span> </span><span class="NLM_article-title">Interaction with CCNH/CDK7 Facilitates CtBP2 Promoting Esophageal Squamous Cell Carcinoma (ESCC) Metastasis via Upregulating Epithelial-Mesenchymal Transition (EMT) Progression</span>. <i>Tumor Biol.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>36</i></span> (<span class="NLM_issue">9</span>),  <span class="NLM_fpage">6701</span>– <span class="NLM_lpage">6714</span>, <span class="refDoi"> DOI: 10.1007/s13277-015-3354-x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1007%2Fs13277-015-3354-x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlslCgsbc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=6701-6714&issue=9&author=J.+Zhangauthor=J.+Zhuauthor=L.+Yangauthor=C.+Guanauthor=R.+Niauthor=Y.+Wangauthor=L.+Jiauthor=Y.+Tian&title=Interaction+with+CCNH%2FCDK7+Facilitates+CtBP2+Promoting+Esophageal+Squamous+Cell+Carcinoma+%28ESCC%29+Metastasis+via+Upregulating+Epithelial-Mesenchymal+Transition+%28EMT%29+Progression&doi=10.1007%2Fs13277-015-3354-x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression</span></div><div class="casAuthors">Zhang, Jianguo; Zhu, Junya; Yang, Lei; Guan, Chengqi; Ni, Runzhou; Wang, Yuchan; Ji, Lili; Tian, Ye</div><div class="citationInfo"><span class="NLM_cas:title">Tumor Biology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">6701-6714</span>CODEN:
                <span class="NLM_cas:coden">TUMBEA</span>;
        ISSN:<span class="NLM_cas:issn">1010-4283</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">CtBP2, as a transcriptional corepressor of epithelial-specific genes, has been reported to promote tumor due to upregulating epithelial-mesenchymal transition (EMT) in cancer cells.  CtBP2 was also demonstrated to contribute to the proliferation of esophageal squamous cell carcinoma (ESCC) cells through a neg. transcriptional regulation of p16INK4A.  In this study, for the first time, we reported that CtBP2 expression, along with CCNH/CDK7, was higher in ESCC tissues with lymph node metastases than in those without lymph node metastases.  Moreover, both CtBP2 and CCNH/CDK7 were pos. correlated with E-cadherin, tumor grade, and tumor metastasis.  However, the concrete mechanism of CtBP2's role in enhancing ESCC migration remains incompletely understood.  We confirmed that CCNH/CDK7 could directly interact with CtBP2 in ESCC cells in vivo and in vitro.  Furthermore, our data demonstrate for the first time that CtBP2 enhanced the migration of ESCC cells in a CCNH/CDK7-dependent manner.  Our results indicated that CCNH/CDK7-CtBP2 axis may augment ESCC cell migration, and targeting the interaction of both may provide a novel therapeutic target of ESCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyjvsAojbLO7Vg90H21EOLACvtfcHk0liRsYFOmxKGjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlslCgsbc%253D&md5=aa3b5fefbb66ee69a6839003001bb1eb</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1007%2Fs13277-015-3354-x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs13277-015-3354-x%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DL.%26aulast%3DGuan%26aufirst%3DC.%26aulast%3DNi%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJi%26aufirst%3DL.%26aulast%3DTian%26aufirst%3DY.%26atitle%3DInteraction%2520with%2520CCNH%252FCDK7%2520Facilitates%2520CtBP2%2520Promoting%2520Esophageal%2520Squamous%2520Cell%2520Carcinoma%2520%2528ESCC%2529%2520Metastasis%2520via%2520Upregulating%2520Epithelial-Mesenchymal%2520Transition%2520%2528EMT%2529%2520Progression%26jtitle%3DTumor%2520Biol.%26date%3D2015%26volume%3D36%26issue%3D9%26spage%3D6701%26epage%3D6714%26doi%3D10.1007%2Fs13277-015-3354-x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ma, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xia, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ning, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wen, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Long, C.</span></span> <span> </span><span class="NLM_article-title">Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation</span>. <i>J. Cancer</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">17</span>),  <span class="NLM_fpage">3149</span>– <span class="NLM_lpage">3155</span>, <span class="refDoi"> DOI: 10.7150/jca.25395</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.7150%2Fjca.25395" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=30210638" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3c3otlGqtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2018&pages=3149-3155&issue=17&author=X.+Maauthor=X.+Kuangauthor=Q.+Xiaauthor=Z.+Huangauthor=Y.+Fanauthor=J.+Ningauthor=J.+Wenauthor=H.+Zhangauthor=J.+Yanauthor=Q.+Zhangauthor=H.+Shenauthor=C.+Long&title=Covalent+CDK7+Inhibitor+THZ1+Inhibits+Myogenic+Differentiation&doi=10.7150%2Fjca.25395"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Covalent CDK7 Inhibitor THZ1 Inhibits Myogenic Differentiation</span></div><div class="casAuthors">Ma Xinqi; Kuang Xielan; Xia Qing; Huang Zixin; Fan Yuting; Ning Jie; Wen Jiajie; Zhang Han; Yan Jianhua; Zhang Qingjiong; Shen Huangxuan; Long Chongde; Kuang Xielan; Shen Huangxuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cancer</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">3149-3155</span>
        ISSN:<span class="NLM_cas:issn">1837-9664</span>.
    </div><div class="casAbstract">Covalent CDK7 inhibitor THZ1 is a newly discovered anti-tumor drug.THZ1 affects the function of transcription factor TFIIH by inhibiting CDK7, which in turn affects RNA polymerase II, and ultimately affects transcription initiation.  Study found that THZ1 could inhibit proliferation and promote apoptosis of several tumor cell lines.  However, there is no report of the potential side effect of THZ1 in normal tissues.  In the course of cancer, the muscle consumption of cachexia needs to be supplemented by the differentiation of muscle cells.  However, the effect of THZ1 on myogenic differentiation remains unclear.  Our study in this article found that THZ1 could both inhibit the differentiation of C2C12 cells and mouse primary myoblasts, also repressing the expression of differentiation-related transcription factors and muscle structural proteins, such as and myogenin, myh3 and MCK.  Moreover, THZ1 could inhibit C2C12 cell proliferation and migration, increase its oxidative stress and promote its apoptosis.  Our data indicates that THZ1 inhibits myogenic differentiation, suggesting that therapies based on THZ1 might have potential side effects on muscle functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQvVmaBIAg3KRJ5E29YNGvQfW6udTcc2eZgS9j2jy5Z87ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3c3otlGqtQ%253D%253D&md5=5f904b5e7aa2158d3f3410381344b38a</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.7150%2Fjca.25395&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.7150%252Fjca.25395%26sid%3Dliteratum%253Aachs%26aulast%3DMa%26aufirst%3DX.%26aulast%3DKuang%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DQ.%26aulast%3DHuang%26aufirst%3DZ.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DNing%26aufirst%3DJ.%26aulast%3DWen%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DYan%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DLong%26aufirst%3DC.%26atitle%3DCovalent%2520CDK7%2520Inhibitor%2520THZ1%2520Inhibits%2520Myogenic%2520Differentiation%26jtitle%3DJ.%2520Cancer%26date%3D2018%26volume%3D9%26issue%3D17%26spage%3D3149%26epage%3D3155%26doi%3D10.7150%2Fjca.25395" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Ke, N.</span>; <span class="NLM_string-name">Ren, Y.</span>; <span class="NLM_string-name">Lopez, J.</span>; <span class="NLM_string-name">Milijovska, S.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Schmidt, D.</span>; <span class="NLM_string-name">Bradley, M.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Fritz, C.</span>; <span class="NLM_string-name">Olson, E.</span></span> <span> </span><span class="NLM_article-title">First-in-Class CDK7 Inhibitor, Induces Robust Apoptosis in Acute Myeloid Leukemia and Demonstrates Durable in Vivo Efficacy</span>.  <i>Proceedings of the EHA 21st congress</i>; <span class="NLM_publisher-loc">Copenhagen</span>, Jun 8–12, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=Y.+Choi&author=S.+Hu&author=N.+Ke&author=Y.+Ren&author=J.+Lopez&author=S.+Milijovska&author=D.+Orlando&author=D.+Schmidt&author=M.+Bradley&author=K.+Sprott&author=C.+Fritz&author=E.+Olson&title=Proceedings+of+the+EHA+21st+congress"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%26atitle%3DFirst-in-Class%2520CDK7%2520Inhibitor%252C%2520Induces%2520Robust%2520Apoptosis%2520in%2520Acute%2520Myeloid%2520Leukemia%2520and%2520Demonstrates%2520Durable%2520in%2520Vivo%2520Efficacy%26btitle%3DProceedings%2520of%2520the%2520EHA%252021st%2520congress%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Jones, L. H.</span></span> <span> </span><span class="NLM_article-title">Precision Retargeting: A Selective Covalent Inhibitor Illuminates CDK7 Biology</span>. <i>Cell Chem. Biol.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">6</span>),  <span class="NLM_fpage">779</span>– <span class="NLM_lpage">780</span>, <span class="refDoi"> DOI: 10.1016/j.chembiol.2019.05.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.chembiol.2019.05.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31226310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXht1Wqu7fK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2019&pages=779-780&issue=6&author=L.+H.+Jones&title=Precision+Retargeting%3A+A+Selective+Covalent+Inhibitor+Illuminates+CDK7+Biology&doi=10.1016%2Fj.chembiol.2019.05.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Precision Retargeting: A Selective Covalent Inhibitor Illuminates CDK7 Biology</span></div><div class="casAuthors">Jones, Lyn H.</div><div class="citationInfo"><span class="NLM_cas:title">Cell Chemical Biology</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">779-780</span>CODEN:
                <span class="NLM_cas:coden">CCBEBM</span>;
        ISSN:<span class="NLM_cas:issn">2451-9448</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  In this issue of Cell Chem. Biol., Olson et al. (2019) develop the first selective CDK7 irreversible inhibitor.  Elegant cell-based studies using a CDK7 mutant that is not covalently engaged by the probe helped decipher the effects of inhibiting the kinase on the cell cycle and gene transcription.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqUOGGohvuYlbVg90H21EOLACvtfcHk0ljCGLT08OAhww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXht1Wqu7fK&md5=ab6ffe4eae4bc407ca8e99d7e25bcfee</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2019.05.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2019.05.012%26sid%3Dliteratum%253Aachs%26aulast%3DJones%26aufirst%3DL.%2BH.%26atitle%3DPrecision%2520Retargeting%253A%2520A%2520Selective%2520Covalent%2520Inhibitor%2520Illuminates%2520CDK7%2520Biology%26jtitle%3DCell%2520Chem.%2520Biol.%26date%3D2019%26volume%3D26%26issue%3D6%26spage%3D779%26epage%3D780%26doi%3D10.1016%2Fj.chembiol.2019.05.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Johannessen, L.</span>; <span class="NLM_string-name">Hu, S.</span>; <span class="NLM_string-name">Ke, N.</span>; <span class="NLM_string-name">Rajagopal, N.</span>; <span class="NLM_string-name">Orlando, D.</span>; <span class="NLM_string-name">Alnemy, S.</span>; <span class="NLM_string-name">Carulli, J.</span>; <span class="NLM_string-name">Hodgson, G.</span>; <span class="NLM_string-name">di Tomaso, E.</span></span> <span> </span><span class="NLM_article-title">SY-1365, a Selective CDK7 Inhibitor, Enhances Carboplatin Activity in Ovarian Cancer Cell Lines and Xenografts, and Transcriptionally Inhibits Homologous Recombination Repair (HRR) Genes</span>.  <i>Proceedings of the 30th EORTC-NCI-AACR Symposium</i>; <span class="NLM_publisher-loc">Dublin, Ireland</span>, Nov 13–16, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Johannessen&author=S.+Hu&author=N.+Ke&author=N.+Rajagopal&author=D.+Orlando&author=S.+Alnemy&author=J.+Carulli&author=G.+Hodgson&author=E.+di+Tomaso&title=Proceedings+of+the+30th+EORTC-NCI-AACR+Symposium"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DJohannessen%26aufirst%3DL.%26atitle%3DSY-1365%252C%2520a%2520Selective%2520CDK7%2520Inhibitor%252C%2520Enhances%2520Carboplatin%2520Activity%2520in%2520Ovarian%2520Cancer%2520Cell%2520Lines%2520and%2520Xenografts%252C%2520and%2520Transcriptionally%2520Inhibits%2520Homologous%2520Recombination%2520Repair%2520%2528HRR%2529%2520Genes%26btitle%3DProceedings%2520of%2520the%252030th%2520EORTC-NCI-AACR%2520Symposium%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Rusan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Christensen, C. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abraham, B. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kwiatkowski, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Buczkowski, K. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bockorny, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rhee, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Terai, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tavares, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Leggett, A. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, T. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Poudel-Neupane, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Silkes, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mudianto, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shimamura, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyerson, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bass, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Watanabe, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gray, N. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Young, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, K. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hammerman, P. S.</span></span> <span> </span><span class="NLM_article-title">Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression</span>. <i>Cancer Discovery</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>8</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">59</span>– <span class="NLM_lpage">73</span>, <span class="refDoi"> DOI: 10.1158/2159-8290.CD-17-0461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1158%2F2159-8290.CD-17-0461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=29054992" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXkslSjtQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2018&pages=59-73&issue=1&author=M.+Rusanauthor=K.+Liauthor=Y.+Liauthor=C.+L.+Christensenauthor=B.+J.+Abrahamauthor=N.+Kwiatkowskiauthor=K.+A.+Buczkowskiauthor=B.+Bockornyauthor=T.+Chenauthor=S.+Liauthor=K.+Rheeauthor=H.+Zhangauthor=W.+Chenauthor=H.+Teraiauthor=T.+Tavaresauthor=A.+L.+Leggettauthor=T.+Liauthor=Y.+Wangauthor=T.+Zhangauthor=T.+J.+Kimauthor=S.+H.+Hongauthor=N.+Poudel-Neupaneauthor=M.+Silkesauthor=T.+Mudiantoauthor=L.+Tanauthor=T.+Shimamuraauthor=M.+Meyersonauthor=A.+J.+Bassauthor=H.+Watanabeauthor=N.+S.+Grayauthor=R.+A.+Youngauthor=K.+K.+Wongauthor=P.+S.+Hammerman&title=Suppression+of+Adaptive+Responses+to+Targeted+Cancer+Therapy+by+Transcriptional+Repression&doi=10.1158%2F2159-8290.CD-17-0461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Suppression of Adaptive Responses to Targeted Cancer Therapy by Transcriptional Repression</span></div><div class="casAuthors">Rusan, Maria; Li, Kapsok; Li, Yvonne; Christensen, Camilla L.; Abraham, Brian J.; Kwiatkowski, Nicholas; Buczkowski, Kevin A.; Bockorny, Bruno; Chen, Ting; Li, Shuai; Rhee, Kevin; Zhang, Haikuo; Chen, Wankun; Terai, Hideki; Tavares, Tiffany; Leggett, Alan L.; Li, Tianxia; Wang, Yichen; Zhang, Tinghu; Kim, Tae-Jung; Hong, Sook-Hee; Poudel-Neupane, Neermala; Silkes, Michael; Mudianto, Tenny; Tan, Li; Shimamura, Takeshi; Meyerson, Matthew; Bass, Adam J.; Watanabe, Hideo; Gray, Nathanael S.; Young, Richard A.; Wong, Kwok-Kin; Hammerman, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Discovery</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">59-73</span>CODEN:
                <span class="NLM_cas:coden">CDAIB2</span>;
        ISSN:<span class="NLM_cas:issn">2159-8274</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Acquired drug resistance is a major factor limiting the effectiveness of targeted cancer therapies.  Targeting tumors with kinase inhibitors induces complex adaptive programs that promote the persistence of a fraction of the original cell population, facilitating the eventual outgrowth of inhibitor-resistant tumor clones.  We show that the addn. of a newly identified CDK7/12 inhibitor, THZ1, to targeted therapy enhances cell killing and impedes the emergence of drug-resistant cell populations in diverse cellular and in vivo cancer models.  We propose that targeted therapy induces a state of transcriptional dependency in a subpopulation of cells poised to become drug tolerant, which THZ1 can exploit by blocking dynamic transcriptional responses, promoting remodeling of enhancers and key signaling outputs required for tumor cell survival in the setting of targeted therapy.  These findings suggest that the addn. of THZ1 to targeted therapies is a promising broad-based strategy to hinder the emergence of drug-resistant cancer cell populations.  Significance: CDK7/12 inhibition prevents active enhancer formation at genes, promoting resistance emergence in response to targeted therapy, and impedes the engagement of transcriptional programs required for tumor cell survival.  CDK7/12 inhibition in combination with targeted cancer therapies may serve as a therapeutic paradigm for enhancing the effectiveness of targeted therapies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2ZQwuLLgYC7Vg90H21EOLACvtfcHk0lih7cZdvtuKRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXkslSjtQ%253D%253D&md5=e0ac792dc39965a556ab66676c344397</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1158%2F2159-8290.CD-17-0461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F2159-8290.CD-17-0461%26sid%3Dliteratum%253Aachs%26aulast%3DRusan%26aufirst%3DM.%26aulast%3DLi%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DChristensen%26aufirst%3DC.%2BL.%26aulast%3DAbraham%26aufirst%3DB.%2BJ.%26aulast%3DKwiatkowski%26aufirst%3DN.%26aulast%3DBuczkowski%26aufirst%3DK.%2BA.%26aulast%3DBockorny%26aufirst%3DB.%26aulast%3DChen%26aufirst%3DT.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DRhee%26aufirst%3DK.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DChen%26aufirst%3DW.%26aulast%3DTerai%26aufirst%3DH.%26aulast%3DTavares%26aufirst%3DT.%26aulast%3DLeggett%26aufirst%3DA.%2BL.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DT.%26aulast%3DKim%26aufirst%3DT.%2BJ.%26aulast%3DHong%26aufirst%3DS.%2BH.%26aulast%3DPoudel-Neupane%26aufirst%3DN.%26aulast%3DSilkes%26aufirst%3DM.%26aulast%3DMudianto%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DL.%26aulast%3DShimamura%26aufirst%3DT.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DBass%26aufirst%3DA.%2BJ.%26aulast%3DWatanabe%26aufirst%3DH.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DYoung%26aufirst%3DR.%2BA.%26aulast%3DWong%26aufirst%3DK.%2BK.%26aulast%3DHammerman%26aufirst%3DP.%2BS.%26atitle%3DSuppression%2520of%2520Adaptive%2520Responses%2520to%2520Targeted%2520Cancer%2520Therapy%2520by%2520Transcriptional%2520Repression%26jtitle%3DCancer%2520Discovery%26date%3D2018%26volume%3D8%26issue%3D1%26spage%3D59%26epage%3D73%26doi%3D10.1158%2F2159-8290.CD-17-0461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sun, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mason, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wilson, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hazard, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yeh, E. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roberts, T. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhao, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span> <span> </span><span class="NLM_article-title">Inhibition of the Transcriptional Kinase CDK7 Overcomes Therapeutic Resistance in HER2-Positive Breast Cancers</span>. <i>Oncogene</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>39</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">50</span>– <span class="NLM_lpage">63</span>, <span class="refDoi"> DOI: 10.1038/s41388-019-0953-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41388-019-0953-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31462705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref101/cit101&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXhs1Krs7zN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=39&publication_year=2020&pages=50-63&issue=1&author=B.+Sunauthor=S.+Masonauthor=R.+C.+Wilsonauthor=S.+E.+Hazardauthor=Y.+Wangauthor=R.+Fangauthor=Q.+Wangauthor=E.+S.+Yehauthor=M.+Yangauthor=T.+M.+Robertsauthor=J.+J.+Zhaoauthor=Q.+Wang&title=Inhibition+of+the+Transcriptional+Kinase+CDK7+Overcomes+Therapeutic+Resistance+in+HER2-Positive+Breast+Cancers&doi=10.1038%2Fs41388-019-0953-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit101R"><div class="casContent"><span class="casTitleNuber">101</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers</span></div><div class="casAuthors">Sun, Bowen; Mason, Seth; Wilson, Robert C.; Hazard, Starr E.; Wang, Yubao; Fang, Rong; Wang, Qiwei; Yeh, Elizabeth S.; Yang, Meixiang; Roberts, Thomas M.; Zhao, Jean J.; Wang, Qi</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">39</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">50-63</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Research</span>)
        </div><div class="casAbstract">Resistance of breast cancer to human epidermal growth factor receptor 2 (HER2) inhibitors involves reprogramming of the kinome through HER2/HER3 signaling via the activation of multiple tyrosine kinases and transcriptional upregulation.  The heterogeneity of induced kinases prevents kinase targeting by a single kinase inhibitor and presents a major challenge to the treatment of therapeutically recalcitrant HER2-pos. breast cancers (HER2+ BCs).  As a result, there is a crit. need for effective treatment that attacks the aberrant kinome activation assocd. with resistance to HER2-targeted therapy.  Here, we describe a novel treatment strategy that targets cyclin-dependent kinase 7 (CDK7) in HER2 inhibitor-resistant (HER2iR) breast cancer.  We show that both HER2 inhibitor-sensitive (HER2iS) and HER2iR breast cancer cell lines exhibit high sensitivity to THZ1, a newly identified covalent inhibitor of the transcription regulatory kinase CDK7.  CDK7 promotes cell cycle progression through inhibition of transcription, rather than via direct phosphorylation of classical CDK targets.  The transcriptional kinase activity of CDK7 is regulated by HER2, and by the receptor tyrosine kinases activated in response to HER2 inhibition, as well as by the downstream SHP2 and PI3K/AKT pathways.  A low dose of THZ1 displayed potent synergy with the HER2 inhibitor lapatinib in HER2iR BC cells in vitro.  Dual HER2 and CDK7 inhibition induced tumor regression in two HER2iR BC xenograft models in vivo.  Our data support the utilization of CDK7 inhibition as an addnl. therapeutic avenue that blocks the activation of genes engaged by multiple HER2iR kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOhWJoycnIULVg90H21EOLACvtfcHk0lih7cZdvtuKRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXhs1Krs7zN&md5=fd8c4b665351ba3df05252a18db2b53d</span></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=10.1038%2Fs41388-019-0953-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41388-019-0953-9%26sid%3Dliteratum%253Aachs%26aulast%3DSun%26aufirst%3DB.%26aulast%3DMason%26aufirst%3DS.%26aulast%3DWilson%26aufirst%3DR.%2BC.%26aulast%3DHazard%26aufirst%3DS.%2BE.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DFang%26aufirst%3DR.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DYeh%26aufirst%3DE.%2BS.%26aulast%3DYang%26aufirst%3DM.%26aulast%3DRoberts%26aufirst%3DT.%2BM.%26aulast%3DZhao%26aufirst%3DJ.%2BJ.%26aulast%3DWang%26aufirst%3DQ.%26atitle%3DInhibition%2520of%2520the%2520Transcriptional%2520Kinase%2520CDK7%2520Overcomes%2520Therapeutic%2520Resistance%2520in%2520HER2-Positive%2520Breast%2520Cancers%26jtitle%3DOncogene%26date%3D2020%26volume%3D39%26issue%3D1%26spage%3D50%26epage%3D63%26doi%3D10.1038%2Fs41388-019-0953-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Guo, L.</span>; <span class="NLM_string-name">Li, J.</span>; <span class="NLM_string-name">Fang, S.</span>; <span class="NLM_string-name">Lee, M.</span>; <span class="NLM_string-name">Zeng, H.</span>; <span class="NLM_string-name">Li, T.</span>; <span class="NLM_string-name">Han, W.</span>; <span class="NLM_string-name">Sun, D.</span>; <span class="NLM_string-name">Huang, Y.</span></span> <span> </span><span class="NLM_article-title">Synthetic Lethality of Combinatory Inhibition of BET and CDK7 in BET(i) Resistant Leukemia Cells</span>.  <i>Proceedings of the 60th ASH Annual Meeting</i>; <span class="NLM_publisher-loc">San Diego, CA</span>, Nov 29, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=L.+Guo&author=J.+Li&author=S.+Fang&author=M.+Lee&author=H.+Zeng&author=T.+Li&author=W.+Han&author=D.+Sun&author=Y.+Huang&title=Synthetic+Lethality+of+Combinatory+Inhibition+of+BET+and+CDK7+in+BET%28i%29+Resistant+Leukemia+Cells"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DGuo%26aufirst%3DL.%26atitle%3DSynthetic%2520Lethality%2520of%2520Combinatory%2520Inhibition%2520of%2520BET%2520and%2520CDK7%2520in%2520BET%2528i%2529%2520Resistant%2520Leukemia%2520Cells%26jtitle%3DProceedings%2520of%2520the%252060th%2520ASH%2520Annual%2520Meeting%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ge, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, J.</span></span> <span> </span><span class="NLM_article-title">Combinational Therapeutic Targeting of BRD4 and CDK7 Synergistically Induces Anticancer Effects in Head and Neck Squamous Cell Carcinoma</span>. <i>Cancer Lett.</i> <span class="NLM_year" style="font-weight: bold;">2020</span>,  <span class="NLM_volume"><i>469</i></span>,  <span class="NLM_fpage">510</span>– <span class="NLM_lpage">523</span>, <span class="refDoi"> DOI: 10.1016/j.canlet.2019.11.027</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1016%2Fj.canlet.2019.11.027" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31765738" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1MXit12jt77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=469&publication_year=2020&pages=510-523&author=W.+Zhangauthor=H.+Geauthor=Y.+Jiangauthor=R.+Huangauthor=Y.+Wuauthor=D.+Wangauthor=S.+Guoauthor=S.+Liauthor=Y.+Wangauthor=H.+Jiangauthor=J.+Cheng&title=Combinational+Therapeutic+Targeting+of+BRD4+and+CDK7+Synergistically+Induces+Anticancer+Effects+in+Head+and+Neck+Squamous+Cell+Carcinoma&doi=10.1016%2Fj.canlet.2019.11.027"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Combinational therapeutic targeting of BRD4 and CDK7 synergistically induces anticancer effects in head and neck squamous cell carcinoma</span></div><div class="casAuthors">Zhang, Wei; Ge, Han; Jiang, Yue; Huang, Rong; Wu, Yaping; Wang, Dongmiao; Guo, Songsong; Li, Sheng; Wang, Yanling; Jiang, Hongbing; Cheng, Jie</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2020</span>),
    <span class="NLM_cas:volume">469</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">510-523</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">The bromodomain and extra-terminal domain protein BRD4 has been recognized as a key oncogenic driver and a druggable target against cancer.  However, these BRD4 inhibitors as monotherapy were moderate in efficacy in preclin. models.  Here we utilized a small-scale drug synergy screen that combined the BRD4 inhibitor (JQ1) with 8 epigenetic or transcriptional targeted chems. and identified THZ1 (a CDK7 inhibitor) acting synergistically with JQ1 against head neck squamous cell carcinoma (HNSCC).  Combinational JQ1 and THZ1 treatment impaired cell proliferation, induced apoptosis and senescence, which were largely recapitulated by dual BRD4 and CDK7 knockdown.  Combinational treatment inhibited tumor growth and progression in 4NQO-induced HNSCC and xenograft animal models.  RNA-sequencing analyses identified hundreds of differentially expressed genes modulated by JQ1 and THZ1, which were significantly enriched in categories including cell cycle and apoptosis.  Mechanistically, combinational treatment reduced H3K27ac enrichment in the super-enhancer region of YAP1, which inactivated its transcription and in turn induced anti-proliferative and pro-apoptotic effects.  Combined BRD4 and CDK7 upregulation assocd. with worst prognosis in HNSCC patients.  Collectively, our findings reveal a novel therapeutic strategy of pharmacol. inhibitions of BRD4 and CDK7 against HNSCC.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXMfxOO0V8crVg90H21EOLACvtfcHk0ljZjkRo1r0C3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXit12jt77J&md5=afdf6a2b4b789bc7f2745dc84eec7355</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2019.11.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2019.11.027%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DGe%26aufirst%3DH.%26aulast%3DJiang%26aufirst%3DY.%26aulast%3DHuang%26aufirst%3DR.%26aulast%3DWu%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DD.%26aulast%3DGuo%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DCheng%26aufirst%3DJ.%26atitle%3DCombinational%2520Therapeutic%2520Targeting%2520of%2520BRD4%2520and%2520CDK7%2520Synergistically%2520Induces%2520Anticancer%2520Effects%2520in%2520Head%2520and%2520Neck%2520Squamous%2520Cell%2520Carcinoma%26jtitle%3DCancer%2520Lett.%26date%3D2020%26volume%3D469%26spage%3D510%26epage%3D523%26doi%3D10.1016%2Fj.canlet.2019.11.027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Posternak, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, M. D.</span></span> <span> </span><span class="NLM_article-title">Strategically Targeting MYC in Cancer</span>. <i>F1000Research</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>5</i></span>,  <span class="NLM_fpage">408</span>, <span class="refDoi"> DOI: 10.12688/f1000research.7879.1</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.12688%2Ff1000research.7879.1" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC1cXotVOhtb4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2016&pages=408&author=V.+Posternakauthor=M.+D.+Cole&title=Strategically+Targeting+MYC+in+Cancer&doi=10.12688%2Ff1000research.7879.1"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Strategically targeting MYC in cancer[version 1; referees: 2 approved]</span></div><div class="casAuthors">Posternak, Valeriya; Cole, Michael D.</div><div class="citationInfo"><span class="NLM_cas:title">F1000Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">5</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">408/1-408/7</span>CODEN:
                <span class="NLM_cas:coden">FRESJL</span>;
        ISSN:<span class="NLM_cas:issn">2046-1402</span>.
    
            (<span class="NLM_cas:orgname">F1000 Research Ltd.</span>)
        </div><div class="casAbstract">MYC is a major driver of cancer cell growth and mediates a transcriptional program spanning cell growth, the cell cycle, metab., and cell survival.  Many efforts have been made to deliberately target MYC for cancer therapy.  A variety of compds. have been generated to inhibit MYC function or stability, either directly or indirectly.  The most direct inhibitors target the interaction between MYC and MAX, which is required for DNA binding.  Unfortunately, these compds. do not have the desired pharmacokinetics and pharmacodynamics for in vivo application.  Recent studies report the indirect inhibition of MYC through the development of two compds., JQ1 and THZ1, which target factors involved in unique stages of transcription.  These compds. appear to have significant therapeutic value for cancers with high levels of MYC, although some effects are MYC-independent.  These approaches serve as a foundation for developing novel compds. to pharmacol. target MYC-driven cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7C9GXC2g647Vg90H21EOLACvtfcHk0ljZjkRo1r0C3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXotVOhtb4%253D&md5=978b38c80f91751343fb3df5c77cab76</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.12688%2Ff1000research.7879.1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.12688%252Ff1000research.7879.1%26sid%3Dliteratum%253Aachs%26aulast%3DPosternak%26aufirst%3DV.%26aulast%3DCole%26aufirst%3DM.%2BD.%26atitle%3DStrategically%2520Targeting%2520MYC%2520in%2520Cancer%26jtitle%3DF1000Research%26date%3D2016%26volume%3D5%26spage%3D408%26doi%3D10.12688%2Ff1000research.7879.1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chipumuro, E.</span>; <span class="NLM_string-name">Siddiquee, Z.</span>; <span class="NLM_string-name">Ganesh, S.</span>; <span class="NLM_string-name">Shui, S.</span>; <span class="NLM_string-name">Shah, A.</span>; <span class="NLM_string-name">Kim, B.</span>; <span class="NLM_string-name">Chen, D.</span>; <span class="NLM_string-name">Pandya, P.</span>; <span class="NLM_string-name">Storr, R.</span>; <span class="NLM_string-name">Wang, W.</span>; <span class="NLM_string-name">Dudek, H.</span>; <span class="NLM_string-name">Lai, C.</span>; <span class="NLM_string-name">Abrams, M.</span>; <span class="NLM_string-name">Brown, B.</span></span> <span> </span><span class="NLM_article-title">Anti-Tumor Activity of a MYC-Targeting Dicer Substrate siRNA in Combination with BRD4/CDK7 Inhibitors</span>.  <i>Proceedings of the AACR 107th Annual Meeting</i>; <span class="NLM_publisher-loc">New Orleans, LA</span>, Apr 16–20, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=E.+Chipumuro&author=Z.+Siddiquee&author=S.+Ganesh&author=S.+Shui&author=A.+Shah&author=B.+Kim&author=D.+Chen&author=P.+Pandya&author=R.+Storr&author=W.+Wang&author=H.+Dudek&author=C.+Lai&author=M.+Abrams&author=B.+Brown&title=Anti-Tumor+Activity+of+a+MYC-Targeting+Dicer+Substrate+siRNA+in+Combination+with+BRD4%2FCDK7+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DChipumuro%26aufirst%3DE.%26atitle%3DAnti-Tumor%2520Activity%2520of%2520a%2520MYC-Targeting%2520Dicer%2520Substrate%2520siRNA%2520in%2520Combination%2520with%2520BRD4%252FCDK7%2520Inhibitors%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520107th%2520Annual%2520Meeting%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Sayaka, O.</span>; <span class="NLM_string-name">Umezaki, S.</span>; <span class="NLM_string-name">Kojima, M.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Shiraishi, Y.</span>; <span class="NLM_string-name">Okudo, M.</span>; <span class="NLM_string-name">Kimura, T.</span></span> <span> </span><span class="NLM_article-title">Substituted Dihydropyrrolopyrazole Derivative</span>. <span class="NLM_patent">US20190256531A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=N.+Iwase&author=Y.+Aga&author=S.+Ushiyama&author=S.+Kono&author=H.+Sunamoto&author=T.+Matsushita&author=O.+Sayaka&author=S.+Umezaki&author=M.+Kojima&author=K.+Onuma&author=Y.+Shiraishi&author=M.+Okudo&author=T.+Kimura&title=Substituted+Dihydropyrrolopyrazole+Derivative"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DIwase%26aufirst%3DN.%26atitle%3DSubstituted%2520Dihydropyrrolopyrazole%2520Derivative%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Aga, Y.</span>; <span class="NLM_string-name">Ushiyama, S.</span>; <span class="NLM_string-name">Iwase, N.</span>; <span class="NLM_string-name">Kono, S.</span>; <span class="NLM_string-name">Sunamoto, H.</span>; <span class="NLM_string-name">Matsushita, T.</span>; <span class="NLM_string-name">Sayaka, O.</span>; <span class="NLM_string-name">Tanaka, M.</span>; <span class="NLM_string-name">Matoyama, M.</span>; <span class="NLM_string-name">Umezaki, S.</span>; <span class="NLM_string-name">Shiraishi, Y.</span>; <span class="NLM_string-name">Onuma, K.</span>; <span class="NLM_string-name">Kojima, M.</span>; <span class="NLM_string-name">Nishiyama, H.</span>; <span class="NLM_string-name">Kimura, T.</span></span> <span> </span><span class="NLM_article-title">Substituted Dihydropyrrolopyrazole Compound</span>. <span class="NLM_patent">US20170313727A1</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=Y.+Aga&author=S.+Ushiyama&author=N.+Iwase&author=S.+Kono&author=H.+Sunamoto&author=T.+Matsushita&author=O.+Sayaka&author=M.+Tanaka&author=M.+Matoyama&author=S.+Umezaki&author=Y.+Shiraishi&author=K.+Onuma&author=M.+Kojima&author=H.+Nishiyama&author=T.+Kimura&title=Substituted+Dihydropyrrolopyrazole+Compound"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DAga%26aufirst%3DY.%26atitle%3DSubstituted%2520Dihydropyrrolopyrazole%2520Compound%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lee, K.-O.</span>; <span class="NLM_string-name">Yoo, J.</span>; <span class="NLM_string-name">Lee, M. J.</span>; <span class="NLM_string-name">Lee, K. W.</span>; <span class="NLM_string-name">Min, J. E.</span>; <span class="NLM_string-name">Kim, J.</span>; <span class="NLM_string-name">Min, K.-N.</span>; <span class="NLM_string-name">Roh, T. C.</span>; <span class="NLM_string-name">Seo, K.-S.</span>; <span class="NLM_string-name">Rhee, H. I.</span>; <span class="NLM_string-name">Lee, J. H.</span>; <span class="NLM_string-name">Jeon, D.-H.</span>; <span class="NLM_string-name">Lim, D. S.</span></span> <span> </span><span class="NLM_article-title">YPN005, an Oral CDK7 Inhibitor, Exhibits a Significant Antitumor Activity in Myc-Driven Cancers</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 3, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.-O.+Lee&author=J.+Yoo&author=M.+J.+Lee&author=K.+W.+Lee&author=J.+E.+Min&author=J.+Kim&author=K.-N.+Min&author=T.+C.+Roh&author=K.-S.+Seo&author=H.+I.+Rhee&author=J.+H.+Lee&author=D.-H.+Jeon&author=D.+S.+Lim&title=YPN005%2C+an+Oral+CDK7+Inhibitor%2C+Exhibits+a+Significant+Antitumor+Activity+in+Myc-Driven+Cancers"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DK.-O.%26atitle%3DYPN005%252C%2520an%2520Oral%2520CDK7%2520Inhibitor%252C%2520Exhibits%2520a%2520Significant%2520Antitumor%2520Activity%2520in%2520Myc-Driven%2520Cancers%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Satyam, L. K.</span>; <span class="NLM_string-name">Poddutoori, R.</span>; <span class="NLM_string-name">Mukherjee, S.</span>; <span class="NLM_string-name">Marappan, S.</span>; <span class="NLM_string-name">Gopinath, S.</span>; <span class="NLM_string-name">Ramachandra, R.</span>; <span class="NLM_string-name">Pothuganti, M. K.</span>; <span class="NLM_string-name">Nayak, S. S.</span>; <span class="NLM_string-name">Nandish, C.</span>; <span class="NLM_string-name">Naik, C.</span>; <span class="NLM_string-name">Ravindra, M. V.</span>; <span class="NLM_string-name">Dabbeeru, M. B.</span>; <span class="NLM_string-name">Nagaraju, A.</span>; <span class="NLM_string-name">Mahankali, B.</span>; <span class="NLM_string-name">Antony, T.</span>; <span class="NLM_string-name">Pandit, C.</span>; <span class="NLM_string-name">Chelur, S.</span>; <span class="NLM_string-name">Daginakatte, G.</span>; <span class="NLM_string-name">Samajdar, S.</span>; <span class="NLM_string-name">Ramachandra, M.</span></span> <span> </span><span class="NLM_article-title">Potent and Selective Inhibition of CDK7 by Novel Covalent Inhibitors</span>.  <i>Proceedings of the AACR 107th Annual Meeting</i>; <span class="NLM_publisher-loc">New Orleans, LA</span>, Apr 16–20, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=L.+K.+Satyam&author=R.+Poddutoori&author=S.+Mukherjee&author=S.+Marappan&author=S.+Gopinath&author=R.+Ramachandra&author=M.+K.+Pothuganti&author=S.+S.+Nayak&author=C.+Nandish&author=C.+Naik&author=M.+V.+Ravindra&author=M.+B.+Dabbeeru&author=A.+Nagaraju&author=B.+Mahankali&author=T.+Antony&author=C.+Pandit&author=S.+Chelur&author=G.+Daginakatte&author=S.+Samajdar&author=M.+Ramachandra&title=Potent+and+Selective+Inhibition+of+CDK7+by+Novel+Covalent+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DSatyam%26aufirst%3DL.%2BK.%26atitle%3DPotent%2520and%2520Selective%2520Inhibition%2520of%2520CDK7%2520by%2520Novel%2520Covalent%2520Inhibitors%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520107th%2520Annual%2520Meeting%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samajdar, S.</span>; <span class="NLM_string-name">Poddutoori, R.</span>; <span class="NLM_string-name">Pandit, C.</span>; <span class="NLM_string-name">Mukherjee, S.</span>; <span class="NLM_string-name">Goswami, R.</span></span> <span> </span><span class="NLM_article-title">Substituted Heterocyclyl Derivatives as CDK Inhibitors</span>. <span class="NLM_patent">US20180362471A9</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Samajdar&author=R.+Poddutoori&author=C.+Pandit&author=S.+Mukherjee&author=R.+Goswami&title=Substituted+Heterocyclyl+Derivatives+as+CDK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSamajdar%26aufirst%3DS.%26atitle%3DSubstituted%2520Heterocyclyl%2520Derivatives%2520as%2520CDK%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Samajdar, S.</span>; <span class="NLM_string-name">Poddutoori, R.</span>; <span class="NLM_string-name">Mukherjee, S.</span>; <span class="NLM_string-name">Goswami, R.</span></span> <span> </span><span class="NLM_article-title">Pyrazolo[1,5-<i>a</i>][1,3,5]triazine and Pyrazolo[1,5-<i>a</i>]pyrimidine Derivatives as CDK Inhibitors</span>. <span class="NLM_patent">US20180258092A9</span>, <span class="NLM_year">2018</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&author=S.+Samajdar&author=R.+Poddutoori&author=S.+Mukherjee&author=R.+Goswami&title=Pyrazolo%5B1%2C5-a%5D%5B1%2C3%2C5%5Dtriazine+and+Pyrazolo%5B1%2C5-a%5Dpyrimidine+Derivatives+as+CDK+Inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSamajdar%26aufirst%3DS.%26atitle%3DPyrazolo%255B1%252C5-a%255D%255B1%252C3%252C5%255Dtriazine%2520and%2520Pyrazolo%255B1%252C5-a%255Dpyrimidine%2520Derivatives%2520as%2520CDK%2520Inhibitors%26date%3D2018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Thode, T.</span>; <span class="NLM_string-name">Li, Z.</span>; <span class="NLM_string-name">Weston, A.</span>; <span class="NLM_string-name">Soldi, R.</span>; <span class="NLM_string-name">Kaadige, M. R.</span>; <span class="NLM_string-name">Vankayalapti, H.</span>; <span class="NLM_string-name">Sharma, S.</span></span> <span> </span><span class="NLM_article-title">Targeting CDK7-Dependent Transcriptional Addiction with Novel, Orally Available Small Molecule Inhibitor Shows Efficacy in Pancreatic Cancer Models</span>.  <i>Proceedings of the AACR Annual Meeting</i>; <span class="NLM_publisher-loc">Atlanta, GA</span>, Mar 29–Apr 3, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=T.+Thode&author=Z.+Li&author=A.+Weston&author=R.+Soldi&author=M.+R.+Kaadige&author=H.+Vankayalapti&author=S.+Sharma&title=Targeting+CDK7-Dependent+Transcriptional+Addiction+with+Novel%2C+Orally+Available+Small+Molecule+Inhibitor+Shows+Efficacy+in+Pancreatic+Cancer+Models"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DThode%26aufirst%3DT.%26atitle%3DTargeting%2520CDK7-Dependent%2520Transcriptional%2520Addiction%2520with%2520Novel%252C%2520Orally%2520Available%2520Small%2520Molecule%2520Inhibitor%2520Shows%2520Efficacy%2520in%2520Pancreatic%2520Cancer%2520Models%26jtitle%3DProceedings%2520of%2520the%2520AACR%2520Annual%2520Meeting%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Choi, Y. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yoon, D. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suh, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Choi, C.-M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, J. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hong, J. Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rho, J. K.</span></span> <span> </span><span class="NLM_article-title">Efficacy of the Novel CDK7 Inhibitor QS1189 in Mantle Cell Lymphoma</span>. <i>Sci. Rep.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>9</i></span> (<span class="NLM_issue">1</span>),  <span class="NLM_fpage">7193</span>, <span class="refDoi"> DOI: 10.1038/s41598-019-43760-z</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fs41598-019-43760-z" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=31076643" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A280%3ADC%252BB3M7ksFKqsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2019&pages=7193&issue=1&author=Y.+J.+Choiauthor=D.+H.+Kimauthor=D.+H.+Yoonauthor=C.+Suhauthor=C.-M.+Choiauthor=J.+C.+Leeauthor=J.+Y.+Hongauthor=J.+K.+Rho&title=Efficacy+of+the+Novel+CDK7+Inhibitor+QS1189+in+Mantle+Cell+Lymphoma&doi=10.1038%2Fs41598-019-43760-z"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Efficacy of the novel CDK7 inhibitor QS1189 in mantle cell lymphoma</span></div><div class="casAuthors">Choi Yun Jung; Kim Dong Ha; Yoon Dok Hyun; Suh Cheolwon; Choi Chang-Min; Choi Chang-Min; Lee Jae Cheol; Hong Jung Yong; Rho Jin Kyung</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">7193</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Mantle cell lymphoma (MCL) is typically an aggressive and rare form of non-Hodgkin lymphoma (NHL) with a poor prognosis despite recent advances in immunochemotherapy and targeted therapeutics against NHL.  New therapeutic agents are needed for MCL.  In this study, we generated a potent inhibitor of cyclin-dependent kinase 7 (CDK7), designated QS1189, and confirmed its anti-cancer effects towards MCL and other lymphomas.  QS1189 was highly selective for CDK7 and showed potent anticancer effects in MCL compared to other targeted therapeutic agents, such as ibrutinib and venetoclax.  Consistent with a conventional CDK7 inhibitor, QS1189 treatment significantly decreased phosphorylation of the carboxyl-terminal domain of RNA polymerase II and transcription-associated genes.  QS1189 induced cell cycle arrest at the G2/M phase and apoptosis.  Interestingly, QS1189 overcame the acquired resistance to venetoclax, which is mediated by Bcl-xL.  Similarly, QS1189 showed potent tumour cell growth inhibition of various lymphomas.  Thus, CDK7 might be a suitable therapeutic target for inhibiting lymphoma, and QS1189 is a promising therapeutic option for various lymphomas and cells with acquired resistance to targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSRiZBZakKAD6qcneEtCi92fW6udTcc2ea_pTycnuSkl7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BB3M7ksFKqsA%253D%253D&md5=c4a0d995b5c52084965c50659a50c15a</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.1038%2Fs41598-019-43760-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fs41598-019-43760-z%26sid%3Dliteratum%253Aachs%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DD.%2BH.%26aulast%3DYoon%26aufirst%3DD.%2BH.%26aulast%3DSuh%26aufirst%3DC.%26aulast%3DChoi%26aufirst%3DC.-M.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DHong%26aufirst%3DJ.%2BY.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26atitle%3DEfficacy%2520of%2520the%2520Novel%2520CDK7%2520Inhibitor%2520QS1189%2520in%2520Mantle%2520Cell%2520Lymphoma%26jtitle%3DSci.%2520Rep.%26date%3D2019%26volume%3D9%26issue%3D1%26spage%3D7193%26doi%3D10.1038%2Fs41598-019-43760-z" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Coates, D. A.</span>; <span class="NLM_string-name">Montero, C.</span>; <span class="NLM_string-name">Patel, B. K. R.</span>; <span class="NLM_string-name">Remick, D. M.</span>; <span class="NLM_string-name">Yadav, V.</span></span> <span> </span><span class="NLM_article-title">Compounds Useful for Inhibiting CDK7</span>. <span class="NLM_patent">WO2019099298A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=D.+A.+Coates&author=C.+Montero&author=B.+K.+R.+Patel&author=D.+M.+Remick&author=V.+Yadav&title=Compounds+Useful+for+Inhibiting+CDK7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCoates%26aufirst%3DD.%2BA.%26atitle%3DCompounds%2520Useful%2520for%2520Inhibiting%2520CDK7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Montero, C.</span></span> <span> </span><span class="NLM_article-title">(<i>E</i>)-1-(4-(Dimethylamino)but-2-enoyl)pyrrolidin-3-yl-4-((3-isopropyl-5-methylpyrazolo[1,5-<i>a</i>]pyrimidin-7-yl)amino)piperidine-1-carboxylate for Inhibiting CDK7</span>. <span class="NLM_patent">US20190144456</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=C.+Montero&title=%28E%29-1-%284-%28Dimethylamino%29but-2-enoyl%29pyrrolidin-3-yl-4-%28%283-isopropyl-5-methylpyrazolo%5B1%2C5-a%5Dpyrimidin-7-yl%29amino%29piperidine-1-carboxylate+for+Inhibiting+CDK7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMontero%26aufirst%3DC.%26atitle%3D%2528E%2529-1-%25284-%2528Dimethylamino%2529but-2-enoyl%2529pyrrolidin-3-yl-4-%2528%25283-isopropyl-5-methylpyrazolo%255B1%252C5-a%255Dpyrimidin-7-yl%2529amino%2529piperidine-1-carboxylate%2520for%2520Inhibiting%2520CDK7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref116"><div class="reference"><strong class="refLabel"><a href="#ref116" class="rightTabRefNumLink">116</a></strong><div class="NLM_citation" id="rightTab-cit116"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nam, K.</span>; <span class="NLM_string-name">Kim, J.</span>; <span class="NLM_string-name">Jeon, Y.</span>; <span class="NLM_string-name">Yu, D.</span>; <span class="NLM_string-name">Seo, M.</span>; <span class="NLM_string-name">Park, D.</span>; <span class="NLM_string-name">Eickhoff, J.</span>; <span class="NLM_string-name">Zischinsky, G.</span>; <span class="NLM_string-name">Koch, U.</span></span> <span> </span><span class="NLM_article-title">Pharmaceutically Active Pyrazolo-Triazine and/or Pyrazolo-Pyrimidine Derivatives</span>. <span class="NLM_patent">WO2019197546A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=K.+Nam&author=J.+Kim&author=Y.+Jeon&author=D.+Yu&author=M.+Seo&author=D.+Park&author=J.+Eickhoff&author=G.+Zischinsky&author=U.+Koch&title=Pharmaceutically+Active+Pyrazolo-Triazine+and%2For+Pyrazolo-Pyrimidine+Derivatives"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit116&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DNam%26aufirst%3DK.%26atitle%3DPharmaceutically%2520Active%2520Pyrazolo-Triazine%2520and%252For%2520Pyrazolo-Pyrimidine%2520Derivatives%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref117"><div class="reference"><strong class="refLabel"><a href="#ref117" class="rightTabRefNumLink">117</a></strong><div class="NLM_citation" id="rightTab-cit117"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Goh, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Novotny-Diermayr, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hart, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Loh, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheong, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jayaraman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">William, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, E. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dymock, B. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ong, K. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ethirajulu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Burrows, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, J. M.</span></span> <span> </span><span class="NLM_article-title">TG02, a Novel Oral Multi-Kinase Inhibitor of CDKs, JAK2 and FLT3 with Potent Anti-Leukemic Properties</span>. <i>Leukemia</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>26</i></span> (<span class="NLM_issue">2</span>),  <span class="NLM_fpage">236</span>– <span class="NLM_lpage">243</span>, <span class="refDoi"> DOI: 10.1038/leu.2011.218</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=10.1038%2Fleu.2011.218" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=21860433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref117/cit117&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;key=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2012&pages=236-243&issue=2&author=K.+Gohauthor=V.+Novotny-Diermayrauthor=S.+Hartauthor=L.+Ongauthor=Y.+Lohauthor=A.+Cheongauthor=Y.+Tanauthor=C.+Huauthor=R.+Jayaramanauthor=A.+Williamauthor=E.+T.+Sunauthor=B.+W.+Dymockauthor=K.+H.+Ongauthor=K.+Ethirajuluauthor=F.+Burrowsauthor=J.+M.+Wood&title=TG02%2C+a+Novel+Oral+Multi-Kinase+Inhibitor+of+CDKs%2C+JAK2+and+FLT3+with+Potent+Anti-Leukemic+Properties&doi=10.1038%2Fleu.2011.218"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit117R"><div class="casContent"><span class="casTitleNuber">117</span><div class="casTitle"><span class="NLM_cas:atitle">TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties</span></div><div class="casAuthors">Goh, K. C.; Novotny-Diermayr, V.; Hart, S.; Ong, L. C.; Loh, Y. K.; Cheong, A.; Tan, Y. C.; Hu, C.; Jayaraman, R.; William, A. D.; Sun, E. T.; Dymock, B. W.; Ong, K. H.; Ethirajulu, K.; Burrows, F.; Wood, J. M.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">236-243</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">TG02 is a novel pyrimidine-based multi-kinase inhibitor that inhibits CDKs 1, 2, 7 and 9 together with JAK2 and FLT3.  It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cells with the main targets being CDKs.  TG02 is anti-proliferative in a broad range of tumor cell lines, inducing G1 cell cycle arrest and apoptosis.  Primary cultures of progenitor cells derived from acute myeloid leukemia (AML) and polycythemia vera patients are very sensitive to TG02.  Comparison with ref. inhibitors that block only one of the main targets of TG02 demonstrate the benefit of combined CDK and JAK2/FLT3 inhibition in cell lines as well as primary cells.  In vivo, TG02 exhibits favorable pharmacokinetics after oral dosing in xenograft models and accumulates in tumor tissues, inducing an effective blockade of both CDK and STAT signaling.  TG02 induces tumor regression after oral dosing on both daily and intermittent schedules in a murine model of mutant-FLT3 leukemia (MV4-11) and prolongs survival in a disseminated AML model with wild-type FLT3 and JAK2 (HL-60).  These data demonstrate that TG02 is active in various models of leukemia and provide a rationale for the ongoing clin. evaluation of TG02 in patients with advanced leukemias.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMelEE91r_BrVg90H21EOLACvtfcHk0lhI4ZlqKofAGA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XitFGgtLc%253D&md5=30af7dc302f9c421924b5b0062e82655</span></div><a href="/servlet/linkout?suffix=cit117&amp;dbid=16384&amp;doi=10.1038%2Fleu.2011.218&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2011.218%26sid%3Dliteratum%253Aachs%26aulast%3DGoh%26aufirst%3DK.%26aulast%3DNovotny-Diermayr%26aufirst%3DV.%26aulast%3DHart%26aufirst%3DS.%26aulast%3DOng%26aufirst%3DL.%26aulast%3DLoh%26aufirst%3DY.%26aulast%3DCheong%26aufirst%3DA.%26aulast%3DTan%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DC.%26aulast%3DJayaraman%26aufirst%3DR.%26aulast%3DWilliam%26aufirst%3DA.%26aulast%3DSun%26aufirst%3DE.%2BT.%26aulast%3DDymock%26aufirst%3DB.%2BW.%26aulast%3DOng%26aufirst%3DK.%2BH.%26aulast%3DEthirajulu%26aufirst%3DK.%26aulast%3DBurrows%26aufirst%3DF.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26atitle%3DTG02%252C%2520a%2520Novel%2520Oral%2520Multi-Kinase%2520Inhibitor%2520of%2520CDKs%252C%2520JAK2%2520and%2520FLT3%2520with%2520Potent%2520Anti-Leukemic%2520Properties%26jtitle%3DLeukemia%26date%3D2012%26volume%3D26%26issue%3D2%26spage%3D236%26epage%3D243%26doi%3D10.1038%2Fleu.2011.218" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref118"><div class="reference"><strong class="refLabel"><a href="#ref118" class="rightTabRefNumLink">118</a></strong><div class="NLM_citation" id="rightTab-cit118"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span>; <span class="NLM_string-name">Lou, Y.</span></span> <span> </span><span class="NLM_article-title">Covalent Inhibitors of CDK-7</span>. <span class="NLM_patent">US20180008604A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=Y.+Chen&author=Y.+Lou&title=Covalent+Inhibitors+of+CDK-7"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit118&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DY.%26atitle%3DCovalent%2520Inhibitors%2520of%2520CDK-7%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref119"><div class="reference"><strong class="refLabel"><a href="#ref119" class="rightTabRefNumLink">119</a></strong><div class="NLM_citation" id="rightTab-cit119"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ciblat, S.</span>; <span class="NLM_string-name">Kabro, A.</span>; <span class="NLM_string-name">Leblanc, M.</span>; <span class="NLM_string-name">Leger, S.</span>; <span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Miller, T.</span>; <span class="NLM_string-name">Roy, S.</span>; <span class="NLM_string-name">Schmidt, D.</span>; <span class="NLM_string-name">Siddiqui, A. M.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Winter, D. K.</span>; <span class="NLM_string-name">Ripka, A.</span>; <span class="NLM_string-name">Li, D.</span>; <span class="NLM_string-name">Zhang, G.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">WO2016058544A1</span>, <span class="NLM_year">2016</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2016&author=S.+Ciblat&author=A.+Kabro&author=M.+Leblanc&author=S.+Leger&author=J.+J.+Marineau&author=T.+Miller&author=S.+Roy&author=D.+Schmidt&author=A.+M.+Siddiqui&author=K.+Sprott&author=D.+K.+Winter&author=A.+Ripka&author=D.+Li&author=G.+Zhang&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit119&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DCiblat%26aufirst%3DS.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref120"><div class="reference"><strong class="refLabel"><a href="#ref120" class="rightTabRefNumLink">120</a></strong><div class="NLM_citation" id="rightTab-cit120"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Chuaqui, C.</span>; <span class="NLM_string-name">Ciblat, S.</span>; <span class="NLM_string-name">Kabro, A.</span>; <span class="NLM_string-name">Piras, H.</span>; <span class="NLM_string-name">Whitmore, K. Matthew</span>; <span class="NLM_string-name">Lund, K.-L.</span>; <span class="NLM_string-name">Bradley, M.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">WO2019143730</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+J.+Marineau&author=C.+Chuaqui&author=S.+Ciblat&author=A.+Kabro&author=H.+Piras&author=K.+Matthew+Whitmore&author=K.-L.+Lund&author=M.+Bradley&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit120&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref121"><div class="reference"><strong class="refLabel"><a href="#ref121" class="rightTabRefNumLink">121</a></strong><div class="NLM_citation" id="rightTab-cit121"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Chuaqui, C.</span>; <span class="NLM_string-name">Ciblat, S.</span>; <span class="NLM_string-name">Kabro, A.</span>; <span class="NLM_string-name">Piras, H.</span>; <span class="NLM_string-name">Whitmore, K. M.</span>; <span class="NLM_string-name">Lund, K.-L.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">WO2019143719</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+J.+Marineau&author=C.+Chuaqui&author=S.+Ciblat&author=A.+Kabro&author=H.+Piras&author=K.+M.+Whitmore&author=K.-L.+Lund&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit121&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref122"><div class="reference"><strong class="refLabel"><a href="#ref122" class="rightTabRefNumLink">122</a></strong><div class="NLM_citation" id="rightTab-cit122"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Marineau, J. J.</span>; <span class="NLM_string-name">Sprott, K.</span>; <span class="NLM_string-name">Schmidt, D.</span></span> <span> </span><span class="NLM_article-title">Inhibitors of Cyclin-Dependent Kinase 7 (CDK7)</span>. <span class="NLM_patent">US20190330218A1</span>, <span class="NLM_year">2019</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2019&author=J.+J.+Marineau&author=K.+Sprott&author=D.+Schmidt&title=Inhibitors+of+Cyclin-Dependent+Kinase+7+%28CDK7%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit122&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DMarineau%26aufirst%3DJ.%2BJ.%26atitle%3DInhibitors%2520of%2520Cyclin-Dependent%2520Kinase%25207%2520%2528CDK7%2529%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1UA2','PDB','1UA2'); return false;">PDB: 1UA2</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HCK" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1HCK','PDB','1HCK'); return false;">PDB: 1HCK</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JQ5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=5JQ5','PDB','5JQ5'); return false;">PDB: 5JQ5</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1U2A" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=1U2A','PDB','1U2A'); return false;">PDB: 1U2A</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i17"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01985">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_66445"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.9b01985?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b01985</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthetic routes to CT7001 and SY-1365 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b01985/suppl_file/jm9b01985_si_001.pdf">PDF</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b01985/suppl_file/jm9b01985_si_001.pdf">jm9b01985_si_001.pdf (111.61 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b01985&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2020.63.issue-14%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b01985%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b01985" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677ac77d3b753ca6","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
